HEALTHCHOICE MANAGED CARE ORGANIZATION AGREEMENT

THIS AGREEMENT (Agreement), effective January 1, 2022, is entered into by and between the Maryland Department of Health (Department) and ____________________ (MCO), a Managed Care Organization with authority to conduct business in the State of Maryland (State).

WHEREAS, the Department has established the Maryland Medicaid Managed Care Program, also known as the Maryland HealthChoice Program (HealthChoice), a waiver program approved by the Centers for Medicare & Medicaid Services (CMS) of the U.S. Department of Health and Human Services (DHHS) under §1115 of the Social Security Act and authorized under Maryland Annotated Code, Health-General Article, §§15-101 et seq.

WHEREAS, the Department desires to provide health care services to Medicaid recipients through the MCO.

WHEREAS, the MCO is engaged in the business of arranging and/or providing health care services.

NOW, THEREFORE, in consideration of the promises and mutual covenants herein contained, the parties hereto agree as follows:

I. DEFINITIONS AND ACRONYMS

A. For the purposes of this agreement, the following terms have the meaning stated:

1. “Administrative Services Organization” means an organization that manages designated administrative functions while the entity contracting the organization retains the risks and liabilities.

2. “CRISP” means the designated regional health information exchange that serves Maryland and the District of Columbia.

3. “Department” means the Maryland Department of Health, as defined in COMAR 10.09.36.01, or its authorized agents acting on behalf of the Department.

4. “Direct and indirect remuneration fees” in PBM contracts may include but are not limited to:

   a. Any pay-to-play for network participation;

   b. Any fees for periodic reimbursement reconciliations to provide a true-up between a target reimbursement rate in a participating pharmacy agreement and the aggregated effective rate actually
realized by a pharmacy or between the aggregate maximum allowable cost (MAC) or adjudicated rate and the aggregate contracted rate; or

c. Any payment mechanism to pharmacies for the fulfillment of quality measures or fee assessed to pharmacies for noncompliance with quality measures.

5. “Doula services” means continuous physical, emotional, and informational support to the birthing parent throughout the prenatal and postpartum periods, provided by a certified doula.

6. “Encounter Data” means information documenting a service to an Enrollee.

7. “Enrollee” means a Medicaid recipient who is enrolled in a managed care organization.

8. “Home visiting services” means services provided by the home visiting program through either of the following evidence-based models:
   a. Healthy Families America (HFA); or
   b. Nurse Family Partnership (NFP).

9. “Medically necessary services” means that the service or benefit is:
   a. Directly related to diagnostic, preventive, curative, palliative, rehabilitative, or ameliorative treatment of an illness, injury, disability, or health condition;
   b. Consistent with current accepted standards of good medical practice;
   c. The most cost-efficient service that can be provided without sacrificing effectiveness or access to care; and
   d. Not primarily for the convenience of the consumer, the consumer's family, or the provider.

10. “Medical loss ratio” means a formula that measures the ratio of MCO spending on medical and related benefits compared to revenue, to
ensure that MCOs are spending a sufficient amount of their premium revenue on medical expenses and other high-impact initiatives.

11. “MLR reporting year” means a period of 12 months consistent with the rating period selected by the Department.

12. “Network provider” means a provider that is a member of the MCO’s provider panel. A network provider is not a subcontractor on the sole basis of its network provider agreement with the MCO.

13. “Pharmacy benefit manager” means a third-party administrator of a prescription drug program for an MCO, including but not limited to network management, drug utilization review, outcome management, and disease management.

14. “Potential enrollee” means a recipient who is authorized by the Department to enroll in a managed care organization.

15. “Practice guidelines” means statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.

16. “Program” means the Medical Assistance Program.

17. "Recipient” means an individual who receives benefits under the State Medical Assistance Program.

18. "Self-referral services" are the health care services listed in COMAR 10.67.06.28 for which, under specified circumstances, the MCO is required to pay, without any requirement of referral by the PCP or MCO, when the enrollee accesses the service through a provider other than the enrollee's PCP.

19. “Spread pricing” means a form of reimbursement in which the pharmacy benefits manager (PBM) retains the difference between the amount the MCO pays the PBM and the amount the PBM reimburses the pharmacy for a drug and its associated costs. Spread pricing does not include the MCO paying the PBM reasonable administrative and transactional costs for services.

20. “State” means the State of Maryland.
21. “State Plan” means an agreement between the State and the Federal government describing how the State administers its Medicaid and CHIP programs. The State Plan includes the groups of individuals to be covered, services to be provided, methodologies for providers to be reimbursed, and the administrative activities underway in the State.

22. “Subcontractor” means an individual or entity that has a contract with an MCO that relates directly or indirectly to the performance of the MCO’s obligations under this contract. A network provider agreement with an MCO does not by itself make the network provider a “subcontractor” to an MCO.

23. “Third party liability” means the legal obligation of third parties (for example, certain individuals, entities, insurers, or programs) to pay part or all the expenditures for medical assistance furnished under a Medicaid state plan. By law, all other available third-party resources must meet their legal obligation to pay claims before the Medicaid program pays for the care of an individual eligible for Medicaid.

B. For the purposes of this agreement, the following terms will be addressed using the stated acronym:

1. ASO – Administrative Services Organization
2. COMAR – Code of Maryland Regulations
3. CMS – Centers for Medicare and Medicaid Services
4. CRISP – Chesapeake Regional Information System for our Patients
5. DHHS – U.S. Department of Health and Human Services
6. DPP – Diabetes Prevention Program
7. EPLS – Excluded Parties List System
8. E&M – Evaluation and Management
9. ePREP – Electronic Provider Revalidation and Enrollment Portal
10. FQHC – Federally Qualified Health Center
11. HSCRC – Health Services Cost Review Commission
II. THE MCO AGREES:

A. General Requirements

1. To comply with Maryland Annotated Code Health-General Article, Title 15 and the Insurance Article provisions referenced therein, the regulations of the HealthChoice Program (see Appendix O), several of which are specifically referenced herein, as well as 42 CFR Part 438, any other applicable provisions of federal law, the Maryland Code, COMAR, transmittals, and guidelines issued by the Department in effect at any time during the term of this Agreement.

2. Notwithstanding any other provision of this Agreement, to be subject to any change in Federal or State law or regulation, or other policy guidance from CMS or the Department that applies during the term of
this Agreement. The MCO retains all rights available to challenge the authority or basis for any such changes.

3. To comply with the federal law provisions pertaining to Title VI of the Civil Rights Act of 1964, Title IX of the Education Amendments of 1972 (regarding education programs and activities), The Age Discrimination Act of 1975, the Rehabilitation Act of 1973, the Americans with Disabilities Act of 1990 as amended, and section 1557 of the Patient Protection and Affordable Care Act, as well as the conflict of interest safeguards described in 42 CFR 438.58 and the prohibitions described in section 1902(a)(4)(C) of the Social Security Act applicable to contracting officers, employees, or independent contractors.

4. To comply with the requirements of section 5006 of the American Recovery and Reinvestment Act and all applicable federal guidance regarding the rights of Indian Enrollees.

5. To comply with the MCO’s continuity of operations plan and disaster recovery plan, along with any directives from the State or the Department, in the event of a state of emergency (or other catastrophic event). This requirement includes keeping up to date the continuity of operations plan and disaster recovery plan, providing the plans to the Department upon request, and ensuring subcontractors maintain and deploy routinely updated continuity of operations plans and disaster recovery plans when necessary.

6. To execute or amend a State Providers’ Amendment to HealthChoice Provider Service Agreements at the same time that the MCO executes a HealthChoice Provider Agreement with a county health department.

7. To comply with the provisions of this Agreement and all appendices contained therein.

8. To execute the Non-Exchange Entity Agreement with the Maryland Health Benefit Exchange (MHBE) and ensure the confidentiality, privacy and security of data accessed by the MCO or exchanged between the MCO and MHBE and compliance with the requirements of the ACA, including 45 CFR 155.260(b)(2) and 45 CFR 155.270(a).
9. To participate in federal grants awarded to the Department and federal grant application processes, including but not limited to the Maternal Opioid Misuse (MOM) Model (Appendix H).

B. Enrollment & Disenrollment

1. To accept enrollments of recipients authorized to enroll into an MCO by the Department and process enrollments in accordance with 42 CFR 438.54 and COMAR 10.67.02.02 (Appendix O).

2. To request disenrollment only for the reasons set forth in COMAR 10.67.02.06D (Appendix O) and 42 CFR 438.56.

3. To comply with the Department’s disenrollment policies and procedures, which are set forth in COMAR 10.67.02.05 and 10.67.02.06 and 10.09.69.04 (Appendix O).

4. To submit to the Department, within thirty (30) days of the date the MCO receives the monthly enrollment listings from the Department, a list of Enrollees who are known to the MCO to have:
   a. Disenrolled from the HealthChoice Program;
   b. Relocated to a geographic area not serviced by the MCO;
   c. Become ineligible to receive HealthChoice Program services from the MCO; or
   d. Died.

5. To submit any additional information the Department requests about the Enrollees referenced in II.B.4 of this Agreement.

6. To process Enrollee updates provided by the Department in a timely manner, including but not limited to Enrollee demographic updates and Enrollee primary care provider selections.

C. Enrollee Rights

1. To permit each Enrollee to choose his or her network provider to the extent possible and appropriate, as set forth in COMAR 10.67.05.05 (Appendix O).

2. To provide practice guidelines to Enrollees and potential Enrollees upon request.
3. To accord Enrollees all the rights available to them under 42 CFR 438.100; to require their network providers to also respect those rights; and to develop written policies governing the protection of those rights.

4. To refrain from discriminating against or using any policy or practice that has the effect of discriminating against Enrollees on the basis of age, sex, gender identity, race, creed, color, marital status, sexual orientation, national origin, physical or mental handicap, health status, or need for health services.

5. Not to prohibit or otherwise restrict the advice that a health care professional, with a contractual, referral, or other arrangement with the MCO, gives to an Enrollee who is a patient of the professional about the health status of the individual or medical care or treatment for the individual’s condition or disease, regardless of whether benefits for such care or treatment are provided under this Agreement, if the professional is acting within the lawful scope of practice.

6. To comply with the requirements governing Enrollee appeals and grievances set forth in COMAR 10.67.09 (Appendix O) and 42 CFR 438, subpart F.

   a. To permit Enrollees to appeal denials, in whole or part, of a payment of service except for administrative denials of unclean claims.

   b. To provide that oral requests for standard appeals be considered the initiation of the appeal to establish the earliest possible filing date without requiring confirmation in writing.

   c. To participate in State fair hearings, including sending legal representations and expert witnesses as appropriate, in accordance with COMAR 10.01.04 and 10.67.09.05 (Appendix O).

7. To provide the MCO enrollee services phone number on the identification card required in COMAR 10.67.04.02E (3).

D. Covered Services

1. To cover, for Enrollees:
a. In accordance with COMAR 10.67.06 and as defined in COMAR 10.67.01.01B (Appendix O), medically necessary covered services under the Maryland Medicaid State Plan (State Plan) in the amount, duration and scope set forth in the State Plan and in accordance with 42 CFR 438.210 and 42 CFR 440.230.

b. Doula services for pregnant and postpartum individuals as part of MCO-covered pregnancy-related benefits.

c. Home visiting services for pregnant and postpartum individuals as well as other Enrollees identified as participating in home visiting services, as part of MCO-covered pregnancy-related benefits.

d. Any services that the MCO voluntarily agrees to provide, the cost of which cannot be included when determining the payment rates under this Agreement.

e. Any services necessary for compliance by the MCO with the requirements of subpart K of 42 CFR Part 438, to the extent such services are necessary for the MCO to comply with 42 CFR 438.910.

f. Any services or settings identified in Appendix E which are offered at the option of the MCO, or which are in-lieu-of services or settings covered under the State Plan, if:
   i. The Department determines that the alternative service or setting is a medically appropriate and cost-effective substitute for the covered service or setting under the State Plan;
   ii. The Enrollee is not required by the MCO to use the alternative service or setting;
   iii. The utilization and actual cost of in-lieu-of services are taken into account when developing the component of the capitation rates that represents the covered State Plan services; and
   iv. CMS approves the services identified in Appendix E as part of the submission of this Agreement.

2. To comply with requirements governing emergency and post-stabilization services under 42 CFR 438.114.

3. To comply with the requirements mandating provider identification of provider-preventable conditions as a condition of payment, as well as
the prohibition against payment for provider-preventable conditions, that are set forth in 42 CFR 434.6(a)(12) and 42 CFR 447.26, and to report all identified provider-preventable conditions in a form or frequency specified by the Department.

E. Quality Improvement

1. To implement an ongoing comprehensive quality assessment and performance improvement program for the services furnished to its Enrollees that includes, but is not limited to:

   a. Performance improvement projects in accordance with 42 CFR 438.330(d);

   b. Collection and submission of performance measurement data in accordance with 42 CFR 438.330 (c);

   c. Mechanisms to detect underutilization and overutilization of services; and

   d. Mechanisms to assess the quality and appropriateness of care furnished to Enrollees with special health care needs.

2. To participate in annual Quality Meetings with the Department to evaluate MCO performance and operations.

3. To participate in all quality improvement activities listed in COMAR 10.67.04.03B (Appendix O).

4. To participate in annual validation and evaluation of MCO provider networks.

5. To comply with the Department’s Network Adequacy Standards (Appendix F).

6. To maintain NCQA accreditation, as set forth in 42 CFR §438.332(b) and COMAR 10.67.03.08 (Appendix O), and to provide the Department a copy of its most recent NCQA accreditation, including:

   a. Accreditation status, survey type, and level;

   b. Accreditation results, including:

      i. Recommended actions or improvements,
ii. Corrective action plans, and

iii. Summaries of findings; and

c. Expiration date of accreditation.

7. To cooperate with any corrective actions and intermediate sanctions arising from the Department’s Performance Monitoring Policy (Appendix D).

F. Service Authorization and Utilization Management

1. To place appropriate limits on services for utilization control, provided that:

   a. The services furnished can reasonably achieve the purpose for which the services are provided;

   b. The services supporting individuals with ongoing or chronic conditions are authorized in a manner that reflects the Enrollee's ongoing need for such services and supports; and

   c. Family planning services are provided in a manner that protects and enables the Enrollee's freedom to choose the method of family planning to be used.

2. To adopt, apply, review, and update any practice guidelines in accordance with the requirements of COMAR 10.67.03.09L (Appendix O) and 42 CFR 438.236, and to disseminate practice guidelines to all affected providers.

3. To have in place, and follow (along with its contractors), written policies and procedures for the processing of requests for initial and continuing authorizations of services and have mechanisms to ensure consistent application of review criteria for authorization decisions, including consultations with specialists, as appropriate.

4. To adhere to the requirements for service authorization and notification set forth in 42 CFR 438.210(d) and COMAR 10.67.09.04 (Appendix O).

5. Pursuant to 42 CFR 438.3(i) and 422.208, not to make payment directly or indirectly under a physician incentive plan to a physician or
physician group as an inducement to reduce or limit medically necessary services furnished to an individual Enrollee.

6. To execute an agreement with the Department’s Independent Review Organization vendor and comply with the standards set forth in COMAR 10.67.13 (Appendix O).

G. Coordination of Care

1. To coordinate care and deliver quality health care to the MCO’s Enrollees by providing all necessary information to the Medicaid Program, its authorized agents, the Administrative Services Organizations with which the Department contracts and to any other entity as directed by the Department, in accordance with applicable federal and state confidentiality laws and regulations.

2. For Enrollees with behavioral health conditions, coordination of care should include but not be limited to:

   a. Participation in monthly collective MCO medical directors’ meetings and one-on-one MCO meetings with the ASO for care coordination,

   b. Cooperation with the Department’s high utilizer pilot program,

   c. Assistance with the development and coordination of appropriate treatment plans for Enrollees,

   d. Provider education and promotion for the Screening, Brief Intervention, and Referral to Treatment (SBIRT) process,

   e. Provider education about the substance use release of information (ROI) process under 42 CFR, Part 2, and

   f. Provider education for Enrollee identification and referrals to the ASO or core service agencies for behavioral health services,

3. To implement procedures to deliver care to and coordinate services for all Enrollees. These procedures must do the following:

   a. Ensure that each Enrollee has an ongoing source of care appropriate to his or her needs and a person or entity formally designated as primarily responsible for coordinating the services accessed by the Enrollee (e.g., a primary care provider);
b. Provide the Enrollee with information on how to contact their designated person or entity;

c. Coordinate the services the MCO furnishes to the Enrollee:
   
   i. Between settings of care, including appropriate discharge planning for short term and long-term hospital and institutional stays;

   ii. With the services the Enrollee receives from any other MCO;

   iii. With the services the Enrollee receives in FFS Medicaid; and

   iv. With the services the Enrollee receives from community and social support providers.

d. Make a best effort to conduct an initial screening of each Enrollee's needs, within 90 days of the effective date of enrollment for all new Enrollees, including subsequent attempts if the initial attempt to contact the Enrollee is unsuccessful;

e. Share with the Department or other MCOs serving the Enrollee the results of any identification and assessment of that Enrollee's needs to prevent duplication of services or benefits;

f. Use CRISP to identify new Enrollees and their potential risk categories and to coordinate with other MCOs as appropriate for transition of care activities;

g. Ensure that each provider furnishing services to Enrollees maintains and shares, as appropriate, an Enrollee health record in accordance with professional standards; and

h. Ensure that in the process of coordinating care, each Enrollee's privacy is protected in accordance with the privacy requirements in 45 CFR parts 160 and 164 subparts A and E, to the extent that they are applicable.

H. Information Requirements

1. To comply with all marketing requirements under 42 CFR 438.104 and COMAR 10.67.04.23 (Appendix O).
2. To comply with the rules, language, and format standards for Enrollee information set forth in 42 CFR 438.10(c) and (d) and COMAR 10.67.05.01 (Appendix O).

   a. To include taglines in the prevalent non-English languages identified by the Department with written materials critical to obtaining services in a conspicuously-visible font size.

3. To provide Enrollees with the model Enrollee handbook developed by the Department and ensure it contains the minimum requirements outlined in 42 CFR 438.10(g)(2) and COMAR 10.67.05.02 (Appendix O).

4. To provide Enrollees with a network provider directory and ensure it contains the minimum information about physicians (including specialists), hospitals, and pharmacies outlined in 42 CFR 438.10(h)(1) and COMAR 10.67.05.02 (Appendix O).

   a. To update paper directories on a monthly basis if the MCO does not have a mobile-enabled electronic directory or quarterly if the MCO has a mobile-enabled electronic directory.

5. To submit changes to Enrollee handbooks and Enrollee notices to the Department for review and approval prior to use and dissemination.

I. Reporting Requirements

1. To prepare and submit to the Department HealthChoice Financial Monitoring Reports in accordance with COMAR 10.67.04.15E (5) and 10.67.04.19-5 (Appendix O).

2. To submit to the Department the reports described in COMAR 10.67.07.03 (Appendix O).

3. To seek and obtain the Department’s approval before making or allowing any material deviations in corporate structure, management, or operations from the MCO application and supporting documentation that was provided and approved pursuant to COMAR 10.67.03 (Appendix O).

4. To maintain a health information system that collects, analyzes, integrates, and reports data, including encounter data and that can achieve the objectives of 42 CFR 438, subpart D; and to comply with
the requirements of 42 CFR 438.242(b) and (c) and COMAR 10.67.04.15 (Appendix O).

5. To submit encounter data that identifies the provider who delivers any items or services to enrollees at a frequency and level of detail to be specified by CMS and the Department, including, at a minimum:
   a. Enrollee and provider identifying information;
   b. Service, procedure, and diagnoses codes;
   c. Allowed, paid, enrollee responsibility, and third-party liability amounts; and
   d. Service, claims submission, adjudication, and payment dates.

6. To identify sub-capitated arrangements and denied claims in the 837 encounter data submissions (refer to the MDH 837 Encounter Companion Guides for the appropriate CN1 segment and data elements).

7. To submit to the Department a list of all State fair hearings held, and decisions rendered during the preceding quarter, within 10 calendar days after the close of each calendar quarter, in the format specified by the Department.

8. To transfer historical utilization data upon request for any members who have disenrolled from the MCO in the timeframe and format specified by the Department.

9. To submit information to the Department for a report that is due to CMS on or before October 1, 2022, and provide other information as needed to ensure ongoing compliance with 42 CFR 438, subpart K (applying parity standards from the Mental Health Parity and Addiction Equity Act), including engaging in the following:
   a. Purchasing a license for and utilizing the URAC Parity Manager Tool;
   b. Providing comprehensive responses and completing all requested fields in the URAC Parity Manager Tool and updating information on an annual basis; and
c. Responding to all follow-up requests by the Department for additional information; and

d. Generating and submitting reports as required by the Department to monitor the impact of non-quantitative limits in operation which may include denial rates, prior authorization rates, utilization trends, and results of interrater reliability surveys.

10. To supply other information requested by the Department, given a reasonable period of notice, for the purposes of Maryland Medicaid Managed Care Program administration or the Department’s monitoring of MCO performance pursuant to 42 CFR 438.66 and COMAR 10.67.04.15 (Appendix O).

11. To report third-party liability collection activities as described in 10.67.04.18 (Appendix O).

J. Financial Requirements

1. To calculate and report a medical loss ratio for each rating year to the Department in the form and manner specified in 42 CFR 438.8 and §II.K of this Agreement.

2. To accept the capitation rates set forth in Appendix C (Managed Care Organization Service Areas and Reimbursement Rates) as payment for services rendered to Enrollees of the Maryland HealthChoice Program.

3. To participate in the Population Health Incentive Program (PHIP) outlined in Appendix N of this Agreement, which is funded at 0.5 percent of the MCO’s total capitation for the term of the Agreement.

4. [To participate in the Department’s stop-loss program in accordance with COMAR 10.67.04.22 (Appendix O) and to accept a stop-loss limit of [redacted] per Enrollee.]

5. To comply with the revised requirements for subsequent very low birth weight supplemental payments, outlined as follows:
   a. The mother had a spontaneous preterm delivery.
   b. The mother has a current singleton pregnancy.
c. The mother is eligible to receive either hydroxyprogesterone caproate or vaginal progesterone.

d. The mother has received the first hydroxyprogesterone caproate injection or first weekly dosing of vaginal progesterone between 16 weeks gestation and 24 weeks gestation and continued receiving injections or vaginal dosing until delivery or week 37 gestation.

e. The mother has received at least two hydroxyprogesterone caproate injections or two weeks of daily vaginal progesterone use.

6. To acknowledge the standards governing the Program’s Rural Access Incentive Program set forth at COMAR 10.67.04.19-3 (Appendix O), and to accept incentive payments developed in accordance with those regulations and 42 CFR 438.6 for the one-year rating period covered by this Agreement, subject to approval by the Department of Budget Management.

7. To comply with requirements established by the Department and the Maryland HSCRC regarding use of the Maternal and Child Population Health Improvement Fund and to accept payments developed in accordance with 42 CFR 438.6 for the one-year rating period covered by this Agreement.

8. To comply with requirements established by the Department regarding incentive funding for COVID-19 vaccinations, and to accept payments developed in accordance with 42 CFR 438.6 for the one-year rating period covered by this Agreement.

9. To accept as payment in full the amounts paid by the Department pursuant to Appendix C, and not to seek or accept additional payment from any Enrollee for any covered service; provided, however, that nothing in this Agreement shall prevent the MCO from seeking coordination of benefits or subrogation recoveries in accordance with applicable rules and regulations.

10. To refrain from making any expenditure for organ transplants, except as provided for in the State Plan and Section 1903(i) of the Social Security Act.
11. Except as provided in Section 1903(i) of the Social Security Act, to refrain from paying for any item or service furnished by any individual or entity to whom the State has failed to suspend payments under the State Plan during any period when there is pending an investigation of a credible allegation of fraud against the individual or entity, as determined by the State in accordance with federal regulations, unless the State determines in accordance with such regulations there is good cause not to suspend such payment.

12. To refrain from making any expenditure with respect to any amount expended for which funds may not be used under the Assisted Suicide Funding Restriction Act of 1997; or with any respect to any amount expended for roads, bridges, stadiums, or any other item or service not covered under the State Plan and Section 1903(i) of the Social Security Act, except as provided for in Section 1903(i) of the Social Security Act.

13. To refrain from paying for an item or service (other than an emergency item or service) for home health care services provided by an agency or organization, unless the agency provides a surety bond as specified in Section 1861(o)(7) of the Social Security Act.

14. Not to hold Enrollees, the Department or DHHS liable for the debts of the MCO or any of its subcapitated providers in the event of the MCO’s insolvency or the insolvency of its subcapitated provider, but nothing in this paragraph shall waive the MCO’s right to be paid for the services that it has provided to its members.

15. Not to hold Enrollees or DHHS liable for the debts of the MCO for services provided to the Enrollee:
   a. In the event that the MCO fails to receive payment from the Department for such services, or
   b. In the event that a health care provider with a contractual, referral, or other arrangement with the MCO fails to receive payment from the Department or the MCO for such services.

16. To make payment to health care providers for items and services which are subject to this Agreement and that are furnished to the Enrollees on a timely basis consistent with the claims payment procedures described in section §1902(a)(37)(A) of the Social Security Act.
2022 Maryland HealthChoice Program Agreement

Act, 42 CFR 447.46 and the applicable provisions of 42 CFR 447.45, Maryland Annotated Code, Insurance Article, §15-1005 and Health-General Article, §15-102.3 unless the health care provider and the MCO agree to an alternate payment schedule.

17. To make pass-through payments to the Maryland Trauma Physician Services Fund, as set forth in Health General Article § 19-130(b)(2), Maryland Annotated Code.

18. To reimburse Maryland hospital providers based on rates approved by the HSCRC.

19. To reimburse network providers for evaluation and management (E&M) codes at the Maryland Medicaid Fee-for-Service rates, at a minimum.

20. To reimburse self-referred services at the Maryland Medicaid Fee-for-Service rates, at a minimum.

21. To acknowledge and adhere to the HealthChoice Financial Sanction Policy, as outlined in Appendix I.

22. To participate in the Maryland Quality Incentive Program as described in Appendix J, contingent upon CMS approval.

23. To reimburse CDC-recognized organizations participating in the HealthChoice Diabetes Prevention Program at a rate equal to or greater than the rates specified in the fee schedule in Appendix K.

K. Medical Loss Ratio

1. To provide to the Department a completed MLR Reporting Template, including the MCO attestation and any additional documentation supporting the MLR reporting template (Appendix G), in accordance with 42 CFR 438.8, by November 15th of the calendar year following the MLR reporting year.

2. To provide a remittance for an MLR reporting year if the MLR for that MLR reporting year does not meet the minimum MLR standard of 85 percent.

3. Newly contracted MCOs.
a. The Department may exclude a newly contracted MCO from MLR requirements for the first year of the MCO's operation.

b. Newly contracted MCOs shall comply with MLR reporting during the next MLR reporting year in which the MCO is operating, even if the first year was not a full 12 months.

4. To report fraud prevention activities to the Department as required by 42 CFR 438.8.

5. To recalculate and resubmit the MLR report for all MLR reporting years affected if the Department makes retroactive changes to the capitation payments that impacts the MLR reporting year.

6. To attest to the accuracy of the calculation of the MLR when submitting its report to the Department.

7. To acknowledge the right to appeal a remittance being due to the Department within 30 days of notice, and that filing the appeal does not stay the obligation to remit the amount owed to the Department.

L. Program Integrity

1. To implement and require its responsible subcontractors to implement procedures that are designed to detect and prevent fraud, waste, and abuse set forth in 42 CFR 438.608 and COMAR 10.67.07 (Appendix O).

2. To designate a compliance officer, who reports directly to the chief executive officer and the board of directors and is responsible for developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements of the contract, and at minimum the following staff members:

   a. An investigator who is responsible for fraud, waste, and abuse investigations;

   b. An auditor who is responsible for identifying potential fraud, waste, and abuse through analysis of claims and related information; and
3. To maintain staffing and resources located in Maryland to identify and investigate potential fraud, waste, and abuse, which shall be based on criteria determined by the Department that may include but are not limited to:
   a. Number of enrollees;
   b. Number of claims received on an annual basis;
   c. Volume of suspected fraudulent and abusive claims currently being detected;
   d. Other factors relating to the vulnerability of the MCO to fraud and abuse; and
   e. An assessment of optimal caseload which can be handled by an investigator on an annual basis.

4. To permit the Department, the Maryland Insurance Administration, and/or DHHS, or any of their respective designees, with respect to the MCO and any of its subcontractors, as required by 42 CFR 438.6(h), to:
   a. Evaluate the quality, appropriateness, and timeliness of services performed through inspection, or other means, including accessing the MCO and its subcontractors’ facilities using enrollment cards and identities established in the manner specified by the Department; and
   b. Inspect and audit any financial records, including but not limited to reimbursement rates.

5. To inform its subcontractors of the provisions of the Social Security Act §1128 B (Criminal Penalties for Acts Involving Federal Health Care Programs).

6. In accordance with Section 1903(m)(4)(B) of the Social Security Act, to report to the State and, upon request, to the Secretary or the Inspector General of the Department of Health and Human Services, the Comptroller General and Enrollees, a description of transactions
between the MCO and a party in interest (as defined in section 1318(b)
of The Public Health Service Act, including the following transactions:

a. Any sale, exchange, or leasing of any property between the MCO
   and such a party.

b. Any furnishing for consideration of goods, services (including
   management services), or facilities between the MCO and such a
   party, but not including salaries paid to employees for services
   provided in the normal course of their employment.

c. Any lending of money or other extension of credit between the
   MCO and such a party.

7. To comply with 42 CFR 438.610 by not knowingly having as a
director, officer, partner, owner of more than five percent (5%) of the
MCO’s equity, a network provider, or a person with an employment,
consulting, or other arrangement with the MCO for the provision of
items and services that are significant and material to the MCO’s
obligations under its Agreement with the Department, who is:

a. Debarred, suspended, or otherwise excluded from participating in
   procurement activities under the Federal Acquisition Regulation or
   from participating in non-procurement activities under regulations
   issued under Executive Order No. 12549;

b. An individual who is an affiliate, as defined in the Federal
   Acquisition Regulation, of a person described in paragraph HH(1)
   above; or

c. An individual or entity that is excluded from participation in any
   Federal health care program under sections 1128 or 1128A of the
   Social Security Act.

8. To acknowledge the sanction provisions under 42 CFR, Part 438,
Subpart I, in Health-General Article §15-103(b)(9), and COMAR
10.67.10.01 (Appendix O).

9. To search the DHHS-OIG’s List of Excluded Individuals/Entities, the
General Services Administration Excluded Parties List System, the
Social Security Administration Death Master File, and the National
Plan & Provider Enumeration System for individuals excluded from
the Medicaid Program. Searches shall be done upon execution of this
Agreement, and the LEIE and EPLS shall be checked at least monthly
thereafter, using the names of all contracted individuals and entities,
those with an ownership or control interest, and their agents and managing employees, in accordance with 42 CFR 455.436.

10. To create and manage mechanisms to conduct verifications with Enrollees whether services billed by network providers were received and provide evidence of verification efforts to the Department at least annually.

11. To require MCO program integrity representatives to attend in-person meetings with the Department and report ongoing efforts to detect and prevent fraud, waste, and abuse.

12. To identify and collect monies owing from responsible third parties liable for the cost of medical care furnished by the MCO to Enrollees in accordance with COMAR 10.67.04.18 (Appendix O).

13. To create and manage mechanisms to detect fraud and abuse and report to the Department’s Office of the Inspector General (OIG), in accordance with OIG protocols.

14. To report excess capitation or other contract overpayments to the Department within 60 calendar days of discovery, in accordance with 42 CFR 438.608(c).

15. To establish edits in the MCO’s claims processing system to cross-reference known deceased Enrollees’ names and dates of death.

16. To perform activities to ensure payments are not issued for deceased Enrollees, including but not limited to analytical reviews of encounter data looking for indications of payments for services after death, including billing patterns (e.g., multiple types of service pre-death and only one type of service after death or large differences in spending before and after death).

17. To provide to the Department, on a monthly basis in a format directed by the Department, data on recoveries from responsible third parties at the claim level, including but not limited to:

a. Paid amount;

b. Other insurance billed/paid;

c. Units billed;
d. Provider information, including NPI and Tax ID.

M. Subcontractors

1. To comply with the requirements for the service or activity delegated under the subcontract set forth in 42 CFR 438.230 and COMAR 10.67.04.17 (Appendix O).

2. To structure compensation to subcontractors conducting utilization management activities so as not to provide incentives for denying, limiting, or discontinuing medically necessary services to any Enrollee, in accordance with 42 CFR 438.210(e).

3. To use the Department’s Ownership and Control Disclosure Form to collect ownership and control, business transaction, and criminal conviction information from the MCO’s subcontractors and delegated vendors, and to furnish that information to the Department upon request.

N. Network Providers

1. To demonstrate, in accordance with 42 CFR 438.207, COMAR 10.67.03.05, COMAR 10.67.05.05, and COMAR 10.67.05.05-1 (Appendix O) that the MCO:
   a. Offers an appropriate range of preventive, primary care, and specialty services adequate for the anticipated number of Enrollees in the MCO’s service areas.
   b. Maintains a network of providers sufficient in number, mix, and geographic distribution to meet the needs of the number of Enrollees in the MCO’s service areas.
   c. Ensures that in-plan individual practitioners, based on full-time equivalency, are assigned no more than the number of enrollees that is consistent with a 200:1 ratio of enrollee to practitioner in the local access area.
   d. Meets the Department’s Network Adequacy Standards (Appendix F) in each service areas the MCO plans to enter or is enrolled.
   e. Demonstrates to the Department's satisfaction the adequacy of its provider network if it cannot meet the Network Adequacy Standards, by providing evidence and assurances of the overall strength of the MCO's network and that the network will enhance
recipients' overall access to quality health care services in the area to be served.

2. To maintain written policies and procedures for selecting and retaining network providers in accordance with the requirements of 42 CFR 438.214 and the applicable provider panel provisions of Maryland Insurance Article § 15-112, Code Ann.

3. To ensure that all its network providers are screened, enrolled, and revalidated by the State as Medicaid providers, in accordance with 42 CFR part 455, subparts B and E, and validate enrollment by verifying against the Department’s full fee-for-service provider file.

4. To require that network providers enroll and comply with the requirements of the Department’s Electronic Provider Revalidation Enrollment Portal (ePREP) in accordance with 42 CFR 438, subpart H.

5. To validate that any network provider rendering or receiving payment for covered services is enrolled and active on the date(s) of service by verifying against the full fee-for-service provider enrollment file from the Department.

6. To accept the Maryland Uniform Credentialing Form for the credentialing of network providers.

7. To refrain from discriminating against providers serving high-risk populations or specializing in conditions requiring costly treatment.

8. To inform all providers at the time of entering into a contract with the MCO about the grievance and appeal system, as set forth in 42 CFR 438.414 and 42 CFR 438.10(g)(2)(xi).

9. To monitor the Department’s correspondence and any database publicizing Department-initiated terminations of providers from the Program.

10. To terminate the contract of, or refrain from contracting with, providers terminated or excluded from participating in the Program.

11. To develop and distribute a provider manual that includes all of the information provided in the Department’s template and required in COMAR 10.67.05.04A(2).
12. To distribute to network providers the MCO’s practice guidelines, as described in 42 CFR 438.236.

13. To ensure services are delivered in a culturally competent manner to all Enrollees, including:
   a. Enrollees with limited English proficiency;
   b. Enrollees with diverse cultural and ethnic backgrounds; and
   c. Enrollees of all genders, sexual orientations, and gender identities.

14. To ensure its provider network can provide physical access, reasonable accommodation, and accessible equipment for Enrollees with physical or mental disabilities.

15. To provide necessary services covered under the contract out of network adequately and timely for Enrollees, for as long as the MCO’s provider network is unable to provide them.

16. To establish coverage, requirements, and reimbursement procedures for doulas who enroll in Maryland Medicaid to provide services for pregnant and postpartum individuals.

17. To establish coverage, requirements, and reimbursement procedures for HVS programs that provide services through approved evidence-based home visiting models.

O. MCO Appeal Rights

1. To acknowledge its right to appeal under the following grounds:
   a. Decision to terminate the MCO’s participation in the Maryland Medicaid Managed Care Program;
   b. Decision to impose a fine or other sanction on the MCO as described in COMAR 10.67.10.01;
   c. Order to provide benefits or services to Enrollees;
   d. Order that the MCO is impaired or in “hazardous financial condition;”
e. An adverse decision by the IRO as described in COMAR 10.67.13.08;

f. The amount of a penalty or incentive as described in COMAR 10.67.04.03;

g. The denial of a hepatitis C payment as described in COMAR 10.67.04.19;

h. Overpayments recovered by the Department;

i. Remittances to the Department related to MLR reporting.

2. To appeal to the Office of Administrative Hearings as specified in COMAR 10.09.36.09 and COMAR 10.01.03 (Appendix O).

3. To acknowledge and agree that the following sanctions take effect immediately and are not subject to stay during the pendency of an appeal:

   a. Any fines imposed;

   b. Orders to provide a benefit or service to Enrollees;

   c. Any full or partial withhold of the capitation payment;

   d. Any remittances to the Department related to MLR; or

   e. Any overpayments recovered by the Department related to program integrity efforts, as described in COMAR 10.67.07.01.

P. Pharmacy

1. To maintain drug review and utilization requirements that comply with 42 USC 1396a (oo), excluding sections (1)(A)(i)(III) and (B), along with the following drug utilization review requirements from 42 CFR 456.703:

   a. Prospective safety edit limitations for opioid prescriptions, on days’ supply for patients not currently receiving opioid therapy for initial prescription fills; quantity of prescription dispensed for initial and subsequent prescription fills; therapeutically-duplicative initial and subsequent opioid prescription fills; and early refills, for subsequent prescription fills.
b. Prospective safety edit limitations for opioid prescriptions on the maximum daily morphine milligram equivalent for treatment of pain, for initial and subsequent prescription fills.

c. A retrospective claims review automated process that indicates prescription fills of opioids in excess of the prospective safety edit limitations specified in Section II.P.1.a-b to provide for the ongoing review of opioid claims data to identify patterns of fraud, abuse, excessive utilization, inappropriate or medically unnecessary care, or prescribing or billing practices that indicate abuse or provision of inappropriate or medically unnecessary care among prescribers, pharmacists, and individuals receiving Medicaid benefits.

d. A process to identify potential fraud or abuse of controlled substances by individuals enrolled under the State Plan, health care providers prescribing drugs to individuals so enrolled, and pharmacies dispensing drugs to individuals so enrolled.

e. Retrospective claims review automated processes to identify when an Enrollee is prescribed an opioid after the Enrollee has been prescribed one or more drugs used for medication assisted treatment of an opioid use disorder or has been diagnosed with an opioid use disorder, in the absence of a new indication to support utilization of opioids (such as new cancer diagnosis or hospice care); and an Enrollee could be at high risk of opioid overdose and should be considered for co-prescription or co-dispensing of any FDA-approved opioid antagonist/reversal agent.

2. To cover outpatient drugs as defined in § 1927(k)(2) of the Social Security Act and comply with the requirements outlined in 42 CFR 438.3(s).

3. Pharmacy Benefit Managers (PBM)

   a. To disclose for each pharmaceutical claim the amount the MCO paid the PBM, and of that amount, the amount paid to the pharmacy, including identifying the dispensing fee and the ingredient cost (if applicable), in a format and frequency determined by the Department.
b. To base PBM reimbursement on the actual amount paid by the PBM to a pharmacy for dispensing and ingredient costs.

c. To manage or delegate to the PBM any drug pricing appeals from pharmacies and resolve all appeals within 21 days of receipt of the request to review.

d. To comply with the requirements in Ins. Art. 15-1611.1 and Ins. Art. 15-1628.3.

e. To require PBMs to consider both ingredient costs and dispensing fees when determining reimbursement to pharmacies.

f. To comply with the prohibition of spread pricing reimbursement in PBM contracting.

4. To comply with the Department’s opioid drug utilization review policies and its corrective managed care regulations set forth in COMAR 10.67.12 (Appendix O), including but not limited to providing provider education about prescribing limits, applying prior authorization requirements, and submitting reports to the Department upon request.

5. To require the PBM to comply with the following prohibitions, which do not preclude the reprocessing of claims due to claims adjudication errors made by the MCO, PBM, or an agent of either entity:

a. To prohibit the PBM from collecting direct or indirect remuneration fees, membership fees, or similar fees from pharmacies or other contracted entities acting on behalf of pharmacies as a condition of claims payment or network inclusion.

b. To prohibit the PBM from implementing retrospective remuneration models, including but not limited to Generic Effective Rates (GERs) and Brand Effective Rates (BERs).

6. To comply with the Department’s high-cost low volume drug policy (Appendix L-1) and Hepatitis C risk pool reimbursement method (Appendix L-2).

7. To conduct an annual audit to review the performance of the PBM in the following areas, at a minimum:
a. Claims processing

b. Payment methodology

c. Allowable adjustments

8. To require in the PBM contract the hiring of an independent third party to complete an annual Service Organization Controls report (SOC-2, type 2) audit over the PBM’s services and activities by the end of the Agreement term.

9. To submit summary reports of the annual audit findings of the audits required under (8) and (9), including any corrective actions that the MCO will mandate of their PBM, in the event issues have been identified by the audit.

10. To submit unredacted agreements between the MCOs and their PBMs to MDH.

11. To disclose to the Department the supplemental rebates allocation methodology between the PBM and the MCO.

12. To disclose to the Department all supplemental rebate revenue from the PBM on the HealthChoice Financial Monitoring Report.

13. To suspend waiver of pharmacy co-pays to comply with the Mental Health Parity and Addiction Equity Act, effective 90 days after the start of the Agreement term (April 1, 2022).

III. THE DEPARTMENT AGREES:

A. General Requirements

1. To pay the MCO in accordance with COMAR and Appendix C, which may be amended throughout the term of the Agreement.

2. To develop capitation rates that are:

   a. Actuarially sound so as to allow the MCO to effectively deliver covered services to Enrollees in a manner compliant with the requirements of this Agreement and 42 CFR 438.4 through 438.7, and 438.602(i); and
b. Based only upon services covered under the State Plan and additional services deemed by the State to be necessary to comply with the requirements of 42 CFR 438, subpart K of this part (applying parity standards from the Mental Health Parity and Addiction Equity Act).

3. To develop PHIP, COVID-19 Vaccine, Maternal and Child Health, and Rural Access incentive payments in accordance with the standards set forth in 42 CFR 438.6(b)(1).

4. [To develop stop-loss insurance in accordance with the standards set forth in 42 CFR 438.4 and 438.5.]

5. To produce and make available to the MCO on a monthly basis remittance advice and the following reports:
   a. MCO Capitation Detail Report;
   b. MCO Capitation Summary Report;
   c. MCO Capitation Report by Rate Group;
   d. MCO Capitated Enrollment Report;
   e. MCO Capitated Enrollment Summary;
   f. MCO Disenrollment Report by Site;
   g. MCO Capitated Disenrollment Summary;
   h. Zip Code Totals within MCO by Provider;
   i. MCO Eligibility and Enrollment Renewal Files; and
   j. Enrollee Bad Address File.

6. To include in the monthly enrollment listings sent to the MCO the adjustments provided by the MCO and accepted by the Department, and other appropriate debit and credit transactions.

7. To provide to the MCO at least 15 days’ notice of any policy changes.

8. To make the accreditation status for the MCO available on the Website as required under 42 CFR 438.10(c)(3), including whether the MCO has been accredited and, if applicable, the name of the accrediting
entity, accreditation program, and accreditation level; and update this information at least annually.

B. Monitoring Requirements

1. To review the ownership and control disclosures submitted by the MCO and those of any of the MCO’s subcontractors, upon request.

2. To collect (including through its agents and contractors) the following information from the MCO to improve the performance of the managed care program, including at a minimum:
   a. Enrollment and disenrollment trends in the MCO;
   b. Member grievance and appeal logs;
   c. Provider complaint and appeal logs;
   d. Findings from the State's External Quality Review process;
   e. Results from any Enrollee or provider satisfaction survey conducted by the State or MCO;
   f. Performance on required quality measures;
   g. Medical management committee reports and minutes;
   h. The annual quality improvement plan for the MCO;
   i. Audited financial and encounter data submitted by the MCO;
   j. The medical loss ratio summary reports required by 42 CFR 438.8; and
   k. Customer service performance data submitted by the MCO and performance data submitted by the beneficiary support system.

C. Prevalent Non-English Languages

1. To specify that, at the time of this Agreement, the prevalent non-English languages spoken by Enrollees and potential Enrollees in the State are as follows:
   a. Amharic
   b. Arabic
   c. Bassi
d. Chinese
e. Farsi
f. French
g. Gujarati
h. Haitian Creole
i. Igbo
j. Korean
k. Portuguese
l. Russian
m. Spanish
n. Tagalog
o. Urdu
p. Vietnamese
q. Yoruba

D. Imposition of Sanctions

1. To give the MCO timely written notice explaining the basis and nature of any sanctions imposed, in accordance with COMAR 10.67.10.01A (Appendix O). Sanctions may include, but are not limited to:

   a. Fines;
   b. Suspension of further enrollment;
   c. Withholding all or part of the capitation payment;
   d. Termination of the Agreement;
   e. Disqualification from future participation in the Maryland Medicaid Managed Care Program; and

2. To provide the MCO notice of appeal rights under COMAR 10.67.10.02 (Appendix O).

3. To permit the MCO the opportunity to take corrective action in accordance with a plan approved by the Department and with COMAR 10.67.10.01B (Appendix O).

IV. THE DEPARTMENT AND THE MCO MUTUALLY AGREE:
A. Contract Term and Grounds for Termination

1. That the term of this Agreement shall begin on January 1, 2022 and terminate on December 31, 2022.

2. That the MCO shall provide written notification to the Department of the MCO's intent to terminate this agreement for any future calendar year by October 1 of the prior year.

3. That the Department reserves the right to terminate this Agreement upon:

   a. Completion or termination of the Section 1115 Research and Demonstration Waiver and Federal funding thereunder;

   b. Notification by the Maryland Department of Budget and Management that State funds are not available for the continuation of the HealthChoice Program;

   c. Determination that the MCO or any agent or employee of the MCO, or any person with an ownership interest in the MCO, or a related party of the MCO, has failed to comply with any applicable law, regulation, or Agreement term, or for other good cause shown, pursuant to COMAR 10.67.10 (Appendix O); or

   d. Determination by the Department of insufficient MCO participation in the HealthChoice Program.

4. That if the Department terminates this Agreement for any reason, it shall not be liable for any costs of the MCO associated with the termination, including but not limited to, any expenditures made by the MCO prior to the termination or related to implementing the termination.

5. That termination of this Agreement shall not discharge the obligations of the MCO with respect to services or items furnished prior to termination, including payment for covered services delivered during the Agreement period, retention of records and restitution to the Department of overpayments.

6. That in the event of the termination of this Agreement either by the Department or by the MCO, the MCO will furnish to the Department all information relating to the reimbursement of any outstanding claims for services rendered to its Enrollees, including those of its...
subcontractors, within forty-five (45) days of the effective date of termination.

7. That prior to termination of this Agreement by the Department, the Department shall provide a pre-termination hearing in accordance with 42 CFR 438.710(b).

B. Payment

1. That there will be a two-sided risk corridor for CY 2022 centered around a 1.6% profit margin as described in Appendix C.

2. That there will be an acuity adjustment during the mid-year rate evaluation and update in CY 2022 as described in Appendix C.

3. That, with the exception of new Enrollees during the period of time between ten days after the Department’s enrollment agent has notified the MCO of a new enrollment and receipt by the MCO of the Department’s next regular monthly payment of capitation payment rates, the MCO is not required to pay for or provide services for any Enrollee for which it has not received a prepaid capitation rate from the Department.

4. That payments made under this Agreement will be denied for new Enrollees enrolled after imposition of such sanction as authorized by 42 CFR §438.702(a)(5):
   a. When the Department determines that the MCO has acted or failed to act as described in 42 CFR §438.700(b)-(d); and
   b. Until CMS or the Department is satisfied that the reason for imposition of the sanction no longer exists and is not likely to recur.

C. Miscellaneous

1. That the MCO and the Department shall enter into a data use agreement with University of Maryland, Baltimore County acting through its Hilltop Institute, to facilitate the secure transmission of data to the Department’s data warehouse.

2. That this Agreement may be modified only in writing by the parties.

3. That this Agreement shall not be transferable or assignable.
4. That any change in Federal or State law or regulation that affects any provision or term of this Agreement shall automatically become a provision or term of this Agreement.

5. That they shall carry out their mutual obligations as herein provided in a manner prescribed by law and in accordance with all applicable regulations and policies as may from time to time be promulgated by DHHS or any other appropriate Federal or State agency, including compliance with the Agreement provisions or conditions required in all procurement contracts and subcontracts as specified under 45 CFR Part 74.

6. That a notice required to be given to the other party under this Agreement, unless specified otherwise, is effective only if the notice is provided in writing and sent by first-class mail, courier or delivery service, or electronic transmittal of original documents with signatures, to the representative and address for that party listed below:
a. Notices to the Department shall be sent to:

Monchel Pridget
Deputy Director, Managed Care
Maryland Department of Health
201 W. Preston Street, Room 214A
Baltimore, MD 21201
monchel.pridget@maryland.gov

b. Notices to the MCO shall be sent to:

_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
IN WITNESS WHEREOF, the parties hereto have hereunder executed this Agreement the day and year first above written.

FOR THE DEPARTMENT:

___________________________________________
Date

_________________________
Signature

APPROVED AS TO FORM AND LEGAL SUFFICIENCY

_________________________
Assistant Attorney General

_________________________
Date

Steven R. Schuh
Deputy Secretary, Health Care Financing
Medicaid Director
Maryland Department of Health
BUSINESS ASSOCIATE AGREEMENT

This Business Associate Agreement (the “Agreement”) is made by and between the Office of Health Care Financing, a unit of the Maryland Department of Health (MDH) (herein referred to as “Covered Entity”) and (hereinafter known as “Business Associate”). Covered Entity and Business Associate shall collectively be known herein as the “Parties.”

WHEREAS, Covered Entity has a business relationship with Business Associate that is memorialized in a separate agreement (the “Underlying Agreement”) pursuant to which Business Associate may be considered a “business associate” of Covered Entity as defined in the Health Insurance Portability and Accountability Act of 1996 including all pertinent privacy regulations (45 C.F.R. Parts 160 and 164) and security regulations (45 C.F.R. Parts 160, 162, and 164), as amended from time to time, issued by the U.S. Department of Health and Human Services as either have been amended by Subtitle D of the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”), as Title XIII of Division A and Title IV of Division B of the American Recovery and Reinvestment Act of 2009 (Pub. L. 111–5), and the HIPAA Omnibus Final Rule of 2013 (collectively, “HIPAA”); and

WHEREAS, the nature of the contractual relationship between Covered Entity and Business Associate may involve the exchange of Protected Health Information (“PHI”) as that term is defined under HIPAA; and

WHEREAS, for good and lawful consideration as set forth in the Underlying Agreement, Covered Entity and Business Associate enter into this Agreement for the purpose of ensuring compliance with the requirements of HIPAA and the Maryland Confidentiality of Medical Records Act (Md. Ann. Code, Health-General §§4-301 et seq.) (“MCMRA”); and

WHEREAS, this Agreement supersedes and replaces any and all Business Associate Agreements the Covered Entity and Business Associate may have entered into prior to the date hereof;

NOW THEREFORE, the premises having been considered and with acknowledgment of the mutual promises and of other good and valuable consideration herein contained, the Parties, intending to be legally bound, hereby agree as follows:

I. DEFINITIONS

A. Catch-all definition. The following terms used in this Agreement, whether capitalized or not, shall have the same meaning as those terms in the HIPAA Rules: Breach, Data Aggregation, Designated Record Set, Disclosure, Health Care Operations, Individual, Minimum Necessary, Notice of Privacy Practices, Protected Health Information, Required by Law, Secretary, Security Incident, Subcontractor, Unsecured Protected Health Information, and Use.
Appendix A

B. **Specific definitions:**

1. **Business Associate.** “Business Associate” shall generally have the same meaning as the term “business associate” at 45 C.F.R. § 160.103, and in reference to the party to this Agreement, shall mean __________________________, the managed care organization (MCO).

2. **Covered Entity.** “Covered Entity” shall generally have the same meaning as the term “covered entity” at 45 C.F.R. § 160.103, and in reference to the party to this Agreement shall mean Office of Health Care Financing.


4. **Protected Health Information (“PHI”).** Protected Health Information or “PHI” shall generally have the same meaning as the term “protected health information” at 45 C.F.R. § 160.103.

II. **PERMITTED USES AND DISCLOSURES OF PHI BY BUSINESS ASSOCIATE**

V. A. Business Associate may only use or disclose PHI as necessary to perform the services set forth in the Underlying Agreement or as required by law.

VI. B. Business Associate agrees to make uses and disclosures and requests for PHI consistent with Covered Entity’s policies and procedures regarding minimum necessary use of PHI.

VII. C. Business Associate may not use or disclose PHI in a manner that would violate Subpart E of 45 C.F.R. Part 164 if done by Covered Entity.

VIII. D. Business Associate may, if directed to do so in writing by Covered Entity, create a limited data set as defined at 45 C.F.R. § 164.514(e)(2), for use in public health, research, or health care operations. Any such limited data sets shall omit any of the identifying information listed in 45 C.F.R. § 164.514(e)(2). Business Associate will enter into a valid, HIPAA-compliant Data Use Agreement as described in 45 C.F.R. § 164.514(e)(4), with the limited data set recipient. Business Associate will report any material breach or violation of the data use agreement to Covered Entity immediately after it becomes aware of any such material breach or violation.

E. Except as otherwise limited in this Agreement, Business Associate may disclose PHI for the proper management and administration or legal responsibilities of the Business Associate, provided that disclosures are Required By Law, or Business Associate obtains reasonable assurances from the person to whom the information is disclosed that it will remain confidential and used or further disclosed only as Required By law or for the purpose for which it was disclosed to the person, and
the person notifies the Business Associate of any instances of which it is aware in which the confidentiality of the information has been breached.

F. The Business Associate shall not directly or indirectly receive remuneration in exchange for any PHI of an individual pursuant to §§ 13405(d)(1) and (2) of the HITECH Act. This prohibition does not apply to the State’s payment of Business Associate for its performance pursuant to the Underlying Agreement.

G. The Business Associate shall comply with the limitations on marketing and fundraising communications provided in § 13406 of the HITECH Act in connection with any PHI of individuals.

III. DUTIES OF BUSINESS ASSOCIATE RELATIVE TO PHI

A. Business Associate agrees that it will not use or disclose PHI other than as permitted or required by the Agreement, the Underlying Agreement, the MCMRA, as Required by Law, or as authorized by Covered Entity, so long as the authorized use or disclosure is permitted by law.

B. Business Associate agrees to use appropriate administrative, technical and physical safeguards to protect the privacy of PHI.

C. Business Associate agrees to use appropriate safeguards, and comply with Subpart C of 45 C.F.R. Part 164 with respect to electronic PHI, to prevent use or disclosure of PHI other than as provided for by the Agreement;

D. 1. Business Associate agrees to report to Covered Entity any use or disclosure of PHI not provided for by the Agreement of which it becomes aware, including Breaches of unsecured PHI as required by 45 C.F.R. § 164.410, and any Security Incident of which it becomes aware without unreasonable delay and in no case later than fifteen (15) calendar days after the use or disclosure.

X. 2. If the use or disclosure amounts to a breach of unsecured PHI, the Business Associate shall ensure its report:

a. Is made to Covered Entity without unreasonable delay and in no case later than fifteen (15) calendar days after the incident constituting the Breach is first known, except where a law enforcement official determines that a notification would impede a criminal investigation or cause damage to national security. For purposes of clarity for this Section III.D.1, Business Associate must notify Covered Entity of an incident involving the acquisition, access, use or disclosure of PHI in a manner not permitted under 45 C.F.R. Part E within fifteen (15) calendar days after an incident even if Business Associate has not conclusively
determined within that time that the incident constitutes a Breach as defined by HIPAA;

**XI.** b. Includes the names of the Individuals whose Unsecured PHI has been, or is reasonably believed to have been, the subject of a Breach;

**XII.** c. Is in substantially the same form as Exhibit A hereto.

**XIII. E.** In addition to its obligations in Sections III. A-D, within 30 calendar days after the incident constituting the Breach is first known, Business Associate shall provide to Covered Entity a draft letter for the Covered Entity to review and approve for use in notifying the Individuals that their Unsecured PHI has been, or is reasonably believed to have been, the subject of a Breach that includes, to the extent possible:

**XIV.** 1. A brief description of what happened, including the date of the Breach and the date of the discovery of the Breach, if known;

**XV.** 2. A description of the types of Unsecured PHI that were involved in the Breach (such as full name, Social Security number, date of birth, home address, account number, disability code, or other types of information that were involved);

**XVI.** 3. Any steps the affected Individuals should take to protect themselves from potential harm resulting from the Breach;

**XVII.** 4. A brief description of what the Business Associate is doing to investigate the Breach, to mitigate losses, and to protect against any further Breaches; and

**XVIII.** 5. Contact procedures for the affected Individuals to ask questions or learn additional information, which shall include a toll-free telephone number, an e-mail address, website, or postal address.

**F.** In the event the Breach occurs through the fault of Business Associate, Business Associate shall be responsible for notifying Individuals by sending via First Class U.S. Mail the approved letter described in Section III(E) no later than 60 calendar days after discovery of the Breach.

**G.** In the event the Breach occurs through the fault of Covered Entity, Covered Entity shall be responsible for notifying Individuals no later than 60 calendar days after Covered Entity receives notice of the Breach from the Business Associate.

**H.** To the extent permitted by the Underlying Agreement, Business Associate may use agents and subcontractors. In accordance with 45 C.F.R. §§ 164.502(e)(1)(ii) and 164.308(b)(2) Business Associate shall ensure that any subcontractors that create, receive, maintain, or transmit PHI on behalf of the Business Associate agree to the same restrictions, conditions, and requirements that apply to the Business Associate with respect to such information, Business Associate must enter into Business Associate Agreements with subcontractors as required by HIPAA;
I. Business Associate agrees it will make available PHI in a designated record set to the Covered Entity, or, as directed by the Covered Entity, to an individual, as necessary to satisfy Covered Entity’s obligations under 45 C.F.R. § 164.524, including, if requested, a copy in electronic format;

J. Business Associate agrees it will make any amendment(s) to PHI in a designated record set as directed or agreed to by the Covered Entity pursuant to 45 C.F.R. § 164.526, or take other measures as necessary to satisfy Covered Entity’s obligations under 45 C.F.R. § 164.526;

K. Business Associate agrees to maintain and make available the information required to provide an accounting of disclosures to the Covered Entity or, as directed by the Covered Entity, to an individual, as necessary to satisfy Covered Entity’s obligations under 45 C.F.R. § 164.528;

L. To the extent the Business Associate is to carry out one or more of Covered Entity's obligation(s) under Subpart E of 45 C.F.R. Part 164, Business Associate will comply with the requirements of Subpart E that apply to the Covered Entity in the performance of such obligation(s);

M. Business Associate agrees to make its internal practices, books, and records, including PHI, available to the Covered Entity and/or the Secretary of HHS for purposes of determining compliance with the HIPAA Rules.

N. Business Associate agrees to mitigate, to the extent practicable, any harmful effect that is known to Business Associate of a use or disclosure of PHI by Business Associate in violation of the requirements of this Agreement.

IV. TERM AND TERMINATION

A. Term. The Term of this Agreement shall be effective as of the effective date of the HealthChoice Managed Care Organization Agreement, and shall terminate when all of the PHI provided by Covered Entity to Business Associate, or the PHI created or received by Business Associate on behalf of Covered Entity, is destroyed or returned to Covered Entity, in accordance with the termination provisions in this Section IV, or on the date the Covered Entity terminates for cause as authorized in paragraph (b) of this Section, whichever is sooner. If it is impossible to return or destroy all of the PHI provided by Covered Entity to Business Associate, or the PHI created or received by Business Associate on behalf of Covered Entity, Business Associate’s obligations under this contract shall be ongoing with respect to that information, unless and until a separate written agreement regarding that information is entered into with Covered Entity.

B. Termination for Cause. Upon Covered Entity's knowledge of a material breach of this Agreement by Business Associate, Covered Entity shall:
Appendix A

1. Provide an opportunity for Business Associate to cure the breach or end the violation and, if Business Associate does not cure the breach or end the violation within the time specified by Covered Entity, terminate this Agreement; or

2. Immediately terminate this Agreement if Business Associate has breached a material term of this Agreement and Covered Entity determines or reasonably believes that cure is not possible.

C. Effect of Termination.

1. Upon termination of this Agreement, for any reason, Business Associate shall return or, if agreed to by Covered Entity, destroy all PHI received from Covered Entity, or created, maintained, or received by Business Associate on behalf of Covered Entity, that the Business Associate still maintains in any form. Business Associate shall retain no copies of the PHI. This provision shall apply to PHI that is in the possession of subcontractors or agents of Business Associate.

2. Should Business Associate make an intentional or grossly negligent Breach of PHI in violation of this Agreement or HIPAA or an intentional or grossly negligent disclosure of information protected by the MCMRA, Covered Entity shall have the right to immediately terminate any contract, other than this Agreement, then in force between the Parties, including the Underlying Agreement.

D. Survival. The obligations of Business Associate under this Section shall survive the termination of this agreement.

V. CONSIDERATION

Business Associate recognizes that the promises it has made in this Agreement shall, henceforth, be detrimentally relied upon by Covered Entity in choosing to continue or commence a business relationship with Business Associate.

VI. REMEDIES IN EVENT OF BREACH OF AGREEMENT

Business Associate hereby recognizes that irreparable harm will result to Covered Entity, and to the business of Covered Entity, in the event of breach by Business Associate of any of the covenants and assurances contained in this Agreement. As such, in the event of breach of any of the covenants and assurances contained in Sections II or III above, Covered Entity shall be entitled to enjoin and restrain Business Associate from any
continued violation of Sections II or III. Furthermore, in the event of breach of Sections II or III by Business Associate, Covered Entity is entitled to reimbursement and indemnification from Business Associate for Covered Entity’s reasonable attorneys’ fees and expenses and costs that were reasonably incurred as a proximate result of Business Associate’s breach. The remedies contained in this Section VI shall be in addition to, not in lieu of, any action for damages and/or any other remedy Covered Entity may have for breach of any part of this Agreement or the Underlying Agreement or which may be available to Covered Entity at law or in equity.

VII. MODIFICATION; AMENDMENT

This Agreement may only be modified or amended through a writing signed by the Parties and, thus, no oral modification or amendment hereof shall be permitted. The Parties agree to take such action as is necessary to amend this Agreement from time to time as is necessary for Covered Entity to comply with the requirements of the HIPAA rules and any other applicable law.

VIII. INTERPRETATION OF THIS AGREEMENT IN RELATION TO OTHER AGREEMENTS BETWEEN THE PARTIES

Should there be any conflict between the language of this Agreement and any other contract entered into between the Parties (either previous or subsequent to the date of this Agreement), the language and provisions of this Agreement shall control and prevail unless the parties specifically refer in a subsequent written agreement to this Agreement by its title and date and specifically state that the provisions of the later written agreement shall control over this Agreement.

IX. COMPLIANCE WITH STATE LAW

The Business Associate acknowledges that by accepting the PHI from Covered Entity, it becomes a holder of medical information under the MCMRA and is subject to the provisions of that law. If the HIPAA Privacy or Security Rules and the MCMRA conflict regarding the degree of protection provided for PHI, Business Associate shall comply with the more restrictive protection requirement.

X. MISCELLANEOUS

A. Ambiguity. Any ambiguity in this Agreement shall be resolved to permit Covered Entity to comply with the Privacy and Security Rules.

B. Regulatory References. A reference in this Agreement to a section in the HIPAA Rules means the section as in effect or as amended.

C. Agency. The Business Associate or Subcontractor is acting as an independent contractor and not as the agent of the Covered Entity or Business Associate. This
Agreement does not give the Covered Entity or Business Associate such control over operational activities so as to make the Business Associate the agent of the Covered Entity, or the Subcontractor the agent of the Business Associate.

D. **No Private Cause of Action.** This Agreement is not intended to and does not create a private cause of action by any individual, other than the parties to this Agreement, as a result of any claim arising out of the Breach of this Agreement, the HIPAA Standards, or other state or federal law or regulation relating to privacy or confidentiality.

E. **Notice to Covered Entity.** Any notice required under this Agreement to be given to Covered Entity shall be made in writing to:

   **XIX.** Lauren E. Boyce  
   **XX.** Privacy Officer  
   **XXI.** Maryland Department of Health  
   Office of Internal Controls and Audit Compliance  
   **XXII.** 201 W. Preston Street, Floor 5  
   **XXIII.** Baltimore, MD 21201-2301  
   **XXIV.** Phone: (410) 767-5411  
   [lauren.boyce1@maryland.gov](mailto:lauren.boyce1@maryland.gov)

   **XXV.**

   F. **Notice to Business Associate.** Any notice required under this Agreement to be given Business Associate shall be made in writing to:

   **Address:** ____________________________________________________________

   ____________________________________________________________

   **Attention:** __________________________________________________________

   **Phone:** _____________________________________________________________

G. **Survival.** Any provision of this Agreement which contemplates performance or observance subsequent to any termination or expiration of this contract shall survive termination or expiration of this Agreement and continue in full force and effect.

H. **Severability.** If any term contained in this Agreement is held or finally determined to be invalid, illegal, or unenforceable in any respect, in whole or in part, such term shall be severed from this Agreement, and the remaining terms contained herein shall continue in full force and effect, and shall in no way be affected, prejudiced, or disturbed thereby.
I. **Terms.** All of the terms of this Agreement are contractual and not merely recitals and none may be amended or modified except by a writing executed by all parties hereto.

J. **Priority.** This Agreement supersedes and renders null and void any and all prior written or oral undertakings or agreements between the parties regarding the subject matter hereof.
XXVI. IN WITNESS WHEREOF and acknowledging acceptance and agreement of the foregoing, the Parties affix their signatures hereto.

<table>
<thead>
<tr>
<th>COVERED ENTITY:</th>
<th>BUSINESS ASSOCIATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>By:</td>
</tr>
<tr>
<td>Name: Steven R. Schuh</td>
<td>Name:</td>
</tr>
<tr>
<td>Title: Deputy Secretary of Health Care Financing and Medicaid Director</td>
<td>Title:</td>
</tr>
<tr>
<td>Date:</td>
<td>Date:</td>
</tr>
</tbody>
</table>
EXHIBIT A

FORM OF NOTIFICATION TO COVERED ENTITY OF BREACH OF UNSECURED PHI

This notification is made pursuant to Section III.2.D(3) of the Business Associate Agreement between the Office of Health Care Financing, a unit of the Maryland Department of Health (MDH), and (Business Associate).

Business Associate hereby notifies MDH that there has been a breach of unsecured (unencrypted) protected health information (PHI) that Business Associate has used or has had access to under the terms of the Business Associate Agreement.

Description of the breach: ____________________________________________________________

__________________________________________________________________________________

Date of the breach: __________________________

Date of discovery of the breach: __________________________

Does the breach involve 500 or more individuals? Yes/No

If yes, do the people live in multiple states? Yes/No

Number of individuals affected by the breach: _____________________________________________

Names of individuals affected by the breach: (attach list)

The types of unsecured PHI that were involved in the breach (such as full name, Social Security number, date of birth, home address, account number, or disability code):

____________________________________________________________________________________

Description of what Business Associate is doing to investigate the breach, to mitigate losses, and to protect against any further breaches:

____________________________________________________________________________________

____________________________________________________________________________________

____________________________________________________________________________________

Contact information to ask questions or learn additional information:

Name: ______________________________________________________________________________

Title: _______________________________________________________________________________

Address:_____________________________________________________________________________

Email Address:___________________________________________________________________

Rev. 09/2021

Page 49 of 97
Phone Number: ________________________________________________
AGREEMENT TO PAY FQHCs FOR OUT-OF-NETWORK EMERGENCY SERVICES

I. PAYMENT REQUIREMENTS

A. Effective October 1, 2010, an MCO shall reimburse an out-of-network federally qualified health center (FQHC) for services provided to an Enrollee that are immediately required due to an unforeseen illness, injury, or condition if:

1. The FQHC participates in the Medical Assistance Program;

2. The FQHC does not have a contract with the MCO;

3. The services are immediately required due to the Enrollee’s unforeseen illness, injury, or condition;

4. The emergent services are provided on site at the FQHC; and

5. The FQHC has, before rendering services, verified with the Enrollee’s primary care provider that the Enrollee cannot be seen within a reasonable amount of time based on the severity of the Enrollee’s condition.

B. An MCO may require that the FQHC provide documentation that the FQHC has obtained the verification required under A(5) of this agreement. An MCO is not required to reimburse an out-of-network FQHC for emergent services provided to an Enrollee if the FQHC fails to provide the documentation.

C. An MCO may require that the FQHC provide documentation that services were required for the reasons identified under A(3) of this agreement. An MCO is not required to reimburse an out-of-network FQHC for emergent services provided to an Enrollee if the FQHC fails to provide the documentation.

D. The rate at which the MCO shall reimburse an out-of-network FQHC for services provided under A of this agreement shall be the rate identified in COMAR 10.67.04.21.

E. For any reimbursement paid by an MCO under A of this agreement, the Program shall pay the MCO the difference between the rates identified in COMAR 10.67.04.21 and COMAR 10.09.08.05-1.

Initial Here: ____________________  Date: ____________________

Rev. 09/2021
MANAGED CARE ORGANIZATION REIMBURSEMENT

This agreement to establish new reimbursement rates is made this ______day of __________, 2021, between the Maryland Department of Health (Department) and ______________________, a Managed Care Organization (MCO).

I. MCO Reimbursement Rates

WHEREAS, the Centers for Medicare and Medicaid Services (CMS) 2020 Medicaid Managed Care Rate Development Guide requires that states include a Medicaid MCO’s rates into the HealthChoice Managed Care Organization Agreement, and amend the Agreement whenever the rates change in accordance with 42 CFR 438.7(c); and

WHEREAS, the Department has established new rates, as set forth in Appendix C, effective January 1, 2022.

1. MCO agrees to accept the reimbursement rates set forth in Appendix C, effective January 1, 2022.

2. The Department agrees to reimburse MCO at the rates set forth in Appendix C, effective January 1, 2022.

II. Coronavirus Disease of 2019 Risk Corridor Reimbursement Methodology

WHEREAS, in response to the Coronavirus Disease of 2019 (Covid-19) and its impact on the economy and the Maryland Medicaid Managed Care Program, the Department has established the following risk corridor reimbursement methodology in response to Covid-19, for calendar year 2022:

1. Structure of the Risk Corridor. The risk corridor will be based on aggregate program-wide experience, excluding Kaiser Permanente of the Mid-Atlantic States (KPMAS), as follows:

   a. A “Combined Ratio” shall be calculated by taking the “Total Expenses” of all the non-KPMAS MCOs and dividing it by the “Total Revenues” of all the non-KPMAS MCOs, where
      i. “Total Revenue” is capitation revenue less reinsurance premiums, and
      ii. “Total Expenses” include Medical expenses (less reinsurance recoveries and including incurred but not reported claims), Administrative Costs, Medical Management, Premium Tax, and Affordable Care Act (ACA) Fee expenses.
iii. [If applicable, a credibility adjustment will be applied to the MCO in accordance with CMS guidelines.]

b. Aggregate risk corridor means that the program-wide experience will be used (excluding KPMAS) to determine which corridor bands apply to MCO.

c. The risk corridor will assume a profit margin of one-point six percent (1.6%) such that the risk corridor’s optimum performance is a Combined Ratio of ninety-eight-point four percent (98.4%).

d. The risk corridors shall be calculated based on their variance from ninety-eight-point four percent (98.4%). For example, Corridor A (see table below) shall be ninety-eight-point four percent (98.4%), plus or minus one-point six percent (1.6%), for a range of ninety-six-point eight percent (96.8%) to one hundred percent (100%). The corridors and the allocations of profit and loss are as follows:

<table>
<thead>
<tr>
<th>Band Label</th>
<th>Risk Corridor Band</th>
<th>MCO Share</th>
<th>State/Federal Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corridor C+</td>
<td>Less than 95.29%</td>
<td>50%</td>
<td>50%</td>
</tr>
<tr>
<td>Corridor B+</td>
<td>95.30% - 96.79%</td>
<td>75%</td>
<td>25%</td>
</tr>
<tr>
<td>Corridor A</td>
<td>96.80% - 100.0%</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>Corridor B-</td>
<td>100.01% - 101.50%</td>
<td>75%</td>
<td>25%</td>
</tr>
<tr>
<td>Corridor C-</td>
<td>Greater than 101.51%</td>
<td>50%</td>
<td>50%</td>
</tr>
</tbody>
</table>

2. **Application of Risk Corridor to MCOs.** All MCOs shall be subject to the same risk corridors (“Band Labels” in the table above) based on the Combined Ratio. For example, if the Combined Ratio percentage is ninety-nine-point five percent (99.5%) (within Corridor A), no corridor adjustments are applied and MCOs retain their individual profits or losses. However, if the Combined Ratio were ninety-six percent (96%) (within Corridor B+), an individual MCO’s profits greater than three-point two percent (3.2%) will be allocated seventy-five percent (75%) to the MCO and twenty-five percent (25%) to State and Federal governments (per table above). The allocations of each MCO’s profits or losses, either to the MCO or to the State and Federal Government, shall depend on (1) the corridor into which the Combined Ratio falls, which determines the risk corridor bands that can apply to an MCO’s profits or losses, and (2) the risk corridor in which that portion of the MCO’s profit or loss percentage falls:
a. For Corridor A, the MCO shall be allocated one hundred percent (100%) of the first three-point two percent (3.2%) of profits.

b. For Corridor B+, profits after three-point two percent (3.2%) to four-point seven percent (4.7%) shall be allocated seventy-five percent (75%) to the MCO and twenty-five percent (25%) to the State and Federal Government. For Corridor B-, the initial one-point five percent (1.5%) of revenue losses shall be allocated seventy-five percent (75%) to the MCO and twenty-five percent (25%) to the State and Federal Government.

c. For Corridor C+, profits over four-point seven percent (4.7%) of revenue shall be allocated fifty percent (50%) to the MCO and fifty percent (50%) to the State and Federal Government. For Corridor C-, revenue losses exceeding one-point five percent (1.5%) shall be allocated fifty percent (50%) to the MCO and the fifty percent (50%) to the State and Federal Government.

3. The Department will make the eighty-five percent (85%) MLR calculation, pursuant to Section II.K of the 2022 HealthChoice Managed Care Organization Agreement, after performing the above aggregate risk corridor calculations. The eighty-five percent (85%) MLR will account for any profits or losses allocated as a result of application of the risk corridor reimbursement methodology.

4. MCO agrees to accept the risk corridor reimbursement methodology set forth in this Appendix C, effective January 1, 2022.

5. The Department agrees to reimburse the MCO in accordance with the risk corridor reimbursement methodology set forth in this Appendix C-1, effective January 1, 2022.

(Continues on next page.)
III. **Mid-Year Acuity Adjustment for Calendar Year 2022**

WHEREAS, in response to the Covid-19 and its impact on the economy and the Maryland Medicaid Managed Care Program, the Department has established the following mid-year acuity adjustment methodology for calendar year 2022:

1. The Department agrees to update the redetermination and enrollment scale for the mid-year acuity adjustment, which calculates the scaled factor of the adjustment, in accordance with the table below.

<table>
<thead>
<tr>
<th>Month</th>
<th>Redetermination</th>
<th>Enrollment Scale</th>
<th>Raw Factor</th>
<th>Scaled Factor</th>
<th>Raw Factor</th>
<th>Scaled Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022-01</td>
<td>18.6%</td>
<td>100.0%</td>
<td>-6.8%</td>
<td>-6.8%</td>
<td>-2.3%</td>
<td>-2.3%</td>
</tr>
<tr>
<td>2022-02</td>
<td>16.3%</td>
<td>81.4%</td>
<td>-6.8%</td>
<td>-5.5%</td>
<td>-2.3%</td>
<td>-1.8%</td>
</tr>
<tr>
<td>2022-03</td>
<td>15.5%</td>
<td>65.0%</td>
<td>-6.8%</td>
<td>-4.4%</td>
<td>-2.3%</td>
<td>-1.5%</td>
</tr>
<tr>
<td>2022-04</td>
<td>15.3%</td>
<td>49.6%</td>
<td>-6.8%</td>
<td>-3.4%</td>
<td>-2.3%</td>
<td>-1.1%</td>
</tr>
<tr>
<td>2022-05</td>
<td>16.9%</td>
<td>34.3%</td>
<td>-6.8%</td>
<td>-2.3%</td>
<td>-2.3%</td>
<td>-0.8%</td>
</tr>
<tr>
<td>2022-06</td>
<td>17.4%</td>
<td>17.4%</td>
<td>-6.8%</td>
<td>-1.2%</td>
<td>-2.3%</td>
<td>-0.4%</td>
</tr>
<tr>
<td>2022-07</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-6.8%</td>
<td>0.0%</td>
<td>-2.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>2022-08</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-6.8%</td>
<td>0.0%</td>
<td>-2.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>2022-09</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-6.8%</td>
<td>0.0%</td>
<td>-2.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>2022-10</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-6.8%</td>
<td>0.0%</td>
<td>-2.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>2022-11</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-6.8%</td>
<td>0.0%</td>
<td>-2.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>2022-12</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-6.8%</td>
<td>0.0%</td>
<td>-2.3%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

**Annual Impact**

-1.96%  -0.65%
2. MCO agrees to accept the mid-year acuity adjustment methodology set forth in this Appendix C, effective January 1, 2022.

3. The Department agrees to reimburse the MCO in accordance with the mid-year acuity adjustment methodology set forth in this Appendix C, effective January 1, 2022.
[INSERT RATE TABLE]
Appendix C

IN WITNESS WHEREOF, the parties hereto have hereunder executed this Appendix the
day and year first above written.

FOR THE DEPARTMENT:

_______________________

____________________________________

Date

Steven R. Schuh
Deputy Secretary, Health Care Financing
Medicaid Director
Maryland Department of Health

FOR THE MCO:

_______________________

____________________________________

Date

Signature
MEMORANDUM

To: HealthChoice Managed Care Organizations

From: Shannon McMahon
Deputy Secretary, Health Care Financing

Date: November 5, 2015

Re: MCO Performance Monitoring Updates

Thank you for your comments on the MCO Performance Monitoring Policies that were originally distributed in 2012. The final Performance Monitoring Policies will take effect in Calendar Year 2016. After consideration of your comments, the following changes were made:

- New Performance Monitoring elements. The Department has added the EPSDT/Healthy Kids Review to replace the PCP Satisfaction Survey and Required Reports Compliance elements from 2012.
- Removed the Consumer Report Card as a Performance Monitoring element.
- Added more detail around enforcement options.
- New Systems Performance Review cycle.
- Deemed 9 SPR elements and 13 SPR individual components.

The Department thanks the four MCOs that submitted comments on policy revisions.

The Performance Monitoring Policies will also be shared at the Quality Assurance Liaison Committee meeting on December 10, 2015.

cc: Jill Spector
    Rosemary Murphey
    Glendora Finch
HEALTHCHOICE MCO PERFORMANCE MONITORING POLICIES

The Department may choose any of the performance enforcement options described, depending on the severity and persistence of the issue. The Department is not required to use the enforcement tools sequentially as a form of “progressive discipline.” Rather, the Department may use its judgment and discretion, as the oversight agency with fiduciary responsibilities, to utilize the appropriate enforcement tool for the situation.

The Department reserves flexibility in the process and timing for rescinding penalties.

**Network Adequacy**
COMAR 10.67.05 sets forth network requirements for MCOs. The Department can act when MCOs are not in compliance with 10.67.05 and/or when a provider or recipient submits a complaint.

**HEDIS Measures**
The Department will send MCOs an annual HEDIS announcement letter containing the specific measures/elements for the coming year. Baseline measures will not be reviewed as part of performance monitoring. Low HEDIS scores could result in a consumer report card star rating change or a financial disincentive in the Value Based Purchasing (VBP) Initiative.

**EPSDT/Healthy Kids Review**
This is a new performance monitoring element. The minimum compliance score for each area is 80%. An assessment is performed for each MCO in each of the following EPSDT components: Health and Developmental History, Comprehensive Physical Examination, Laboratory Tests/At-Risk Screenings, Immunizations, and Health Education and Anticipatory Guidance.

**Systems Performance Review**
To relieve administrative burdens on MCOs, the Department is switching to administering full SPRs for each MCO on a three-year cycle, beginning in SPR Reporting Year 2016 (Review Year CY 2015). On an annual basis, in order to assess MCO CAP implementation, auditors will only review elements or components which received a “partially met” or “unmet.” MCOs failing to fully implement CAPs for multiple, consecutive years will receive full reviews on an annual basis until reaching 100% on all standards.
## Part 1. Enforcement Guidelines – Minor Problems

<table>
<thead>
<tr>
<th>Examples of Minor Problems</th>
<th>MCO Network Adequacy</th>
<th>HEDIS Performance</th>
<th>Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/Healthy Kids Review</th>
<th>Systems Performance Review (SPR)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Minor provider or recipient complaint.</td>
<td>One year with 30% or more elements with scores below the National Medicaid HEDIS Mean (NHM). Two consecutive years with 30% or more elements with scores below the NHM.</td>
<td>Receives less than 80% in one or more components for a review year.</td>
<td>Does not receive a “Met” in an element or component.</td>
</tr>
</tbody>
</table>
### Part 2. Enforcement Guidelines – Moderate Problems

<table>
<thead>
<tr>
<th>Examples of Moderate Problems</th>
<th>MCO Network Adequacy</th>
<th>HEDIS Performance</th>
<th>EPSDT/Healthy Kids Review</th>
<th>SPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent minor provider or recipient complaints PCP to recipient ratio appears inadequate but recipients are still able to access a PCP.</td>
<td>Three years in a row or three years within a five-year period with 30% or more elements with scores below the NHM.</td>
<td>Receives less than 80% in one or more components for two review years -- this score could be for the same component or different components.</td>
<td>Receives an “Unmet” score two years in a row on the same element (without components) or an “unmet” or “partially met” score on the same component.</td>
<td></td>
</tr>
</tbody>
</table>

| Enforcement | Written CAP within 30 days of finding. Geo-Access Report. Financial sanctions. Required to pay for out-of-network care and transportation. | Letter to MCO advising of monitoring policy, measures below the NHM, and enforcement options. Freeze auto assignments in areas of the state as determined by the Department. | Written CAP within 45 days of presentation of preliminary report. Focused provider education project of specific component for two calendar years. | Second Partially Met score on component will be changed to an Unmet score. Written CAP within 45 days of presentation of preliminary report. Focused EQRO audit of specific elements or components on an annual basis. Monitoring of CAP by EQRO on quarterly basis, with failure to implement linked to freezing auto-assignments, freezing voluntary assignments, or financial sanctions. |

Rev. 09/2021

Page 62 of 97
## Part 3. Enforcement Guidelines – Major Problems

<table>
<thead>
<tr>
<th>Examples of Major Problems</th>
<th>MCO Network Adequacy</th>
<th>HEDIS Performance</th>
<th>EPSDT/Healthy Kids Review</th>
<th>SPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent PCP to recipient ratio appears inadequate (greater than 1:500) but recipients are still able to access a PCP. No access to OB/GYN and/or no choice of PCP.</td>
<td>Four years in a row or four years within a five-year period with 30% or more elements with scores below the NHM. Four years in a row or four years within a five-year period with any of the HEDIS VBP measures with scores below the NHM.</td>
<td>Receives less than 80% in one or more components for three consecutive years, or for three years within a five-year period – this score could be for the same component or different components.</td>
<td>Receives an “Unmet” score three or more years in a row on the same element (without components) or an “unmet” or “partially met” score on the same component.</td>
<td></td>
</tr>
<tr>
<td>CAP within 10 days of finding. Geo Access Report. Financial Sanction. Required to pay for out-of-network care and transportation. Allow recipients in problem service area(s) to voluntarily disenroll from MCO immediately.</td>
<td>Letter to MCO advising of monitoring policy, measures below the NHM, and enforcement options. Freeze auto assignments in areas of the state as determined by</td>
<td>Written CAP within 45 days of presentation of preliminary report. Monitoring of CAP by EQRO on quarterly basis, with failure to implement linked to freezing auto-assignments or financial sanctions. Focused provider education project of</td>
<td>Second Partially Met score on component will be changed to an Unmet score. Written CAP within 45 days of presentation of preliminary report. Focused EQRO audit of specific elements or components on an</td>
<td></td>
</tr>
<tr>
<td>Freeze auto assignments in problem service area(s).</td>
<td>Freeze voluntary enrollment in problem service area(s).</td>
<td>Freeze the MCO to all future enrollment in problem service area(s) (moving current recipients into another MCO of their choice). Additional financial sanctions beyond paying for out-of-network care and transportation. Contract termination/MCO closure in all affected counties.</td>
<td>the Department. Freeze voluntary enrollment in areas of the state as determined by the Department. Financial sanctions other than enrollment freeze. Contract termination and MCO closure in all counties.</td>
<td>specific component for three calendar years. Freeze auto assignments in areas of the state determined by the Department.</td>
</tr>
</tbody>
</table>
MANAGED CARE ORGANIZATION SERVICE AREA PARTICIPATION, OPTIONAL SERVICES AND BENEFITS, AND IN-LIEU-OF SERVICES AND SETTINGS

This agreement to designate Service Area Participation, Optional Services or Benefits, and In-Lieu-Of Services or Settings is made this ______ day of ____________, 2021, between the Maryland Department of Health (Department) and _____________________, a Managed Care Organization (MCO).

A. Definitions.

All terms capitalized herein shall have the same meaning as those in the HealthChoice Managed Care Organization agreement, except that the following terms shall have the meanings stated:

1. “Participation” means the arrangement under which the MCO arranges for and/or provides services to Enrollees in approved Service Areas, subject to applicable provisions of federal law, the Maryland Code, COMAR, transmittals, and guidelines issued by the Department in effect at any time during the term of this Agreement. “Participation” includes the MCO’s enrollment of Medicaid recipients who have selected the MCO and those auto-assigned by the Department.

2. “Service Areas” means the 23 counties and Baltimore City that comprise the State of Maryland.

3. “Open” means any Service Area that the MCO has participated in during the previous calendar year.

4. “Closed” means any Service Area in which the MCO has never participated.

5. “Involuntarily Frozen” means any Service Area in which the Department freezes the auto-assignment of enrollees in a Service Area, for reasons including, but not limited to, insufficient provider networks and imposition of sanctions.

6. “Voluntarily Frozen” means any Service Area in which the MCO requests freezing the auto-assignment of enrollees. Being “Voluntarily Frozen” remains in effect for two calendar years.

7. “Request to Open” means a request by the MCO to Open any Service Area that was previously Closed, Voluntarily Frozen, or Involuntarily Frozen, pending review and approval by the Department.
8. “In-Lieu-Of Service or Setting” means a medically appropriate, cost-effective substitute for a covered service or setting under the State Plan. An Enrollee is not required to use the alternative service or setting.

9. “Optional Service or Benefit” means any service that the MCO voluntarily agrees to provide whose cost is not included in the capitation rates determined in Appendix C or future iterations of this Agreement.

B. The MCO agrees:

1. To express its intent to Open, Request to Open, or request to be Voluntarily Frozen in a Service Area during the term of this Agreement, effective January 1, 2022, as identified in this Appendix in accordance with 42 CFR 438.207;

2. That a Request to Open and a request to be Voluntarily Frozen are subject to review and approval by the Department before they become effective;

3. That the Department’s approval of a request to be Voluntarily Frozen in a Service Area does not stay any obligation under this Agreement to accept and serve Enrollees who select the MCO;

4. To provide the Optional Services or Benefits and In-Lieu-Of Services and Setting during the term of this Agreement, effective January 1, 2022, as identified in this Appendix in accordance with 42 CFR 438.3(e);

C. The Department and the MCO agree:

1. That the costs of any Optional Services or Benefits shall not be included when determining the capitation rates identified in Appendix C of this Agreement or future capitation rate calculations;

2. That the utilization and actual cost of In-Lieu-Of Services or Settings shall be taken into account in developing the component of future capitation rates that represents the covered State Plan services, unless a statute of regulation explicitly requires otherwise; and

3. That the provision of services identified in this Appendix is subject to approval of this Agreement by the Centers for Medicare and Medicaid Services.
### MCO SERVICE AREA PARTICIPATION

<table>
<thead>
<tr>
<th>Service Area</th>
<th>Current Participation Status</th>
<th>No Change</th>
<th>Request to Open</th>
<th>Voluntary Enrollment Freeze</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allegany</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne Arundel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baltimore City</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baltimore County</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calvert</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caroline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carroll</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cecil</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorchester</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frederick</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garrett</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harford</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Howard</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montgomery</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prince George's</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Queen Anne's</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>St. Mary's</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somerset</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Talbot</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Washington</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wicomico</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Worcester</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### OPTIONAL BENEFITS OFFERED BY THE MCO

|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
|                                |                               |                               |                               |                               |
IN-LIEU-OF SERVICES PROVIDED BY THE MCO

The Department has determined the following alternative services or settings are medically appropriate and cost-effective substitutes for the covered services or settings identified in the State Plan:

<table>
<thead>
<tr>
<th>Service/Setting 1</th>
<th>Service/Setting 2</th>
<th>Service/Setting 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IN WITNESS WHEREOF, the parties hereto have hereunder executed this Appendix the day and year first above written.

FOR THE DEPARTMENT:

Date

Steven R. Schuh
Deputy Secretary, Health Care Financing
Medicaid Director
Maryland Department of Health

FOR THE MCO:

Date

Signature
NETWORK ADEQUACY STANDARDS

To comply with the requirements of 42 CFR 438.68, MDH is responsible for developing minimum time and distance standards for HealthChoice MCO provider networks. MDH developed these standards by adapting the Health Service Delivery (HSD) standards for Maryland Medicare Advantage plans and the current HealthChoice regional and distance network standards. For each provider type, MCOs must meet either the time or distance standard for each county in the MCO’s service area.

<table>
<thead>
<tr>
<th>Provider Type</th>
<th>Urban¹</th>
<th>Suburban²</th>
<th>Rural³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Max Time (min)</td>
<td>Max Distance (miles)</td>
<td>Max Time (min)</td>
</tr>
<tr>
<td>Primary Care</td>
<td>15</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Primary Care - Pediatric</td>
<td>15</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>15</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Diagnostic Laboratory/X-Ray</td>
<td>15</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Gynecology</td>
<td>15</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Prenatal Care⁴</td>
<td>15</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Acute Inpatient Hospitals</td>
<td>20</td>
<td>10</td>
<td>45</td>
</tr>
<tr>
<td>Core Specialties (Cardiology, ENT, Gastroenterology, Neurology, Ophthalmology, Orthopedics, Surgery, Urology)</td>
<td>30</td>
<td>15</td>
<td>60</td>
</tr>
<tr>
<td>Major Specialties (Allergy and Immunology, Dermatology, Endocrinology, Infectious Diseases, Nephrology, Pulmonology)</td>
<td>30</td>
<td>15</td>
<td>80</td>
</tr>
<tr>
<td>Pediatric Sub-Specialties (Cardiology, Gastroenterology, Neurology, Surgery)</td>
<td>30</td>
<td>15</td>
<td>80</td>
</tr>
</tbody>
</table>

ADDITIONAL NETWORK REQUIREMENTS

¹ Urban Counties: Baltimore City
² Suburban Counties: Anne Arundel, Baltimore, Carroll, Harford, Howard, Montgomery, Prince George’s
³ Rural Counties: Allegany, Calvert, Caroline, Cecil, Charles, Dorchester, Frederick, Garrett, Kent, Queen Anne’s, St. Mary’s, Somerset, Talbot, Washington, Wicomico, Worcester
⁴ Prenatal Care providers include obstetricians and certified nurse midwives. Family practitioners who provide prenatal care and deliveries may be considered in areas where there is a shortage of obstetricians.

Rev. 09/2021
HealthChoice MCOs must meet all network requirements set forth in COMAR 10.67.05, including:

1. Offering an appropriate range of preventive, primary care, and specialty services adequate for the anticipated number of Enrollees in the MCO’s service areas.
2. Maintaining a network of providers sufficient in number, mix, and geographic distribution to meet the needs of the number of Enrollees in the MCO’s service areas.
3. Ensuring that in-plan individual practitioners, based on full-time equivalency, are assigned no more than the number of enrollees that is consistent with a 200:1 ratio of enrollee to practitioner in the local access area.
4. Maintaining written policies and procedures for selecting and retaining network providers in accordance with the requirements of 42 CFR 438.214 and the applicable provider panel provisions of Maryland Insurance Article § 15-112, Code Ann.
5. Ensuring that all network providers are screened, enrolled, and revalidated by the State as Medicaid providers, in accordance with 42 CFR part 455, subparts B and E, and validate enrollment by verifying against the Department’s full fee-for-service provider file.
6. Accepting the Maryland Uniform Credentialing Form for the credentialing of network providers.
7. Refraining from discriminating against providers serving high-risk populations or specializing in conditions requiring costly treatment.
8. Informing all providers at the time of entering into a contract with the MCO about the grievance and appeal system, as set forth in 42 CFR 438.414 and 42 CFR 438.10(g)(2)(xi).
9. Monitoring the Department’s correspondence and any database publicizing Department-initiated terminations of providers from the Program.
10. Terminating the contract of, or refraining from contracting with, providers terminated or excluded from participating in the Program.
11. Developing and distribute a provider manual that includes all of the information provided in the Department’s template and required in COMAR 10.67.05.04A(2).
12. Ensuring services are delivered in a culturally competent manner to all enrollees, including enrollees with limited English proficiency; enrollees with diverse cultural and ethnic backgrounds; and enrollees of all genders, sexual orientations, and gender identities.
13. Ensuring its provider network can provide physical access, reasonable accommodation, and accessible equipment for Enrollees with physical or mental disabilities.
14. Providing necessary services covered under the contract out of network adequately and timely for a particular Enrollee, for as long as the MCO’s provider network is unable to provide them.

MONITORING AND ENFORCEMENT

HealthChoice MCOs will be required to give assurances to MDH annually, along with supporting documentation, demonstrating their provider network’s capacity to serve enrollees in a format specified by MDH. When an MCO cannot demonstrate adequate coverage for 90% of enrollees in a
service area at the required time or distance, MDH may freeze auto-assignments in the impacted service area.

When an MCO proposes expansion into a new county, MDH will evaluate its provider network according to the time and distance standards in that service area. If the MCO can demonstrate adequate coverage for 90% of enrollees at the required time or distance standards in the county for each provider type, MDH will allow the MCO to open in that county.

If an MCO can otherwise demonstrate to the Department's satisfaction the adequacy of its provider network notwithstanding its inability to meet these requirements, the Department may, in its discretion, approve the network if special circumstances exist which, considered along with the overall strength of the MCO's network, establish that the Department's approval of the network will enhance recipients' overall access to quality health care services in the area to be served.
CMS Medical Loss Ratio (MLR) Standards
CY 2021

MCO Name: MCO Provider Number(s):

INTENTIONAL MISREPRESENTATION OR FALSIFICATION OF ANY INFORMATION CONTAINED IN THIS REPORT MAY BE PUNISHABLE BY FINE AND/OR IMPRISONMENT UNDER FEDERAL LAW

CERTIFICATION BY CHIEF FINANCIAL OFFICER OR ADMINISTRATOR OF MCO

I HEREBY CERTIFY that I have read the above statement and that I have examined the accompanying information prepared by ____________________________ (MCO name) for the CMS MLR reporting period beginning ____________ and ending ____________, and that to the best of my knowledge and belief, it is a true, correct and complete statement prepared from the books and records of the MCO in accordance with 42 CFR §438.8, except as noted.

________________________________________________________________________
(Signed)
Chief Financial Officer or Administrator of MCO(s)

________________________________________
Title

________________________________________
Date

Name and Telephone Number of Person to Contact for More Information
Instructions for completion of Medical Loss Ratio (MLR) Reporting Template

42 CFR §438.8 - *Medical Loss Ratio (MLR) standards*

States must require that MCOs calculate and report an MLR for the rating period that begins in 2020

**Worksheet 2 (Reporting Template)**

- **Line 1:** MCO Reporting: Name of MCO
- **Line 2:** Incurred Period: Period (calendar year) services were incurred
- **Line 3:** Report date: As of June 30th following the incurred period
- **Line 4:** Contact Name: MCO contact name
- **Line 5:** Phone Number of MCO contact
- **Line 6:** e-mail address of MCO contact
- **Line 7:** Due date of submission to MDH: September 30th following the incurred period
- **Line 8:** MLR Calculation - Please complete lines i. through vi. And line xi (lines viii. - x. are calculated cells)

**Worksheet 3 (Credibility Table) - Table developed by CMS Office of the Actuary**

The calculation illustrated in cell C17 is for annual member months between 48,000 or 96,000. Please modify cell C17 to reflect the range of your annual member months.

MCOs with annual member months greater than 380,000 would have a credibility adjustment of zero.

**Attestation MLR form** - In addition to submission of this Excel file, please complete the Word version of the attached attestation document.

In addition to completing this file and separate attestation document, please provide the following:

1. Include a separate audited financial underwriting exhibit reflecting HealthChoice only experience for the current reporting year.

2. Provide documentation (as needed) supporting the methodology used to allocate expenses under multiple expense categories as stated on the reporting template in worksheet 2.
MARYLAND HEALTHCHOICE ONLY PRODUCT LINE

1. MCO Reporting: MCO A

2. Incurred Period: January 1, 2021 - December 31, 2021

3. Reported as of: June 30, 2022

4. Contact Person: Jane Doe

5. Phone Number: xxx-xxx-xxxx

6. E-mail Address: abc@def.com

7. Report due to MDH: November 15, 2022

8. MLR Calculation:

   (Aggregate for all Medicaid Eligibility Groups)

   (Sample Calculation)

   (Notes) Reporting Components:

   (i.a) Total incurred claims. $ 47,400,000
<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i.b) PBM Spread (admin &amp; profit) reported in i.a.</td>
<td>$-</td>
</tr>
<tr>
<td>(i.c.) Total net incurred claims (i.a – i.b)</td>
<td>$47,400,000</td>
</tr>
<tr>
<td>42 CFR §438.8(e)(3) (Program Integrity Requirements)</td>
<td></td>
</tr>
<tr>
<td>(ii) Expenditures on quality improving activities.</td>
<td>$900,000</td>
</tr>
<tr>
<td>(iii) Expenditures related to activities compliant with 42 CFR §438.608(a)(1) through (5), (7), (8) and (b).</td>
<td>$150,000</td>
</tr>
<tr>
<td>(iv) Non-claims costs.</td>
<td>$6,450,000</td>
</tr>
<tr>
<td>(v) Premium revenue.</td>
<td>$60,000,000</td>
</tr>
<tr>
<td>Split between Prem &amp; Inc. Tax</td>
<td></td>
</tr>
<tr>
<td>(vi) Taxes, licensing and regulatory fees.</td>
<td>$1,840,000</td>
</tr>
<tr>
<td>(vii) Methodology(ies) for allocation of expenditures.</td>
<td>See instructions worksheet</td>
</tr>
<tr>
<td>(ix) Any credibility adjustment applied.</td>
<td>2.40%</td>
</tr>
<tr>
<td>(x) The calculated MLR (after credibility adjustment)</td>
<td>85.4%</td>
</tr>
</tbody>
</table>
(xi) Any remittance owed to the State, if applicable. $- \\

(xii) Member Months 75,000
Credibility Table for Medicaid and CHP Managed Care Plans effective for services incurred January 1, 2017*

<table>
<thead>
<tr>
<th>Reporting Year Member Months</th>
<th>Credibility Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 5,400</td>
<td>Non-credible</td>
</tr>
<tr>
<td>5,400</td>
<td>8.40%</td>
</tr>
<tr>
<td>12,000</td>
<td>5.70%</td>
</tr>
<tr>
<td>24,000</td>
<td>4.00%</td>
</tr>
<tr>
<td>48,000</td>
<td>2.90%</td>
</tr>
<tr>
<td>96,000</td>
<td>2.00%</td>
</tr>
<tr>
<td>192,000</td>
<td>1.50%</td>
</tr>
<tr>
<td>380,000</td>
<td>1.00%</td>
</tr>
<tr>
<td>&gt;380,000</td>
<td>Fully Credible</td>
</tr>
</tbody>
</table>

*Adjustment applied rounded to the nearest tenth using linear interpolation.
Same table (developed by CMS Office of the Actuary) as provided in last year’s template

<table>
<thead>
<tr>
<th>Member Months</th>
<th>Calculated Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>75,000</td>
<td>2.40%</td>
</tr>
</tbody>
</table>

(Note: as needed, please adjust formula to reflect your actual member months)
MATERNAL OPIOID MISUSE (MOM) MODEL AGREEMENT

This agreement to participate in the Center for Medicare and Medicaid Innovation-funded (CMMI) Maternal Opioid Misuse Grant (MOM Grant), contingent upon continued funding by CMMI, is made this ______ day of ____________, 2021, between the Maryland Department of Health (Department) and ____________________, a Managed Care Organization (MCO).

The Department and the MCO agree as follows:

A. In the Transition Period (January 2022 – June 2022) and Implementation Period (July 2022 – December 2022) of Model Year 3 of the MOM model, the Department agrees to:

1. Comply with all requirements of the MOM model as outlined by CMMI, including the obligations included in the MOM model funding.
2. Contract with the MCO, including continued execution of the Data Use Agreement (DUA) annually. Ensure provision of usable data needed to operate and evaluate the MOM Model when amending the DUA.
3. Coordinate with the MCO in support of information-sharing, to the extent permitted by law and under the DUA.
4. Establish separate DUA with the Hilltop Institute at UMBC (UMBC) and CRISP to facilitate the sharing of claims and encounters data as well as other data needed for MCOs, as defined in Section B of this Amendment, to fulfill quarterly reporting requirements laid out by CMMI.
5. Facilitate technical assistance to support MCO data submission, per Section B.
6. Provide per member, per month reimbursement to MCOs for provision of MOM model services in accordance with Section A(6), to provide the following services, at a minimum, on a monthly basis to MOM model participants:
   i. Ensure MOM model participants access at least one physical or behavioral health care services billable to Medicaid, including:
      1. Physical health care: Maternity care and relevant primary care services, including medication for opioid use disorder (MOUD); and
2. Behavioral health care: Mental health and other appropriate substance use disorder services beyond MOUD.
   ii. Coordinate care, engage participants and provide referrals for community and other support services to complement the current set of Medicaid-covered services to meet MOM model participants’ comprehensive needs, including screening and referral for health-related social needs, measurement of patient activation and to satisfy at least one of the following model components per month:
      1. Comprehensive care management;
      2. Care coordination;
      3. Health promotion;
      4. Individual and family support; and
      5. Referral to community/support services.

c. Receive the per member, per month reimbursement of $207 in accordance with Section A(6), to conduct substantive outreach for MOM model participants who are disengaged from care (i.e., who have not received a physical or behavioral health care service during a given calendar month for up to two consecutive months per MOM model participant).

d. Support the collection of required data to CMMI for purposes of preparing quarterly monitoring reporting in accordance with award, including:
   i. Data as outlined in the MOM Model Data Dictionary including:
      1. Health care utilization data, to be generated by UMBC and securely provided to MCOs;
      2. MOM model intervention activities, MOM-required screenings and other required data; and
   ii. Patient Activation Measure data, to be collected via the Insignia Flourish® tool.

e. Receive from other data sources such as designated case managers, CRISP and UMBC.

f. Enter all collected data into the CMMI-designed WinForm tool and format data files in accordance with technical specifications laid out by CMMI.

g. Submit required data to CMMI in accordance with award, including:
   i. Data as outlined in the MOM Model Data Dictionary through the CMS-designed Gateway portal; and
   ii. Patient Activation Measure data through the Insignia Flourish® tool.

C. Corrective Action and Termination

1. **General.** The MCO shall comply with the MOM model responsibilities as set forth in this contractual agreement.

2. **Notification of Issues.** The MCO shall notify the Department’s MOM model Authorized Official Representative (AOR) and Project Director within 10 business days of any significant problems or risks related to the administrative, financial, or programmatic aspects of the award during the performance period of this contractual agreement.
Significant problems or risks include any event, issue, or circumstance that could prevent the MCO from timely achieving any of the responsibilities identified in this contractual agreement or otherwise negatively impact the ability of MCO to implement the MOM model.

MOM Model AOR: Tricia Roddy  
Phone: 410-767-5609  
Email: tricia.roddy@maryland.gov

MOM Model Project Director: Laura Goodman  
Phone: 410-767-5683  
Email: laura.goodman@maryland.gov

3. **Modifications to the Agreement.** Modifications to this Agreement must be made only in writing and will be signed by the authorized representative of each party.

4. **Corrective Action.** The Department may in its sole discretion elect to permit the MCO to take appropriate corrective action to remedy an issue that has placed the MCO at risk of non-compliance with this contract or if the Department determines that the MCO is out of compliance with the contractual requirements. Corrective action is not available to address an action or deficiency that endangers public welfare.

5. **Termination for Cause.** If the MCO fails to fulfill its obligations under this Agreement properly and on time, or otherwise violates any provision of the Agreement, the Department may terminate the Agreement by written notice to the MCO. The notice shall specify the acts or omissions relied upon as cause for termination. The Department shall pay the MCO fair and equitable compensation for satisfactory performance prior to receipt of notice of termination for cause, less the amount of damages caused by the Department’s breach. If the damages are more than the compensation payable to the Department, the Department will remain liable after termination and the Department can affirmatively collect damages. This provision may be subject to the limitations set forth by law in the Maryland Tort Claims Act, Maryland Code, State Government Article, Title 12, and Maryland Code, State Government Article, Title 12, Subtitle 2.

D. The terms and conditions of this Appendix are contingent upon the availability of MOM model funding. If available funding is reduced, this Agreement may be reduced in scope so that available funding is not exceeded, or terminated under Section C.

E. Any delays or extensions to the MOM model by CMMI may result in an amendment to this Appendix.
IN WITNESS WHEREOF, the parties hereto have hereunder executed this Appendix the day and year first above written.

FOR THE DEPARTMENT:

_______________________
Date

Steven R. Schuh
Deputy Secretary, Health Care Financing
Medicaid Director
Maryland Department of Health

FOR THE MCO:

_________________________
Date

Signature

MCO Legal Name:____________________
MCO DBA: _________________________
MCO Tax Identification Number:________
MCO National Provider Identification Number:________________
MCO Address:_______________________

_________________________
HEALTHCHOICE FINANCIAL SANCTION POLICY

This policy outlines financial sanctions that the Maryland Department of Health (MDH) may levy on Managed Care Organizations (MCOs). It does not address other sanctions available under COMAR 10.67.10 which may be used in addition to or instead of the financial sanctions described in this policy.

MDH may impose any of the financial sanctions described, depending on the severity and persistence of the issue. MDH is not required to use the sanctions sequentially as a form of “progressive discipline.” Rather, MDH may use its judgment and discretion, as the oversight agency with fiduciary responsibilities, to utilize the appropriate sanction for the situation. MDH reserves flexibility in the process and timing for rescinding sanctions.

DEFINITIONS

Corrective Action Plan: A written, detailed plan to address non-conformity with a law, regulation, contract term, policy, or deadline.

Deficiency: A failure to comply with any applicable law, regulation, contract term, policy, or deadline established by MDH or its designees. Each failure to comply is a separate deficiency.

FINANCIAL SANCTION GUIDELINES

1. MDH may impose any of the financial sanctions described below.

2. MDH shall notify an MCO of a deficiency in writing to explain the basis and nature of the deficiency, as well as any sanctions MDH will impose.

3. For any deficiency, MDH may impose a sanction of up to $1,000,000 multiplied by the MCO’s market share percentage at the beginning of the term of the Agreement in effect.

   a. The notice may include an opportunity for the MCO to submit a plan to take corrective action. The corrective action plan (CAP) will be subject to the review and approval of MDH.

   b. Should the MCO submit and implement a CAP and it fails to remedy the identified deficiencies, MDH may impose the following financial sanctions, in addition to any sanctions initially imposed for the deficiency:

      i. One failure to implement: up to $100,000 multiplied by the MCO’s market share percentage;
ii. Two failures to implement: up to $500,000 multiplied by the MCO’s market share percentage; and

iii. Three or more failures to implement: up to $1,000,000 multiplied by the MCO’s market share percentage.

Example: At the start of CY 2022, MCO A has a 20% market share of the HealthChoice program. MCO A is deficient in the first quarter because it has not complied with the MDH’s timing requirements for enrollee appeals. MDH issues notice of the deficiency, imposes a financial sanction of $25,000 times the market share percentage (resulting in a $5,000 fine), and requires MCO A to submit a CAP that is reviewed quarterly. MCO A then fails to implement the CAP, and the Department issues another sanction of up to $20,000. MCO A’s second failure to implement the CAP results in a sanction up to $100,000, and three or more failures to implement the CAP results in a sanction up to $200,000.

4. If the deficiency involves a failure to submit a report or CAP, submission of an inaccurate or incomplete report or CAP, or a failure to provide other information requested by MDH or its designee, MDH may impose a sanction of $250 for each calendar day the information has not been submitted or is late, inaccurate or incomplete.

   a. An MCO may request an extension and guidance up to 24 hours prior to the deadline for submission, which MDH may approve or deny.

   b. The sanction will be applied at 5:00 PM on each day the information is not submitted, inaccurate, or incomplete.

   c. MDH may double the total sanction assessed for each 14-day period that the information has not been submitted or is late, inaccurate, or incomplete.

5. Any financial sanctions described in this policy or implemented under this policy shall not preclude or otherwise impact MDH’s pursuit and recovery of actual damages incurred by MDH resulting from the MCO’s deficiencies related to its duties and obligations as an MCO in the HealthChoice program.

6. Financial sanctions will be deducted from the MCO’s capitation payment and deposited in the HealthChoice Performance Incentive Fund, in compliance with Health-General Art. § 15-103.3.

7. This policy shall apply, at MDH’s discretion, to noncompliance regardless of the timing of the noncompliant activity.
MARYLAND QUALITY INCENTIVE PROGRAM (M-QIP) REQUIREMENTS

Contingent on CMS approval, the M-QIP Program will be implemented to improve quality outcomes, reduce ED utilization for Ambulatory Sensitive Conditions, and increase access to specialty care. The program applies to physician and certain non-physician practitioners employed by or affiliated with the University of Maryland.

I. Eligible providers as defined below will be eligible for enhanced payments for patient care services provided. For purposes of M-QIP, an eligible provider is limited to the following provider types employed by or affiliated with the Faculty Physicians Inc. (FPI) at the University of Maryland:

   A. Doctors of Medicine
   B. Doctors of Osteopathy
   C. Certified Registered Nurse Anesthetists (CRNAs)
   D. Certified Registered Nurse Practitioners
   E. Physician Assistants
   F. Certified Nurse Midwives (CNMs)
   G. Clinical Social Workers (CSWs)
   H. Clinical Psychologists
   I. Optometrists
   J. Physical Therapist
   K. Occupational Therapist
   L. Speech Therapist
   M. Audiologists

II. The M-QIP program applies only to MCOs that have a contract with FPI. The MCO will not be responsible for services that they do not cover or are carved out of the HealthChoice Benefit Package.

III. The MCO shall continue to pay their negotiated base rates to eligible providers throughout the year.

IV. M-QIP will be funded through a separate payment term pool. The separate payment term pool will contain a set dollar amount for each contract period.

V. MCOs contracted with FPI will receive quarterly payments from the Department. These MCOs will be required to reimburse FPI from these funds according to a schedule determined by the Department.
HEALTHCHOICE DIABETES PREVENTION PROGRAM (DPP) FEE SCHEDULES

There are two reimbursement methodologies available to MCOs for HealthChoice DPP. **MCOs are required to pay contracted CDC-recognized type 2 diabetes prevention programs at least the minimum rates outlined in each methodology.**

Section I outlines the session and performance payment approach for reimbursing in-person and virtual CDC-recognized type 2 diabetes prevention programs. Section II outlines the milestone/bundled payment approach for reimbursing virtual CDC-recognized type 2 diabetes prevention programs only.

**Section 1: HealthChoice Session and Performance-Based Reimbursement Methodology for In-Person and Virtual DPP Providers**

Participating in-person and virtual CDC-recognized type 2 diabetes prevention programs must use the make-up modifiers when submitting claims for make-up sessions using TS and VM modifiers with any code that has a session attached to it (except for the first session). In-person programs should always use the TS modifier for makeup sessions. Virtual programs should always use the VM modifier for their makeup sessions.

HCPCS code G9891 is a code used to track attendance and indicate that the CDC-recognized type 2 diabetes prevention program furnished a session that was not accounted for using an attendance performance goal code, such as G9874 (4 core sessions attended). G9891 is a non-payable code for reporting services of sessions furnished to participants (i.e. core sessions 2-3, 5-8, and 10-16).

Table 1. *HealthChoice DPP Session-Based Reimbursement Methodology for Minimum Payment Levels for In-Person and Virtual DPP Providers*

<table>
<thead>
<tr>
<th>Session/Event</th>
<th>HCPCS Code and Description</th>
<th>Payment</th>
<th>In-Person Make-up Session</th>
<th>Virtual Session⁶</th>
<th>Virtual Make-Up Session</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 1</td>
<td>G9873⁷ - 1st core session attended</td>
<td>$100</td>
<td>None⁸</td>
<td>GT⁸</td>
<td>None⁸</td>
<td>Can be used 1 time in 365 days³</td>
</tr>
<tr>
<td>Session 2-4</td>
<td>G9874 - 4 total core sessions attended⁹</td>
<td>$120</td>
<td>TS¹¹</td>
<td>GT</td>
<td>VM¹²</td>
<td>Can be used 1 time in 365 days³</td>
</tr>
</tbody>
</table>

---

⁵ In-person programs may conduct make-up sessions online, via some other virtual modality, or over the phone; these are still considered to be delivering the program in-person.

⁶ Virtual DPP refers to online, distance learning or combination delivery modes (combination only when online and distance learning DPP services are rendered).

⁷ CDC-recognized type 2 diabetes prevention programs must have confirmed self-referred individuals’ eligibility through a blood test, or provider note indicating history of GDM, prior to billing for this code.

⁸ The modifier GT refers to “via interactive audio and video telecommunications systems.”

⁹ In cases where MCOs allow individuals to switch DPP Providers after starting the program, the MCO may need to make an exception to the "can be used 1 time in 365 days" limitation.

¹⁰ The modifier TS refers to “follow-up service.” In-person programs may only use TS to indicate a makeup session of any modality.
Appendix K

<table>
<thead>
<tr>
<th>Session/Event</th>
<th>HCPCS Code and Description</th>
<th>Payment</th>
<th>Modifiers</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 5-9</td>
<td>G9875 - 9 total core sessions attended</td>
<td>$140</td>
<td>TS</td>
<td>GT VM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session 10-19</td>
<td>G9876 - 2 core maintenance sessions attended in months 7-9 (weight loss goal not achieved or maintained)¹⁴</td>
<td>$40</td>
<td>TS</td>
<td>GT VM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session 20-22</td>
<td>G9877 - 2 core maintenance sessions attended in months 10-12 (weight loss goal not achieved or maintained)¹⁵</td>
<td>$40</td>
<td>TS</td>
<td>GT VM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of Sessions</td>
<td>G9891¹⁶ - MDPP session reported as a line-item on a claim for a payable MDPP service</td>
<td>$0</td>
<td>None</td>
<td>GT None</td>
</tr>
</tbody>
</table>

Performance Payments

HCPCS codes G9878 and G9879 are both enhanced payments for performance: weight loss achieved or maintained for months 7-9 and 10-12. These codes may only be used in conjunction with either HCPCS code G9880 (5% weight loss) or G9881 (9% weight loss).

Table 2. HealthChoice DPP Performance-Based Reimbursement Methodology for In-Person and Virtual DPP Providers

<table>
<thead>
<tr>
<th>Session/Event</th>
<th>HCPCS Code and Description</th>
<th>Payment</th>
<th>Modifiers</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>¹⁰ Bill with counter code G9891 two times to indicate completion of core sessions 2 and 3.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹¹ The modifier VM refers to “virtual make-up session.” Virtual programs may only use VM to indicate a makeup session.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹² Bill with counter code G9891, four times to indicate completion of core sessions 5, 6, 7, and 8.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹³ Bill with counter code G9891 one time to indicate completion of first of two core maintenance sessions in months 7-9.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹⁴ Bill with counter code G9891 one time to indicate completion of first of two core maintenance sessions in months 10-12.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹⁵ A HCPCS G-code for a session furnished by the billing supplier that counts toward achievement of the attendance performance goal for the payable MDPP services HCPCS G-code. This CPT code is used to track attendance. This is a non-payable code for reporting services of sessions furnished to participants (i.e. core sessions 2-3, 5-8, and 10-16.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 1: CDC-recognized Type 2 Diabetes Prevention Programs

<table>
<thead>
<tr>
<th>Service Description</th>
<th>In-Person Make-up Session</th>
<th>Virtual Session</th>
<th>Virtual Make-Up Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>5% Weight Loss</td>
<td>$100</td>
<td>None</td>
<td>GT8</td>
</tr>
<tr>
<td>9% Weight Loss</td>
<td>$50</td>
<td>None</td>
<td>GT</td>
</tr>
<tr>
<td>Session 10-19 with at least 5% weight loss</td>
<td>$80</td>
<td>TS11</td>
<td>VM12</td>
</tr>
<tr>
<td>Session 20-22 with at least 5% weight loss</td>
<td>$80</td>
<td>TS</td>
<td>VM</td>
</tr>
</tbody>
</table>

**Assuming the enrollee attends all sessions and all performance outcomes are met, the total payment per enrollee for the CDC-recognized type 2 diabetes prevention programs based on these rates is $670.**

For community and/or virtual DPP providers whose organizations do not meet the descriptions provided for the place of service code set, they may use the place of service code ‘99’.¹⁹

These HCPCS codes may not be billed with or as nutritional counseling, evaluation and management codes, or other procedure codes when billing for the National DPP lifestyle change program.

---

¹⁷ In order to bill G9878 for enhanced attendance, must also bill or have previously billed for weight loss achieved from baseline at either 5% (G9880) or 9% (G9881). Bill with counter code G9891 one time to indicate completion of first of two core maintenance sessions in months 7-9.

¹⁸ In order to bill G9879 for enhanced attendance in this period, must also bill or have previously billed for weight loss achieved from baseline at either 5% (G9880) or 9% (G9881). Bill with counter code G9891 one time to indicate completion of first of two core maintenance sessions in months 10-12.

**Section II: HealthChoice Milestone/Bundled Reimbursement Methodology for Virtual DPP Providers**

Table 3, below, lists the recommended HCPCS codes and reimbursement for HealthChoice DPP under the virtual DPP milestone/bundled reimbursement methodology. Flexibility in bundled payment distribution across milestones 1-3 and the 5% and 9% performance payouts will be allowed so long as the total payment per enrollee for the CDC-recognized type 2 diabetes prevention program meets or exceeds $670.

Table 3. *HealthChoice DPP Milestone/Bundled Reimbursement Methodology for Virtual DPP Providers*

<table>
<thead>
<tr>
<th>Session/Event</th>
<th>HCPCS Code and Description</th>
<th>Payment</th>
<th>In-Person Make-up Session</th>
<th>Virtual Make-Up Session</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milestone 1: May be billed at enrollment or initiation into program; scale is issued; or 1st core session attended</td>
<td>Available codes: G98736 - 1st core session attended E1639 [20] 0488T [21]</td>
<td>$220</td>
<td>Not applicable</td>
<td>GT8</td>
<td>None</td>
</tr>
<tr>
<td>Milestone 2: Billed at 4 core sessions attended</td>
<td>G9874 - 4 total core sessions attended</td>
<td>$160</td>
<td>Not applicable</td>
<td>GT</td>
<td>VM12</td>
</tr>
<tr>
<td>Milestone 3: Billed at 9 core sessions attended</td>
<td>G9875-9 core sessions attended</td>
<td>$140</td>
<td>Not applicable</td>
<td>GT</td>
<td>VM</td>
</tr>
<tr>
<td>Performance: 5% weight loss achieved</td>
<td>G9880 – 5 percent weight loss from baseline achieved</td>
<td>$125</td>
<td>Not applicable</td>
<td>GT</td>
<td>None</td>
</tr>
<tr>
<td>Performance: 9% weight loss achieved</td>
<td>G9881 - 9 percent weight loss from</td>
<td>$25</td>
<td>Not applicable</td>
<td>GT</td>
<td>None</td>
</tr>
</tbody>
</table>

---

[20] E1639: Durable Medical Equipment (DME)
[21] 0488T: Preventive behavior change, online/electronic intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days
As indicated for Milestone 1, MDH will accept one of three possible codes for enrollment or initiation into the program as a first milestone and allow claiming for the scale using either 1) G9873; 2) E1639; or 3) 0488T.

Assuming the enrollee attends and meets all milestones and achieves the 5% and 9% performance outcomes, total payment per enrollee for virtual CDC-recognized type 2 diabetes prevention programs based on these rates should equal $670.

ICD-10 Diagnosis Codes, Descriptions and DPP Provider Assignment Guidance

The following ICD-10 diagnosis codes may be used for billing:

Table 4. Elevated Blood Glucose Level and Gestational Diabetes ICD-10 Codes

<table>
<thead>
<tr>
<th>ICD-10 Code</th>
<th>Description – Elevated Blood Glucose Level</th>
<th>ICD-10 Code</th>
<th>Description - Gestational Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>R73.01</td>
<td>Impaired fasting glucose</td>
<td>Z86.32(^{22})</td>
<td>Personal history of gestational diabetes</td>
</tr>
<tr>
<td>R73.02</td>
<td>Impaired glucose tolerance - Oral</td>
<td>R73.03</td>
<td>Prediabetes</td>
</tr>
</tbody>
</table>

Table 5. BMI ICD-10 Codes for BMI 23.0 and greater

<table>
<thead>
<tr>
<th>ICD-10 Code</th>
<th>Description – Body Mass Index</th>
<th>ICD-10 Code</th>
<th>Description – Body Mass Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z68.23</td>
<td>Body mass index (BMI) 23.0-23.9, adult</td>
<td>Z68.34</td>
<td>Body mass index (BMI) 34.0-34.9, adult</td>
</tr>
<tr>
<td>Z68.24</td>
<td>Body mass index (BMI) 24.0-24.9, adult</td>
<td>Z68.35</td>
<td>Body mass index (BMI) 35.0-35.9, adult</td>
</tr>
<tr>
<td>Z68.25</td>
<td>Body mass index (BMI) 25.0-25.9, adult</td>
<td>Z68.36</td>
<td>Body mass index (BMI) 36.0-36.9, adult</td>
</tr>
<tr>
<td>Z68.26</td>
<td>Body mass index (BMI) 26.0-26.9, adult</td>
<td>Z68.37</td>
<td>Body mass index (BMI) 37.0-37.9, adult</td>
</tr>
<tr>
<td>Z68.27</td>
<td>Body mass index (BMI) 27.0-27.9, adult</td>
<td>Z68.38</td>
<td>Body mass index (BMI) 38.0-38.9, adult</td>
</tr>
<tr>
<td>Z68.28</td>
<td>Body mass index (BMI) 28.0-28.9, adult</td>
<td>Z68.39</td>
<td>Body mass index (BMI) 39.0-39.9, adult</td>
</tr>
<tr>
<td>Z68.29</td>
<td>Body mass index (BMI) 29.0-29.9, adult</td>
<td>Z68.41</td>
<td>Body mass index (BMI) 40.0-44.9, adult</td>
</tr>
<tr>
<td>Z68.30</td>
<td>Body mass index (BMI) 30.0-30.9, adult</td>
<td>Z68.42</td>
<td>Body mass index (BMI) 45.0-49.9, adult</td>
</tr>
<tr>
<td>Z68.31</td>
<td>Body mass index (BMI) 31.0-31.9, adult</td>
<td>Z68.43</td>
<td>Body mass index (BMI) 50-59.9, adult</td>
</tr>
<tr>
<td>Z68.32</td>
<td>Body mass index (BMI) 32.0-32.9, adult</td>
<td>Z68.44</td>
<td>Body mass index (BMI) 60.0-69.9, adult</td>
</tr>
<tr>
<td>Z68.33</td>
<td>Body mass index (BMI) 33.0-33.9, adult</td>
<td>Z68.45</td>
<td>Body mass index (BMI) ≥ 70, adult</td>
</tr>
</tbody>
</table>

\(^{22}\) DPP providers should include Z86.32 as primary code for all individuals indicating history of gestational diabetes after confirming not currently pregnant.
HIGH-COST LOW VOLUME DRUG RISK MITIGATION POLICY

Maryland’s Department of Health (the Department) has instituted a risk mitigation policy effective January 1, 2021 to protect the HealthChoice program from utilization fluctuations related to very high cost drugs. The policy covers both Physician Administered Drugs and retail pharmacy drugs that have an expected annual cost over $400,000. The specific drugs covered are listed in Exhibit I of this document. The list of drugs is subject to change during the year if a new drug received FDA approval and is a covered Medicaid service with an expected annual cost over $400,000. No previously approved and covered drugs will be added to the list during the year. If a new drug is approved and reaches the market after this analysis is complete, the Department will evaluate the expected cost of the drug at the NDC level and will add it to the list if the expected annual cost is over $400,000. The list of covered drugs will be reviewed annually to add in drugs that have increased in price or remove drugs that have decreased in price.

Under this new mitigation policy, costs of the High-Cost Low Volume drugs listed in Exhibit I are removed from the rate setting base data and are not included in the standard capitation rate paid to HealthChoice Managed Care Organizations (MCOs). The MCOs are still responsible for authorizing, managing, and paying all claims related to the high-cost drugs, and will invoice the Department for any incurred expenses on a quarterly basis. The MCOs are expected to develop and adhere to medical necessity criteria to ensure that all instances of utilization of drugs listed in Exhibit I follow best clinical practices. The Department reserves the right to audit medical necessity criteria and review the utilization of all High-Cost Low Volume Drugs to ensure adherence to appropriate criteria.
The NDC list will be updated throughout the calendar year if additional drugs are identified.

*Zolgensma NDC List: 71894011001, 71894011501, 71894012002, 71894012103, 71894012203, 71894012303, 71894012404, 71894012504, 71894012604, 71894012705, 71894012805, 71894012905, 71894013006, 71894013106, 71894013206, 71894013307, 71894013407, 71894013507, 71894013608, 71894013708, 71894013808, 71894013909, 71894014009, 71894014109

Shading indicates the drug is a pipeline drug that is included for the risk mitigation policy based on the expected cost.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>NDC Code</th>
<th>J Code (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abecma</td>
<td>59572051501</td>
<td>J9999, J3490, J3590</td>
</tr>
<tr>
<td>Abecma</td>
<td>59572051502</td>
<td>J9999, J3490, J3590</td>
</tr>
<tr>
<td>Abecma</td>
<td>59572051503</td>
<td>J9999, J3490, J3590</td>
</tr>
<tr>
<td>Actimmune</td>
<td>75987011111</td>
<td>J9216</td>
</tr>
<tr>
<td>Actimmune</td>
<td>42238011112</td>
<td>J9216</td>
</tr>
<tr>
<td>Amondys 45</td>
<td>60923022702</td>
<td>J3490, J3590</td>
</tr>
<tr>
<td>Breyanzi</td>
<td>73153090001</td>
<td>J9999, J3490, J3590</td>
</tr>
<tr>
<td>Cinryze</td>
<td>42227008105</td>
<td>J0598</td>
</tr>
<tr>
<td>Empaveli</td>
<td>73606001001</td>
<td>J3490, J3590, C9399</td>
</tr>
<tr>
<td>Evkeeza</td>
<td>61755001001</td>
<td>J3490, J3590</td>
</tr>
<tr>
<td>Evkeeza</td>
<td>61755001301</td>
<td>J3490, J3590</td>
</tr>
<tr>
<td>Novoseven</td>
<td>00169720101</td>
<td>J7189</td>
</tr>
<tr>
<td>Nulibry</td>
<td>731290000101</td>
<td>J3490</td>
</tr>
<tr>
<td>Orfadin</td>
<td>66658020490</td>
<td>J8499</td>
</tr>
<tr>
<td>Orladeyo</td>
<td>72769010101</td>
<td>J8499</td>
</tr>
<tr>
<td>Orladeyo</td>
<td>72769010201</td>
<td>J8499</td>
</tr>
<tr>
<td>Oxlumo</td>
<td>71336100201</td>
<td>J0224</td>
</tr>
<tr>
<td>Ravicti</td>
<td>75987005006</td>
<td>J8499</td>
</tr>
<tr>
<td>Revcovi</td>
<td>57665000201</td>
<td>J3590, J3490</td>
</tr>
<tr>
<td>Soliris</td>
<td>25682000101</td>
<td>J1300</td>
</tr>
<tr>
<td>Vimizim</td>
<td>68135010001</td>
<td>J1322</td>
</tr>
<tr>
<td>Viltepso</td>
<td>73292001101</td>
<td>J1427</td>
</tr>
<tr>
<td>Spinraza</td>
<td>64406005801</td>
<td>J2326</td>
</tr>
<tr>
<td>Zolgensma</td>
<td>see list below *</td>
<td>J3590</td>
</tr>
</tbody>
</table>

*Zolgensma NDC List:
HEPATITIS C RISK POOL REIMBURSEMENT METHOD

The Department has also instituted a new method for paying for Hepatitis C treatments in the capitation rates while controlling for differences in treatment volume across MCOs. The new method eliminates the previous Hepatitis C case rate and instead funds Hepatitis C by including the expenses in the capitation rating cohorts. After the contract period has ended, the Hepatitis C prescriptions provided by MCO will be compared to the amount funded via the capitation rates, and a risk pool will be calculated to protect MCOs from adverse selection. The key aspects of the risk pool are:

1. The risk pool will not be budget neutral, meaning that MDH will add/remove dollars to the initial Hepatitis C funding provided via the capitation rates
2. The cost per prescription used in developing the capitation rates will be adjusted via a risk corridor based on the actual cost per prescription for the Medicaid program
   a. Risk corridor has one band of +/- 2% that is 100% MCO risk, with the State absorbing all of the risk outside of the first +/- 2%
3. The adjusted cost per prescription will be multiplied by the number of prescriptions provided by the MCO to calculate a normalized cost
4. The normalized cost will be compared to the funding received via the capitation rates based on the MCO-specific membership distribution
5. The difference between actual funding and normalized cost will be paid to/recouped from the MCOs
CMS INTEROPERABILITY AND PATIENT ACCESS FINAL RULE REQUIREMENTS

The Centers for Medicare and Medicaid Services (CMS) Interoperability and Patient Access Final Rule (CMS-9115-F) focuses on driving interoperability and patient access to health information by facilitating the free and secure flow of data. CMS partnered with the Office of the National Coordinator (ONC) for Health Information Technology to identify Health Level 7® (HL7) Fast Healthcare Interoperability Services® (FHIR) Release 4.0.1 as the foundational standard to support data exchange via secure application programming interfaces (APIs). Additionally, CMS is adopting the standards for FHIR-based APIs finalized by Health and Human Services (HHS) in the ONC 21st Century Cures Rule at 45 CFR 170.215.

The CMS Interoperability Rule requires each Medicaid Managed Care Organization (MCO) to establish, based upon the standards finalized in the ONC 21st Century Cures Rule (45 CFR 170.213 & 215): (I) Patient Access API (42 CFR 438.242(b)(5)); (II) Provider Directory API (42 CFR 438.242(b)(6)); (III) Payer to Payer Data Exchange (42 CFR 438.62(b)(1)(vi)). Each MCO must implement and maintain a secure, HL7 FHIR Release 4.0.1 standards-based API. The Provider Directory and Patient Access APIs are required to be implemented by January 1, 2021. However, due to COVID-19, CMS will not enforce these new requirements until July 1, 2021. Payers must implement a process for the payer-to-payer data exchange by January 1, 2022.

I. **Patient Access API.** To allow patients to easily access their claims information, including cost, as well as a defined subset of clinical information.

II. **Provider Directory API.** To avail a searchable public provider directory displaying certain information. Provider directory information must be accessible and searchable via a standards-based API.

III. **Payer-to-Payer Data Exchange.** To enable the exchange of certain patient clinical data (i.e., the U.S. Core Data for Interoperability [USCDI] version 1 data set), at the patient’s request, between payers allowing patients to create a cumulative health record that moves across payers.

CMS requires that the implementation of the above APIs is supplemented with additional components, such as an educational page for patients about sharing their health information with third parties. For these requirements, MCOs should refer to the Final Rule, located here: [https://www.federalregister.gov/documents/2020/05/01/2020-05050/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-interoperability-and](https://www.federalregister.gov/documents/2020/05/01/2020-05050/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-interoperability-and).
HEALTHCHOICE POPULATION HEALTH INCENTIVE PROGRAM

Effective January 1, 2022, the Department shall establish the HealthChoice Population Health Incentive Program (PHIP).

Performance Measures and Funding

An MCO may be eligible for an incentive payment for the following performance measures:

1) Ambulatory care visits for Supplemental Security Income (SSI) adults
2) Ambulatory care visits for Supplemental Security Income (SSI) children
3) HEDIS asthma medication ratio
4) HEDIS comprehensive diabetes care—HbA1c poor control (>9.0%)
5) Lead screening measures:
   (a) Lead screening measure for children 12-23 months old
   (b) HEDIS lead screening in children
6) HEDIS postpartum care
7) HEDIS risk of continued opioid use—≥31 days covered
8) HEDIS timeliness of prenatal care

Each measure identified shall be valued equally at a proportional share of available incentive funds, except for measures (5)(a) and (b), which are each valued at half of the available incentive funds relative to one of the other measures.

There shall be two rounds of potential incentive payments an MCO may earn. Total PHIP funding shall be determined prior to the measurement year and included in the MCO contract. (For CY 2022, PHIP will be funded at 0.5% of an MCO’s total capitation.) All PHIP payments shall be funded independently from and outside of MCO capitation payments during a given calendar year.

Each MCO shall be eligible for no more than 1 percent of the plan’s measurement year capitation payments, excluding supplemental payments outside of capitation, as total payment from Round One and Round Two.

If the Department determines that the score for any measure may not be comparable to the previous year’s score due to alterations in measure specifications or other factors, the Department may exclude the measure from the PHIP and adjust the incentive valuation in accordance with the remaining performance measures.
Round One Incentives

An MCO may earn two types of incentives in Round One:
1) A performance incentive payment; and
2) An improvement incentive payment.

If an MCO does not report a performance measure or an MCO has a performance score of zero percent, then the MCO is awarded no performance or improvement incentive payments for this measure.

Round One Performance Incentive Payments

Performance incentive payments for Round One shall be based on the following categories for each performance measure:

1) Superlative performance, meaning the performance measure’s score is at or above the 90\textsuperscript{th} percentile of HEDIS Medicaid performance nationwide during the measurement year, or estimated 90\textsuperscript{th} percentile among Maryland HealthChoice MCO performance for non-HEDIS performance measures.

2) Very strong performance, meaning the performance measure’s score is between the 75\textsuperscript{th} to 89\textsuperscript{th} percentiles of HEDIS Medicaid performance nationwide during the measurement year, or between the estimated 75\textsuperscript{th} to 89\textsuperscript{th} percentiles among Maryland HealthChoice MCO performance for non-HEDIS performance measures.

3) Strong performance, meaning the performance measure’s score is between the 50\textsuperscript{th} to 74\textsuperscript{th} percentiles of HEDIS Medicaid performance nationwide during the measurement year, or between the estimated 50\textsuperscript{th} to 74\textsuperscript{th} percentiles among Maryland HealthChoice MCO performance for non-HEDIS performance measures.

Payments for Round One performance incentives shall be allocated as follows:

1) For superlative performance, an MCO may earn 100 percent of the incentive allocation for the performance measure.

2) For very strong performance, an MCO may earn 66.6 percent of the incentive allocation for the performance measure.

3) For strong performance, an MCO may earn 33.3 percent of the incentive allocation for the performance measure.

Any MCO earning a performance measure score below the 50\textsuperscript{th} percentile of HEDIS Medicaid performance nationwide during the measurement year on a HEDIS-based measure, or below the calculated 50\textsuperscript{th} percentile among Maryland HealthChoice MCO performance for a non-HEDIS measure, shall be ineligible for a Round One performance incentive payment.
Appendix N

Round One Improvement Incentive Payments

An MCO may earn an improvement incentive payment for any performance measure if the following conditions are met:

1) The MCO demonstrates improvement of at least 0.5 percentage points in the measure compared to the previous measurement year, and
2) The performance measure score is at or above the 50th percentile of HEDIS Medicaid performance nationwide on a HEDIS-based measure, or the 50th percentile of Maryland HealthChoice MCO performance for a non-HEDIS measure.

For each measure demonstrating improvement, an MCO would receive one-third of one-eighth of the total capitation at risk for the program (0.5 percent of MCO capitation).

Please note:
- An MCO earning a superlative performance incentive payment for a performance measure is ineligible for an improvement incentive payment for the same measure.
- For any performance measures in which a lower score indicates stronger performance, year-over-year improvement is demonstrated by a reduction in the score for that measure.
- If an MCO is missing or zero-valued for a performance measure in the previous year, then no improvement incentive will be awarded in the measurement year.

Round Two Incentives

An MCO may qualify for payments under Round Two if the following conditions are met:

1) The MCO earned above 80 percent of possible Round One incentives.
2) The MCO did not have penalties applied during the measurement year for failure to meet the HEDIS MCO Performance Monitoring Policy included in the MCO contract.

Any remaining funds that were unallocated during Round One may be awarded to eligible MCOs in Round Two for a maximum incentive award of up to 1 percent of its total capitation payment during the PHIP measurement year, excluding supplemental payments outside of capitation. If any remaining funds that were unallocated during Round One are not sufficient to settle all qualifying MCOs up to 1 percent of capitation in Round Two, then the leftover funds will be awarded proportionally among qualifying MCOs based on enrollment.

If additional funds remain after both Round One and Round Two, the Department may, within its discretion, allocate the funding as follows:

1) Make additional payments to MCOs that are below 1 percent of capitation based on improvement or performance, or
2) Place remaining funds into a non-lapsing pool, subject to approval by the Maryland Department of Budget and Management.
Chapter 05 Maryland Medicaid Managed Care Program: Access

01 Access Standards: Addressing Enrollees' Individualized Needs ..................................................................... 178
02 Access Standards: Enrollee Handbook and Provider Directory ......................................................................... 179
03 Access Standards: Outreach .................................................................................................................................. 184
04 Access Standards: Information for Providers ........................................................................................................ 186
05 Access Standards: PCPs and MCO's Provider Network .......................................................................................... 188
05-1 Access Standards: Specialty Provider Network .................................................................................................. 191
06 Geographical Access ................................................................................................................................................ 193
07 Access Standards: Clinical and Pharmacy Access ................................................................................................. 198
08 Emergency Services Access ....................................................................................................................................... 202
09 Access: Hospitals ......................................................................................................................................................... 204

Chapter 06 Maryland Medicaid Managed Care Program: Benefits

01 Required Benefits Package — In General .................................................................................................................. 204
02 Benefits — Primary Care Services ........................................................................................................................... 206
03 Benefits — Physician and Advanced Practice Nurse Specialty Care Services ....................................................... 206
04 Benefits — Pharmacy Services .................................................................................................................................. 207
05 Benefits — Home Health Services ............................................................................................................................ 210
06 Benefits — Habilitation Services for Medicaid Expansion Populations ................................................................. 211
07 Benefits — Inpatient Hospital Services ...................................................................................................................... 211
08 Benefits — Outpatient Hospital Services ................................................................................................................ 213
09 Benefits — Transplants ................................................................................................................................................. 213
11 Benefits — Diagnostic and Laboratory Services ..................................................................................................... 213
12 Benefits — Long-Term Care Facility Services ......................................................................................................... 214
13 Benefits — Disposable Medical Supplies and Durable Medical Equipment .......................................................... 214
14 Benefits — Vision Care Services ............................................................................................................................... 215
15 Benefits — Podiatry Services ....................................................................................................................................... 215
16 Benefits — Outpatient Rehabilitative Services ......................................................................................................... 216
17 Benefits — Oxygen and Related Respiratory Equipment ......................................................................................... 216
18 Benefits — Dialysis Services ...................................................................................................................................... 216
19 Benefits — Family Planning Services ......................................................................................................................... 216
20 Benefits — EPSDT Services ........................................................................................................................................ 216
21 Benefits — Pregnancy-Related Services ...................................................................................................................... 218
22 Benefits — Case Management Services for HIV-Infected Individuals .................................................................... 219
23 Benefits — Hospice Care Services ............................................................................................................................. 219
24 Benefits — Diabetes Prevention and Care Services ................................................................................................. 220
25 Benefits — Blood and Blood Products ....................................................................................................................... 221
26 Benefits — Primary Mental Health Services ............................................................................................................. 221
Chapter 07 Maryland Medicaid Managed Care Program: Program Integrity...... 228
  .01 Requirements to Detect and Prevent Fraud, Waste, and Abuse. ......................... 228
  .02 Access to Information. ......................................................................................... 231
  .03 Reporting ................................................................................................................ 232

Chapter 08 Maryland Medicaid Managed Care Program: Non-Capitated Covered
Services ....................................................................................................................... 235
  .01 Scope ..................................................................................................................... 235
  .02 Behavioral Health Non-Capitated Covered Services ............................................. 235
  .03 Nonbehavioral Health Fee-For-Service Benefits .................................................. 301

Chapter 09 Maryland Medicaid Managed Care Program: MCO Dispute Resolution
Procedures .................................................................................................................. 302
  .01 MCO Enrollee Services ......................................................................................... 302
  .02 MCO Enrollee Complaint Process ....................................................................... 303
  .02-1 Member Complaints — Time Frames for MCOs to Respond to the Department. 305
  .03 MCO Provider Complaint Process ...................................................................... 305
  .03-1 Independent Review Organization (IRO). .............................................................. 307
  .03-2 Provider Complaints — Time Frames for MCOs to Respond to the Department. 307
  .04 MCO Actions and Decisions ................................................................................ 308
  .05 MCO Appeal Process for Enrollees ...................................................................... 311

Chapter 10 Maryland Medicaid Managed Care Program: Sanctions ............ 316
  .01 Sanction by the Department ................................................................................. 316
  .01-1 Sanction by Center for Medicare and Medicaid Services (CMS) .................... 316
  .02 Appeal .................................................................................................................. 316
  .03 Incentives ............................................................................................................. 317

Chapter 11 Maryland Medicaid Managed Care Program: Contribution to Graduate
Medical Education Costs .......................................................................................... 318
  .01 Scope ..................................................................................................................... 318
  .02 GME Allocation Payment .................................................................................... 318

Chapter 12 Maryland Medicaid Managed Care Program: Corrective Managed
Care ............................................................................................................................... 319
  .01 General .................................................................................................................. 319
  .02 Corrective Managed Care Plan ............................................................................ 320
  .03 Enrollee Notice ..................................................................................................... 322
  .04 Effective Date of Enrollment .............................................................................. 323
  .05 Enrollee Appeal .................................................................................................... 323
Title 10 MARYLAND DEPARTMENT OF HEALTH
Subtitle 01 PROCEDURES
Chapter 04 Fair Hearing Appeals Under the Maryland State Medical Assistance Program

.01 Definitions.

A. In this chapter, the following terms have the meanings indicated.

B. Terms Defined.

(1) “Administrative law judge” means an individual appointed by the Chief Administrative Law Judge under State Government Article, §9-1604, Annotated Code of Maryland, or designated by the Chief Administrative Law Judge under State Government Article, §9-1607, Annotated Code of Maryland, to adjudicate contested cases at the Maryland Office of Administrative Hearings.

(2) “Action by an MCO” means:

(a) Denial or limited authorization of a requested service, including:

(i) The type or level of service;

(ii) Requirements for medical necessity;

(iii) Appropriateness;

(iv) Setting; or

(v) Effectiveness of a covered benefit;

(b) Reduction, suspension, or termination of a previously authorized service;

(c) Denial, in whole or part, of payment for a service;
(d) Failure to provide services in a timely manner;

(e) Failure to act within the required time frames; or

(f) The denial of an enrollee’s request to dispute a financial liability, including:

   (i) Cost sharing;

   (ii) Copayments;

   (iii) Premiums;

   (iv) Deductibles;

   (v) Coinsurance; or

   (vi) Other enrollee financial liabilities.


4) “Appellant” means any individual who requests a fair hearing for the reasons specified in Regulation .02 of this chapter or that individual’s authorized representative.

5) “Authorized representative” has the same meaning as in Regulation .12.

6) “Consolidated Services Center” means a call center operated by the Maryland Health Benefit Exchange to assist consumers who apply for, or participate in, Insurance Affordability Programs offered through the Maryland Health Connection.

7) “Delegate agency” means the:

   (a) Department of Human Services and its affiliated local departments which, under contractual agreements with the Department, determine initial and continuing eligibility in the Program; and

   (b) Maryland Health Benefit Exchange and its designated affiliates.

8) “Department” means the Maryland Department of Health, the single state agency which, pursuant to Title XIX of the Social Security Act, implements fair hearing requirements for Program applicants and recipients.

9) “Insurance affordability program” means a program that is one of the following:
(a) The Maryland State Medicaid program;

(b) The Maryland Children’s Health Insurance Program (CHIP), including the program known as Maryland Children’s Health Program (MCHP) Premium;

(c) A State basic health program established under §1331 of the Affordable Care Act;

(d) A program that makes available to eligible individuals coverage in a qualified health plan through the Maryland Health Benefit Exchange with advance payments of the premium tax credit established under §36B of the Internal Revenue Code; and

(e) A program that makes available to eligible individuals coverage in a qualified health plan through the Maryland Health Benefit Exchange with cost-sharing reductions established under §1402 of the Affordable Care Act.

(10) “Maryland Health Benefit Exchange” means the unit of State government that determines initial and continuing eligibility for the MAGI-based insurance affordability programs, including, by delegation, certain eligibility in the Program.

(11) “Maryland Health Connection” means the electronic eligibility system maintained by the Maryland Health Benefit Exchange.

(12) “MCO” means a managed care organization qualified to participate in the Program under COMAR 10.67.04.

(13) “Program” means the Department’s Medical Assistance Program.

.02 Opportunity for a Fair Hearing.

A. An opportunity for a fair hearing shall be granted if:

(1) A Program applicant claims their application for Program eligibility is denied;

(2) A Program applicant claims that the determination of eligibility received through Maryland Health Connection is incorrect;

(3) A Program applicant claims their application for eligibility, or any part thereof, is not acted upon within:

(a) 30 days from the date of application to an insurance affordability program;

(b) 45 days from the date of application for aged or blind applicants to the Program; or

(c) 60 days from the date of application to the Program in the case of determination of disability;
(4) A Program recipient asserts their claim for Program services has been erroneously denied or is not acted upon with reasonable promptness;

(5) A Program recipient asserts that the Program has acted erroneously;

(6) A Program recipient residing in a skilled nursing facility or nursing home asserts that the recipient has been or will be erroneously transferred or discharged;

(7) A Program recipient asserts that the Program has made an erroneous decision related to nursing home preadmission and annual review; or

(8) A Program participant in an MCO is appealing an action by an MCO and the appeal has been filed within 120 days from the date specified in the notice from the MCO as required by COMAR 10.67.09.05.

B. The administrative law judge may not grant a fair hearing if the sole issue is a federal or State law requiring an automatic change adversely affecting some or all Program recipients.

.03 Notification of Right to Request a Fair Hearing.

A. The Program, delegate agency, or MCO shall notify an individual and his or her authorized representative, if previously designated by the individual or recognized as valid by the Program, in writing:

(1) Of the right to obtain a fair hearing;

(2) Of the method to obtain the hearing; and

(3) That the individual may represent himself or use an authorized representative at a fair hearing.

B. The notification specified in §A of this regulation shall:

(1) Be provided by the Program, the MCO, or the delegate agency when:

(a) The individual applies for Program benefits;

(b) Any Program, MCO, or delegate agency action affects the individual’s claim to Program benefits;

(c) A skilled nursing facility or a nursing facility notifies the individual that the individual is to be transferred or discharged; and
(d) The individual receives an adverse determination by the Department or delegate agency with regard to skilled nursing facility or a nursing facility preadmission screening and annual resident review;

(2) Include a statement of the action the Program, MCO, skilled nursing facility, or nursing facility intends to take;

(3) Include the reasons for the intended action;

(4) Include the specific regulations that support, or the change in federal or State law that requires, the action;

(5) Include an explanation of the individual’s right to request a fair hearing, including that expenses incurred in connection with a fair hearing, such as transportation and baby-sitting costs, but not including attorney's fees, shall be paid by the Department when incurred by the appellant and may be paid by the Department when incurred by the appellant's witnesses;

(6) Include information about fair hearings;

(7) Include an explanation of the circumstances under which assistance is continued if a fair hearing is requested, as provided in Regulation .04B of this chapter;

(8) Identify who may act as an authorized representative of the appellant in the fair hearing process, explain how an applicant or recipient may designate an authorized representative, and provide information about designation procedures under 10.09.04.12;

(9) Specify that the appellant or the appellant’s authorized representative may generally examine the appellant’s records upon reasonable notice to the Program, MCO, or delegate agency; and

(10) Except as specified in §C of this regulation, be mailed at least 10 days before the date of action.

C. The notice specified in §A of this regulation may be mailed less than 10 days before but not later than the date of action if:

(1) The Program has information confirming the recipient’s death;

(2) The Program receives a clear written statement signed by a recipient that:

(a) The recipient no longer wishes services; or

(b) Gives information that requires termination or reduction of services and indicates that the recipient understands that this change in services is the result of supplying that information;
(3) The recipient has been admitted to an institution where the recipient is ineligible under the Program for further services;

(4) Subject to Regulation .10B(4) of this chapter, the recipient's whereabouts are unknown and the post office returns to the Program or delegate agency mail directed to the recipient indicating no forwarding address;

(5) The Program establishes that the recipient has been accepted for Program services by another local jurisdiction, State, territory, or commonwealth;

(6) The recipient's physician prescribes a change in the level of care;

(7) The notice involves an adverse determination made with regard to preadmission screening requirements;

(8) The date of action will occur in less than 10 days and the action involves a long-term care facility's resident transfer or discharge, in which case the notification shall be made as soon as practicable before transfer or discharge in accordance with 42 CFR §438.12;

(9) The Program has facts indicating that action should be taken because of probable fraud by the recipient and the facts have been verified, if possible, through secondary sources, in which case the notification may be mailed 5 days before the date of action; or

(10) The action is an eligibility determination, in which case notice shall be given at the same time as the determination.

.04 Request for Fair Hearing.

A. Statement of Request.

(1) Any individual, either himself or through an authorized representative, may request a fair hearing by giving a clear statement, oral, electronic, or written, to any member of the Department or delegate agency, that the individual desires an opportunity to present for review any matter which is the proper subject of a fair hearing as provided in Regulation .02 of this chapter. The request shall be made by:

(a) Contacting the Program’s Office of Health Services in writing, by telephone or by fax, if the appeal concerns a recipient’s services being denied, suspended, terminated, or reduced;

(b) Contacting the Maryland Health Benefits Exchange in writing, by telephone, by email, or by fax, if the appeal concerns an applicant’s eligibility for insurance affordability programs;

(c) Contacting the Consolidated Services Center maintained by the Maryland Health Benefit Exchange in writing, by telephone, by email, or by fax, if the appeal concerns eligibility for insurance affordability programs; or
(d) Contacting the Office of Administrative Hearings in person, by mail, or by fax, if the appeal concerns the appellant’s eligibility for insurance affordability programs.

(2) The Program’s Office of Health Services, the Consolidated Services Center, or the delegate agency that receives the request for a hearing shall assist the appellant or the appellant’s authorized representative in preparing the request.

(3) The Program's Office of Health Services, the Consolidated Services Center, or the delegate agency that receives a written statement requesting an appeal shall:

   (a) Immediately forward an applicant’s statement to the Office of Administrative Hearings;

   (b) Indicate whether the appeal is for a determination of eligibility under an insurance affordability program or for conventional Medicaid; and

   (c) Note in its correspondence with the Office of Administrative Hearings if the appeal:

      (i) Concerns the medical necessity of a denied benefit or service to an MCO enrollee or an application for eligibility insurance affordability programs;

      (ii) Meets the Program’s criteria for an expedited resolution because the Program has determined that taking the time for a standard resolution could seriously jeopardize the individual’s life or health or ability to attain, maintain, or regain maximum function; and

      (iii) Must be heard and decided upon within 3 working days after the Office of Administrative Hearings receives the fair hearing request.

(4) Appeals of eligibility determinations for insurance affordability programs requested through the Maryland Health Connection shall automatically be transmitted to the Office of Administrative Hearings.

(5) If a request for a hearing is made by someone other than the applicant or recipient, the Office of Administrative Hearings shall:

   (a) Treat the appeal as timely noted if it complies with §D of this regulation unless no documentation is provided on or before the hearing date;

   (b) Accept appropriate documentation, up to and including the date of the fair hearing, demonstrating that the representative is authorized; and

   (c) Accept the representation of any member of the bar of Maryland that the individual appellant is his or her client without further documentation.

B. Acknowledgement. The Office of Administrative Hearings shall:

   (1) Promptly acknowledge any request for a fair hearing;
(2) Give advance notice in writing of the date, time, and place of the fair hearing; and

(3) Provide the appellant with the information specified in Regulation .03B of this chapter.

C. Postponements.

(1) If any party notifies the Office of Administrative Hearings that either the time or place designated by the Office of Administrative Hearings is not convenient to the party, and requests a different time or place for the fair hearing, the administrative law judge shall designate another time or place convenient to the parties if the administrative law judge deems that the party has sufficient reason for requesting the change.

(2) If the appellant is employed during the periods when fair hearings are normally held, the administrative law judge shall attempt to schedule the hearing so that the appellant will not be required to miss employment.

D. Timeliness of Appeal. A request for a fair hearing may not be granted unless the request in §A of this regulation is:

(1) Postmarked, delivered in person, or sent by email or facsimile to the Office of Health Services within 120 days of the receipt of the notification specified in Regulation .03A of this chapter, if the appeal concerns services provided or denied by an MCO;

(2) Postmarked, delivered in person, or sent by email or facsimile to the Office of Health Services within 90 days of the receipt of the notification specified in Regulation .03A of this chapter, if the appeal concerns services provided or denied by the fee-for-service program; or

(3) Postmarked, delivered in person, or sent by facsimile to the Office of Administrative Hearings; or emailed to Maryland Health Benefit Exchange; telephoned or faxed to the Consolidated Services Center or postmarked, telephoned, faxed, or delivered in person to the delegate agency within 90 days of the receipt of the notification specified in Regulation .03A of this chapter if the appeal concerns the appellant’s eligibility.

E. Dismissal.

(1) The Program, the delegate agency, or the Office of Administrative Hearings may dismiss a request for a fair hearing when the appeal has been:

   (a) Withdrawn in writing addressed to the Office of Administrative Hearings, or in writing, by telephone, or by fax to the Office of Health Services, or in writing, by telephone, or electronically to the Maryland Health Benefit Exchange or other delegate agency, by the appellant or his authorized representative; or

   (b) Abandoned.
(2) An appellant shall be deemed to have abandoned the appellant’s request for a fair hearing if the appellant fails to appear for the fair hearing on the established date without good cause as determined by the administrative law judge.

F. Program’s Response. In responding to timely filed requests for a fair hearing, the Office of Administrative Hearings:

(1) May respond to a series of individual requests for hearing by conducting a single group hearing;

(2) May consolidate hearings only in cases in which the sole issue involved is one of federal or State law or policy;

(3) Shall follow the regulations of this chapter governing hearings in all group hearings; and

(4) Shall permit each applicant to present the appellant’s own case or be represented by the appellant’s authorized representative.

.05 Pre-Hearing Procedures.

A. A hearing summary shall be prepared containing pertinent information detailing the specific action that is the basis for the appeal. The summary shall be forwarded to the appellant or the appellant’s authorized representative and to the Office of Administrative Hearings at least 6 days before the hearing date.

B. The appellant and the Department or MCO may request the names of all witnesses that the other party intends to call at the fair hearing.

.06 Hearing Procedures.

A. The appellant, the Program, the MCO, and the delegate agency shall have the opportunity to:

(1) Present witnesses;

(2) Present documentary evidence;

(3) Present oral and written argument without undue interference;

(4) Establish all facts and circumstances the administrative law judge judges to be pertinent; and

(5) Question or refute any testimony or evidence, including an opportunity to confront and cross-examine all witnesses the administrative law judge judges to be adverse.
B. All parties that wish to call a witness at the hearing shall subpoena the witness in accordance with Office of Administrative Hearings procedures in COMAR 28.02.01.11. The appellant or authorized representative may subpoena any employees of the Department, MCO, or delegate agency whose action is being contested by the appellant or whose testimony may be relevant to the issues under consideration as determined by the administrative law judge.

C. Right to Review Record.

(1) If the Program, MCO, or delegate agency introduces as evidence documents from the case record, special investigation file, or other sources, the appellant shall have the opportunity to examine the:

(a) Persons who prepared the documents; and

(b) Case record or special investigation file for the purpose of discovering information favorable to the appellant’s case.

(2) Except as specified in Regulation .05A of this chapter, in addition to the rights specified in §C(1) of this regulation and for purposes of defining reasonable notice under Regulation .03B(9) of this chapter, the appellant or the appellant’s authorized representative shall have the opportunity to examine the appellant’s case record or investigation file upon reasonable notice to the Program, the MCO, or the delegate agency as specified in COMAR 07.01.02.04.

(3) The Program shall have access to relevant portions of the appellant’s medical record in accordance with Health-General Article, §4-305, Annotated Code of Maryland.

D. When a hearing involves a medical issue, such as a diagnosis, an examining physician's report or a medical review team's decision, an additional medical assessment of the appellant's condition shall be obtained and made part of the record if the administrative law judge considers it necessary. Any additional medical assessment shall be made by a person other than the person who made the original medical assessment and shall be obtained at the Department's expense.

E. The delegate agency shall be a party to the fair hearing if the fair hearing involves an issue of eligibility.

F. Appeal for an Individual Enrolled in an MCO.

(1) The parties to the appeal for an individual enrolled in an MCO include the MCO, the enrollee, and the enrollee’s representative or the personal representative of a deceased enrollee’s estate.

(2) If the appeal concerns the medical necessity of a denied, reduced, suspended, or terminated benefit or service to an MCO enrollee, and if the fair hearing meets the Department-established criteria for an expedited hearing as provided in Regulation .04A(3)(b)(ii) of this chapter, the Office of Administrative Hearings shall:
(a) Schedule the hearing and render a bench decision within 3 working days after the Office of Administrative Hearings receives the fair hearing request; and

(b) Issue a follow-up written decision within 30 days of rendering the bench decision if the Office of Administrative Hearings, the appellant or the appellant’s authorized representative, and the MCO agree that a written decision is necessary.

(3) All other appeals from MCO decisions shall be:

(a) Scheduled for a hearing within 30 days of receipt of the appeal and decided on within 30 days of the hearing; and

(b) Otherwise governed by COMAR 10.67.09.05.

.07 The Record.

A. A verbatim recording of the fair hearing shall be made. Nonrecorded or confidential information, which the appellant does not have an opportunity to hear or see, may not be made a part of the hearing record. One transcribed copy of the recording shall be supplied to the appellant at no cost if the appellant takes a further appeal.

B. The following shall constitute the exclusive record of the hearing:

(1) The transcript or recording of testimony and exhibits, or an official report containing the substance of what happened at the hearing;

(2) All papers and requests filed in the proceeding; and

(3) The administrative law judge’s decision.

C. The recording of testimony shall remain in the custody of the Office of Administrative Hearings for a period not to exceed 2 years, or until all litigation involving the decision is terminated. All other components of the record shall remain in the custody of the Program for a period not to exceed 2 years, or until all litigation involving the decision is terminated.

.08 Findings, Timing of Decision, and Effect of Decision.

A. Findings.

(1) The administrative law judge shall:

(a) Prepare a written summary of findings and conclusions based exclusively on the record; and
(b) Make a decision based on his findings and conclusions.

(2) The summary of findings and conclusions shall:

(a) State the evidence, policies, regulations, or laws upon which the administrative law judge's decision is based; and

(b) Provide written notice to the appellant that, if they are not satisfied with the decision, they may seek additional appeals as specified in §C of this regulation.

B. Timing of Hearing Decision.

(1) If the appellant is not enrolled in an MCO, the administrative law judge shall forward to the appellant a copy of the findings, conclusions, and decision within 90 days from the earlier of the following:

(a) The date the appellant postmarked, delivered in person, or sent by email or facsimile to the Office of Health Services a request for a fair hearing pursuant to Regulation .04D(1) of this chapter;

(b) The date the appellant postmarked, delivered in person, or sent by facsimile to the Office of Administrative Hearings or the delegate agency a request for a fair hearing pursuant to Regulation .04D(2) of this chapter;

(c) The date the appellant emailed, postmarked or delivered in person to the Maryland Health Benefit Exchange a request for a fair hearing pursuant to Regulation .04D(2) of this chapter; or

(d) The date the appellant called or sent by facsimile to the Consolidated Services Center a request for a fair hearing pursuant to Regulation .04D(2) of this chapter.

(2) If the appellant is enrolled in an MCO, the administrative law judge shall forward to the appellant or the appellant’s authorized representative a copy of the findings, conclusions, and decision within:

(a) 3 working days after the Office of Administrative Hearings receives the fair hearing request if the appeal concerns the medical necessity of a denied benefit or service, and the hearing that meets the criteria, as determined by the Department, for an expedited hearing as provided in Regulation .04A(3)(b)(ii) of this chapter; or

(b) 30 days of the hearing if the appeal does not concern the medical necessity of a denied benefit or service.

(3) If the date of the fair hearing is postponed at the appellant's request, the length of the postponement may not be counted as part of any of the time periods specified in §B(1) or (2) of this regulation.
C. Appeal Rights.

(1) Any party may seek administrative review of the administrative law judge’s decision as provided in Health-General Article, §§2-206 and 2-207, Annotated Code of Maryland, and subsequent judicial review as provided in State Government Article, §10-215, Annotated Code of Maryland, except if the appeal is solely of a decision of the Maryland Health Benefit Exchange, in which case any party may seek judicial review as provided in State Government Article, §10-215, Annotated Code of Maryland.

(2) An administrative law judge’s decision adverse to the appellant shall be implemented immediately.

(3) To the extent an administrative law judge’s decision upholds the determination of the Maryland Health Benefit Exchange with respect to an applicant for an insurance affordability program described in Regulation .01B(9)(a)—(e), the applicant may appeal to the United States Department of Health and Human Services.

D. Effect of Decision.

(1) When the decision requires action by the delegate agency, that agency shall notify the Program of its compliance with the decision.

(2) When the decision is favorable to the appellant, or when the Department, Program, or delegate agency grants the appellant the relief the appellant requests before the decision, the Department, Program, or delegate agency, where applicable, shall:

(a) Authorize corrected payments or relief retroactive to the date the incorrect action was taken; and

(b) If appropriate, provide for admission or readmission of the appellant to a facility.

(3) Any payment or action by the Department, Program, or delegate agency in §D(2) of this regulation may not constitute a waiver of the Department’s, Program’s or delegate agency’s sovereign immunity from suit.

(4) When the decision is favorable to the appellant and is an MCO service, the MCO shall authorize or provide the disputed services no later than 72 hours from the date it receives notice reversing the MCO’s determination.

.09 Confidentiality.

A. If the appellant waives in writing his privilege of confidentiality as to the fair hearing, the administrative law judge shall permit members of the public to attend the hearing.
B. The administrative law judge may cause the removal of any member of the public whose conduct impedes the orderly progress of the hearing, or recess the hearing until it may proceed in orderly fashion.

C. The administrative law judge may exclude from the hearing individuals who have not given the Department or MCO advance notice of their intention to attend if the size of the hearing room is too small to accommodate them.

.10 Benefits During Appeals Process.

A. Benefits Pending Outcome of the Hearing.

(1) The Program may terminate or reduce services effective as of the date specified in the notice if the Program timely mails the notice as required under Regulation .03 of this chapter and:

(a) The appellant or the appellant’s authorized representative does not timely request a hearing in accordance with Regulation .04 of this chapter; or

(b) The appellant or the appellant’s authorized representative withdraws in writing or abandons a request for a fair hearing.

(2) Except as provided in §A(3) of this regulation, the Program may not terminate or reduce services until a decision is rendered after the hearing if:

(a) The Program timely mails the notice as required under Regulation .03 of this chapter; and

(b) The appellant requests a hearing before the date specified in the notice.

(3) The Program may terminate or reduce services before an administrative law judge renders a decision after a hearing if:

(a) The administrative law judge determines at the hearing that the sole issue is one of federal or State law or policy, or the request for a fair hearing is withdrawn in writing or abandoned; and

(b) The Program includes in the notification required by Regulation .03 of this chapter that services are to be terminated or reduced pending the hearing decision.

(4) The MCO shall continue benefits pending the outcome of the State fair hearing as described in COMAR 10.67.09.05F.

B. Reinstating Benefits.
(1) If the Program terminates or reduces services pursuant to §A of this regulation, the Program may reinstate services if a Program recipient requests a hearing not more than 10 days after the date specified in the notice.

(2) The reinstated services shall continue until a hearing decision, unless, at the hearing, the administrative law judge determines that the sole issue is one of federal or State law or policy.

(3) The Program shall reinstate and continue services until a decision is rendered after a hearing if:

(a) Action is taken without the advance notice being given to the recipient as required by Regulation .03 of this chapter;

(b) The recipient requests a hearing within 10 days of the mailing of the notice; and

(c) The Program determines that the action resulted from other than the application of federal or State law or policy.

(4) If a recipient's whereabouts are unknown, as indicated by the return of unforwardable Program mail directed to the recipient, any discontinued services shall be reinstated if the recipient’s whereabouts become known during the time the recipient is eligible for services.

(5) The administrative law judge may provide for an additional period during which time the request for a fair hearing will result in reinstatement of a recipient’s assistance to be continued until the hearing decision.

.11 Applicability of Regulations.

If a conflict exists between this chapter and the Rules of Procedure of the Office of Administrative Hearings in COMAR 28.02.01, this chapter shall govern.

.12 Authorized Representatives.

A. Definitions.

(1) “Authorized representative” means an individual or organization acting responsibly on behalf of the applicant or recipient in accordance with §§B, C, D, and E of this regulation, in assisting with an applicant or recipient’s application, renewal of eligibility, appeals, and other ongoing communications with the agency.

(2) “Signature” includes electronic, including telephonically recorded, signatures and handwritten signatures transmitted by facsimile or other electronic transmissions.

B. Designating an Authorized Representative.
(1) An applicant or recipient may designate any individual or organization to serve as an authorized representative.

(2) An authorized representative may be designated either:

   (a) In writing, including the applicant or recipient’s signature; or

   (b) By providing proof of legal authority to act on behalf of an applicant or recipient.

(3) Legal authority includes, but is not limited to those who are the:

   (a) Applicant or, if applicant or recipient is a minor, recipient’s parent;

   (b) Applicant or recipient’s legal guardian, if one has been appointed, or a person who has in good faith filed an application to be appointed the applicant or recipient’s legal guardian but who has not yet been appointed the applicant or recipient’s legal guardian;

   (c) Applicant or recipient’s healthcare surrogate as defined in Health General Article, §5-605, Annotated Code of Maryland;

   (d) Personal representative of the applicant or recipient’s estate, or a person who has in good faith filed an application to be appointed the personal representative of the applicant or recipient’s estate but who has not yet been appointed the personal representative of the applicant or recipient’s estate;

   (e) Individual appointed to make legal or medical decisions on behalf of the applicant or recipient pursuant to a validly executed power of attorney; or

   (f) Attorney or paralegal retained by the individual.

(4) For individuals who lack the capacity to designate an authorized representative and for whom no other individual or organization has the legal authority to act under §B(2) of this regulation, an authorized representative can be any individual or organization acting responsibly on behalf of the applicant or recipient who:

   (a) In good faith, is acting in the best interest of the applicant or recipient; and

   (b) Declares the applicant or recipient lacks legal capacity, and for organizations, declares that its directors, employees, officers or employers, if any, do not have a direct financial interest in the outcome of the fair hearing.

(5) For individuals who lack the capacity to designate an authorized representative, for whom no other individual or organization has the legal authority to act under §B(2) of this regulation, and on behalf of whom no individual or organization covered by §B(4) of this regulation is willing and able to act, an authorized representative can be any individual or
organization with a direct financial interest in the outcome of the hearing or whose employer has a direct financial interest in the outcome of the hearing who:

(a) In good faith is acting in the best interest of the applicant or recipient;

(b) Declares that the applicant or recipient lacks legal capacity; and

(c) Declares that to the best of his or her belief, no other individual or organization is willing and able to act on the applicant or recipient’s behalf.

C. Time for Authorization. Designation of an authorized representative or the declarations by an individual or organization required under §B(4) and (5) of this regulation to become an authorized representative can take place at any time, including, but not limited to, the time of application, upon redetermination, upon filing an appeal, and at the appeal hearing.

D. Validity of Representation. The power to act as an authorized representative is valid until the applicant or recipient modifies the authorization or notifies the agency that the representative is no longer authorized to act on his or her behalf, or the authorized representative informs the agency that the authorized representative is no longer acting in such capacity, or there is a change in the legal authority upon which the individual or organization’s authority was based. This notice shall be in writing and shall include the applicant or recipient’s signature or the authorized representative’s signature as appropriate.

E. Powers of Authorized Representative. Authorized representatives may be authorized to:

(1) Sign an application on the applicant’s behalf;

(2) Complete and submit an update, a renewal form, or respond to a request for redetermination;

(3) Receive copies of the applicant or recipient’s notice and other communications from the agency; and

(4) Act on behalf of the applicant or recipient in all matters with the agency including appeals.

F. Obligations of the Authorized Representative. An authorized representative:

(1) Is responsible for fulfilling all the responsibilities encompassed within the scope of the authorized representation as described in §E of this regulation to the same extent as the individuals the authorized representative represents; and

(2) Shall agree to maintain, or be legally bound to maintain, the confidentiality of any information regarding the applicant or recipient provided by the agency.
G. Authorized Representatives Through an Organization. A provider, staff member or volunteer of an organization shall sign an agreement that he or she will adhere to the federal regulations governing authorized representatives as laid out in 42 CFR §435.923 or 45 CFR §155.227, or both, as well as relevant State and federal laws concerning conflicts of interest and confidentiality of information.
Subtitle 09 Medical Care Programs
Chapter 69 Maryland Medicaid Managed Care Program: Rare and Expensive Case Management

.01 Purpose.

A. The purpose of the Rare and Expensive Case Management (REM) program is to provide case management services and subspecialty care for Maryland Medicaid Managed Care Program eligible individuals with rare and expensive conditions.

B. The program is designed to provide Maryland Medicaid Managed Care Program eligible individuals diagnosed with qualifying rare and expensive conditions the following benefits when the individual elects to participate in the program:

   (1) Case management services; and

   (2) REM optional services.

.02 Definitions.

A. In this chapter, the following terms have the meanings indicated.

B. Terms Defined.

   (1) "Activities of daily living" means tasks or activities that include but are not limited to bathing, feeding, toileting, dressing, and ambulation.

   (2) "Business day" means any day except Saturday, Sunday, or a holiday on which State offices are closed.

   (3) "Caregiver" means a willing and able individual who is trained in providing care to the participant.

   (4) "Case management" means assessing, planning, coordinating, and monitoring the delivery of medically necessary health-related services.

   (5) "Case management provider" means the Department's designee, or a subcontractor of the designee, which provides case management to participants assigned to it by the Department.

   (6) "Case manager" means, an individual who is:

       (a) A social worker with active and nationally recognized certification in case management or an RN;
(b) Employed by the Department's designee; and

(c) Assigned by the Department’s designee to manage the care of some or all of the participants.

(7) "Cause" means a significant change in medical condition such that it is no longer medically efficacious for the individual to remain in the MCO as determined by the Department.

(8) "Certified medication technician (CMT)" means an individual who:

(a) Completes a 20-hour course in medication administration approved by the Maryland Board of Nursing;

(b) Is certified by the Maryland Board of Nursing under COMAR 10.39.04; and

(c) Performs medication administration tasks delegated by a nurse in accordance with COMAR 10.27.11.

(9) "Certified nursing assistant (CNA)" means an individual who:

(a) Is certified by the Maryland Board of Nursing under COMAR 10.39.05; and

(b) Routinely performs nursing tasks delegated by a nurse in accordance with COMAR 10.27.11.

(10) "Certified nursing assistant certified as a CMT (CNA-CMT)" means an individual who:

(a) Is certified by the Maryland Board of Nursing under COMAR 10.39.05 and 10.39.04;

(b) Completes a 20-hour course in medication administration approved by the Maryland Board of Nursing; and

(c) Routinely performs nursing tasks including medication administration tasks delegated by a nurse in accordance with COMAR 10.27.11.

(11) "Chiropractor" means an individual who is licensed by the Maryland State Board of Chiropractic Examiners to practice chiropractic in Maryland.

(12) "Delegated nursing services" means nursing services provided to a participant by a CNA, CNA-CMT, HHA, or HHA-CMT under the supervision of an RN in accordance with COMAR 10.27.11.

(13) "Dental service provider" means an individual who is licensed and legally authorized to practice dentistry in the state in which the service is provided.
(14) "Department" means the Department of Health, as defined in COMAR 10.09.36.01, or its authorized agents acting on behalf of the Department.

(15) "Dietitian-nutritionist" means an individual who is licensed as a dietitian-nutritionist by the Maryland State Board of Dietetic Practice to practice dietetics in Maryland.

(16) "Early and periodic screening, diagnosis, and treatment (EPSDT)" means the provision, to individuals younger than 21 years old, of preventive health care pursuant to 42 CFR §441.50 et seq., as amended, and other health care services, diagnostic services, and treatment services that are necessary to correct or ameliorate defects, physical and mental illnesses, and conditions discovered by EPSDT screening services.

(17) "EPSDT-certified provider" means a physician, physician assistant or nurse practitioner who is certified by the Department's EPSDT program to provide well-child services according to the Department's periodicity schedule and program standards to enrollees younger than 21 years old.

(18) "EPSDT periodicity schedule" means the list approved by the Department of required or recommended preventive health care services for children and adolescents.

(19) "EPSDT services" means:

(a) Screening services provided by an EPSDT-certified provider that are required or recommended on the EPSDT periodicity schedule; and

(b) Health care services performed to diagnose, treat, or refer problems or conditions discovered during the comprehensive well-child service.

(20) "Evaluation" means a determination of the health status of a patient in a patient's home or any other appropriate setting by a licensed professional for the purpose of designing an individual plan of care, which incorporates the modalities of treatment that will promote optimal functional ability and recuperation.

(21) "Family member" means an adult who:

(a) Lives with or provides care to the participant; and

(b) Is not paid to provide the care under the REM program.

(22) "HealthChoice" means Maryland Medicaid’s Statewide mandatory managed care program as defined in COMAR 10.67.04.

(23) "Home" has the meaning stated in COMAR 10.09.53.01.

(24) "Home health agency" means an agency licensed by the Department in accordance with COMAR 10.07.10.
(25) "Home health aide (HHA)" means an individual who meets all the conditions of participation specified in:

(a) 42 CFR §484.36; and

(b) Health Occupations Article, Title 8, Annotated Code of Maryland.

(26) "Home health aide certified as a CMT (HHA-CMT)" means an individual who:

(a) Meets all the conditions of participation specified in 42 CFR §484.36 and Health Occupations Article, Title 8, Annotated Code of Maryland; and

(b) Completes a 20-hour course in medication administration approved by the Maryland Board of Nursing.

(27) "Hospital" means an institution licensed by and providing services in accordance with Health-General Article, §19-301, Annotated Code of Maryland.

(28) "Individualized education program (IEP)" means a written description of special education and related services developed by an IEP team to be implemented to meet the individual needs of a child.

(29) "Individualized family service plan (IFSP)" means a written plan for providing early intervention and other services to an eligible child and the child’s family developed by an IFSP team.

(30) "Interdisciplinary team" means the group comprised of the case manager and relevant service providers to develop the case management plan under the overall direction and coordination of the case manager, in consultation with the participant and, when applicable, the participant's family.

(31) "Intermediate care facility for individuals with intellectual disabilities or individuals with related conditions (ICF-IID)" means an institution licensed by the Department under COMAR 10.07.20 that provides health-related services or health rehabilitative services for individuals with intellectual disabilities or related conditions.

(32) "Licensed practical nurse (LPN)" means an individual licensed to practice licensed practical nursing as defined in Health Occupations Article, §8-301, Annotated Code of Maryland.

(33) "Managed care organization (MCO)" has the meaning stated in Health-General Article, §15-101, Annotated Code of Maryland.

(34) "Medical Assistance" means the program administered by the State under Title XIX of the Social Security Act which provides comprehensive medical and other health-related care for categorically eligible and medically needy individuals.
(35) "Medically necessary" means that the service or benefit is:

(a) Directly related to diagnostic, preventive, curative, palliative, rehabilitative, or ameliorative treatment of an illness, injury, disability, or health condition;

(b) Consistent with current accepted standards of good medical practice;

(c) The most cost-efficient service that can be provided without sacrificing effectiveness or access to care; and

(d) Not primarily for the convenience of the participant, the participant’s family, or the provider.

(36) "Medicare" means the federal program that provides benefits to the aged and disabled under Title XVIII of the Social Security Act, 42 U.S.C. §1395 et seq.

(37) "Nurse" means an individual who is licensed to practice as a registered nurse (RN) or a licensed practical nurse (LPN) in the jurisdiction in which services are provided.

(38) "Nurse practitioner" means an individual who is licensed and certified to practice as a nurse practitioner in the jurisdiction in which services are provided.

(39) "Nursing facility" has the meaning stated in COMAR 10.09.10.01B.

(40) "Nutritional counseling" means the assessment of the participant’s nutritional status and education about improving their nutritional status provided by a licensed dietitian-nutritionist.

(41) "Nutritional supplements" means enteral feeding which is medically indicated as either the sole source of nutrition or a supplement that enhances the physical well-being of the participant.

(42) "Occupational therapist" means an individual licensed by the Maryland State Board of Occupational Therapy Practice to practice occupational therapy in Maryland.

(43) "Participant" means an eligible individual who is enrolled in the Program.

(44) "Physician" means an individual who is licensed or otherwise legally authorized to practice in the jurisdiction in which the services are rendered.

(45) "Physician assistant" means an individual who is licensed to practice medicine with physician supervision as stated in the Health Occupations Article, §§15-301(d) and (e) and 15-302, Annotated Code of Maryland.

(46) "Plan of care" means the document which governs a participant's care management which includes the:
(a) Case management assessment report;

(b) Interdisciplinary plan of care; and

(c) Case management plan.

(47) "Preauthorization" means the approval required from the Department or its designee before specific services may be rendered.

(48) "Primary care provider (PCP)" means a physician, physician assistant, or nurse practitioner who is the primary coordinator of care for the participant, and whose responsibility it is to provide accessible, continuous, comprehensive, and coordinated health care services covering the full range of benefits required by the Maryland Medicaid Managed Care Program, as specified in COMAR 10.67.06.

(49) "Private duty nursing" means skilled nursing services for participants, who require more individual and continuous care than is available under the home health program, which are provided by a registered nurse (RN) or a licensed practical nurse (LPN), in a participant’s home or another setting when normal life activities take the participant outside his or her home.

(50) "Program", unless the context indicates otherwise, has the meaning stated in COMAR 10.09.36.01B.

(51) "Progress note" means a signed and dated written notation by the RN, LPN, CNA, CNA-CMT, HHA, or HHA-CMT, which:

(a) Summarizes facts about the care given and the participant's response during a given period of time;

(b) Specifically addresses the established goals of treatment;

(c) Is consistent with the participant's plan of care; and

(d) Is written during the course of care.

(52) "Provider" means an individual, agency, or facility, which is enrolled in the Program through an agreement with the Department, and has been identified as a Program provider by the issuance of a provider number.

(53) "Rare and expensive case management (REM)" means a Maryland Medical Assistance program that provides case management services and optional services to eligible individuals with specific rare and expensive conditions.

(54) "Rare and expensive condition" means a medical diagnosis or condition identified in Regulation .16 of this chapter.
(55) "Registered nurse (RN)" means an individual licensed to practice registered nursing as defined in Health Occupations Article, §8-301, Annotated Code of Maryland.

(56) "REM optional services" means the services listed in Regulations .09 and .10 of this chapter, which meet the general requirements under Regulation .08 of this chapter.

(57) "Residential service agency" means an agency licensed by the Department in accordance with COMAR 10.07.05.

(58) "Residential treatment center" means any institution which falls within the jurisdiction of Health-General Article, §19-308, Annotated Code of Maryland, and is licensed as required by COMAR 10.07.04 or other applicable standards established by the state in which the service is provided.

(59) "Social worker" means an individual who is licensed by the Maryland State Board of Social Work Examiners to practice social work in Maryland.

(60) "Speech-language pathologist" means an individual who is licensed by the Maryland Board of Examiners for Audiologists, Hearing Aid Dispensers, and Speech-Language Pathologists to practice speech-language pathology in Maryland.

.03 REM Eligibility.

A. An individual is eligible to participate in the REM program if the individual:

(1) Is eligible for Maryland Medicaid Managed Care as specified in COMAR 10.67.02.01; and

(2) Has one or more of the diagnoses specified in Regulation .17 of this chapter; and

(3) Elects to participate in the REM program.

B. The Department shall render a determination of an individual's eligibility within 5 business days on receipt of:

(1) A completed REM application;

(2) Any requested documentation verifying an individual meets the criteria set forth in §A of this regulation; and

(3) Verbal or written confirmation an individual elects to participate.
.04 Participant Enrollment and Disenrollment.

A. Anyone may refer an individual into the REM program including, but not limited to a:

(1) Family member;

(2) Physician;

(3) Discharge planner;

(4) Hospital;

(5) Clinic;

(6) Social worker; and

(7) Managed care organization (MCO).

B. The Department shall enroll an individual determined eligible in the REM program when:

(1) All pertinent documentation regarding needed medical services is received, reviewed, and approved;

(2) Confirmation of the individual's election to participate in the program is received; and

(3) The individual is being discharged from an institution or transitioning from an MCO and service coordination is complete.

C. When an MCO participant is referred to the REM program for enrollment, the MCO shall:

(1) Provide confirmation of the qualifying diagnosis to the Department; and

(2) Continue to provide the MCO participant's care until the Department confirms the diagnosis and enrolls the MCO participant into REM.

D. An individual shall be enrolled in or auto-assigned into an MCO as specified in COMAR 10.67.02, not later than 60 days from the date the individual becomes ineligible for REM, as a result of changes in the diagnosis or age group criteria specified in Regulation .17 of this chapter, except when the individual was allowed to remain in REM in accordance with §I of this regulation.

E. A REM participant may elect to disenroll from REM and enroll in an MCO by notifying the Department of that decision except when the individual was allowed to remain in REM in accordance with §I of this regulation.

F. Election to Remain in MCO.
(1) An individual who becomes eligible for REM while enrolled in an MCO may elect to remain in an MCO by notifying the Department of that decision.

(2) When a REM-eligible individual elects to remain in an MCO, the Department, in consultation with the MCO and the REM-eligible individual, may determine whether the MCO can appropriately meet the individual's medical needs within the parameters of the program benefit package as described in COMAR 10.67.06.

(3) If the MCO determines it cannot appropriately meet the individual's medical needs, the MCO shall submit to the Department written justification for its decision.

(4) If the Department determines the MCO can meet the individual's medical needs, the Department shall notify the MCO of its decision in writing.

(5) If the Department determines that the MCO cannot appropriately meet the individual’s needs, the Department shall issue a written determination to the individual and the MCO which includes:

(a) The reason for the determination; and

(b) An explanation of the individual’s right to appeal the determination according to the procedures set forth in COMAR 10.01.04.

(6) If the Department determines that the MCO can appropriately meet the individual's medical needs, the individual's election becomes effective and cannot be revoked without cause for a period of 1 year from the effective date.

G. The Department shall allow an individual who, immediately before enrollment in REM, was receiving medical services from a specialty clinic or other setting to continue to receive services in that setting on enrollment in the REM program when the provider is willing to participate as a Medical Assistance fee-for-service provider.

H. An individual eligible for REM who has elected to enroll in an MCO or to remain enrolled in an MCO may not receive REM services under the REM program.

I. The Department shall disenroll from the REM program a participant who no longer meets the conditions specified in Regulation .03 of this chapter unless:

(1) The participant does not meet the condition under Regulation .03A(1) of this chapter because the participant becomes eligible for Medicare; and

(2) At the time the participant became eligible for Medicare the participant was approved for and was receiving private duty nursing, CNA, CNA-CMT, HHA, or HHA-CMT services under the REM program.
J. An individual disenrolled from REM by the Department who maintains HealthChoice eligibility is subject to the MCO enrollment provisions specified in COMAR 10.67.02 except when the individual was allowed to remain in REM in accordance with §I of this regulation.

.05 Benefits.

A REM participant is eligible for the following:

A. Fee-for-service Medical Assistance benefits available to a Medical Assistance participant not enrolled in an MCO;

B. Services described in Regulations .10 and .11 of this chapter when determined medically necessary by the Department;

C. A case management assessment performed by a REM case manager who shall:

   (1) Gather all relevant information needed to determine the participant’s condition and needs including the participant’s medical records;

   (2) Consult with the participant's current service providers; and

   (3) Evaluate the relevant information and complete a needs analysis including medical, psychosocial, environmental, and functional assessments; and

D. Case management services performed by a REM case manager who shall:

   (1) When necessary, assist the REM participant, offering the participant a choice, if possible, in selecting and obtaining a PCP, who may be a specialist to the participant’s condition, giving preference to any pre-established relationships between the participant and the participant’s PCP;

   (2) Develop a plan of care in consultation with the participant, the participant's family members as authorized by the participant when possible, the PCP, and other providers rendering care that:

      (a) Includes the participant's health status and needs for medical, health-related, housing, and social services including, but not limited to:

         (i) All pertinent diagnoses including the REM qualifying diagnosis;

         (ii) Type, frequency, and duration of services;

         (iii) Treatment goals for each type of service;

         (iv) Medical equipment and supplies;
(v) Medication;
(vi) Social support structure;
(vii) Current service providers;
(viii) Assigned level of care;
(ix) Nutritional status;
(x) Education or vocational information;
(xi) Current living arrangement; and
(xii) Emergency plan, if appropriate; and

(b) Is developed in consultation with the interdisciplinary team;

(3) Implement the plan of care and assist the participant in gaining access to medically necessary services by linking the participant to those services;

(4) Monitor service delivery, perform record reviews, and maintain contacts with the participant, services providers, and family members to evaluate the participant's condition and progress and to determine whether revision is needed in the plan of care or in services' delivery;

(5) As necessary, initiate and implement modifications to the plan of care and communicate these changes to the participant, parents or caregivers, and pertinent health care providers;

(6) Monitor a participant's receipt of EPSDT services as specified in COMAR 10.67.06; and

(7) Assist the participant with the coordination of school health-related services such as the IEP or the IFSP as described in COMAR 10.09.50.

.06 Requirements for Provider Qualification.

A. A case manager providing case management under this chapter shall be:

(1) An RN; or

(2) A social worker.

B. The following professionals providing services under this chapter to REM participants shall be licensed, certified, or otherwise legally authorized to practice in the jurisdiction in which the services are rendered:
(1) Physicians;
(2) Physician Assistants;
(3) Nurse Practitioners;
(4) RNs and LPNs;
(5) Chiropractors;
(6) Dentists;
(7) Dietitian-Nutritionists;
(8) Occupational therapists;
(9) Social workers;
(10) Speech-language pathologists; and
(11) CNAs, HHAs, CNA-CMTs, and HHA-CMTs.

C. A provider rendering services pursuant to this chapter shall meet all applicable licensure and certification requirements of the jurisdiction in which the provider is providing services.

D. A provider rendering services to REM participants, pursuant to this chapter, may not have current sanctions or current disciplinary actions imposed by:

(1) The jurisdictional licensing or certification authority;
(2) The Medicare Program;
(3) The Program; or
(4) Other federally funded healthcare programs.

.07 Conditions for Participation — General Requirements.

A provider rendering services pursuant to this chapter shall:

A. Meet the applicable conditions for participation set forth in COMAR 10.09.36;

B. Meet the provider qualification requirements specified in Regulation .06 of this chapter for its provider type;
C. Meet the specific conditions for provider participation set forth in this chapter;

D. Provide services in accordance with the applicable requirements of this chapter and all other relevant State and local laws and regulations;

E. Verify the qualifications of all subcontracted or employed professionals and individuals engaged by the provider agency to render services covered under this chapter and provide a copy of their current licensure and credentials on request to the Department;

F. Provide services to REM program participants in a manner consistent with the REM participant’s plan of care; and

G. When the Department determines it is necessary, participate in the interdisciplinary team meetings for the purpose of:

(1) Developing and implementing a participant's treatment plan or plan of care with the Department; or

(2) Accessing a specific service.

.08 Specific Conditions for Provider Participation.

A. Case Management Providers. To participate in the Program, a case management provider shall meet the conditions set forth in Regulations .06 and .07 of this chapter.

B. Chiropractic Service Providers. To participate in the Program, the chiropractic service provider shall:

(1) Meet the:

(a) Conditions set forth in Regulation .07 of this chapter; and

(b) Requirements for chiropractic providers specified in COMAR 10.43.04;

(2) Develop a goal-directed treatment plan that is based on an evaluation conducted during the initial assessment, which requires:

(a) A review or evaluation of the treatment plan 30 days after the initial assessment; and

(b) A review and update of the treatment plan every 90 days; and

(3) Render services in accordance with orders written by a physician, physician assistant, or nurse practitioner.

C. Dental Service Providers. To participate in the Program, the dental service provider shall meet the:
(1) Conditions set forth in Regulation .07 of this chapter; and

(2) Requirements for dental providers specified in COMAR 10.09.05.

D. Nutritional Supplement Providers. To participate as a provider of nutritional supplements, a provider shall meet the:

(1) Conditions of participation as set forth in Regulation .07 of this chapter; and

(2) Criteria of the conditions for participation for pharmacy providers set forth in COMAR 10.09.03.

E. Shift Private Duty Nursing/CNA/CNA-CMT/HHA/HHA-CMT Providers. To participate as a provider agency for shift private duty nursing, CNA, CNA-CMT, HHA, or HHA-CMT services, a provider shall:

(1) Meet the conditions set forth in Regulation .07 of this chapter;

(2) Meet all requirements of conditions for participation set forth in COMAR 10.09.53.03;

(3) Participate in interdisciplinary team meetings, when requested by the Department or its designee;

(4) Develop a goal-directed written nursing care plan that is based on an evaluation conducted during the initial assessment, which requires:

   (a) A review or evaluation of the nursing care plan 30 days after the initial assessment; and

   (b) A review and update of the nursing care plan every 90 days;

(5) Ensure timesheets are signed by the individual rendering services;

(6) Ensure a nurse's, CNA’s, CNA-CMT’s, HHA’s, or HHA-CMT’s shift to be not more than a total of 60 hours per week or 16 consecutive hours and that the individual is off 8 or more hours before starting another shift unless otherwise authorized by the Department;

(7) Obtain the participant's signature or the signature of the participant's witness on the provider's official forms to verify receipt of service; and

(8) Be licensed as a:

   (a) Residential service agency in accordance with COMAR 10.07.05; or

   (b) Home health agency in accordance with COMAR 10.07.10 which meets the conditions of participation specified by the Medicare program in 42 CFR §484.36.
F. Occupational Therapy Providers. To participate in the Program as a provider of occupational therapy services, a provider shall:

(1) Meet the conditions set forth in Regulation .07 of this chapter;

(2) Be a self-employed occupational therapist licensed according to COMAR 10.46.01;

(3) Be an agency or clinic which employs occupational therapists or be a Program provider of home health services under COMAR 10.09.04; and

(4) Develop a goal-directed written treatment plan that is based on an evaluation conducted during the initial assessment which requires:

(a) A review or evaluation of the treatment plan 30 days after the initial assessment; and

(b) A review and update of the treatment plan every 90 days.

G. Speech-Language Pathology Providers. To participate in the Program, a speech-language pathology provider shall:

(1) Meet the conditions set forth in Regulation .07 of this chapter;

(2) Be a self-employed speech-language pathologist according to COMAR 10.41.03 or be a Program provider of home health services under COMAR 10.09.04;

(3) Be an agency or clinic that employs speech-language pathologists; and

(4) Develop a goal-directed written treatment plan that is based on an initial assessment, which requires:

(a) A review or evaluation of the treatment plan 30 days after the initial assessment; and

(b) A review and update of the treatment plan every 90 days.

.09 Covered Services — General Requirements.

For participants in the REM program, the Program covers and shall reimburse for services specified in Regulations .10 and .11 of this chapter when these services are:

A. Medically necessary;

B. Prescribed by a:

(1) Physician;
(2) Physician assistant; or

(3) Nurse practitioner;

C. Preauthorized, when required, by the Department;

D. Rendered in accordance with accepted health professional standards;

E. Rendered in accordance with the treatment plan or physician's, physician assistant’s, or nurse practitioner’s order, or both; and

F. Delivered by an enrolled Medical Assistance provider.

.10 Covered Services.

A. Chiropractic services are covered for REM participants when:

(1) Services are provided to a REM participant who is 21 years old or older;

(2) Services are provided by a physician or chiropractor;

(3) The qualifying REM diagnosis or related illness shows deterioration or worsening symptoms and other traditional treatments have been ineffective;

(4) The treatment enhances or restores the participant's level of functioning; or

(5) Symptoms resulting from the REM diagnosis or related illness impairs a participant's activities of daily living.

B. Dental services are covered when services are:

(1) Provided to a REM participant who is 21 years old or older; and

(2) Rendered as specified in COMAR 10.09.05.

C. Nutritional counseling services are covered when services are provided:

(1) To a REM participant who is 21 years old or older; and

(2) By a dietitian-nutritionist.

D. Nutritional supplements are covered when the services:
(1) Include nutritional supplements or enteral feeding when medically necessary other than those administered by tube; and

(2) Are as described in COMAR 10.09.03.

E. The Department shall cover a physician's, physician assistant’s, or nurse practitioner’s participation at interdisciplinary team meetings when the case manager, in conjunction with the team or specific team members, convenes the team meeting for the purpose of developing or reviewing the REM participant's plan of care to ensure continuity of care or access to a specific service.

F. Occupational therapy services are covered when services are provided:

   (1) To a REM participant who is 21 years old or older;

   (2) By an occupational therapist; and

   (3) In accordance with COMAR 10.46.01 and 10.46.02.

G. Speech-language pathology services include only those services that are provided:

   (1) To a REM participant who is 21 years old or older;

   (2) By a speech-language pathologist; and

   (3) In accordance with COMAR 10.41.02 and 10.41.03.

.11 Covered Optional Services — Private Duty Nursing, Certified Nursing Assistant, Certified Nursing Assistant Certified as a Certified Medication Technician, Home Health Aide and Home Health Aide Certified as a Certified Medication Technician.

A. The Program shall cover shift nursing services provided by an RN or LPN when:

   (1) The services are more individualized and continuous than what is available under the home health program;

   (2) The services are delivered to the participant in the participant's home, in school, or in other normal life activity setting or settings which occur outside the participant's home;

   (3) Services are provided to a REM participant who is 21 years old or older;

   (4) Services are rendered in accordance with COMAR 10.09.53;

   (5) Services are rendered in accordance with Health Occupations Article, Title 8, Annotated Code of Maryland;
(6) Sufficient documentation concerning the services provided is maintained by the RN or LPN including:

   (a) Verification of the participant's receipt of services as documented by the participant's signature or the signature of the participant's witness on the provider's official forms; and

   (b) Signed and dated progress notes which are reviewed monthly by the RN supervisor;

(7) The nurse's shift is limited to not more than a total of 60 hours per week or 16 consecutive hours and the nurse is off 8 or more hours before starting another shift unless otherwise authorized by the Department;

(8) Services are rendered by an RN or an LPN who is certified in cardiopulmonary resuscitation and the certification is renewed every 2 years;

(9) Services are preauthorized in accordance with the criteria set forth in COMAR 10.09.53; and

(10) Monthly supervisory visits of an RN or an LPN are:

   (a) Conducted and documented by an RN supervisor; and

   (b) Based on acceptable standards of practice.

B. The Program shall cover services provided by a CNA or CNA-CMT when:

   (1) The CNA or CNA-CMT is certified by the Maryland Board of Nursing and meets all the requirements to render services pursuant to Health Occupations Article, Title 8, Annotated Code of Maryland;

   (2) The CNA-CMT has completed the training and has been certified by the Maryland Board of Nursing as a CMT;

   (3) Services are of a scope that is more individual and continuous than what is available under the home health program;

   (4) The services provided include but are not limited to:

      (a) Assistance with activities of daily living when performed in conjunction with other delegated nursing services; or

      (b) Other health care services properly delegated by an RN or an LPN pursuant to Health Occupations Article, Title 8, Annotated Code of Maryland;

   (5) Services are rendered by a CNA or CNA-CMT who is certified in cardiopulmonary resuscitation and the certification is renewed every 2 years;
(6) The CNA’s or CNA-CMT’s shift is limited to not more than a total of 60 hours per week or 16 consecutive hours and the CNA or CNA-CMT has 8 hours or more off before starting another shift unless otherwise authorized by the Department;

(7) Sufficient documentation concerning the services provided is maintained by the CNA or CNA-CMT including:

(a) Verification of the participant's receipt of services as documented by the participant's signature or the signature of the participant's witness on the provider's official forms; and

(b) Signed and dated progress notes which are reviewed every 2 weeks by the RN supervisor;

(8) Supervisory visits are conducted and documented every 2 weeks by an RN;

(9) The services are included in the REM participant's plan of care developed by the case manager; and

(10) Services are preauthorized by the Department.

C. The Program shall cover services provided by a HHA or HHA-CMT when:

(1) Services are provided by an unlicensed individual who meets all the conditions of participation specified by the Medicare program in 42 CFR §484.36 and Health Occupations Article, Title 8, Annotated Code of Maryland;

(2) The HHA-CMT has completed the training and has been certified by the Maryland Board of Nursing as a CMT;

(3) Services are more individualized and continuous than what is available under the home health program;

(4) The services provided include but are not limited to:

(a) Assistance with activities of daily living when performed in conjunction with other delegated nursing services; or

(b) Other health care services properly delegated by an RN or LPN pursuant to Health Occupations Article, Title 8, Annotated Code of Maryland;

(5) Services are rendered by a HHA or HHA-CMT who is certified in cardiopulmonary resuscitation and the certification is renewed every 2 years;

(6) The HHA’s or HHA-CMT’s shift is limited to not more than a total of 60 hours per week or 16 consecutive hours and the HHA or HHA-CMT has 8 hours or more off before starting another shift unless otherwise authorized by the Department;
(7) Sufficient documentation is maintained by the HHA or HHA-CMT including:

(a) Verification of the participant's receipt of services as documented by the participant's signature or the signature of the participant's witness on the provider's official forms; and

(b) Signed and dated progress notes which are reviewed every 2 weeks by the RN supervisor;

(8) Supervisory visits are conducted and documented every 2 weeks by an RN;

(9) The services are included in the REM participant's plan of care developed by the case manager; and

(10) Services are preauthorized by the Department.

.12 Limitations.

A. The Department shall pay for services specified in this chapter delivered to a REM participant only if the services have been ordered by the participant's physician or nurse practitioner, and preauthorized, when necessary, by the Department or its designee.

B. For REM participants, the Department may not pay for the following comparable case management services:

(1) HIV targeted case management as described in COMAR 10.09.32, except for HIV Diagnostic Evaluation Services as described in COMAR 10.09.32.03C and .04A; and

(2) Model Waiver case management as described in COMAR 10.09.27.

C. The REM program does not cover the following:

(1) Shift private duty nursing, CNA or CNA-CMT, or HHA or HHA-CMT services rendered by a nurse, CNA, HHA, CNA-CMT, or HHA-CMT who is a member of the participant's immediate family or who ordinarily resides with the participant;

(2) Services which are not medically necessary;

(3) Services not supervised by an RN when delivered by the following:

(a) An RN or an LPN;

(b) A CNA;

(c) An HHA;
(d) A CNA-CMT; or

(e) An HHA-CMT.

(4) REM optional services not preauthorized as required by the Department or its designee;

(5) REM optional services not prescribed by the participant's physician, physician assistant, or nurse practitioner;

(6) Services specified in this chapter which duplicate or supplant services rendered by the participant's family caregivers or primary caregivers as well as other insurance, privilege, entitlement, or Program services that the participant receives or is eligible to receive;

(7) Services provided for the convenience or preference of the participant or the primary caregiver rather than required by the participant's medical condition;

(8) Speech, language, or occupational therapy services rendered in a classroom setting; and

(9) Shift private duty nursing, CNA, CNA-CMT, HHA, or HHA-CMT services ordered by a physician assistant.

.13 Preauthorization Requirements.

A. Except for initial assessments unless otherwise specified, preauthorization by the Department or its designee is required for all services under Regulations .10 and .11 of this chapter.

B. The Department or its designee shall issue preauthorization when the Department:

(1) Determines that services are medically necessary; and

(2) Authorizes the services before the initiation or continuance of the requested service.

C. Authorization of services shall be rescinded by the Department or its designee when:

(1) The participant is admitted to a hospital, residential treatment center, nursing facility, or ICF/IID;

(2) The participant is no longer REM eligible;

(3) The Department determines the care is no longer medically necessary; or

(4) The participant dies.
.14 Payment Procedures — Request for Payment.

A. A provider shall submit a request for payment for the services covered under this chapter according to the procedures set forth in COMAR 10.09.36.

B. Billing time limitations for the services covered under this chapter are the same as those set forth in COMAR 10.09.36.

C. The Department shall pay for covered services at the lower of:

   (1) The lowest price, including negotiated contract prices, that is offered to any other purchaser for the same or similar service during the same time period, after extending to the Program all rebates, coupons, and negotiated discounts;

   (2) The actual charge billed by the provider; or

   (3) Any fee schedule developed for reimbursement of the same service provided under Medical Assistance.

D. Effective July 1, 2019, the Department shall pay $412.22 for a case management assessment, as described in Regulation .05C of this chapter.

E. Effective July 1, 2019, the Department shall make payments monthly for case management services at one of the rates specified below:

   (1) Level of Care 1: $304.38;

   (2) Level of Care 2: $181.41; or

   (3) Level of Care 3: $95.75.

F. The rates found in §E of this regulation are the monthly rates paid by the Department for a participant receiving case management as follows:

   (1) Level of Care 1 is intensive level of case management, assessment, and coordination of services for a participant who:

       (a) Is acutely ill;

       (b) Has an unstable clinical condition;

       (c) Has an exacerbated chronic illness; or

       (d) Has a newly diagnosed condition;
(2) Level of Care 2 is case management to a participant who has a history of exacerbations of medical issues requiring services on an ongoing basis to attain stable service or treatment plans; and

(3) Level of Care 3 is case management that is required on an ongoing basis to monitor a participant’s stability and treatment plans.

.15 Recovery and Reimbursement.

Recovery and reimbursement under this chapter are set forth in COMAR 10.09.36.

.16 Cause for Suspension or Removal and Imposition of Sanctions.

Cause for suspension or removal and imposition of sanctions is set forth in COMAR 10.09.36.

.17 Table of Rare and Expensive Disease Diagnosis.

<table>
<thead>
<tr>
<th>ICD10</th>
<th>ICD 10 Description</th>
<th>Age Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>B20</td>
<td>Human immunodeficiency virus (HIV) disease</td>
<td>0—20</td>
</tr>
<tr>
<td>C96.0</td>
<td>Multifocal and multisystemic Langerhans-cell histiocytosis</td>
<td>0—64</td>
</tr>
<tr>
<td>C96.5</td>
<td>Multifocal and unisystemic Langerhans-cell histiocytosis</td>
<td>0—64</td>
</tr>
<tr>
<td>C96.6</td>
<td>Unifocal Langerhans-cell histiocytosis</td>
<td>0—64</td>
</tr>
<tr>
<td>D61.01</td>
<td>Constitutional (pure) red blood cell aplasia</td>
<td>0—20</td>
</tr>
<tr>
<td>D61.09</td>
<td>Other constitutional aplastic anemia</td>
<td>0—20</td>
</tr>
<tr>
<td>D66</td>
<td>Hereditary factor VIII deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>D67</td>
<td>Hereditary factor IX deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>D68.0</td>
<td>Von Willebrand’s disease</td>
<td>0—64</td>
</tr>
<tr>
<td>D68.1</td>
<td>Hereditary factor XI deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>D68.2</td>
<td>Hereditary deficiency of other clotting factors</td>
<td>0—64</td>
</tr>
<tr>
<td>E70.0</td>
<td>Classical phenylketonuria</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.1</td>
<td>Other hyperphenylalaninemias</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.20</td>
<td>Disorder of tyrosine metabolism, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.21</td>
<td>Tyrosinemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.29</td>
<td>Other disorders of tyrosine metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.30</td>
<td>Albinism, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.40</td>
<td>Disorders of histidine metabolism, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.41</td>
<td>Histidinemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.49</td>
<td>Other disorders of histidine metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Points</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>E70.5</td>
<td>Disorders of tryptophan metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E70.8</td>
<td>Other disorders of aromatic amino-acid metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.0</td>
<td>Maple-syrup-urine disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.10</td>
<td>Isovaleric acidemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.11</td>
<td>3-methylglutaconic aciduria</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.118</td>
<td>Other branched-chain organic acidurias</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.120</td>
<td>Methylmalonic acidemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.121</td>
<td>Propionic acidemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.128</td>
<td>Other disorders of propionate metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.19</td>
<td>Other disorders of branched-chain amino-acid metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.2</td>
<td>Disorder of branched-chain amino-acid metabolism, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E71.310</td>
<td>Long chain/very long chain acyl CoA dehydrogenase deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.311</td>
<td>Medium chain acyl CoA dehydrogenase deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.312</td>
<td>Short chain acyl CoA dehydrogenase deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.313</td>
<td>Glutaric aciduria type II</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.314</td>
<td>Muscle carnitine palmitoyltransferase deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.318</td>
<td>Other disorders of fatty-acid oxidation</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.32</td>
<td>Disorders of ketone metabolism</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.39</td>
<td>Other disorders of fatty-acid metabolism</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.41</td>
<td>Primary carnitine deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.42</td>
<td>Carnitine deficiency due to inborn errors of metabolism</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.50</td>
<td>Peroxisomal disorder, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.510</td>
<td>Zellweger syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.511</td>
<td>Neonatal adrenoleukodystrophy</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.518</td>
<td>Other disorders of peroxisome biogenesis</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.520</td>
<td>Childhood cerebral X-linked adrenoleukodystrophy</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.521</td>
<td>Adolescent X-linked adrenoleukodystrophy</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.522</td>
<td>Adrenomyeloneuropathy</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.528</td>
<td>Other X-linked adrenoleukodystrophy</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.529</td>
<td>X-linked adrenoleukodystrophy, unspecified type</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.53</td>
<td>Other group 2 peroxisomal disorders</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.540</td>
<td>Rhizomelic chondrodysplasia punctata</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.541</td>
<td>Zellweger-like syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.542</td>
<td>Other group 3 peroxisomal disorders</td>
<td>0—64</td>
</tr>
<tr>
<td>E71.548</td>
<td>Other peroxisomal disorders</td>
<td>0—64</td>
</tr>
<tr>
<td>Code</td>
<td>Condition</td>
<td>Range</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>E72.01</td>
<td>Cystinuria</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.02</td>
<td>Hartnup’s disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.03</td>
<td>Lowe’s syndrome</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.04</td>
<td>Cystinosis</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.09</td>
<td>Other disorders of amino-acid transport</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.11</td>
<td>Homocystinuria</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.12</td>
<td>Methylene tetrahydrofolate reductase deficiency</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.19</td>
<td>Other disorders of sulfur-bearing amino-acid metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.20</td>
<td>Disorder of urea cycle metabolism, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.21</td>
<td>Argininemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.22</td>
<td>Arginosuccinic aciduria</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.23</td>
<td>Citrullinemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.29</td>
<td>Other disorders of urea cycle metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.3</td>
<td>Disorders of lysine and hydroxylysine metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.4</td>
<td>Disorders of ornithine metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.51</td>
<td>Non-ketotic hyperglycinemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.52</td>
<td>Trimethylaminuria</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.53</td>
<td>Primary hyperoxaluria</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.59</td>
<td>Other disorders of glycine metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.81</td>
<td>Disorders of gamma aminobutyric acid metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E72.89</td>
<td>Other specified disorders of amino-acid metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.00</td>
<td>Glycogen storage disease, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.01</td>
<td>von Gierke disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.02</td>
<td>Pompe disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.03</td>
<td>Cori disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.04</td>
<td>McArdle disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.09</td>
<td>Other glycogen storage disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.12</td>
<td>Hereditary fructose intolerance</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.19</td>
<td>Other disorders of fructose metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.21</td>
<td>Galactosemia</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.29</td>
<td>Other disorders of galactose metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E74.4</td>
<td>Disorders of pyruvate metabolism and gluconeogenesis</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.00</td>
<td>GM2 gangliosidosis, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.01</td>
<td>Sandhoff disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.02</td>
<td>Tay-Sachs disease</td>
<td>0—20</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Range</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>E75.09</td>
<td>Other GM2 gangliosidosis</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.10</td>
<td>Unspecified gangliosidosis</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.11</td>
<td>Mucolipidosis IV</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.19</td>
<td>Other gangliosidosis</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.21</td>
<td>Fabry (-Anderson) disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.22</td>
<td>Gaucher disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.23</td>
<td>Krabbe disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.240</td>
<td>Niemann-Pick disease type A</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.241</td>
<td>Niemann-Pick disease type B</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.242</td>
<td>Niemann-Pick disease type C</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.243</td>
<td>Niemann-Pick disease type D</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.248</td>
<td>Other Niemann-Pick disease</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.25</td>
<td>Metachromatic leukodystrophy</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.26</td>
<td>Sulfatase deficiency</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.29</td>
<td>Other sphingolipidosis</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.3</td>
<td>Sphingolipidosis, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.4</td>
<td>Neuronal ceroid lipofuscinosis</td>
<td>0—20</td>
</tr>
<tr>
<td>E75.5</td>
<td>Other lipid storage disorders</td>
<td>0—20</td>
</tr>
<tr>
<td>E76.01</td>
<td>Hurler’s syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.02</td>
<td>Hurler-Scheie syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.03</td>
<td>Scheie’s syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.1</td>
<td>Mucopolysaccharidosis, type II</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.210</td>
<td>Morquio A mucopolysaccharidoses</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.211</td>
<td>Morquio B mucopolysaccharidoses</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.219</td>
<td>Morquio mucopolysaccharidoses, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.22</td>
<td>Sanfilippo mucopolysaccharidoses</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.29</td>
<td>Other mucopolysaccharidos</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.3</td>
<td>Mucopolysaccharidosis, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>E76.8</td>
<td>Other disorders of glucosaminoglycan metabolism</td>
<td>0—64</td>
</tr>
<tr>
<td>E77.0</td>
<td>Defects in post-translational mod of lysosomal enzymes</td>
<td>0—20</td>
</tr>
<tr>
<td>E77.1</td>
<td>Defects in glycoprotein degradation</td>
<td>0—20</td>
</tr>
<tr>
<td>E77.8</td>
<td>Other disorders of glycoprotein metabolism</td>
<td>0—20</td>
</tr>
<tr>
<td>E79.1</td>
<td>Lesch-Nyhan syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E79.2</td>
<td>Myoadenylate deaminase deficiency</td>
<td>0—64</td>
</tr>
<tr>
<td>E79.8</td>
<td>Other disorders of purine and pyrimidine metabolism</td>
<td>0—64</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Range</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>E79.9</td>
<td>Disorder of purine and pyrimidine metabolism, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>E80.3</td>
<td>Defects of catalase and peroxidase</td>
<td>0—64</td>
</tr>
<tr>
<td>E84.0</td>
<td>Cystic fibrosis with pulmonary manifestations</td>
<td>0—64</td>
</tr>
<tr>
<td>E84.11</td>
<td>Meconium ileus in cystic fibrosis</td>
<td>0—64</td>
</tr>
<tr>
<td>E84.19</td>
<td>Cystic fibrosis with other intestinal manifestations</td>
<td>0—64</td>
</tr>
<tr>
<td>E84.8</td>
<td>Cystic fibrosis with other manifestations</td>
<td>0—64</td>
</tr>
<tr>
<td>E84.9</td>
<td>Cystic fibrosis, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>E88.40</td>
<td>Mitochondrial metabolism disorder, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>E88.41</td>
<td>MELAS syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E88.42</td>
<td>MERRF syndrome</td>
<td>0—64</td>
</tr>
<tr>
<td>E88.49</td>
<td>Other mitochondrial metabolism disorders</td>
<td>0—64</td>
</tr>
<tr>
<td>E88.89</td>
<td>Other specified metabolic disorders</td>
<td>0—64</td>
</tr>
<tr>
<td>F84.2</td>
<td>Rett’s syndrome</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.0</td>
<td>Congenital nonprogressive ataxia</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.1</td>
<td>Early-onset cerebellar ataxia</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.2</td>
<td>Late-onset cerebellar ataxia</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.3</td>
<td>Cerebellar ataxia with defective DNA repair</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.4</td>
<td>Hereditary spastic paraplegia</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.8</td>
<td>Other hereditary ataxias</td>
<td>0—20</td>
</tr>
<tr>
<td>G11.9</td>
<td>Hereditary ataxia, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.0</td>
<td>Infantile spinal muscular atrophy, type I (Werdnig-Hoffman)</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.1</td>
<td>Other inherited spinal muscular atrophy</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.21</td>
<td>Amyotrophic lateral sclerosis</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.22</td>
<td>Progressive bulbar palsy</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.29</td>
<td>Other motor neuron disease</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.8</td>
<td>Other spinal muscular atrophies and related syndromes</td>
<td>0—20</td>
</tr>
<tr>
<td>G12.9</td>
<td>Spinal muscular atrophy, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>G24.1</td>
<td>Genetic torsion dystonia</td>
<td>0—64</td>
</tr>
<tr>
<td>G24.8</td>
<td>Other dystonia</td>
<td>0—64</td>
</tr>
<tr>
<td>G25.3</td>
<td>Myoclonus</td>
<td>0—5</td>
</tr>
<tr>
<td>G25.9</td>
<td>Extrapyramidal and movement disorder, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>G31.81</td>
<td>Alpers disease</td>
<td>0—20</td>
</tr>
<tr>
<td>G31.82</td>
<td>Leigh’s disease</td>
<td>0—20</td>
</tr>
<tr>
<td>G31.9</td>
<td>Degenerative disease of nervous system, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>G32.81</td>
<td>Cerebellar ataxia in diseases classified elsewhere</td>
<td>0—20</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Range</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>G37.0</td>
<td>Diffuse sclerosis of central nervous system</td>
<td>0–64</td>
</tr>
<tr>
<td>G37.5</td>
<td>Concentric sclerosis (Balo) of central nervous system</td>
<td>0–64</td>
</tr>
<tr>
<td>G71.00</td>
<td>Muscular dystrophy, unspecified</td>
<td>0–64</td>
</tr>
<tr>
<td>G71.01</td>
<td>Duchenne or Becker muscular dystrophy</td>
<td>0–64</td>
</tr>
<tr>
<td>G71.02</td>
<td>Facioscapulohumeral muscular dystrophy</td>
<td>0–64</td>
</tr>
<tr>
<td>G71.09</td>
<td>Other specified muscular dystrophies</td>
<td>0–64</td>
</tr>
<tr>
<td>G71.11</td>
<td>Myotonic muscular dystrophy</td>
<td>0–64</td>
</tr>
<tr>
<td>G71.2</td>
<td>Congenital myopathies</td>
<td>0–64</td>
</tr>
<tr>
<td>G80.0</td>
<td>Spastic quadriplegic cerebral palsy</td>
<td>0–64</td>
</tr>
<tr>
<td>G80.1</td>
<td>Spastic diplegic cerebral palsy</td>
<td>0–20</td>
</tr>
<tr>
<td>G80.3</td>
<td>Athetoid cerebral palsy</td>
<td>0–64</td>
</tr>
<tr>
<td>G82.50</td>
<td>Quadriplegia, unspecified</td>
<td>0–64</td>
</tr>
<tr>
<td>G82.51</td>
<td>Quadriplegia, C1-C4 complete</td>
<td>0–64</td>
</tr>
<tr>
<td>G82.52</td>
<td>Quadriplegia, C1-C4 incomplete</td>
<td>0–64</td>
</tr>
<tr>
<td>G82.53</td>
<td>Quadriplegia, C5-C7 complete</td>
<td>0–64</td>
</tr>
<tr>
<td>G82.54</td>
<td>Quadriplegia, C5-C7 incomplete</td>
<td>0–64</td>
</tr>
<tr>
<td>G91.0</td>
<td>Communicating hydrocephalus</td>
<td>0–20</td>
</tr>
<tr>
<td>G91.1</td>
<td>Obstructive hydrocephalus</td>
<td>0–20</td>
</tr>
<tr>
<td>I67.5</td>
<td>Moyamoya disease</td>
<td>0–64</td>
</tr>
<tr>
<td>K91.2</td>
<td>Postsurgical malabsorption, not elsewhere classified</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.1</td>
<td>Chronic nephritic syndrome with focal and segmental glomerular lesions</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.2</td>
<td>Chronic nephritic syndrome w diffuse membranous glomrlneph</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.3</td>
<td>Chronic neph syndrome w diffuse mesangial prolif glomrlneph</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.4</td>
<td>Chronic neph syndrome w diffuse endocaply prolif glomrlneph</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.5</td>
<td>Chronic nephritic syndrome w diffuse mesangiocap glomrlneph</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.6</td>
<td>Chronic nephritic syndrome with dense deposit disease</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.7</td>
<td>Chronic nephritic syndrome w diffuse crescentic glomrlneph</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.8</td>
<td>Chronic nephritic syndrome with other morphologic changes</td>
<td>0–20</td>
</tr>
<tr>
<td>N03.9</td>
<td>Chronic nephritic syndrome with unsp morphologic changes</td>
<td>0–20</td>
</tr>
<tr>
<td>N08</td>
<td>Glomerular disorders in diseases classified elsewhere</td>
<td>0–20</td>
</tr>
<tr>
<td>N18.1</td>
<td>Chronic kidney disease, stage 1</td>
<td>0–20</td>
</tr>
<tr>
<td>N18.2</td>
<td>Chronic kidney disease, stage 2 (mild)</td>
<td>0–20</td>
</tr>
<tr>
<td>N18.3</td>
<td>Chronic kidney disease, stage 3 (moderate)</td>
<td>0–20</td>
</tr>
<tr>
<td>N18.4</td>
<td>Chronic kidney disease, stage 4 (severe)</td>
<td>0–20</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Range</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>N18.5</td>
<td>Chronic kidney disease, stage 5</td>
<td>0—20</td>
</tr>
<tr>
<td>N18.6</td>
<td>End stage renal disease</td>
<td>0—20</td>
</tr>
<tr>
<td>N18.9</td>
<td>Chronic kidney disease, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>Q01.9</td>
<td>Encephalocele, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>Q02</td>
<td>Microcephaly</td>
<td>0—20</td>
</tr>
<tr>
<td>Q03.0</td>
<td>Malformations of aqueduct of Sylvius</td>
<td>0—20</td>
</tr>
<tr>
<td>Q03.1</td>
<td>Atresia of foramina of Magendie and Luschka</td>
<td>0—20</td>
</tr>
<tr>
<td>Q03.8</td>
<td>Other congenital hydrocephalus</td>
<td>0—20</td>
</tr>
<tr>
<td>Q03.9</td>
<td>Congenital hydrocephalus, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>Q04.3</td>
<td>Other reduction deformities of brain</td>
<td>0—20</td>
</tr>
<tr>
<td>Q04.5</td>
<td>Megalencephaly</td>
<td>0—20</td>
</tr>
<tr>
<td>Q04.6</td>
<td>Congenital cerebral cysts</td>
<td>0—20</td>
</tr>
<tr>
<td>Q04.8</td>
<td>Other specified congenital malformations of brain</td>
<td>0—20</td>
</tr>
<tr>
<td>Q05.0</td>
<td>Cervical spina bifida with hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.1</td>
<td>Thoracic spina bifida with hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.2</td>
<td>Lumbar spina bifida with hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.3</td>
<td>Sacral spina bifida with hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.4</td>
<td>Unspecified spina bifida with hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.5</td>
<td>Cervical spina bifida without hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.6</td>
<td>Thoracic spina bifida without hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.7</td>
<td>Lumbar spina bifida without hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.8</td>
<td>Sacral spina bifida without hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q05.9</td>
<td>Spina bifida, unspecified</td>
<td>0—64</td>
</tr>
<tr>
<td>Q06.0</td>
<td>Amyelia</td>
<td>0—64</td>
</tr>
<tr>
<td>Q06.1</td>
<td>Hypoplasia and dysplasia of spinal cord</td>
<td>0—64</td>
</tr>
<tr>
<td>Q06.2</td>
<td>Diastematomyelia</td>
<td>0—64</td>
</tr>
<tr>
<td>Q06.3</td>
<td>Other congenital cauda equina malformations</td>
<td>0—64</td>
</tr>
<tr>
<td>Q06.4</td>
<td>Hydromyelia</td>
<td>0—64</td>
</tr>
<tr>
<td>Q06.8</td>
<td>Other specified congenital malformations of spinal cord</td>
<td>0—64</td>
</tr>
<tr>
<td>Q07.01</td>
<td>Arnold-Chiari syndrome with spina bifida</td>
<td>0—64</td>
</tr>
<tr>
<td>Q07.02</td>
<td>Arnold-Chiari syndrome with hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q07.03</td>
<td>Arnold-Chiari syndrome with spina bifida and hydrocephalus</td>
<td>0—64</td>
</tr>
<tr>
<td>Q30.1</td>
<td>Agenesis and underdevelopment of nose, cleft or absent nose only</td>
<td>0—5</td>
</tr>
<tr>
<td>Q30.2</td>
<td>Fissured, notched and cleft nose, cleft or absent nose only</td>
<td>0—5</td>
</tr>
<tr>
<td>Q31.0</td>
<td>Web of larynx</td>
<td>0—20</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Value</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Q31.8</td>
<td>Other congenital malformations of larynx, atresia or agenesis of larynx only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q32.1</td>
<td>Other congenital malformations of trachea, atresia or agenesis of trachea only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q32.4</td>
<td>Other congenital malformations of bronchus, atresia or agenesis of bronchus only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q33.0</td>
<td>Congenital cystic lung</td>
<td>0—20</td>
</tr>
<tr>
<td>Q33.2</td>
<td>Sequestration of lung</td>
<td>0—20</td>
</tr>
<tr>
<td>Q33.3</td>
<td>Agenesis of lung</td>
<td>0—20</td>
</tr>
<tr>
<td>Q33.6</td>
<td>Congenital hypoplasia and dysplasia of lung</td>
<td>0—20</td>
</tr>
<tr>
<td>Q35.1</td>
<td>Cleft hard palate</td>
<td>0—20</td>
</tr>
<tr>
<td>Q35.3</td>
<td>Cleft soft palate</td>
<td>0—20</td>
</tr>
<tr>
<td>Q35.5</td>
<td>Cleft hard palate with cleft soft palate</td>
<td>0—20</td>
</tr>
<tr>
<td>Q35.9</td>
<td>Cleft palate, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.0</td>
<td>Cleft hard palate with bilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.1</td>
<td>Cleft hard palate with unilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.2</td>
<td>Cleft soft palate with bilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.3</td>
<td>Cleft soft palate with unilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.4</td>
<td>Cleft hard and soft palate with bilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.5</td>
<td>Cleft hard and soft palate with unilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.8</td>
<td>Unspecified cleft palate with bilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q37.9</td>
<td>Unspecified cleft palate with unilateral cleft lip</td>
<td>0—20</td>
</tr>
<tr>
<td>Q39.0</td>
<td>Atresia of esophagus without fistula</td>
<td>0—3</td>
</tr>
<tr>
<td>Q39.1</td>
<td>Atresia of esophagus with tracheo-esophageal fistula</td>
<td>0—3</td>
</tr>
<tr>
<td>Q39.2</td>
<td>Congenital tracheo-esophageal fistula without atresia</td>
<td>0—3</td>
</tr>
<tr>
<td>Q39.3</td>
<td>Congenital stenosis and stricture of esophagus</td>
<td>0—3</td>
</tr>
<tr>
<td>Q39.4</td>
<td>Esophageal web</td>
<td>0—3</td>
</tr>
<tr>
<td>Q42.0</td>
<td>Congenital absence, atresia and stenosis of rectum with fistula</td>
<td>0—5</td>
</tr>
<tr>
<td>Q42.1</td>
<td>Congenital absence, atresia and stenosis of rectum without fistula</td>
<td>0—5</td>
</tr>
<tr>
<td>Q42.2</td>
<td>Congenital absence, atresia and stenosis of anus with fistula</td>
<td>0—5</td>
</tr>
<tr>
<td>Q42.3</td>
<td>Congenital absence, atresia and stenosis of anus without fistula</td>
<td>0—5</td>
</tr>
<tr>
<td>Q42.8</td>
<td>Congenital absence, atresia and stenosis of other parts of large intestine</td>
<td>0—5</td>
</tr>
<tr>
<td>Q42.9</td>
<td>Congenital absence, atresia and stenosis of large intestine, part unspecified</td>
<td>0—5</td>
</tr>
<tr>
<td>Q43.1</td>
<td>Hirschsprung’s disease</td>
<td>0—15</td>
</tr>
<tr>
<td>Q44.2</td>
<td>Atresia of bile ducts</td>
<td>0—20</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Range</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Q44.3</td>
<td>Congenital stenosis and stricture of bile ducts</td>
<td>0—20</td>
</tr>
<tr>
<td>Q44.6</td>
<td>Cystic disease of liver</td>
<td>0—20</td>
</tr>
<tr>
<td>Q45.0</td>
<td>Agenesis, aplasia and hypoplasia of pancreas</td>
<td>0—5</td>
</tr>
<tr>
<td>Q45.1</td>
<td>Annular pancreas</td>
<td>0—5</td>
</tr>
<tr>
<td>Q45.3</td>
<td>Other congenital malformations of pancreas and pancreatic duct</td>
<td>0—5</td>
</tr>
<tr>
<td>Q45.8</td>
<td>Other specified congenital malformations of digestive system</td>
<td>0—10</td>
</tr>
<tr>
<td>Q60.1</td>
<td>Renal agenesis, bilateral</td>
<td>0—20</td>
</tr>
<tr>
<td>Q60.4</td>
<td>Renal hypoplasia, bilateral</td>
<td>0—20</td>
</tr>
<tr>
<td>Q60.6</td>
<td>Potter’s syndrome, with bilateral renal agenesis only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.02</td>
<td>Congenital multiple renal cysts, bilateral only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.19</td>
<td>Other polycystic kidney, infantile type, bilateral only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.2</td>
<td>Polycystic kidney, adult type, bilateral only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.3</td>
<td>Polycystic kidney, unspecified, bilateral only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.4</td>
<td>Renal dysplasia, bilateral</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.5</td>
<td>Medullary cystic kidney, bilateral only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q61.9</td>
<td>Cystic kidney disease, unspecified, bilateral only</td>
<td>0—20</td>
</tr>
<tr>
<td>Q64.10</td>
<td>Exstrophy of urinary bladder, unspecified</td>
<td>0—20</td>
</tr>
<tr>
<td>Q64.12</td>
<td>Cloacal extrophy of urinary bladder</td>
<td>0—20</td>
</tr>
<tr>
<td>Q64.19</td>
<td>Other extrophy of urinary bladder</td>
<td>0—20</td>
</tr>
<tr>
<td>Q75.0</td>
<td>Craniosynostosis</td>
<td>0—20</td>
</tr>
<tr>
<td>Q75.1</td>
<td>Craniofacial dysostosis</td>
<td>0—20</td>
</tr>
<tr>
<td>Q75.2</td>
<td>Hypertelorism</td>
<td>0—20</td>
</tr>
<tr>
<td>Q75.4</td>
<td>Mandibulofacial dysostosis</td>
<td>0—20</td>
</tr>
<tr>
<td>Q75.5</td>
<td>Oculomandibular dysostosis</td>
<td>0—20</td>
</tr>
<tr>
<td>Q75.8</td>
<td>Other congenital malformations of skull and face bones</td>
<td>0—20</td>
</tr>
<tr>
<td>Q77.4</td>
<td>Achondroplasia</td>
<td>0—1</td>
</tr>
<tr>
<td>Q77.6</td>
<td>Chondroectodermal dysplasia</td>
<td>0—1</td>
</tr>
<tr>
<td>Q77.8</td>
<td>Other osteochondrodysplasia with defects of growth of tubular bones and spine</td>
<td>0—1</td>
</tr>
<tr>
<td>Q78.0</td>
<td>Osteogenesis imperfecta</td>
<td>0—20</td>
</tr>
<tr>
<td>Q78.1</td>
<td>Polyostotic fibrous dysplasia</td>
<td>0—1</td>
</tr>
<tr>
<td>Q78.2</td>
<td>Osteopetrosis</td>
<td>0—1</td>
</tr>
<tr>
<td>Q78.3</td>
<td>Progressive diaphyseal dysplasia</td>
<td>0—1</td>
</tr>
<tr>
<td>Q78.4</td>
<td>Enchondromatosis</td>
<td>0—1</td>
</tr>
<tr>
<td>Q78.6</td>
<td>Multiple congenital exostoses</td>
<td>0—1</td>
</tr>
</tbody>
</table>
.18 Appeals Procedures.

Appeal procedures are as set forth in COMAR 10.01.04 and 10.09.36.

Subtitle 67 MARYLAND HEALTHCHOICE PROGRAM
Chapter 01 Maryland Medicaid Managed Care Program: Definitions

.01 Definitions.

A. Except as expressly limited, in COMAR 10.67.01—.12 the following terms have the meanings indicated.

B. Terms Defined.

(1) "ACOG guidelines" means the American College of Obstetricians and Gynecologists' Guidelines for Perinatal Care that specify the recommended periodicity and content of prenatal, perinatal, and postpartum care, and are incorporated by reference in COMAR 10.67.04.01.

(2) "Acquired immune deficiency syndrome (AIDS)" has the meaning stated in COMAR 10.52.06.01B.

(3) "Action" means:
(a) Denial or limited authorization of a requested service, including:

(i) The type or level of service;

(ii) Requirements for medical necessity;

(iii) Appropriateness;

(iv) Setting; or

(v) Effectiveness of a covered benefit.

(b) Reduction, suspension, or termination of a previously authorized service;

(c) Denial, in whole or part, of payment for a service;

(d) Failure to provide services in a timely manner;

(e) Failure of an MCO to act within the required time frames; or

(f) The denial of an enrollee’s request to dispute a financial liability, including:

(i) Cost sharing;

(ii) Copayments;

(iii) Premiums;

(iv) Deductibles;

(v) Coinsurance; or

(vi) Other enrollee financial liabilities.

(4) "Activities of daily living" means, in the context of COMAR 10.09.69, bathing, feeding, toileting, dressing, and ambulation;

(5) "Adjusted clinical group (ACG)" means a method for categorizing individuals into a case mix category based on the diagnoses assigned by their clinicians over a predetermined period of time.

(6) Administrative Services Organization.

(a) "Administrative services organization (ASO)" means an organization with which the Department contracts to assist in the management of behavioral health services.
(b) "Administrative services organization" does not mean an organization that directly provides health care services to waiver-eligible individuals.

(7) "Advanced practice nurse" means a nurse practitioner, nurse midwife, nurse anesthetist, or nurse psychotherapist who is licensed and certified under Health Occupations Article, Title 8, Annotated Code of Maryland, and COMAR 10.27.01

(8) "Aged" has the meaning stated in COMAR 10.09.24.02B.

(9) "AIDS payment category" means one of the two payment categories represented as individual rate cells within the rate table set forth in COMAR 10.67.04.19B(4)(b) to which enrollees with AIDS are assigned pursuant to COMAR 10.67.04.19B(2)(c)(ii).

(10) "Alcohol abuse" has the meaning stated in Health-General Article, §8-101(e), Annotated Code of Maryland.

(11) "Ancillary services" means diagnostic and somatic therapeutic services, including but not limited to radiology, laboratory services, cardiac diagnostics, neurology diagnostics, occupational therapy, physical therapy, durable medical equipment, disposable medical supplies, audiology, speech therapy, and cardiac rehabilitation therapy.

(12) "Annual quality assurance (QA) audit" means a systems performance review and a clinical care review.

(13) "Appeal" means a request for review of an action.

(14) "Applicant" means an entity that seeks approval from the Department to operate as a managed care organization in the Maryland Medicaid Managed Care Program.

(15) "Benefits package" means a set of health care services to which an MCO's enrollees are entitled, when the services are medically necessary, and which the MCO delivers to its enrollees either through providers with which it has employment or contractual relationships, or through reimbursement for services provided to the MCO's enrollees.

(16) "Blind" means having a condition in which a person is certified by an ophthalmologist as having either central visual acuity of 20/200 or less in the better eye with correcting glasses, or a field defect in which the peripheral field has contracted to such an extent that the widest diameter of the visual field subtends an angular distance of no greater than 20 degrees.

(17) "Business day" means any day except Saturday, Sunday, or a holiday on which State offices are closed.

(18) "Caller abandonment rates" means the percentage of calls terminated by callers without speaking to a live operator.
(19) "Caller average hold time" means an average amount of time a call is on hold after being answered.

(20) "Caller service level" means the speed of answering the telephone.

(21) "Capitation payment" means the sum of money paid in advance on a monthly per capita basis by the Department for a fixed benefit package.

(22) "CARF" means the Commission on Accreditation of Rehabilitation Facilities (also known as the Rehabilitation Accreditation Commission), which is an organization that:

(a) Establishes quality standards for rehabilitative services; and

(b) Determines, in the context of its accreditation process, the extent to which rehabilitative service providers are in compliance with CARF quality standards.

(23) "Case management" means, assessing, planning, coordinating, monitoring, and arranging the delivery of medically necessary health-related services.

(24) "Case management contractor" means, in the context of COMAR 10.09.69, the Department's designee, or a subcontractor of the designee, which provides case management to participants assigned to it by the Department.

(25) "Case manager" means, in the context of COMAR 10.09.69, the individual who:

(a) Is employed by the Department's designee or a case management contractor;

(b) Is assigned by a case management contractor to manage the care of some or all of the participants assigned to that case management contractor;

(c) Participates in the meetings of the interdisciplinary team;

(d) Is responsible for the development of an individual's case management plan by the interdisciplinary team;

(e) Is responsible for implementing the participant's case management plan; and

(f) Is responsible for modifying the case management plan when information regarding a change in the participant's condition or status is received.

(26) "CDS license" means the State licensure authorizing a health care practitioner to prescribe controlled dangerous substances.

(27) "Certified nursing assistant" means, in the context of COMAR 10.09.69, an individual:

(a) Certified as a nursing assistant by the Maryland Board of Nursing; and
(b) Who performs nursing tasks delegated by a registered nurse or licensed practical nurse pursuant to Health Occupations Article, Title 8, Annotated Code of Maryland.

(28) "Child in State-supervised care" means a waiver-eligible child who is in the care and custody of a State agency pursuant to a court order or a voluntary placement agreement, including, but not limited to, waiver-eligible children:

(a) Under the supervision of the Department of Juvenile Services;

(b) In kinship or foster care under the Department of Human Services; and

(c) In residential treatment centers or psychiatric hospitals for the first 30 days after admission.

(29) "Child with a special health care need" means an individual younger than 21 years old, regardless of marital status, suffering from a moderate to severe chronic health condition:

(a) With significant potential or actual impact on health and ability to function;

(b) Which requires special health care services; and

(c) Which is expected to last longer than 6 months.

(30) "Chronic hospital" has the meaning stated in COMAR 10.09.06.01B(4).

(31) "Clinical care review" means a review of the quality of clinical health care delivered by an MCO, which is:

(a) Required by federal law; and

(b) A component of an annual quality assurance (QA) audit.

(32) "CMS" means Centers for Medicare and Medicaid Services.

(33) "Cold call marketing" means any unsolicited personal contact by the MCO with a potential enrollee for the purpose of marketing.

(34) "Commissioner" means the Maryland Insurance Commissioner of the Maryland Insurance Administration.

(35) "Community-based substance abuse program" means a program that:

(a) Is certified by the Office of Health Care Quality (OHCQ); and

(b) Provides services in community settings not regulated by the Health Services Cost Review Commission.
(36) "Complaint" means an expression of dissatisfaction that results in either an appeal or a grievance.

(37) "Contract year" means the period of time to which the Maryland Medicaid Managed Care Program agreement between the Department and an MCO applies.

(38) "Core service agency (CSA)" means, in the context of COMAR 10.67.08, the county or multicounty authority, designated under Health-General Article, Title 10, Subtitle 12, Annotated Code of Maryland, and approved by the Department, that is responsible for planning, managing, and monitoring publicly funded mental health services.

(39) "Corporation" means:

(a) An entity formed under and meeting the requirements of Corporations and Associations Article, §2-101 et seq., Annotated Code of Maryland; or

(b) A foreign corporation registered with the Maryland Department of Assessments and Taxation.

(40) "County" means a county of this State and, unless expressly provided otherwise, Baltimore City.

(40-1) "Credibility adjustment" means an adjustment to the MLR for a partially credible MCO to account for a difference between the actual and target MLRs that may be due to random statistical variation.

(41) "Days" means, unless otherwise expressly indicated, calendar days.

(42) "DEA license" means the federal license authorizing a health care practitioner to prescribe controlled substances.

(42-1) "Definitive drug test" means drug screening tests that include:

(a) The ability to identify individual drugs and distinguish between structural isomers, but not necessarily stereoisomers, using:

(i) Gas chromatography or mass spectrometry; and

(ii) Liquid chromatography or mass spectrometry;

(b) Qualitative or quantitative results;

(c) All source types for specimen selection;

(d) Specimen validity testing, per day, 1—22 or more drug classes including metabolites, if performed.
(43) "Department" means the Maryland Department of Health, as defined in COMAR 10.09.36.01, or its authorized agents acting on behalf of the Department.

(44) "Diagnostic evaluation services (DES)" has the meaning stated in COMAR 10.09.32.01B, and includes the services described in COMAR 10.09.32.04A.

(45) Direct Medical Education Costs (DME Costs).

(a) "Direct medical education costs (DME costs)" means costs associated with providing graduate medical education that are measurable using accounting data.

(b) "Direct medical education costs (DME costs)" includes, but is not limited to:

(i) Salaries;

(ii) Supervision costs; and

(iii) Allocated overhead.

(46) "Disabled" has the meaning stated in COMAR 10.09.24.02B.

(47) "Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)" means the provision, to individuals younger than 21 years old, of preventive health care pursuant to 42 CFR §441.50 et seq. (1981), and other health care services, diagnostic services, and treatment services that are necessary to correct or ameliorate defects and physical and mental illnesses and conditions discovered by EPSDT screening services.

(48) "Emergency medical condition" means a medical condition characterized by sudden onset and symptoms of sufficient severity, including severe pain, that the absence of immediate medical attention could reasonably be expected by a prudent lay person, who possesses an average knowledge of health and medicine, to result in:

(a) Placing the patient's health, or with respect to a pregnant woman, the health of the woman or unborn child in serious jeopardy;

(b) Serious impairment to bodily functions; or

(c) Serious dysfunction of any bodily organ or part.

(49) "Emergency services" means those health care services that are provided in a hospital emergency facility after the sudden onset of a medical condition that manifests itself by symptoms of sufficient severity, including severe pain, that the absence of immediate medical attention could reasonably be expected by a prudent lay person, who possesses an average knowledge of health and medicine, to result in:
(a) Placing the patient's health, or with respect to a pregnant woman, the health of the woman, or her unborn child, in serious jeopardy;

(b) Serious impairment to bodily functions; or

(c) Serious dysfunction of any bodily organ or part.

(50) "Encounter data" means information documenting a service to an enrollee.

(51) "Enrollee" has the meaning indicated in Health-General Article, §15-101(b), Annotated Code of Maryland.

(52) "EPSDT-certified provider" means a physician or nurse practitioner who is certified by the Department's EPSDT program to provide comprehensive well-child services according to the Department's periodicity schedule and program standards to enrollees younger than 21 years old.

(53) "EPSDT comprehensive well-child services" means:

(a) All the screening services provided by an EPSDT-certified provider that are required or recommended on the EPSDT periodicity schedule; and

(b) Health care services to diagnose, treat, or refer problems or conditions discovered during the comprehensive well-child service.

(54) "EPSDT partial or interperiodic well-child service" means:

(a) A well-child service provided at times different than those outlined in the EPSDT periodicity schedule; or

(b) Any encounter by a health care practitioner necessary to diagnose or identify a condition and recommend a course of treatment.

(55) "EPSDT periodicity schedule" means the Departmentally approved list of required or recommended preventive health care services which are to be performed at specified ages.

(56) "Evaluations" means, in the context of COMAR 10.09.69, a determination of the health status of a patient in a patient's home or any other appropriate setting by a licensed professional for the purpose of designing an individual plan of care which incorporates the modalities of treatment which will promote optimal functional ability and recuperation.

(57) "External quality review organization (EQRO)" means a utilization and quality control peer review entity or a private review agent meeting the requirements of §1902(a)(30) of the Social Security Act, 42 U.S.C. §1396a(a)(30), which performs an independent external review of health care services furnished under a contract under §1903(m) of the Social Security Act, 42 U.S.C. §1396b.
(58) "Family planning" means providing individuals with the information and means to prevent unwanted pregnancy and maintain reproductive health.

(59) "Federally qualified health center (FQHC)" means a clinic which either:

(a) Receives a grant under §329, 330, or 340 of the Public Health Services Act, 42 U.S.C. §254c;

(b) Meets the requirements for a grant under §329, 330, or 340 of the Public Health Services Act, 42 U.S.C. §254c; or

(c) Qualifies as a FQHC pursuant to a waiver from the Secretary of the U.S. Department of Health and Human Services of one or more of the requirements for receiving a grant under §329, 330, or 340 of the Public Health Services Act, 42 U.S.C. §254c.

(60) "Fiscal year (FY)" means the time period beginning the preceding July 1 and ending on June 30 of the referenced year.

(61) "Free-standing birth center" means a free-standing facility not associated with a hospital that provides nurse midwife services under Health Occupations Article, Title 8, Subtitle 6, Annotated Code of Maryland.

(61-1) "Full credibility" means a standard for which the experience of an MCO is determined to be sufficient for the calculation of an MLR with a minimal chance that the difference between the actual and target MLR is not statistically significant.

(62) "Graduate medical education (GME)" means the training of physician interns and residents after completion of a medical degree program.

(63) "Graduate medical education costs (GME costs)" means the amount it costs a hospital to train physician interns and residents after their completion of a medical degree program, including both direct medical education costs and indirect medical education costs.

(64) "Grievance" means an expression of dissatisfaction about any matter other than an action, including but not limited to:

(a) The quality of care or services provided, and aspects of interpersonal relationships such as rudeness of a provider or employee;

(b) Failure to respect the enrollee’s rights regardless of whether remedial action is requested; or

(c) A dispute over an extension of time proposed by the MCO to make an authorized decision.
(65) "HCQIS" means the Health Care Quality Improvement System produced by the Centers for Medicare and Medicaid Services.

(66) "Health care service" has the meaning stated in Health-General Article, §19-132, Annotated Code of Maryland.

(67) "HealthChoice Financial Monitoring Report (HFMR)" means an annual financial report of an MCO's MMMCP-related activities during a specified calendar year that:

(a) Is submitted to the Department by an MCO pursuant to COMAR 10.67.04.15;

(b) Serves as a supplemental schedule to an MCO's quarterly and annual reports to the Maryland Insurance Administration; and

(c) Includes a completed HFMR form provided by the Department and any supplemental schedules required by the Department.

(68) "Health home" means a provider designated to offer enhanced care coordination and management services to individuals affected by, or at risk for, chronic conditions.

(69) "Health maintenance organization (HMO)" has the meaning stated in Health-General Article, §19-701, Annotated Code of Maryland.

(70) Health Service Needs Information.

(a) "Health service needs information" means an instrument to identify new Maryland Medicaid Managed Care Program enrollees who require immediate or specialized health care services.

(b) "Health service needs information" does not mean an initial health screen performed by an MCO.

(71) "HEDIS" means the Healthcare Effectiveness Data Information Set, a set of indicators of managed care plan performance developed by the National Committee for Quality Assurance.

(72) "Hepatitis C" means having one of the following as a primary, secondary, tertiary, or level 4 diagnosis:

(a) 070.41 — Acute or Unspecified Hepatitis C with hepatic coma;

(b) 070.44 — Chronic Hepatitis C with hepatic coma;

(c) 070.51 — Acute or unspecified Hepatitis C without mention of hepatic coma; or

(d) 070.54 — Chronic Hepatitis C without mention of hepatic coma.
(73) "Hepatitis C plan risk factor" means an MCO-specific risk adjustment factor reflecting the level of risk associated with the proportion of the MCO's HIV/AIDS enrollees who also have Hepatitis C.

(74) "HIPAA" means the Health Insurance Portability and Accountability Act, a federal law enacted on August 21, 1996, whose purpose is to improve the efficiency and effectiveness of the health care system by standardizing the electronic exchange of administrative and financial data, provide security requirements for transmitted information, and protect the privacy of identifiable health information.

(75) "Historical diagnostic period" means the time period under consideration for the cumulative chronological determination of an enrollee's Hepatitis C status and ending:

(a) For the initial rate adjustment period, on June 30 of the calendar year before the rate year; or

(b) For the mid-year rate adjustment period, on December 31 of the calendar year before the rate year.

(76) "HIV" means infection with the human immunodeficiency virus.

(77) "HIV/AIDS" means:

(a) Infection with the human immunodeficiency virus; or

(b) Acquired immune deficiency syndrome.

(78) "HIV/AIDS enrollee" means an enrollee who is infected with HIV or has AIDS and is assigned to an HIV or AIDS payment category.

(79) "HIV payment category" means one of the four payment categories represented as individual rate cells within the rate tables set forth in COMAR 10.67.04.19B(4)(a) and (b), to which enrollees with HIV are assigned pursuant to COMAR 10.67.04.19B(1)(c)(ii) or (2)(c)(i).

(80) "Home", in the context of COMAR 10.09.69, has the meaning stated in COMAR 10.09.53.

(81) "Home health agency" means, in the context of COMAR 10.09.69, an agency licensed by the Department in accordance with COMAR 10.07.10.

(82) "Home health aide" means, in the context of COMAR 10.09.69, an individual who meets all the conditions of participation specified in:

(a) 42 CFR §484.36; and

(b) Health Occupations Article, Title 8, Annotated Code of Maryland.
(83) "Homeless person" means an individual who, as defined by §340 of the Public Health Services Act, lacks housing, without regard to whether an individual is a member of a family, including an individual:

(a) Who is a resident in transitional housing; or

(b) Whose primary residence during the night is a supervised public or private facility that provides temporary living accommodations.

(84) "Hospital" has the meaning stated in Health-General Article, §19-301, Annotated Code of Maryland.

(85) "HSCRC" means the Health Services Cost Review Commission, an independent agency functioning in the Department with the powers and duties set forth in Health-General Article, §19-201 et seq., Annotated Code of Maryland.

(86) "Indirect medical education costs (IME costs)" means costs associated with providing graduate medical education that, although not measurable using accounting data, are subject to assessment by application of a regression analysis methodology that:

(a) Estimates teaching hospitals' extra costs attributable to factors including, but not necessarily limited to the:

(i) Lower productivity of inexperienced residents, and

(ii) Adoption of advanced technology; and

(b) Controls, where possible, for confounding variables such as differences in:

(i) Area labor costs,

(ii) Uncompensated care, and

(iii) Case mix.

(87) "Individualized education program (IEP)" means a written description of special education and related services developed by a multidisciplinary team to be implemented to meet the individual needs of a child pursuant to COMAR 13A.05.01.09.

(88) "Individualized family service plan (IFSP)" means a written plan for providing early intervention and other services to an eligible child and the child's family pursuant to COMAR 13A.13.01.02B.

(89) "Individual with a developmental disability" means an individual who, as defined in P.L. 101-330, Americans with Disabilities Act of 1990, 42 U.S.C. §12101 et seq., has a physical or mental impairment arising before the age of 22, except for the sole diagnosis of mental
disorder, that substantially limits one or more major life activities, and which may include, but is not limited to, an intellectual disability, specific learning disabilities, head injury, epilepsy, and muscular dystrophy.

(90) "Individual with a physical disability" means an individual who, as defined in P.L. 101-330, the Americans with Disabilities Act of 1990, 42 U.S.C. §12101 et seq., has a physical impairment, either sensory or motor, that substantially limits one or more major life activities, and which may include, but is not limited to, orthopedic impairment, vision, speech, or hearing impairment, cerebral palsy, epilepsy, muscular dystrophy, multiple sclerosis, cancer, heart disease, HIV/AIDS, and tuberculosis.

(91) "Initial health screen" means the comprehensive evaluation performed by the PCP, that includes a comprehensive history and physical examination to determine the new enrollee's baseline health status and health needs.

(92) "Initial rate adjustment period" has the meaning stated in COMAR 10.67.04.19-4A.

(93) "Inmate" means an individual who is serving time for a criminal offense and is confined involuntarily in State or federal prisons, jail, detention centers, or other penal facilities or who has been placed on home detention.

(94) Institution for Mental Disease.

(a) "Institution for mental disease (IMD)" means a hospital, nursing facility, or other institution of more than 16 beds that is primarily engaged in providing diagnosis, treatment, or care of persons with mental diseases or substance abuse problems, including medical attention, nursing care, and related health care services.

(b) "Institution for mental disease (IMD)" includes the following categories of facilities, if the particular facility has more than 16 beds:

(i) Psychiatric hospitals;

(ii) Residential treatment centers;

(iii) In the context of admissions of enrollees who are 21 years old or older, intermediate care facilities-alcoholic (ICF-A) facilities; and

(iv) Residential drug-free treatment programs.

(c) "Institution for mental disease" does not include intermediate care facilities-alcoholic (ICF-A) facilities, except in the context of admission of enrollees who are 21 years old or older.

(95) "Interdisciplinary team" means, in the context of COMAR 10.09.69, the group convened and conducted by the case manager, consisting of the case manager and relevant service providers, that established the case management plan under the overall direction and
coordination of the case manager and in consultation with the participant and, when applicable, the participant's family.

(96) "Intermediate care facility for individuals with intellectual disabilities or persons with related conditions (ICF/IID)" means a residential facility providing care and services for individuals with an intellectual disability or developmental disabilities, or both.

(96-1) "Limited English proficiency" means the special need status of potential enrollees and enrollees who do not speak English as their primary language and who have a limited ability to read, write, speak, or understand English, and are therefore eligible to receive language assistance for a particular type of service, benefit, or encounter.

(97) "Local access area" means the local geographical area, as identified by the zip code groupings in COMAR 10.67.05.06D, that is located within the relevant MCO’s service area and in which the relevant enrollee resides.

(98) "Local transportation grantee agency" means the county entity, usually the local health department, that receives transportation grant funds pursuant to COMAR 10.09.19.

(99) "Long-term care facility" means a chronic hospital, a chronic rehabilitation hospital, a nursing facility, or a special pediatric hospital.

(100) Long-Term Care Services.

(a) "Long-term care services" means the medical and support services required by an individual who, due to chronic illness or mental or physical disability, requires long-term care facility services over an extended period of time.

(b) "Long-term care services" includes services provided to a patient in a long-term care facility after the 30th day of continuous care following the enrollee's admission to the facility.

(c) "Long-term care services" do not include services provided to an enrollee admitted to a long-term care facility for a stay of less than 31 days of continuous care following the enrollee's admission to the facility.

(101) "Loss ratio" means the ratio of an MCO's:

(a) Net medical expenses plus medical management expenses which:

(i) Are quantified according to COMAR 10.67.04.19-5;

(ii) Relate solely to the MCO's MMMCP line of business; and

(iii) Are incurred during a specified period; and

(b) Net revenues which:
(i) Relate solely to the MCO's MMMCP line of business; and

(ii) Are earned during the same specified period in which the expenses referenced in §B(98)(a) of this regulation are incurred.

(102) "Managed care organization (MCO)" has the meaning stated in Health-General Article, §15-101, Annotated Code of Maryland.

(103) "Marketing" means any communication, from an MCO to a Medicaid recipient who is not enrolled in that MCO, that can reasonably be interpreted as intended to influence the recipient:

(a) To enroll in that particular MCO; or

(b) To not enroll in or to disenroll from another MCO.

(104) "Marketing materials" means materials that are produced in any medium, by or on behalf of an MCO, that can reasonably be interpreted as intended to market to potential enrollees.

(105) "Maryland Children's Health Program" means the State program for uninsured, low-income children with federal matching funds provided under Title XXI of the Social Security Act.

(106) "Maryland Medicaid Managed Care Program (MMMCP)" means the Medicaid reform program established in this subtitle, as authorized by Health-General Article, Title 15, Subtitle 1, Annotated Code of Maryland, and by a §1115 waiver issued by the federal government.

(107) "Medicaid" has the meaning stated in COMAR 10.09.24.02.

(108) "Medical Assistance" has the meaning stated in COMAR 10.09.24.02.

(109) "Medical day care for adults" means a program of medically supervised, health-related services provided in an ambulatory setting to medically handicapped adults who, due to their degrees of impairment, need health maintenance and restorative services supportive to their community living.

(110) "Medical day care for children" means a program of medically supervised health-related services provided in an ambulatory setting to children with complex medical needs who do not require 24-hour inpatient care, but, due to their specialized medical needs, cannot be managed in a typical day care setting.

(111) "Medical expense" means costs incurred by an MCO in connection with providing health care services to its enrollees.
(111-1) "Medical loss ratio (MLR)" means a formula that measures the ratio of MCO spending on medical and related benefits compared to revenue, to ensure MCOs are spending a sufficient amount of their premium revenue on medical expenses and other high-impact initiatives.

(112) "Medically necessary" means that the service or benefit is:

   (a) Directly related to diagnostic, preventive, curative, palliative, rehabilitative, or ameliorative treatment of an illness, injury, disability, or health condition;

   (b) Consistent with current accepted standards of good medical practice;

   (c) The most cost efficient service that can be provided without sacrificing effectiveness or access to care; and

   (d) Not primarily for the convenience of the consumer, the consumer's family, or the provider.

(113) "Medically needy" has the meaning stated in COMAR 10.09.24.02.

(114) "Medical management expense" means costs incurred by an MCO in connection with outreach and utilization management activities as specified in COMAR 10.67.04.19-5.

(115) "Medical necessity" means what is medically necessary.

(115-1) "Medically underserved area" means an area designated by the Health Resources and Services Administration (HRSA) as having shortages of primary care, dental care, or mental health providers.

(116) "Medicare" means the federal program that provides benefits to the aged and disabled under Title XVIII of the Social Security Act.

(117) "MIA" means the Maryland Insurance Administration.

(118) "Mid-year rate adjustment period" has the meaning stated in COMAR 10.67.04.19-4A.

(119) "MIEMSS" means the Maryland Institute for Emergency Medical Service Systems.

(119-1) "MLR reporting year" means a period of 12 months consistent with the rating period selected by the Department.

(120) "Model Waiver Program" means the Home Care for Disabled Children under a Model Waiver as established in COMAR 10.09.27.

(120-1) "National Diabetes Prevention Program" means an evidence-based diabetes prevention program established by the Centers for Disease Control and Prevention.
(121) "Net medical expenses" means an MCO's total medical expenses less reinsurance recoveries.

(122) "Net revenues" means an MCO's total revenues less reinsurance premiums.

(123) "Network" has the same meaning as "provider panel", as specified in this regulation.

(123-1) "Network provider" means a provider that is a member of the MCO’s provider panel.

(123-2) "No credibility" means a standard for which the experience of an MCO is determined to be insufficient for the calculation of an MLR.

(123-3) "Non-claims costs" means expenses for administrative services other than:

(a) Incurred claims;

(b) Expenditures on activities that improve health care quality;

(c) Licensing and regulatory fees; or

(d) Federal and State taxes.

(124) "Nursing facility" has the meaning stated in COMAR 10.09.10.01B.

(125) Nutritional Counseling.

(a) "Nutritional counseling" means, in the context of COMAR 10.09.69, the review of the patient's nutritional status and advice on its improvement when medically necessary.

(b) "Nutritional counseling" includes family education provided by either a licensed dietitian or licensed nutritionist.

(126) "Nutritional supplements" means, in the context of COMAR 10.09.69, enteral feeding which is either the sole source of nutrition or a supplement which enhances the physical well-being of the patient and is medically indicated.

(127) "Ombudsman” or “ombudsman program" has the meaning stated in Health-General Article, §15-101(g), Annotated Code of Maryland.

(128) "Out-of-plan provider" means a provider that is neither the employee nor the subcontractor of the enrollee's assigned MCO.

(129) "Outreach services" means efforts to contact enrollees and bring them into care, as described in COMAR 10.67.05.03.

(130) "Overpayment" means:
(a) Any payment made by the Program to a provider in excess of the correct Program payment amount for a service; or

(b) Any payment for services under COMAR 10.67.06 made by the Program or an MCO which at the time of payment, or at a subsequent date, is determined to be inappropriate, inaccurate or in excess of the correct amount of the procedural code billed, for reasons including but not limited to:

(i) Improper claiming;

(ii) Lack of medical necessity;

(iii) Unacceptable practices;

(iv) Fraud, waste, or abuse; or

(v) Provider mistake.

(130-1) "Partial credibility" means a standard for which the experience of an MCO is determined to be sufficient for the calculation of an MLR but with a non-negligible chance that the difference between the actual and target medical loss ratios is statistically significant.

(131) "Peer review organization" means an organization qualified by the Centers for Medicare and Medicaid Services in accordance with 42 CFR 462 that reviews health care practitioners, and the health care services they order or furnish, utilizing other practitioners from the same field of practice.

(132) "Personal care" has the meaning stated in COMAR 10.09.20.01B.

(133) "Plan of care" means, in the context of COMAR 10.09.69, the document which governs a participant's care management, and which:

(a) Includes the:

   (i) Case management assessment report;

   (ii) Interdisciplinary plan of care; and

   (iii) Case management plan;

(b) Is composed of the participant's health status and needs for medical, health-related, housing, and social services including, but not limited to:

   (i) All pertinent diagnoses;

   (ii) Functional status;
(iii) Type, frequency, and duration of services;

(iv) Treatment goals for each type of service;

(v) Medication;

(vi) Social support structure;

(vii) Current service providers;

(viii) Assigned level of care;

(ix) Diet;

(x) Current living arrangement; and

(xi) Emergency plan, if appropriate; and

(c) Is established in consultation with the interdisciplinary team.

(134) "Postpartum" means within 2 months after delivery of a child.

(135) "Poststabilization care services" means covered services, related to an emergency medical condition, that are provided after an enrollee is stabilized in order to maintain the stabilized condition, or under the circumstances described in 42 CFR §438.114(e), as amended, to improve or resolve the enrollee's condition.

(136) "Potential enrollee" means a Medicaid recipient who is determined eligible for the HealthChoice program but is not yet an enrollee of a specific MCO.

(137) "Practitioner" means an individual who is licensed, certified, or otherwise authorized under Health Occupations Article, Annotated Code of Maryland, or under the laws of the District of Columbia or a state contiguous to Maryland, to provide health care services in the ordinary course of business or practice of a profession or in an approved education or training program.

(138) "Preauthorization", in the context of COMAR 10.09.69, has the meaning stated in COMAR 10.09.53.

(139) "Pregnant" means the period beginning with conception and ending at delivery.

(139-1) "Presumptive drug tests" means drug screening tests that include:

(a) Any number of drug classes;

(b) Any number of devices;
(c) Sample validation; and

(d) The use of:

(i) Direct optical observation;

(ii) Instrument assisted direct optical observation; or

(iii) Instrumented chemistry analyzers.

(140) "Primary care" means medical care that addresses a patient's general health needs, including the coordination of the patient's health care, with the responsibility for the prevention of disease, promotion and maintenance of health, treatment of illness, maintenance of the enrollee's health records, and referral for medically necessary specialty care.

(141) "Primary care provider (PCP)" means a practitioner who is the primary coordinator of care for the enrollee, and whose responsibility it is to provide accessible, continuous, comprehensive, and coordinated health care services covering the full range of benefits required by the Maryland Medicaid Managed Care Program, as specified in COMAR 10.67.06.

(142) "Primary care residency slots" means, in the context of COMAR 10.67.11, positions in a teaching hospital's residency program occupied after completion of a medical degree program by physicians who have trained in family medicine, internal medicine, pediatrics, or obstetrics and gynecology.

(143) "Primary mental health services" means the clinical evaluation and assessment of mental health services needed by an individual and the provision of services or referral for additional services as deemed medically necessary by a primary care provider.

(144) "Private duty nursing" means, in the context of COMAR 10.09.69, skilled nursing services for recipients who require more individual and continuous care than is available under the Medicaid State Plan, and which are provided by a registered nurse or a licensed practical nurse, in a recipient's own home or another setting when normal life activities take the recipient outside his or her home.

(145) "Program", unless the context indicates otherwise, has the meaning stated in COMAR 10.09.36.01B.

(146) "Progress note" means, in the context of COMAR 10.09.69, a signed and dated written notation by the home care nurse, home health aide, or certified nursing assistant which:

(a) Summarizes facts about the care given and the participant's response during a given period of time;

(b) Specifically addresses the established goals of treatment;
(c) Is consistent with the participant's case management plan; and

(d) Is written during the course of care.

(147) "Provider" has the same meaning as "health care provider", as stated in Health-General Article, §19-132, Annotated Code of Maryland.

(148) "Provider panel" means that group of providers employed by the MCO or with which the MCO contracts to provide services to the MCO's enrollees under the MCO's health benefit plan, which is at least equivalent to the benefits specified in COMAR 10.67.06.

(149) "Public institution" has the meaning stated in COMAR 10.09.24.02.

(150) "Quality assurance plan (QAP)" means a document or series of documents that set forth an MCO's strategy for systematically monitoring, evaluating, and improving all facets of MCO operations, including, but not limited to, clinical health care delivery, enrollee assistance and outreach services, and administrative services.

(151) "Rare and expensive case management" means the method of health care delivery provided to individuals with rare and expensive conditions.

(152) "Rare and expensive condition" means a medical diagnosis or condition identified in COMAR 10.09.69.

(153) "Rate adjustment period" has the meaning stated in COMAR 10.67.02.19-4A.

(153-1) "Rate year" has the meaning stated in COMAR 10.67.04.19-4A.

(154) "Readily accessible" means electronic information and services which comply with modern accessibility standards such as:

(a) Section 508 guidelines;

(b) Section 504 of the Rehabilitation Act; or

(c) W3C’s Web Content Accessibility Guidelines (WCAG) 2.0 AA and successor versions.

(155) "Reasonable allowable costs" means costs that are related to the provision of covered Medicaid services and are determined to be allowable in accordance with Medicare principles of reasonable cost reimbursement in 42 CFR 413, subject to the limitations specified in COMAR 10.09.08.05C.

(156) "Recipient" or "Program recipient" means an individual who is certified as eligible to receive Medical Assistance benefits, as provided in COMAR 10.09.24.
(157) "REM optional services" means, in the context of COMAR 10.09.69, the services which meet the general requirements under Regulation .08 and are listed in Regulations .10 and .11 of that chapter.

(158) "School-based health center (SBHC)" means a provider located on school grounds that meets the requirements set forth in COMAR 10.09.76.

(159) "Secretary" means the Secretary of Health.

(160) "Self-referral services" are the health care services listed in COMAR 10.67.06.28 for which, under specified circumstances, the MCO is required to pay, without any requirement of referral by the PCP or MCO, when the enrollee accesses the service through a provider other than the enrollee's PCP.

(161) "Service area" means a geographical area, comprised of one or more of Maryland's counties, with each selected county included in its entirety.

(162) "Service year" in the context of COMAR 10.67.04.19-5, means the calendar year in which an MCO incurs the expenses reported pursuant to COMAR 10.67.04.15E(5)(c).

(163) "Somatic care" means medical care that addresses an individual’s physical health care needs.

(164) "Special needs population" means a group of recipients who share a special health care need as specified in COMAR 10.67.04.04.

(165) "Special rehabilitation hospital" has the meaning stated in Health-General Article, §19-307(a)(iii), Annotated Code of Maryland.

(166) "Specialty behavioral health services" means any behavioral health services other than primary behavioral health services.

(167) "Specialty care" means health care services that are either outside the PCP's scope of practice or, in the judgment of the PCP, are not services that the PCP customarily provides, is specifically trained for, or is experienced in.

(168) "Specialty care residency slots" means, in the context of COMAR 10.67.11, positions in a teaching hospital's residency program occupied after completion of a medical degree program by physicians who have trained in specialties other than family medicine, internal medicine, pediatrics, or obstetrics and gynecology.

(169) "Spend down" means a procedure by which an individual applying for Medical Assistance who is otherwise ineligible due to excess income becomes eligible by deducting incurred medical expenses from excess income.
(170) "State fair hearing" means a hearing, conducted by the Office of Administrative
Hearings, for the purpose of ensuring the right of recipients to be treated in a fair and unbiased
manner in their efforts to resolve disputes with the Department or an MCO.

(171) "Subcontract" means a written agreement between an MCO and a third party, under
which the third party performs any one or more of the MCO's obligations required by the
Department.

(172) "Subcontractor" means an individual or entity that has a contract with an MCO that
relates directly or indirectly to the performance of the MCO’s obligations under its contract with
the Department; provided, however, that a contract does not by itself cause an MCO’s network
provider to be a subcontractor.

(173) "Substantial minority" means an ethnic or linguistic group that comprises 5 percent or
more of the Medicaid population in the county to be served.

(174) "Supplemental Security Income (SSI)" means a federally administered program
providing benefits to needy aged, blind, and disabled individuals under Title XVI of the Social

(175) "Systems performance review (SPR)" means an assessment, as a component of the
quality assurance (QA) audit, of quality assurance operations taking place in the MCO.

(176) "Teaching hospital" means a hospital that:

(a) Had HSCRC-approved rates for FY 1995 that included an allowance for GME costs; and

(b) During the contract year, operates a graduate medical education program that is
accredited by the Accreditation Council for Graduate Medical Education.

(177) "Temporary Cash Assistance (TCA)" means a form of cash assistance provided,
pursuant to Article 88A, §44A et seq., Annotated Code of Maryland, to assistance units which
are technically and financially eligible.

(178) "Tertiary care" means health care services provided by highly specialized health care
providers which are usually diagnostic or therapeutic in nature and often require highly
sophisticated technological and support facilities.

(179) "Urgent care" means health care services for a medical condition that manifests itself
by symptoms of sufficient severity that the absence of medical attention within 48 hours could
reasonably be expected, by a prudent layperson who possesses an average knowledge of health
and medicine, to result in an emergency medical condition.

(180) "Waiver-eligible" means an individual who qualifies for enrollment in the Maryland
Medicaid Managed Care Program.
(181) "Whistleblower" means an individual who exposes any kind of information or activity that alleges any violation of regulation, statute, contract, policy, or unethical behavior that may be indicative of an individual or entity committing fraud, waste, or abuse against the Medicaid program.

(182) "Witness", in the context of COMAR 10.09.69, has the meaning stated in COMAR 10.09.53.
Chapter 02 Maryland Medicaid Managed Care Program: Eligibility and Enrollment

.01 Eligibility.

A. Criteria. Except as provided in §B of this regulation, a Program recipient shall be enrolled in the Maryland Medicaid Managed Care Program, described in this chapter, if the recipient is eligible for receipt of Medical Assistance benefits by qualifying:

   (1) As categorically needy or medically needy under COMAR 10.09.24, unless the recipient is:

      (a) 65 years old or older;

      (b) Newly eligible and 64 1/2 years old or older;

      (c) Eligible to receive Medicare benefits;

      (d) Determined medically needy under a spend down; or

      (e) Otherwise certified for a period of less than 6 months;

   (2) For the Pregnant Women and Children's Program on or after January 1, 1997, unless the recipient enters the Program during the postpartum period; or

   (3) For the Maryland Children's Health Program on or after July 1, 1998.

B. A recipient is not eligible for the Maryland Medicaid Managed Care Program if the recipient:

   (1) Has been, or is expected to be, continuously institutionalized for more than:

      (a) 90 successive days in a long-term care facility; or

      (b) 30 successive days in an institution for mental disease (IMD);

   (2) Is institutionalized in an intermediate care facility for individuals with intellectual disabilities or persons with related conditions (ICF/IID);

   (3) Is enrolled in:

      (a) Home Care for Disabled Children under a Model Waiver, pursuant to COMAR 10.09.27;

      (b) The Family Planning Waiver Program pursuant to COMAR 10.09.58; or
(c) The Employed Individuals with Disabilities Program pursuant to COMAR 10.09.41;

(4) Is a child receiving adoption subsidy who is covered under the parent's private insurance;

(5) Is a child under State supervision receiving adoption subsidy who lives outside of the State;

(6) Is a child in an out-of-State placement; or

(7) Is an inmate as defined in COMAR 10.67.01.01.

.02 Enrollment.

A. The Department shall make available through its website and upon request provide a paper copy of the following:

(1) Materials regarding each MCO providing services in the eligible individual’s county of residence including, but not limited to:

   (a) Information about how to access the provider directory and drug formulary, with instructions for how to request paper copies if needed;

   (b) A schedule of the benefits offered, including any benefits offered beyond the basic required package described in COMAR 10.67.06;

   (c) Which, if any, benefits are provided directly by the Department;

   (d) If applicable, a list of services that the MCO does not provide, reimburse for, or provide coverage of, because of moral or religious objections, and information about where and how to obtain these services;

   (e) The requirements for each MCO to provide adequate access to covered services, including the network adequacy standards established in COMAR 10.67.05; and

   (f) Quality and performance indicators for each MCO, including enrollee satisfaction; and

(2) Materials about the managed care program, including:

   (a) The MCO enrollment and disenrollment process; and

   (b) The basic features of managed care.

(3) Any forms necessary to select an MCO; and
(4) The toll-free telephone number of the enrollment unit.

B. Only the Department, or its designee, is authorized to enroll individuals into MCOs.

C. A participant found eligible for Maryland Medicaid under 42 U.S.C §1902(a)(10)A(i) shall be assigned to:

(1) The MCO the participant chooses at the time of application; or

(2) If the participant does not choose, an MCO with available capacity that is accepting new participants in the participant’s service area.

D. Except for a participant found eligible as described in §C of this regulation, a participant, including a child in foster care or kinship care, shall:

(1) Have 28 days from the day the Department mails its eligibility notification in which to select an MCO; or

(2) Be assigned to an MCO with available capacity that is accepting new participants in the participant’s service area.

E. All Managed Care Program eligible family members who live in the same household shall be assigned to the same MCO.

F. Newborns.

(1) A newborn shall be automatically enrolled from birth in its biological mother’s MCO.

(2) The MCO is responsible for the newborn’s health care from birth until the newborn enrolls into another MCO.

(3) A newborn, automatically assigned to its biological mother’s MCO, is not eligible to change MCOs for family unity as described in COMAR 10.67.02.06A(1)(b) and (c) during the first 90 days of enrollment.

G. Effective Date of Enrollment. Enrollment in an MCO shall be effective at 12:01 a.m. on the 10th calendar day beginning with the day on which the Department notifies the MCO of the enrollment.

H. Upon the approval of the Department and the MCO, a participant may select an MCO that does not serve the participant’s service area.

I. The Department or its designee shall submit the enrollee's choice of PCP to the enrollee's selected MCO at the time of enrollment.
.03 Health Service Needs Information.

A. The Department, MCO, or agents of the Department or MCO shall attempt to complete the health service needs information at the time of enrollment.

B. The Department shall transmit any information obtained from health service needs information to the enrollee’s MCO within 5 business days.

C. Upon its receipt and review of the health service needs information, an MCO shall take appropriate action to ensure that a new enrollee, who needs special or immediate health care services, as identified by the health service needs information, receives them in a timely manner.

D. If the Department does not transmit health services needs information for an enrollee to the MCO within 10 days of enrollment, the MCO shall make at least two attempts to conduct an initial screening of the enrollee’s needs, within 90 days of the effective date of enrollment. At least one of these attempts shall be during non-working hours.

E. The Department shall inform an enrollee identified in connection with the health service needs information as having a behavioral health problem that the individual may self-refer to the behavioral health ASO for services as described in COMAR 10.09.59 and 10.09.80.

.04 Assignment to Primary Care Provider (PCP).

A. Within 10 days of the notification of enrollment of a new enrollee or within 10 days of any event that requires a change in an existing enrollee's PCP, an MCO shall notify the enrollee of the enrollee's PCP assignment.

B. A Program recipient with no previous affiliation with any of the providers on the MCO's primary care provider panel who:

   1) Indicates a preference for a participating PCP during the enrollment process shall be assigned to that PCP unless the MCO documents in writing, for good cause, its inability to assign the enrollee to that PCP; or

   2) Fails to make known any preference for a PCP shall be assigned to a PCP whose location satisfies the access standards specified in COMAR 10.67.05.06E.

C. Before changing an enrollee’s PCP, the MCO shall obtain the Department’s approval at least 60 days before the reassignment is effective unless:

   1) The PCP has decided to stop practicing;

   2) The PCP has terminated the relationship with an enrollee due to the enrollee’s behavior;

   3) The change is requested by the enrollee; or
(4) The age limits of the PCP's practice no longer meet the needs of the enrollee.

.05 Reassignment.

A. Once every 12 months, a Program recipient may elect to:

(1) Maintain enrollment with the recipient's current MCO;

(2) Enroll in another MCO in the recipient's local access area; or

(3) Enroll in an MCO outside the recipient’s local access area, upon the approval of the Department and the MCO.

B. The Department shall notify the enrollee no less than 60 days before the start of each new enrollment period.

C. The Department shall reassign into the same MCO from which the recipient was last enrolled any recipient disenrolled from an MCO who, within 120 days of disenrollment, regains:

(1) Eligibility for Medicaid; or

(2) Maryland Medicaid Managed Care Program eligibility lost for any of the reasons listed in Regulation .06B of this chapter.

D. The MCO shall assign the recipient to the primary care provider of record at the time of the recipient's disenrollment.

E. A Program participant who has been disenrolled from an MCO because the Department terminated the MCO's contract shall be assigned to another MCO subject to Regulation .02D of this chapter.

.06 Disenrollment.

A. Enrollee-Initiated Disenrollment for Cause.

(1) An enrollee may disenroll from an MCO and enroll into another MCO if:

(a) The enrollee moves to a county that is not served by the enrollee's present MCO;

(b) The family members are enrolled in different MCOs and the adult enrollee requests that other family members be enrolled in one of the MCOs in which another family member is currently enrolled;
(c) The enrollee requests enrollment into the MCO that contracts with the PCP of any other
family member who is not a HealthChoice enrollee;

(d) The enrollee moves or becomes homeless, creating a transportation hardship that may
be resolved by enrollment into another MCO serving the enrollee's new local access areas;

(e) The enrollee requests a change of MCO within 90 days after the termination of the
enrollee's primary care provider's (PCP's) contract if the PCP's contract with the enrollee's MCO,
MCO's medical management group, or its subcontractors is terminating for the following
reasons:

   (i) By the MCO for reasons other than the quality of care or the PCP's failure to comply
with contractual requirements related to quality assurance activities; or

   (ii) The MCO's reduction of PCP's reimbursement to the extent that the reduction in rate
is greater than the actual change in capitation paid to the MCO by the Department, and the MCO
and PCP's inability to negotiate a mutually acceptable rate;

(f) The enrollee is automatically assigned to an MCO or it is the enrollee's initial
enrollment in an MCO as follows:

   (i) Only one request during the first 90 days of automatic assignment or initial
enrollment into an MCO; and

   (ii) The enrollee is not hospitalized at the time of the request;

(g) The MCO terminates its contract with the Department in which case:

   (i) The MCO shall provide written notice to the recipient at least 60 days before the date
on which the MCO will exit the HealthChoice Program;

   (ii) The MCO shall include in the notice the name and provider number of the PCP
assigned to the recipient and the telephone number of the enrollment broker;

   (iii) The Department shall send a notice to every enrollee of the MCO regarding the
MCO's termination of its contract with the Department, at least 30 days before the effective date
of the termination of the contract;

   (iv) An enrollee shall have at least 30 days before the effective date of the MCO's
contract termination with the Department to choose another MCO, or will be assigned to another
MCO; and

   (v) An enrollee may choose another MCO one additional time within at least 90 days
after reenrollment into the new MCO;

(h) The MCO is acquired by another entity in which case:
(i) The MCO shall provide written notice to the recipient at least 60 days before the date on which the MCO will exit the HealthChoice Program;

(ii) The MCO shall include in the notice the name and provider number of the PCP assigned to the recipient and the telephone number of the enrollment broker;

(iii) The Department shall send a notice to every enrollee of the MCO regarding the change in ownership, 30 days before the effective date of the change of ownership;

(iv) An enrollee shall have 30 days before the change of ownership to disenroll from the MCO into another participating MCO;

(v) If an enrollee does not choose to disenroll in accordance with §A(1)(f)(ii) of this regulation, the enrollee will be reenrolled in the newly purchased MCO; and

(vi) An enrollee may choose another MCO one additional time within at least 90 days after reenrollment in the newly purchased MCO;

(i) The MCO does not, because of moral or religious objections, cover the service the enrollee seeks;

(j) All of the following apply:

(i) The enrollee needs related services to be performed at the same time;

(ii) Not all related services are available within the network; and

(iii) The enrollee's PCP or other provider determines that receiving the services separately would subject the enrollee to unnecessary risk; or

(k) The Department imposes the intermediate sanction specified in 42 CFR §438.702(a) and (b), as amended.

(2) The Department shall provide timely notification to the affected MCO of an enrollee's intention to disenroll under §A of this regulation.

(3) The Department shall allow disenrollments, subject to the Department's approval, for other reasons, including but not limited to:

(a) Poor quality of care;

(b) Lack of access to services covered under the contract; or

(c) Access to providers experienced in dealing with the enrollee's health care needs.
(4) Enrollees shall make an oral or written request to the Department's enrollment agent for disenrollment.

B. Department-Initiated Disenrollment. The Department shall disenroll from an MCO an enrollee:

(1) Subject to the MCO or long-term care facility obtaining the Department’s determination that the enrollee’s institutionalization has been medically necessary, who has been continuously institutionalized for a period of more than 90 successive days in a long-term care facility;

(2) Upon admission to an intermediate care facility for individuals with intellectual disabilities or persons with related conditions (ICF/IID);

(3) Determined eligible for rare and expensive case management pursuant to COMAR 10.09.69;

(4) Who loses Medicaid eligibility or who changes to an assistance category not eligible for MCO enrollment, subject, however, to Regulation .01 of this chapter;

(5) Upon the termination of the contract between the enrollee's MCO and the Department;

(6) Who has died;

(7) Who has not been validly enrolled in the MCO;

(8) Who is 65 years old or older;

(9) Who is an inmate of a public institution, including a State operated institution or facility; or

(10) Who is eligible to receive Medicare benefits.

C. The Department may disenroll individuals from an MCO which the Maryland Insurance Administration has put into rehabilitation or liquidation pursuant to Health-General Article, §15-102.2, Annotated Code of Maryland.

D. MCO Initiated Disenrollment.

(1) An MCO may request disenrollment of an enrollee who has:

(a) Moved outside of the MCO's service area; or

(b) Become ineligible for continued enrollment for one of the reasons specified in §B of this regulation.
(2) An MCO may not request disenrollment as specified in 42 CFR §438.56(b)(2), as amended.

E. Effective Date of Disenrollment.

(1) Except as specified in §E(2)—(6) of this regulation, an enrollee's disenrollment is effective on the 10th calendar day after the enrollee selects a new MCO.

(2) An enrollee's disenrollment shall take effect:

(a) Immediately when the enrollee dies;

(b) From the first day of the month following the month that the enrollee lost Medicaid eligibility;

(c) On the first day of the month following the month in which the Department receives the required notification, when the enrollee permanently relocates outside of the State; or

(d) From the first day of the month following the month in which the Department verifies an enrollee is an inmate.

(3) When an enrollee becomes eligible for Medicare, the enrollee’s disenrollment from the MCO is effective on the:

(a) First day of the month following the month in which the Program receives notice of Medicare eligibility; or

(b) Last day of the month before the month in which the enrollee turns 65 years old.

(4) Termination of enrollment resulting from termination of the contract between the Department and an MCO shall be effective on the date the Department terminates the contract.

(5) Termination of enrollment resulting from the MCO being placed into rehabilitation or liquidation by the Maryland Insurance Administration shall be effective on the date the Department notifies the MCO of the disenrollment.

(6) In the case of an enrollee's death, the Department has the right to recover any capitation payments made on behalf of an enrollee for the period beginning on the date of death.

F. An MCO shall:

(1) Make a good faith effort to give written notice to the Department when enrollees have the right to change MCOs under §A(1)(e) of this regulation 90 days before the effective date of the termination;
(2) Provide the Department with a list of the affected enrollees in a format specified by the Department; and

(3) If applicable, provide the termination survey required under COMAR 10.67.04.17B(4).

G. The Department shall notify enrollees who may change MCOs under §A(1)(e) of this regulation.

H. At the Department’s discretion, an MCO may be required to reimburse the Department for the costs associated with the mailing of the notifications in §G of this regulation.
Chapter 03 Maryland Medicaid Managed Care Program: MCO Application

.02 Application.

A. When applying for participation in the Maryland Medicaid Managed Care Program as an MCO, an applicant shall submit an application to the Secretary in the form that the Secretary requires.

B. An applicant may omit from its application any information or documents that it has previously submitted to the Department, if:

   (1) The information or documents are up to date; and

   (2) The applicant identifies in its application the information and documents that it has omitted.

.03 Organization, Operations, and Financing.

Except as provided in Regulation .02B of this chapter, an MCO applicant shall include the following information or descriptions in its application:

A. An indication whether the applicant is an operating HMO with a certificate of authority from the Maryland Insurance Administration;

B. A written legal history of the applicant, specific as to dates and parties involved, that includes, but is not limited to:

   (1) Predecessor corporations;

   (2) Mergers;

   (3) Reorganizations; and

   (4) Changes of ownership;

C. A copy of the articles of incorporation of the applicant, and any amendments to it, certified by the Maryland Department of Assessments and Taxation;

D. A copy of the applicant's current bylaws, certified by the appropriate corporate officer;

E. A written description providing a reason if the applicant has ever defaulted on a contract or otherwise had a contract terminated;
F. If the applicant is an HMO, the most recent annual loss ratio report provided to the Maryland Insurance Administration pursuant to Insurance Article, §5-605, Annotated Code of Maryland;

G. A copy of the applicant's business plan provided to the Maryland Insurance Administration pursuant to Insurance Article, §5-605, Annotated Code of Maryland.

H. Evidence of compliance with Maryland Workers' Compensation Law, as follows:

(1) Except as provided in §H(2) of this regulation, the applicant shall submit:

(a) The policy number of its Workers' Compensation insurance coverage; and

(b) The name of its Workers' Compensation insurance carrier; or

(2) If self-insured, the applicant shall submit a certificate of compliance evidencing employee coverage under Workers' Compensation Law, as provided in Labor and Employment Article, Title 9, Annotated Code of Maryland;

I. The names, addresses, and official capacities of the managing employees or other individuals responsible for the conduct of the affairs of the applicant, including concise position descriptions and background, citing education, training, and experience, for, but not limited to, the applicant's:

(1) Plan administrator;

(2) Medical director;

(3) Medical records director;

(4) Enrollment/disenrollment director;

(5) Quality assurance director;

(6) Case management director;

(7) Utilization control manager; and

(8) Grievance director and marketing director;

J. A full disclosure of the extent and nature of any contracts or arrangements, including any possible conflicts of interest between the applicant and any individual specified in §I of this regulation;

K. The name and address of each person with a 5 percent or more ownership or controlling interest in the applicant or in any subcontractor or supplier in which the applicant has direct or
indirect ownership of 5 percent or more, including identifying whether any person named is related to any other named person as either spouse, parent, child, or sibling;

L. A list of any subcontractors or suppliers owned by the applicant, indicating the percent of financial interest held;

M. A history of any subcontractors with whom the applicant has had business transactions totaling more than $25,000 during the 12-month period ending on the date of application;

N. A description of the applicant's corporate and organizational structure, and an organizational chart, with detailed lines of authority indicating the relationships among the board of directors, the administrative component, and the medical and health service delivery component of the applicant including, but not limited to, staff positions responsible for the plan's key management functions enumerated in §I of this regulation;

O. A description of all current contractual relationships between the applicant and subcontractors for administrative/management, health, and marketing services, including the subcontractors' names;

P. A description of any contracts the applicant intends to enter into before beginning operation as an MCO;

Q. The name of any person or persons holding an ownership or controlling interest in excess of 5 percent in the applicant, or who is an agent or managing employee of the applicant, who has been subject to a conviction as defined at 42 U.S.C. §1320a-7(i), or a sanction for a Program-related offense;

R. Copies of all standard subcontracts with service and administrative providers who are not salaried employees of the applicant, including identification of any provision in subcontracts which differ from the standard subcontract;

S. A description of the method by which the applicant will accomplish cost avoidance or recovery in the case of third-party liability; and

T. Copies of the applicant's written Medicaid marketing plan including:

(1) A description of how the applicant plans to address the special access provisions in COMAR 10.67.05.01D; and

(2) Sample version of all material and communication the applicant would like to distribute to potential enrollees, including but not limited to:

(a) Brochures;

(b) Fact sheets; and
An applicant that is not a Maryland certified HMO shall include in its application the following information or descriptions:

A. A table labeled "Insurance Coverage", specifying the applicant's coverage in insurance types including, but not limited to, reinsurance, risk of insolvency, medical malpractice, general liability, and fidelity bond, and detailing the:

(1) Carrier;

(2) Entity covered;

(3) Description of coverage including deductibles, coinsurance, and minimum and maximum benefits;

(4) Premium in effect;

(5) Any additional policies to cover new risks associated with anticipated MCO functions; and

(6) Any other pertinent arrangements;

B. Evidence of the applicant's insurance for general liability and medical malpractice in the minimum amounts of $1,000,000 per loss and $3,000,000 in the aggregate;

C. Evidence that the applicant has on hand sufficient liquid funds or a reasonably adequate cash flow to meet all organizational and administrative expenses incurred or expected to be incurred before commencing operations;

D. An explanation detailing how the applicant would, if approved, protect itself from insolvency;

E. A description of how the applicant would, if approved, limit its financial risk;

F. Document that the applicant has deposited, in a trust account with the State treasury, $100,000 in cash or government securities of the type described in Insurance Article, §5-701(b), Annotated Code of Maryland;

G. A financial statement audited by an independent certified public accountant of the financial condition of the applicant, including:

(1) Assets, liabilities, and minimum tangible net equity;
(2) A prospective budget and expected cash flow analysis of the applicant for the first 24 months of its anticipated operation demonstrating financial stability based on reasonable assumptions; and

(3) Any other financial information required by the Commissioner to adequately conduct financial examination of an applicant; and

H. A power of attorney executed by the applicant appointing the Commissioner and the Commissioner's authorized deputies as the true and lawful attorney of the applicant in and for the State upon which may be served all lawful process in any action, proceeding, or cause of action arising in this State against the applicant regarding the solvency and financial condition of the applicant.

.05 Access and Capacity.

A. An MCO applicant shall include in its application the following information or descriptions:

(1) A map or maps showing the county or counties in which the applicant proposes to provide health care services, and the service area boundaries.

(2) The name and address of each of the applicant's service delivery sites, and, if applicable, the type of facility licensure of each site, grouped by county;

(3) If the applicant is an HMO, the applicant's total prepaid enrollment or client population as of the date of application, with a breakdown by payment source, including Medicare, Medicaid, commercial group, commercial individual, and other enrollment;

(4) If the applicant is an HMO, the total of the applicant's current unduplicated fee-for-service patient count, with a breakdown by payment source, including Medicaid, Medicare, commercial group, commercial individual, and other patients (including self-pay);

(5) The name and address of each of the applicant's primary and specialty care providers, provided in a format specified by the Department, for distribution to recipients in enrollment packets;

(6) The following information, grouped by medical specialty and county, regarding each individual practitioner, including primary care providers and specialists, who will act as a health care provider for the applicant:

(a) Name, address, and practice location or locations, including a separate line for each location;

(b) State licensure number;

(c) Specialty, if applicable, indicating the type of services to be provided on behalf of the applicant;
(d) Whether the provider will be a primary care provider;

(e) A description of the practitioner's employment relationship to the applicant, including, but not limited to:

(i) A salaried employee;

(ii) A subcontractor;

(iii) An employee of a subcontractor; or

(iv) Any other form of contractual or employment relationship;

(f) Any restrictions as to age of patients or numbers of enrollees the provider will serve;

(7) The procedures for assuring proper credentialing and recredentialing of providers;

(8) Documentation that the MCO applicant is able to meet the access standards set forth in COMAR 10.67.05 in each service area the MCO applicant plans to enter;

(9) Documentation of any reasons for which they are unable to meet the access requirements of COMAR 10.67.05 in any service area;

(10) For each primary care practice location, a specification of:

(a) The name, address, and hours of operation; and

(b) The staffing at each location, expressed in full-time equivalencies and grouped by medical specialty; and

(11) Written protocols detailing how the applicant will provide 24-hour per day, 7-day per week coverage for emergency medical situations, including compliance with MIEMSS protocols and the federal Emergency Medical Treatment and Active Labor Act.

B. The service area in §A(1) of this regulation shall include at least two underserved counties as defined in §C of this regulation.

C. An underserved county is a county in which less than three current MCOs are participating and accepting new enrollments.

D. If there are no underserved counties, applications will not be accepted.

.06 Access and Capacity: Benefits and Appointments.

An MCO applicant shall include in its application the following information or descriptions:
A. Written evidence of the applicant's preparedness to provide benefits equivalent to the benefit level mandated by the Maryland Medical Assistance Program as described in COMAR 10.67.05;

B. A description of any benefits the applicant proposes to provide in addition to those required by the Maryland Medicaid Managed Care Program, including:

   (1) Whether there are any limitations on these services; and

   (2) The name, medical specialty, location, and employment status as enumerated in Regulation .05F(5) of this chapter, of any providers rendering additional services;

C. A copy of the written procedures specifying how an enrollee may select and change primary care providers;

D. A written explanation of the applicant's plan to provide adequate case management and continuity of care, including its policies and procedures concerning:

   (1) Case management;

   (2) Making appointments;

   (3) Appointment no-shows;

   (4) Follow-up for appointment no-shows who are at-risk patients; and

   (5) Referral claims and reimbursement for authorized noncontractual and out-of-plan provider services;

E. Documentation of the applicant's preparedness to collaborate with providers of self-referral services, and reimburse at the Department's established fee-for-service rate, for permissible self-referred services as defined in COMAR 10.67.06.28;

F. Documentation of the applicant's preparedness to provide the full range of EPSDT services;

G. Documentation of the applicant’s preparedness to work with the Department’s behavioral health ASO for coordination of somatic care, behavioral health care, and all appropriate drug utilization review.

H. A written explanation of the prospective MCO's plan for providing monthly updates to primary care providers of the enrollees assigned to them;

I. Documentation of the applicant's plan to satisfy statutory requirements that enrollees be notified of due dates for obtaining immunizations, examinations, and other wellness services;
J. Documentation of how the applicant will provide timely access to health care services, including but not limited to:

1. Waiting time for telephone calls to be answered;
2. Obtaining appointments; and
3. Waiting times in practitioners' offices;

K. Documentation of access provisions to address the needs of enrollees who:

1. Do not speak English;
2. Are deaf; or
3. Have one or more physical, mental, or developmental disabilities;

L. The applicant's proposed written utilization management program that specifies, at a minimum, policies and procedures for:

1. Referral processes;
2. Services requiring preauthorization, including mechanisms for ensuring consistent application and requesting provider consultation when appropriate;
3. Criteria for determining medical necessity;
4. Provider responsibilities for utilization management activities;
5. Case management processes;
6. Utilization tracking mechanisms and the determination of over-utilization and under-utilization of health care services;
7. Integration of activities with quality improvement for provider profiling; and
8. Appeals and grievance processes;

M. The applicant's proposal to establish and utilize a consumer advisory board, including:

1. The anticipated composition of the board;
2. Identifying staff responsible for serving board needs; and
3. Proposed mechanisms by which the board will furnish the MCO with regular enrollee input;
N. A written description of the applicant's proposed member services unit, including a consumer services hotline, describing how the applicant will use this:

1. As an information source for enrollees;
2. To respond to enrollees' needs and requests in a timely manner; and
3. To facilitate enrollees' access to needed health care services, including how the hotline will function as a point of entry for complaint resolution and internal grievance procedures;

O. A written Enrollee Outreach Plan that:

1. Describes how the MCO intends to comply with the outreach, quality assurance, and provision of health care services requirements of Health-General Article, §15-103(b)(9), Annotated Code of Maryland; and
2. To the extent that the materials are relevant to the requirements of §O(1) of this regulation, may incorporate by reference written materials provided by the applicant in response to other elements of its application; and

P. Documentation of any service the MCO elects not to provide, reimburse for, or provide coverage of, because of a moral or religious objection, which shall:

1. Be provided to the Department whenever an MCO adopts the policy during the term of the contract;
2. Be consistent with the provisions of 42 CFR §438.10, as amended; and
3. Be provided to enrollees within 90 days after adopting the policy with respect to any particular service.

.07 Access and Capacity: Contracts and Provider Applications.

An MCO applicant shall include in its application the following information or descriptions:

A. A description of the applicant's hiring and subcontracting policies, which shall correspond to the requirements of Insurance Article, §15-112, Annotated Code of Maryland;

B. A blank copy of the provider application form;

C. Documentary assurances that the applicant and its health care providers furnish access on a nondiscriminatory basis, in accordance with State and federal law, to all of their enrollees regardless of gender, race, age, religion, national origin, physical or mental disability, or type of illness or condition;
D. If the applicant is an HMO that will require its panel providers to participate in the MCO, documentation of the mechanism the MCO will use to make an equitable distribution of enrollees among its panel providers so that no provider is assigned a disproportionate number of enrollees;

E. Written evidence of the applicant's organizational capacity to provide special programs adequate to meet the individual needs of all enrollees, including:

   (1) Outreach;

   (2) Case management;

   (3) Home visiting;

   (4) Disease management;

   (5) Prevention and wellness education; and

   (6) All Medicaid-covered services required to comply with State statutes and regulations mandating health and behavioral health services for children in State-supervised care;

F. A written explanation of the applicant's plan for ensuring that each primary and specialty care provider receives a copy of the MCO's Medicaid requirements manual, and any other information necessary to facilitate full compliance with all federal and State Medicaid requirements within 2 weeks after the provider has entered into a contract or has begun employment with the MCO, and updated as necessary thereafter; and

G. A description of the applicant's plan to accommodate the cultural and ethnic diversity of the populations to be served.

.08 National Committee on Quality Assurance (NCQA) Accreditation.

Effective July 1, 2012 an MCO applicant shall be NCQA accredited within 2 years of their effective date as an MCO.

.09 Quality Assurance System — General.

An applicant shall include in its application the following information or descriptions:

A. The applicant's proposed quality assurance plan, that contains, at a minimum, all elements specified by Health-General Article, §15-103(b)(9)(i), Annotated Code of Maryland;

B. A description of any written procedures or protocols regarding physician and nursing care practice the applicant intends to use;
C. A description of the applicant's peer review committee structure and process;

D. A copy of the applicant's case management plan;

E. A description of all mechanisms to be used to ensure the quality of any services, including administrative and clinical, that the applicant intends to delegate to subcontractors;

F. The name and a description of the published standards or guidelines for maintenance of medical records the applicant will follow;

G. A description of how providers will be apprised of medical records, utilization review, and case management requirements;

H. A description of the applicant's system for ensuring inclusion in the medical record of reports of health care services or diagnostic testing performed in a referral setting;

I. A written description of the applicant's internal review system for the handling, monitoring, and resolution of provider complaints, grievances, and appeals;

J. Evidence of an adequate system for medical record retention and retrieval that meets, at minimum, all requirements of Health-General Article, §15-103(b)(9)(xiv), Annotated Code of Maryland;

K. Documentary evidence that the applicant requires school-based clinics to provide information concerning health care services provided to their enrollees;

L. A copy of the applicant's practice guidelines used to assist practitioners in approaching health care issues in a systematic, appropriate manner;

M. A copy of the applicant's health education plan;

N. A written description of the applicant's complaint resolution protocol, which shall, at minimum:

   (1) Include an internal grievance procedure by which an enrollee who is dissatisfied with the applicant or its providers may seek recourse within the applicant;

   (2) Specify what constitutes a grievance;

   (3) Provide for prompt resolution of complaints;

   (4) Require participation in the grievance process by individuals within the MCO who have the authority to require corrective action;

   (5) Specify how the MCO will handle formal appeals by enrollees;
Appendix O

(6) Include a form that enrollees will use when filing a grievance, including foreign language versions for any substantial minorities in the applicant's proposed MCO service area;

(7) Identify the steps in the grievance process, and what personnel will be responsible for receiving, processing, monitoring, and responding to grievances;

(8) Specify how the enrollee will be informed that the enrollee's grievance is being investigated, and the protocols by which grievances will be resolved;

(9) Describe what methods will be used to inform enrollees about the operation of the grievance procedure; and

(10) Describe whether manual or automated processes will be used to track enrollees' complaints, determine any patterns of complaints, and report findings to the proposed MCO's quality assurance or quality improvement system; and

O. A copy of the MCO's provider education plan.

.10 Special Needs Populations.

An MCO applicant shall include in its application the following information or descriptions:

A. A narrative description of the clinical expertise and experience of the MCO's network for special needs populations in a format specified by the Department;

B. Written evidence of the applicant's ability to comply with specific quality access, data, and performance measurements to satisfy the general requirements for all special needs populations specified in COMAR 10.67.04.04;

C. Written evidence, including treatment protocols, of the applicant’s ability to provide the range of clinical and support services specified in COMAR 10.67.04.05—.10 and .13, to ensure appropriate and coordinated services to the following special populations:

(1) Children with special health care needs;

(2) Individuals with a physical disability;

(3) Individuals with a developmental disability;

(4) Pregnant and postpartum women;

(5) Individuals who are homeless; and

(6) Individuals with HIV/AIDS; and
D. Referral protocols that demonstrate the conditions under which PCPs will make the arrangements for children with special health care needs to be referred to MCO specialty care networks and when appropriate the behavioral health ASO for services as described in COMAR 10.09.59 or 10.09.80.

.11 Management Information System and Data Reporting.

An MCO applicant shall include in its application the following information or descriptions:

A. A description of the applicant's management information system, including, but not limited to:

   (1) Capacities, including:

      (a) The ability to generate and transmit electronic claims data consistent with the Medicaid Statistical Information System (MSIS) requirements or successor systems;

      (b) The ability to collect and report data on enrollee and provider characteristics and on all services furnished to enrollees through an encounter data system;

      (c) The ability to screen the data collected for completeness, logic, and consistency; and

      (d) The ability to collect and report data from providers in standardized formats using secure information exchanges and technologies utilized for Medicaid quality improvement and care coordination efforts;

   (2) Software;

   (3) Characteristics; and

   (4) Ability to interface with other systems;

B. A description of the applicant's operational procedures for generating service-specific encounter data;

C. Evidence of the applicant's ability to report, on a monthly basis, service-specific encounter data in UB04 or CMS1500 format;

D. A description of the applicant's operational procedures for generating financial reports, including, but not limited to:

   (1) Annual audits;

   (2) Annual financial statements; and
(3) Quarterly unaudited financial statements;

E. Evidence of the applicant’s ability to collect and report all data necessary to derive indicators for Healthcare Effectiveness Data and Information Set (HEDIS); and

F. A description of the applicant’s procedures for verifying the accuracy and timeliness of reported data, including data from network providers the MCO was compensating on the basis of capitation payments or other payment arrangements that are not fee-for-service.
Chapter 04 Maryland Medicaid Managed Care Program: Managed Care Organizations

.02 Conditions for Participation.

A. An MCO shall have sufficient provider capacity to provide health care services to Program recipients residing in a geographic region no smaller in size than one county or the City of Baltimore.

B. An MCO shall comply with COMAR 10.09.36.

C. An MCO shall enter a memorandum of understanding with each local health department (LHD) in its service area addressing the method by which the MCO and the LHD will collaborate and communicate on matters of mutual interest and concern, including but not limited to the responsibility of the LHD for contact tracing for sexually transmitted diseases and directly observed therapy for tuberculosis.

D. Assurance Against Insolvency.

   (1) An MCO shall be actuarially sound.

   (2) An applicant shall possess an initial surplus in the amount of $1,500,000 as specified in Health-General Article, §15-102.4(a)(2)(ii), Annotated Code of Maryland.

   (3) If the Commissioner determines and reports to the Secretary that the applicant has an initial surplus that is at least $1,250,000 but less than $1,500,000, before approval the Department shall designate funds in trust sufficient to provide an initial surplus of $1,500,000.

   (4) If the Commissioner determines and reports to the Secretary that the applicant’s initial surplus is less than $1,250,000 before approval the Department may, at its discretion, designate funds in trust in an amount equal to:

      (a) The sum of the amounts due to the owners of the applicant from the Department for Medicaid services provided on a fee-for-service basis, so long as the owners of the applicant have waived in writing their right to receive Medicaid payments until such time as the Department is permitted to remove its funds from the trust account pursuant to §D(6) of this regulation; or

      (b) If a financial guarantor with sufficient net worth and an adequate history of generating net income agrees to pay claims against the MCO in the case of insolvency, the difference between $1,250,000 and the applicant's initial surplus.

   (5) If, in accordance with §D(4) of this regulation, the Department designates funds sufficient to increase the applicant’s initial surplus to $1,250,000, the Department shall designate $250,000 in trust for the applicant.
(6) Funds designated by the Secretary pursuant to §D(3)—(5) of this regulation shall remain in trust until such time as the Commissioner has determined that the MCO meets the minimum statutory surplus requirements based on the MCO’s annual report submitted pursuant to Insurance Article, §5-605, Annotated Code of Maryland.

(7) Before approval of an applicant, the Secretary shall notify the Commissioner whether the Secretary has placed any money in trust under this section.

(8) In the event of insolvency, the MCO shall cover continuation of services to enrollees for the duration of the period for which capitation payment has been made.

(9) An MCO shall meet the solvency standards established by the State for private HMOs, or be licensed or certified by the State as a risk-bearing entity except if the MCO:

(a) Is a public entity; or

(b) Is, or is controlled by, one or more federally qualified health centers and meets the solvency standards established by the State for those centers;

(c) Has its solvency guaranteed by the State.

E. Health Care Delivery. An MCO shall:

(1) Provide the services set forth in COMAR 10.67.06 promptly and continuously, consistent with good medical practice and community professional standards;

(2) Conform with and fulfill the requirements of 42 CFR §422.128, as amended, and provide adult enrollees with written information on advance directives which shall:

(a) Include a description of applicable State law; and

(b) Reflect a change in State law as soon as possible, but not later than 90 days after the effective date of the change.

(3) Provide each enrollee within 10 days of notification to the MCO of the enrollee’s enrollment with a distinctive, durable identification card, clearly indicating the bearer to be a member of the MCO and containing, at a minimum:

(a) The enrollee's Medicaid number;

(b) The MCO's consumer services hotline telephone number;

(c) The Department's enrollee hotline telephone number; and

(d) Enrollee's assigned primary care provider's name and telephone number;
(4) Provide enrollees, within 30 days before the intended effective date, written notice when there is a significant change in the nature or location of services provided; and

(5) Provide on the card required in §E(3) of this regulation, on a separate prescription benefit card, or other technology, prescription billing information that:

(a) Complies with the standards set forth in the National Council for Prescription Drug Programs pharmacy ID card prescription benefit card implementation guide at the time of issuance of the card or other technology; or

(b) Includes, at a minimum, the following data elements:

(i) The name or identifying trademark of the MCO;

(ii) The name and identification number of the recipient;

(iii) The telephone number that providers may call for pharmacy benefit assistance; and

(iv) All electronic transaction routing information and other numbers required by the MCO or its benefit administrator to process a prescription claim electronically.

F. An MCO:


(2) May not discriminate against an enrollee on any basis, including, but not limited to, age, sex, race, creed, color, marital status, sexual orientation, gender identity, national origin, physical or mental handicap, health status, or need for health care services;

(3) Shall prepare and make available all publications in a manner consistent with COMAR 10.67.05.01A, including, but not limited to:

(a) Provider directories;

(b) Enrollee handbooks;

(c) Health education materials; and

(d) Informational brochures.

H. An MCO shall permit the enrollment of a waiver-eligible Program recipient who is enrolled by the Department or who selects the MCO, unless the MCO's enrollment meets or exceeds any enrollment limits mutually agreed to by the Department and the MCO.

I. MCO Local Access Area Participation.

(1) Effective January 1, 2014, an MCO shall open in all local access areas located within the same county in which the MCO chooses to participate.

(2) The MCO shall provide written notification to the Department of the MCO's intent to participate and accept new enrollees in each of the counties by September 15 for the next calendar year.

(3) The MCO's decision to accept new enrollees is in effect from January 1 to December 31 unless the Department decides there is adequate justification to waive this requirement, which includes, but is not limited to, a rate cut or an MCO exit from the market.

(4) Unless the Department approves a shorter time frame, an MCO that exits the Program during the calendar year shall submit their exit transition plan to the Department 120 days prior to the effective date of the exit.

(5) If the MCO has not participated in a county for a period of 12 or more consecutive months, the MCO may participate and accept new enrollees in that county by notifying the Department at least 30 days before accepting new enrollees.

(6) An MCO that voluntarily freezes for new enrollments in a county shall remain frozen in that county for the remainder of the calendar year and the following calendar year.

(7) If system modifications require longer than 30 days to implement, the effective date may be extended.

(8) The MCO shall follow the access standards specified in COMAR 10.67.05.06 and .05-1.

J. In counties where the MCO decides to stop accepting new enrollees, the MCO shall:

(1) Continue to accept enrollees who regain eligibility within 120 days of becoming ineligible for the Program;

(2) Accept newborns if the mother is an MCO member at the time of birth; and

(3) Accept the family members of enrollees enrolled with the MCO before the effective date that the MCO stopped accepting new enrollees.

K. An HMO that is approved as an MCO and that requires its panel providers to participate in an MCO shall submit for review by the Secretary its plan to assure the equitable distribution of
enrollees and to ensure that a provider is not assigned a disproportionate number of enrollees, as required by Health-General Article, §15-102.5, Annotated Code of Maryland.

L. An MCO shall comply with the provisions of Insurance Article, §15-112, Annotated Code of Maryland when credentialing providers, and during the credentialing process the MCO:

(1) May not discriminate against particular providers that serve high-risk populations or specialize in conditions that require costly treatment;

(2) May not employ or contract with providers excluded from participation in federal health care programs under either §1128 or 1128A of the Social Security Act; and

(3) Shall give the affected providers written notice of the reason for its decision if the MCO declines to include the providers in its network.

M. The requirements of Regulation .17A(2) of this chapter, or §L(1) of this regulation, may not be construed to:

(1) Require an MCO to contract with providers beyond the number necessary to meet the needs of its enrollees;

(2) Preclude an MCO from using different reimbursement amounts:

(a) For different specialties; or

(b) For different practitioners in the same specialty; or

(3) Preclude an MCO from establishing measures that are designed to maintain quality of services and control costs, consistent with its responsibilities to enrollees.

N. Disclosure of Provider Incentive Plans.

(1) An MCO shall disclose to the Department the information on its provider incentive plans listed in 42 CFR §417.479(h)(1):

(a) Prior to approval of its contract or agreement; and

(b) Upon the contract's or agreement's anniversary or renewal effective date.

(2) An MCO shall include in the disclosures required by §N(1) of this regulation information sufficient for the Department to determine whether the incentive plans meet the requirements of 42 CFR §417.479(d)—(g) and, as applicable (i), when there exist compensation arrangements under which payment for designated health services furnished to an individual on the basis of a physician referral would otherwise be denied under §1903(a) of the Social Security Act.
O. When making a referral, an MCO shall use the uniform consultation referral form adopted by the Maryland Insurance Administration at COMAR 31.10.12.06.

P. An MCO shall meet all other requirements of applicable State and federal law including but not limited to:

   (1) Title VI of the Civil Rights Act of 1964;

   (2) Title IX of the Education Amendments of 1972 regarding education programs and activities;

   (3) The Age Discrimination Act of 1975;

   (4) The Rehabilitation Act of 1973;

   (5) Any laws regarding privacy and confidentiality;

   (6) Any laws that pertain to enrollee rights;

   (7) 45 CFR Part 74, as amended, including particular attention to requirements at 45 CFR §§74.42, 74.43, 74.44, 74.48, and 74.53(a) and (b), and Appendix A; and

   (8) Section 1557 of the Affordable Care Act.

Q. An MCO shall meet all program integrity requirements as set forth in COMAR 10.67.07.

R. The following applies to the Department's Health Home Program as described in COMAR 10.09.33:

   (1) The MCO may not provide services that duplicate the CMS reimbursed health home services for members participating in the State's Health Home Program;

   (2) The State shall inform the MCO of members assigned to the State's Health Home Program so that the MCO can prepare to coordinate care with the health homes;

   (3) The MCO shall provide a point of contact for the health homes to the State who shall share with all the enrolled health homes;

   (4) The MCO shall make referrals to the health homes of members who meet the criteria for enrollment in the program;

   (5) To facilitate this process, the State shall provide information to the MCO on all the enrolled health homes in the MCO's service areas; and

   (6) The MCO shall assist the health homes as necessary in accessing somatic care services for health home recipients.
.03 Quality Assessment and Improvement.

A. An MCO shall have a continuous, systematic program designed to monitor, measure, evaluate, and improve the quality of health care services delivered to enrollees including individuals with special health care needs. At a minimum, the MCO shall:

(1) Comply with all applicable federal and State laws and regulations;

(2) Comply with all access and quality standards and levels of performance established by the Department including all standards for individuals with special health care needs in Regulations.04—.10 of this chapter; and

(3) Be able to provide the Department with timely accurate information in areas including but not limited to:

   (a) Provider networks;

   (b) Utilization of services; and

   (c) Identification and management of individuals with special health care needs, including but not limited to:

      (i) Enrollees with HIV;

      (ii) Pregnant women;

      (iii) Enrollees with disabilities;

      (iv) Adult enrollees with diabetes;

      (v) Pediatric enrollees with asthma; and

      (vi) Children with special health care needs.

B. An MCO shall participate in all quality assessment activities required by the Department to determine if the MCO is providing medically necessary enrollee health care. These activities include, but are not limited to:

(1) A Systems Performance Review (SPR) performed by an external quality review organization hired by the Department to assess an MCO’s structure and operations in order to determine its ability to provide health care to its enrollees as follows:

   (a) The SPR shall include, but not be limited to:
(i) MCO's Quality Assessment and Improvement program;

(ii) Enrollee rights;

(iii) Access and availability of services;

(iv) Care management;

(v) Enrollee outreach;

(vi) Utilization management and review; and

(vii) MCO organization, operations, and financial management;

(b) The results of the SPR shall be reported in draft to the MCOs for comment;

(c) MCO shall submit all comments and any required corrective action within 45 days of receipt of draft report; and

(d) The Department shall issue a final report of the SPR results;

(2) The annual collection, validation, and evaluation of the latest approved version of the Healthcare Effectiveness Data and Information Set (HEDIS) in order to assess the access to and quality of services provided, in addition to any additional performance measures specified by the Department or CMS;

(3) The annual collection and evaluation of a set of performance measures with targets as determined by the Department as follows:

(a) The composition of the core performance measures is listed in §B(3)(d)—(f) of this regulation;

(b) Each year before the audit period begins, the Department shall identify and obtain public input on all measures to be collected as well as the target for each;

(c) In accordance with COMAR 10.67.10, MCOs may receive financial or other types of incentives or disincentives based on performance measure results;

(d) Effective January 1, 2017, the core performance measures are:

(i) Adolescent well care visits;

(ii) Adult Body Mass Index (BMI) assessment;

(iii) Ambulatory care for Supplemental Security Income (SSI) adults;
(iv) Ambulatory care for Supplemental Security Income (SSI) children;

(v) Breast cancer screening;

(vi) Childhood immunizations — Combo 3;

(vii) Comprehensive diabetes care — HbA1c testing;

(viii) Controlling high blood pressure;

(ix) Immunization for adolescents;

(x) Lead screening for children 12—23 months old;

(xi) Asthma medication ratio;

(xii) Postpartum care; and

(xiii) Well child visits, 3—6 years old;

(e) Effective January 1, 2019, the core performance measures are:

(i) Adolescent well care visits;

(ii) Ambulatory care for SSI adults;

(iii) Ambulatory care for SSI children;

(iv) Asthma medication ratio;

(v) Breast cancer screening;

(vi) Comprehensive diabetes care — HbA1c control (<8.0%);

(vii) Controlling high blood pressure;

(viii) Lead screening for children 12 through 23 months old; and

(ix) Well child visits in the first 15 months of life;

(f) Effective January 1, 2021, the core performance measures are:

(i) Adolescent well care visits;

(ii) Ambulatory care for SSI adults;
(iii) Ambulatory care for SSI children;

(iv) Asthma medication ratio;

(v) Breast cancer screening;

(vi) Comprehensive diabetes care — HbA1c control (<8.0%);

(vii) Controlling high blood pressure;

(viii) Lead screening for children 12 through 23 months old;

(ix) Postpartum care; and

(x) Well child visits in the first 15 months of life;

(g) Starting with the 2019 performance measures, the Department shall implement the following methodology for imposing penalties and incentives:

(i) There shall be three levels of performance;

(ii) Performance shall be evaluated separately for each measure, and each measure shall have equal weight;

(iii) On any of the measures in §B(3)(f)(i)—(ix) of this regulation for which the MCO does not meet the minimum target, as determined by the Department, a penalty of 1/9 of 1 percent of the total capitation amount paid to the MCO during the measurement year shall be collected;

(iv) The total amount of the penalties as described in §B(3)(h)(iii) of this regulation may not exceed 1 percent of the total capitation amount paid to the MCO during the same measurement year;

(v) On any of the measures in §B(3)(f) of this regulation for which the MCO meets or exceeds the incentive target, as determined by the Department, the MCO shall be paid an incentive payment of up to 1/9 of 1 percent of the total capitation paid to the MCO during that measurement year;

(vi) The total amount of the incentive payments as described in §B(3)(h)(v) of this regulation paid to the MCOs each year may not exceed the total amount of the penalties as described in §B(3)(g)(iii) of this regulation collected from the MCOs in that same year, plus any additional funds allocated to the Department for a quality initiative; and

(vii) Any funds remaining after the payment of the incentives due under §B(3)(h)(v) of this regulation shall be distributed to the MCOs receiving the four highest normalized scores for Value Based Purchasing for all ten performance measures at a rate calculated by multiplying
each MCO’s adjusted enrollment as of December 31 of the measurement year by a per enrollee amount;

(h) Starting with the 2021 performance measures, the Department shall implement the following methodology for imposing penalties and incentives:

(i) There shall be three levels of performance;

(ii) Performance shall be evaluated separately for each measure, and each measure shall have equal weight;

(iii) On any of the measures in §B(3)(f) of this regulation for which the MCO does not meet the minimum target, as determined by the Department, a penalty of 1/10 of 1 percent of the total capitation amount paid to the MCO during the measurement year shall be collected if the conditions in §B(3)(h)(iv) of this regulation do not apply;

(iv) If the Department’s actuary determines that the MCO’s total capitation amount for the measurement year does not meet the actuarial soundness definition described in 42 CFR §438.4 after collection of the total penalty amount described in §B(3)(h)(iii) of this regulation, the Department’s actuary shall calculate the maximum penalty the Department shall apply that results in the MCO’s total capitation for the measurement year remaining actuarially sound;

(v) If the MCO’s penalty amount is reduced as described in §B(3)(h)(iv) of this regulation, the Department may impose any of the additional sanctions described in COMAR 10.67.10;

(vi) The total amount of the penalties as described in §B(3)(h)(iii) of this regulation may not exceed 1 percent of the total capitation amount paid to the MCO during the same measurement year;

(vii) On any of the measures in §B(3)(f) of this regulation for which the MCO meets or exceeds the incentive target, as determined by the Department, the MCO shall be paid an incentive payment of up to 1/10 of 1 percent of the total capitation paid to the MCO during that measurement year;

(viii) The total amount of the incentive payments as described in §B(3)(h)(vii) of this regulation shall be paid to the MCOs with total amount of the penalties as described in §B(3)(h)(iii) of this regulation collected from the MCOs in that same year, plus additional reserves in the HealthChoice Performance Incentive Fund if the total amount of the penalties collected is insufficient to pay the total amount of the incentive payments;

(ix) 40 percent of any funds remaining after the payment of the incentives due under §B(3)(h)(vii) of this regulation shall be distributed to the MCOs earning net incentives with the four highest normalized scores, at a rate calculated by multiplying each MCO’s adjusted enrollment as of December 31 of the measurement year by a per-enrollee amount;
(x) MCOs earning net disincentives are ineligible to receive the funds described in §B(3)(h)(ix) of this regulation;

(xi) 25 percent of any funds remaining after the payment of the incentives due under §B(3)(h)(vii) of this regulation shall be distributed to the MCOs that the Department determines have demonstrated performance improvement in the measurement year, provided that the MCOs use the funding to target performance improvement in areas defined by the Department;

(xii) 25 percent of any funds remaining after the payment of the incentives due under §B(3)(h)(vii) of this regulation shall be retained for health improvement programs under the Maryland Medicaid Managed Care Program;

(xiii) 10 percent of any funds remaining after the payment of the incentives due under §B(3)(h)(vii) of this regulation shall be used to establish a reserve in the HealthChoice Performance Incentive Fund, to be used in any calendar year when the amount of penalties collected is insufficient to pay incentives earned by MCOs; and

(xiv) If the amount in the HealthChoice Performance Incentive Fund exceeds $5,000,000, the Department shall equally allocate the remaining 10 percent of funds for use in §B(3)(h)(ix)—(xii);

(i) The adjusted enrollment amount in §§B(3)(g)(vii) and B(3)(h)(ix) of this regulation shall be calculated by:

(ii) Multiplying four times the enrollment of the MCO with the highest normalized score;

(iii) Multiplying three times the enrollment of the MCO with the second highest normalized score;

(iv) Multiplying two times the enrollment of the MCO with the third highest normalized score; and

(iv) Using the actual enrollment of the MCO with the fourth highest normalized score;

(j) The per enrollee amount in §§B(3)(g)(vii) and B(3)(h)(ix) of this regulation shall be calculated by dividing the sum of the calculations in §B(3)(i)(i)—(iv) of this regulation into the funds remaining as described in §§B(3)(g)(vii) and B(3)(h)(ix) of this regulation; and

(k) The methodology described in §B(3)(a)—(j) of this regulation shall remain in effect through December 31, 2021;

(4) An annual enrollee satisfaction survey using the latest version of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey tool, conducted by an NCQA-certified CAHPS vendor;
(5) An annual Maryland Healthy Kids audit in order to determine the quality of the clinical care provided to all children younger than 21 years old enrolled in the HealthChoice Program as follows:

(a) The audit shall include a review of a sample of medical records from each provider reviewed during the calendar year to assess clinical care;

(b) The results of the audit that are below minimum EPSDT standards may result in corrective action required by both the provider and the MCO; and

(c) The Department shall issue a final report of the audit results;

(6) Performance improvement projects to be conducted by the MCOs that focus on clinical or nonclinical areas as determined by the Department or CMS and include the following:

(a) Measurement of performance using objective quality indicators;

(b) Implementation of system interventions to achieve improvement in quality;

(c) Evaluation of effectiveness of interventions;

(d) Planning and initiation of activities to sustain improvement; and

(e) Reporting of results to the Department or CMS; and

(7) Validation and evaluation of MCO provider networks to ensure compliance with the network adequacy and access standards set forth in COMAR 10.67.05.

C. If an MCO is assessed as deficient in accordance with federal and State standards, the MCO shall submit a plan of corrective action to the Department.

D. An MCO shall provide the Department a copy of its most recent NCQA accreditation, including:

(1) Accreditation status, survey type, and level;

(2) Accreditation results, including:

(a) Recommended actions or improvements;

(b) Corrective action plans; and

(c) Summaries of findings; and

(3) Expiration date of the accreditation.
.03-1 MCO Rural Access Incentive.

A. Eligibility for Rural Access Incentive. During the months specified in §B(1) and (2) of this regulation, the Department shall make an incentive payment to an MCO for any rural county in which the MCO is accepting new members, provided the MCO has a current MCO provider agreement.

B. Payment of Rural Access Incentive.

   (1) June Payment. The June payments to MCOs meeting the requirements specified in §A of this regulation from January 1 through June 30 shall be paid prospectively in May based on June enrollment.

   (2) December Payment. The December payments to MCOs meeting the requirements specified in §A of this regulation from July 1 through December 31 shall be paid prospectively in November based on December enrollment.

C. Amount of Rural Access Incentive.

   (1) The Department shall allocate a maximum of $11,000,000 for each of the payments in §B(1) and (2) of this regulation, among each of the rural counties specified in §D of this regulation, based on the total MCO enrollment in each county.

   (2) An eligible MCO shall receive a portion of the funds allocated to the rural county based on the ratio of the eligible MCO’s enrollment to the total enrollment for all eligible MCOs in the county combined with the fund distribution methodology described in §E of this regulation.

   (3) Effective January 1, 2017, any outstanding funds not awarded in §C(2) of this regulation shall be distributed to all MCOs in accordance with each MCO’s Statewide enrollment, regardless of participation in a rural area or whether an MCO is accepting new members.

D. Rural Enrollment Counties. For purposes of this regulation, the following are rural counties:

   (1) Allegany;

   (2) Caroline;

   (3) Cecil;

   (4) Dorchester;

   (5) Frederick;

   (6) Garrett;

   (7) Kent;
(8) Queen Anne's;

(9) Somerset;

(10) Talbot;

(11) Washington;

(12) Wicomico; and

(13) Worcester.

E. Funds Distribution. A percentage of the funds allocated will be distributed based on the number of MCOs accepting new enrollments in each rural county as follows:

1. Two MCOs, 50 percent of funds;

2. Three MCOs, 75 percent of funds; and

3. Four or more MCOs, 100 percent of funds.

.03-2 HealthChoice Population Health Incentive Program (PHIP).

A. Effective January 1, 2022, the Department shall establish the HealthChoice Population Health Incentive Program (PHIP).

B. An MCO may be eligible for an incentive payment for the following performance measures:

1. Ambulatory care visits for Supplemental Security Income (SSI) adults;

2. Ambulatory care visits for Supplemental Security Income (SSI) children;

3. HEDIS asthma medication ratio;

4. HEDIS comprehensive diabetes care — HbA1c poor control (>9%);

5. Lead screening measures:

   a. Lead screening measure for children 12—23 months old; and

   b. HEDIS lead screening in children;

6. HEDIS postpartum care;

7. HEDIS risk of continued opioid use — >=31 days covered; and
(8) HEDIS timeliness of prenatal care.

C. Each measure identified in §B of this regulation shall be valued equally at a proportional share of available incentive funds, except for measures §B(5)(a) and (b), which are each valued at half of the available incentive funds relative to one of the other measures.

D. There shall be two rounds of potential incentive payments an MCO may earn.

E. Subject to budget approval, total PHIP funding shall be determined prior to the measurement year and included in the MCO contract.

F. All PHIP payments shall be funded independently from and outside of MCO capitation payments during a given calendar year.

G. Each MCO shall be eligible for no more than 1 percent of the plan’s measurement year capitation payments, excluding supplemental payments outside of capitation, as total payment from round one and round two.

H. If the Department determines that the score for any measure identified in §B of this regulation may not be comparable to the previous year’s score due to alterations in measure specifications or other factors, the Department may exclude the measure from the PHIP and adjust the incentive valuation in accordance with the remaining performance measures.

I. Round One Incentives.

(1) An MCO may earn two types of incentives in round one:

(a) A performance incentive payment; and

(b) An improvement incentive payment.

(2) If an MCO does not report a performance measure or an MCO has a performance score of 0 percent, then the MCO is awarded no performance or improvement incentive payments for this measure.

(3) Performance Incentive Payments for Round One.

(a) Performance incentive payments shall be based on the following categories for each performance measure:

(i) Superlative performance, meaning the performance measure’s score is at or above the 90th percentile of HEDIS Medicaid performance nationwide during the measurement year, or estimated 90th percentile among Maryland HealthChoice MCO performance for non-HEDIS performance measures;
(ii) Very strong performance, meaning the performance measure’s score is between the 75th and 89th percentiles, inclusive, of HEDIS Medicaid performance nationwide during the measurement year, or between the estimated 75th and 89th percentiles, inclusive, among Maryland HealthChoice MCO performance for non-HEDIS performance measures; or

(iii) Strong performance, meaning the performance measure’s score is between the 50th and 74th percentiles, inclusive, of HEDIS Medicaid performance nationwide during the measurement year, or between the estimated 50th and 74th percentiles, inclusive, among Maryland HealthChoice MCO performance for non-HEDIS performance measures.

(b) Payments for round one performance incentives shall be allocated as follows:

(i) For superlative performance, an MCO may earn 100 percent of the incentive allocation for the performance measure;

(ii) For very strong performance, an MCO may earn 66.6 percent of the incentive allocation for the performance measure;

(iii) For strong performance, an MCO may earn 33.3 percent of the incentive allocation for the performance measure; and

(iv) Any MCO earning a performance measure score below the 50th percentile of HEDIS Medicaid performance nationwide during the measurement year on a HEDIS-based measure, or below the calculated 50th percentile among Maryland HealthChoice MCO performance for a non-HEDIS measure, shall be ineligible for a round one performance incentive payment.

(4) Round One Improvement Incentive Payments.

(a) An MCO may earn an improvement incentive payment of 33.3 percent of the incentive allocation for any performance measure if the following conditions are met:

(i) The MCO demonstrates improvement of at least 0.5 percentage points in the measure compared to the previous measurement year; and

(ii) The performance measure score is at or above the 50th percentile of HEDIS Medicaid performance nationwide on a HEDIS-based measure, or the 50th percentile of Maryland HealthChoice MCO performance for a non-HEDIS measure.

(b) An MCO earning a superlative performance incentive payment for a performance measure is ineligible for an improvement incentive payment for the same measure.

(c) For any performance measures in which a lower score indicates stronger performance, year-over-year improvement is demonstrated by a reduction in the score for that measure.
(d) If an MCO is missing or zero-valued for a performance measure in the previous year, then no improvement incentive will be awarded in the measurement year.

J. Round Two Incentive Payments.

(1) An MCO may qualify for payments under round two if the following conditions are met:

(a) The MCO earned above 80 percent of possible round one incentives; and

(b) The MCO did not have penalties applied during the measurement year for failure to meet the HEDIS MCO Performance Monitoring Policy included in the MCO contract.

(2) Any remaining funds that were unallocated during round one may be awarded to eligible MCOs in round two for a maximum incentive award of up to 1 percent of its total capitation payment during the PHIP measurement year, excluding supplemental payments outside of capitation.

(3) If any remaining funds that were unallocated during round one are not sufficient to settle all qualifying MCOs up to 1 percent of capitation in round two, then the leftover funds will be awarded proportionally among qualifying MCOs based on enrollment.

K. If additional funds remain after both round one and round two, the Department may, within its discretion, allocate the funding as follows:

(1) Make additional payments to MCOs that are below 1 percent of capitation based on improvement or performance; or

(2) Place remaining funds into a nonlapsing pool.

.04 Special Needs Populations.

A. An MCO shall provide health care services to enrollees who are members of special needs populations.

B. Special needs populations consist of the following non-mutually exclusive populations:

(1) Children with special health care needs;

(2) Individuals with a physical disability;

(3) Individuals with a developmental disability;

(4) Pregnant and postpartum women;

(5) Individuals who are homeless;
(6) Individuals with HIV/AIDS; and

(7) Children in State-supervised care.

C. General Requirements for Special Needs Populations.

(1) An MCO shall demonstrate that its pediatric and adult primary care providers (PCPs) and specialists are clinically qualified based upon generally accepted community standards to provide or arrange for the provision of appropriate health care services to individuals who are members of a special needs population. The MCO shall submit to the Department referral protocols that demonstrate the conditions under which PCPs will make the arrangements for referrals to specialty care networks.

(2) Clinical qualifications are to be determined through the MCO's credentialing and recredentialing processes, including a review of the provider's medical education, special training, and work history and experience.

(3) Specialty and subspecialty providers shall:

(a) Have experience in treating individuals within a special needs population;

(b) Have experience in interdisciplinary medical management; and

(c) Understand the relationship between somatic and behavioral health care issues and interventions.

(4) The MCO shall demonstrate the use of a primary care system of care delivery which includes a comprehensive plan of care for an enrollee who is a member of a special needs population and which uses a coordinated and continuous case management approach, involving the enrollee and, as appropriate, the enrollee's family, guardian, or caregiver, in all aspects of care, including primary, acute, tertiary, and home care.

(5) To meet the commitment outlined in §C(4) of this regulation, an MCO shall:

(a) Provide case management services to adult and pediatric enrollees as appropriate;

(b) Have the capacity to perform home visits as part of the ongoing case management program and have the ability to respond to urgent care needs while in the enrollee's home;

(c) Ensure that, if warranted, a case manager is assigned to an enrollee at the time of the initial health screen by the MCO;

(d) Ensure that the PCP, who may also be the specialist, shall be the admitting or referring provider for all hospital admissions;

(e) Ensure that it will:
(i) Collaborate with inpatient facilities in facilitating preadmission and discharge planning, and

(ii) Communicate all post-discharge home and community arrangements to the enrollee, the PCP, and, as appropriate, the enrollee's family, guardian, and caregiver;

(f) Document the plan of care and treatment modalities provided to enrollees in special populations, assuring that the plan of care:

(i) Is updated at least annually, when the enrollee’s circumstances or needs change significantly, or at the enrollee’s request; and

(ii) Involves the enrollee and, as appropriate, the enrollee's family, guardian, and caregiver in care decisions; and

(g) Be familiar with community and social support providers for the special populations.

(6) An MCO shall make documented outreach efforts to contact and educate enrollees who fail to appear for appointments or who have been noncompliant with a regimen of care. These efforts may include, but may not be limited to, notification:

(a) By mail;

(b) By telephone;

(c) By email;

(d) By text messaging; and

(e) Through face-to-face contact.

(7) Referral to Local Health Department.

(a) An MCO shall make a written referral, or ensure that the enrollee's provider makes a written referral, to the local health department (LHD) for the county in which an enrollee resides, for assistance in bringing into care an enrollee for whom the MCO has been unsuccessful in its documented out-reach efforts pursuant to §C(6) of this regulation, within 10 business days of whichever first occurs:

(i) The third consecutive missed appointment; or

(ii) The MCO or the enrollee's provider identifies the enrollee's repeated noncompliance with a regimen of care.

(b) The MCO may not include information about an enrollee's HIV status on the form used to refer an enrollee to the local health department.
(8) An MCO shall subject its decision to deny a service authorization request or to authorize a service in an amount, duration, or scope that is less than requested, for an enrollee who is a member of special needs population to utilization review that includes review by a health care professional who has appropriate clinical expertise in treating the enrollee's condition or disease.

(9) An MCO shall identify a special needs coordinator, who shall:

(a) Serve as a point of contact for health care services information and referral for members of special needs populations;

(b) Be skilled in communications with, and sensitive to the unique needs of, members of special needs populations, their families, guardians, and caregivers;

(c) Participate on the MCO's consumer advisory board, pursuant to Regulation .12 of this chapter, as a representative of special needs populations;

(d) Serve as a resource to MCO providers and enrollees on the requirements of P.L. 101-330, Americans with Disabilities Act of 1990, 42 U.S.C. §12101 et seq.; and

(e) Maintain a log of each denial of treatment and the outcome of the utilization review conducted pursuant to §C(8) of this regulation.

(10) An MCO shall have mechanisms in place to allow enrollees with special health care needs to access a specialist directly as appropriate for the enrollee’s condition and identified needs.

.05 Special Needs Populations — Children with Special Health Care Needs.

A. An MCO shall meet the standards set forth in this regulation for treating children with special health care needs.

B. The Department shall maintain a record of the complaints received through the Department's enrollee and provider hotlines which involve the denial of care for children and review these complaint logs as part of its quality assurance system.

C. An MCO shall demonstrate that its therapies provider network is adequate by demonstrating its:

(1) Providers' pediatric specialties;

(2) Collaboration with schools that provide IEP or IFSP services to its enrollees, where available; and

(3) Provision of family-focused services and development of family-focused plans of care.
D. An MCO shall provide case management services to children with special health care needs as appropriate. For complex cases involving multiple medical interventions or social services, or both, a multidisciplinary team shall be used to review and develop the plan of care for special health care needs children.

E. An MCO shall provide coordinated care for special health care needs children in State-supervised care.

F. An MCO shall refer child victims of alleged abuse, neglect, or sexual offense to an appropriate provider capable of:

   (1) Determining if the alleged abuse, neglect, or sexual offense occurred;

   (2) Determining if medical intervention is needed; and

   (3) Ensuring the preservation of evidence.

G. An MCO shall ensure coordination with the Department’s Early and Periodic Screening, Diagnosis and Treatment (EPSDT) program.

H. An MCO shall establish protocols for effecting medically necessary service referrals to specialty care providers for children with special health care needs.

I. The service referrals referenced in §H of this regulation shall:

   (1) Include services intended to improve or preserve the continuing health and quality of life for children with special health care needs, regardless of the ability of the services to effect permanent cure; and

   (2) Be made when the child is:

       (a) Identified as being at risk of a developmental delay by the developmental screen required by EPSDT;

       (b) Experiencing a delay of 25 percent or more in any developmental area as measured by appropriate diagnostic instruments and procedures;

       (c) Manifesting atypical development or behavior; or

       (d) Diagnosed with a physical or mental condition that has a high probability of resulting in developmental delay.

J. An MCO shall provide durable medical equipment to a special needs child in a timely manner.
K. When a child, who is an MCO enrollee, is diagnosed with a special health care need requiring a plan of care which includes specialty services, and that health care need was undiagnosed at the time of enrollment, the parent or guardian of that child may request approval from the MCO for a specific out-of-network specialty provider to provide those services when the MCO does not have a local in-network specialty provider with the same professional training and expertise who is reasonably available and provides the same service and modality, subject to the following provisions:

(1) If the MCO denies the request for an out-of-network provider referral, the child's parent or guardian may initiate the complaint and appeal process set forth at COMAR 10.67.09.05;

(2) If at any time the MCO decides to terminate or reduce services provided by the approved out-of-network provider, the child's parent or guardian may initiate the complaint and appeal process set forth at COMAR 10.67.09.05;

(3) The MCO shall continue to cover the services of the out-of-network provider during the course of the appeal until such time as the Office of Administrative Hearings issues its decision.

.06 Special Needs Populations — Individuals with a Physical Disability.

A. An MCO shall meet the standards set forth in this regulation for treating an individual with a physical disability.

B. An MCO shall demonstrate that its providers for durable medical equipment and assistive technology provide the appropriate services and are clinically qualified to provide these services to the individual with a physical disability.

C. Before placement of an individual with a physical disability into an intermediate or long-term care facility, an MCO shall:

(1) Recommend that an individual with a physical disability be transferred to an intermediate or long-term care facility only after assessing the needs of the individual and the ability of the MCO to meet these needs in the community as supplemented by other Medicaid services;

(2) Conduct a second opinion review of the case, performed by the MCO's medical director, before a transfer to an intermediate care facility or a long-term care facility is implemented; and

(3) If the MCO's medical director determines that the transfer to an intermediate or long-term care facility is medically necessary and that the expected stay will be greater than 30 days, obtain approval from the Department before making the transfer.

D. An MCO shall utilize individuals with expertise in disabilities to review its marketing and informational forms and publications, which shall be provided in alternative formats with reasonable accommodation to people with a physical disability.
E. An MCO shall provide education for the MCO's member services staff, triage staff, and case managers on special communications requirements for individuals with physical disabilities.

.07 Special Needs Populations — Individuals with a Developmental Disability.

A. An MCO shall meet the standards set forth in this regulation for treating an individual with a developmental disability.

B. An MCO shall ensure that its case managers have experience or training related to developmental disabilities.

C. An MCO shall utilize individuals with expertise in disabilities to review its marketing and informational forms and publications, which shall be provided in alternative formats with reasonable accommodation to people with developmental disabilities.

D. An MCO shall provide education for the MCO's member services staff, triage staff, and case managers on special communications requirements for individuals with developmental disabilities.

.08 Special Needs Populations — Pregnant and Postpartum Women.

A. An MCO shall meet the standards set forth in this regulation for treating pregnant and postpartum women.

B. An MCO shall ensure access to prenatal care for pregnant women and postpartum care for postpartum women by:

   (1) Scheduling an appointment for the first prenatal visit and seeing the woman within 10 days of request;

   (2) Scheduling an appointment for a postpartum woman and seeing the woman within 10 days of request:

   (3) Arranging for an adequate network of providers including obstetricians, gynecologists, perinatologists, neonatologists, anesthesiologists, and advanced practice nurses who are capable of addressing complex maternal and infant health issues; and

   (4) Linking a pregnant woman with a pediatric provider before delivery.

C. An MCO shall ensure that prenatal providers:

   (1) Complete a prenatal risk assessment, using an instrument approved by the Department, at the first prenatal visit; and

   (2) Within 10 days of completing the prenatal risk assessment, forward this instrument to the local health department in the jurisdiction in which the pregnant enrollee lives.
D. The Department may not include questions about a woman's HIV infection status on the prenatal risk assessment instrument.

E. An MCO shall refer pregnant and postpartum women with a substance use disorder to the behavioral health ASO for substance use treatment within 24 hours of request.

F. An MCO shall refer pregnant and postpartum women, infants, and children younger than 5 years old to the WIC (Special Supplemental Nutrition Program for Women, Infants, and Children) Program, and shall provide to WIC necessary medical information to determine WIC nutritional eligibility.

G. An MCO shall follow, at a minimum, the American College of Obstetricians and Gynecologists (ACOG) guidelines for pregnant and postpartum women.

H. An MCO shall provide risk-related medical and nonmedical preventive treatment services, including nutrition counseling by licensed nutritionists or dietitians and smoking cessation education and treatment for pregnant and postpartum women.

I. An MCO shall provide HIV counseling, including a risk assessment and information about possible transmission of HIV to the fetus.

J. An MCO shall offer its pregnant and postpartum enrollees voluntary HIV counseling and testing following the requirements of COMAR 10.67.06.

K. An MCO shall arrange for the appropriate emergency transfer of pregnant women, newborns, and infants to tertiary care centers.

.09 Special Needs Populations — Homeless Individuals.

An MCO's initial health screen shall attempt to identify homeless individuals and link them to the appropriate provider of services.

.10 Special Needs Populations — Individuals with HIV/AIDS.

A. An MCO shall meet the standards set forth in this regulation for treating individuals with HIV/AIDS.

B. HIV/AIDS Specialist.

(1) An MCO shall allow an enrollee with HIV/AIDS to choose an HIV/AIDS specialist for treatment and coordination of primary and specialty care.

(2) To qualify as an HIV/AIDS specialist, a health care provider shall be board certified in the field of infectious diseases by a member board of the American Board of Medical Specialties or:
(a) Hold a current, valid, unrevoked, and unsuspended Maryland license or certification as a:

(i) Doctor of medicine;

(ii) Doctor of osteopathy;

(iii) Nurse practitioner; or

(iv) Physician's assistant being supervised by a medical doctor;

(b) Have provided direct, continuous, ongoing care for at least 20 patients with HIV over the past 2 years; and

(c) Have completed one of the following requirements:

(i) If a medical doctor, certified physician's assistant being supervised by a medical doctor, or doctor of osteopathy, at least 30 hours of HIV-related continuing medical education category I credits over the past 2 years;

(ii) If a nurse practitioner, at least 30 hours of HIV-related continuing education units over the past 2 years;

(iii) If a medical doctor, certified physician's assistant being supervised by a medical doctor, doctor of osteopathy, or a nurse practitioner, an accredited training program over the past year; or

(iv) If a medical doctor, certified physician's assistant being supervised by a medical doctor, doctor of osteopathy, or a nurse practitioner, has completed the American Academy of HIV Medicine (AAHIVM) credentialing examination.

C. AIDS Case Management Services.

(1) An MCO shall ensure that an enrollee with HIV/AIDS receives case management services that:

(a) Link the enrollee with the full range of available benefits;

(b) Link the enrollee with any additional needed services including:

(i) Mental health services;

(ii) Substance abuse services;

(iii) Medical services;
(iv) Social services;
(v) Financial services;
(vi) Counseling services;
(vii) Educational services;
(viii) Housing services; and
(ix) Other required support services;

(c) Ensure timely and coordinated access to medically necessary levels of care that support continuity of care across the continuum of service providers;

(d) Are performed by licensed physicians, physician assistants, advanced practice nurses, registered nurses, social workers, or other individuals who are appropriately trained, experienced, and supervised by a licensed practitioner; and

(e) Include, but are not limited to:

(i) Initial and ongoing assessment of the enrollee's needs and personal support systems, including the MCO offering an enrollee one face-to-face meeting during the initial assessment and documenting the enrollee's acceptance or declination of the face to face meeting;

(ii) Development of a comprehensive, individualized service plan, using a multidisciplinary approach;

(iii) Coordination of the services required to implement the plan;

(iv) Periodic reevaluation and adaptation of the plan as necessary over the life of the enrollee;

(v) Development of an outreach system for the enrollee and family by which the case manager and primary care provider track services received, clinical outcomes, and the need for additional follow-up; and

(vi) Serving as an effective enrollee advocate to resolve differences between the enrollee and providers of care pertaining to the course or content of therapeutic interventions.

(2) An enrollee diagnosed with HIV/AIDS shall be offered case management services by the MCO at any time after diagnosis. An enrollee who has previously refused these services may request case management from the MCO at any time.

D. Diagnostic Evaluation Service (DES) Assessment.
(1) An MCO shall offer a diagnostic evaluation service (DES) assessment annually and document the enrollee's acceptance or declination.

(2) The DES shall consist of a comprehensive medical and psychosocial assessment.

(3) A DES provider shall use assessment and care plan forms used by the Department for adult and pediatric assessments.

(4) An individual shall select a DES provider from an approved list of sites, and may select a DES provider which is not part of the individual's MCO if so desired.

(5) An MCO and other qualified institutions may become DES providers as provided in COMAR 10.09.32.03C.

E. An individual with HIV/AIDS who has a substance use disorder shall be referred to the behavioral health ASO for substance abuse treatment within 24 hours of request.

F. Clinical Trials.

(1) An MCO may refer enrollees who are individuals with HIV/AIDS to facilities or organizations that can provide the enrollees' access to clinical trials.

(2) An MCO shall provide enrollees with HIV/AIDS access to clinical trials in accordance with COMAR 10.67.06.26-1.

.12 Consumer Advisory Board.

A. An MCO shall establish a consumer advisory board to facilitate the receipt of input from enrollees.

B. The consumer advisory board membership shall:

(1) Consist of enrollees and enrollees' family members, guardians, or caregivers; and

(2) Be comprised of no less than one third representation from the MCO’s special needs populations, or their representatives and the MCO’s special needs coordinator.

C. The consumer advisory board shall meet at least 6 times a year.

.13 Children in State-Supervised Care.

A. An MCO shall provide or arrange to provide all Medicaid-covered services required to comply with State statutes and regulations mandating health and mental health services for children in State-supervised care.
Appendix O

B. An MCO shall ensure the continuity and coordination of care, provided locally to the extent the services are available, to an enrollee who is a child in State-supervised care.

C. An enrollee who is a child in State-supervised care who moves shall be disenrolled from the recipient's MCO and enrolled in an alternative MCO if the recipient's current MCO does not serve the geographic region to which the child has been relocated.

D. An MCO shall expedite a change of providers within its provider panel upon the move of an enrollee who is a child in State-supervised care to a new geographic area served by the MCO.

E. On request of the responsible State or local agency, a child in State-supervised care may be disenrolled from the current MCO and enrolled in an MCO serving the group facility in which the child resides, members of the foster care family, or other children in foster care placement with the child.

F. Enrollee Self-Referral. An MCO shall permit the self-referral of a child in State-supervised care to an EPSDT certified provider for an initial examination, including a mental health screen, and shall pay for all portions of the examination except for the mental health screen, which shall be paid for by the Specialty Mental Health System.

G. Coordination with Responsible Agency. An MCO shall appoint a liaison to coordinate services to a child in State-supervised care with the responsible State or local agencies.

.14 Referral to Behavioral Health ASO.

A. An MCO is responsible for providing medically necessary primary behavioral health services to their enrollees.

B. An enrollee may self-refer to the behavioral health ASO for services described in COMAR 10.09.59 or 10.09.80.

C. If an enrollee’s primary care physician determines that primary behavioral health services are not sufficient to meet the enrollee’s needs, the primary care physician shall refer the enrollee to the behavioral health ASO for services described in COMAR 10.09.59 or 10.09.80.

D. If an MCO determines that primary behavioral health services are not sufficient to meet the enrollee’s needs, the MCO shall refer the enrollee to the behavioral health ASO for services described in COMAR 10.09.59 or 10.09.80.

E. An MCO shall cooperate with the behavioral health ASO in developing referral procedures and protocols.

.15 Data Collection and Reporting.

A. An MCO shall notify the Department immediately when it has knowledge of an enrollee's death.
B. Encounter Data.

(1) An MCO shall submit encounter data reflecting 100 percent of provider-enrollee encounters, in CMS1500 and UB04 format or an alternative format previously approved by the Department.

(2) An MCO may use alternative formats including:

(a) ASC X12N 837 and NCPDP formats; and

(b) ASC X12N 835 format, as appropriate.

(3) An MCO shall submit encounter data that identifies the provider who delivers any items or services to enrollees at a frequency and level of detail to be specified by CMS and the Department, including, at a minimum:

(a) Enrollee and provider identifying information;

(b) Service, procedure, and diagnoses codes;

(c) Allowed, paid, enrollee responsibility, and third-party liability amounts; and

(d) Service, claims submission, adjudication, and payment dates.

(4) An MCO shall report encounter data within 60 calendar days after receipt of the claim from the provider.

(5) An MCO shall submit encounter data utilizing a secure on-line data transfer system.

C. Monthly Reports.

(1) An MCO shall provide an updated list of the PCP's assigned enrollees to each PCP at least on a monthly basis.

(2) An MCO shall participate in the electronic enrollment reconciliation process to identify discrepancies in enrollment data between the Department and the MCO.

D. Quarterly Reports. An MCO shall submit to the Department:

(1) Within 30 calendar days of the close of each calendar quarter, quality assurance reports including, but not limited to:

(a) Quality assurance committee meeting minutes reflecting major quality assurance corrective action plans, initiatives, and activities; and
(b) An analysis of recipient appeal and grievance logs including significant trends or anomalies, what caused the trend or anomaly, and any actions taken to address the trend or anomaly;

(2) Within 30 calendar days after the close of each calendar quarter, in the format specified by the Department, a list of all pre-service denials or reduction of services or benefits issued by the MCO or MCO subcontractors during the preceding quarter.

(3) Within 30 calendar days of the close of each calendar quarter, third-party liability collection activities as described in Regulation .18D of this chapter.

(4) In a format specified by the Department, amounts the MCO has cost-avoided and recovered and the number of cases the MCO has handled in each case area during the quarter.

(5) Not later than 45 days after the end of each quarterly rebate period, drug utilization data necessary for the Department to bill manufacturers for rebates in accordance with §1927(b)(1)(A) of the Social Security Act, that:

(a) Include, at a minimum, the following information by National Drug Code of each covered outpatient drug dispensed or covered by the MCO:

(i) Total number of units of each dosage form;

(ii) Total number of units of each dosage strength; and

(iii) Total number of units of each dosage package size; and

(b) Distinguish utilization data for covered outpatient drugs that are subject to discounts under the 340B drug pricing program.

(6) Within 10 calendar days after the close of each calendar quarter, in the format specified by the Department, a list of all State fair hearing outcomes during the preceding quarter.

E. Annual Reports. Except as provided in §E(5) of this regulation, an MCO shall submit to the Department annually, within 90 days after the end of the calendar year:

(1) A summary of the information contained in §D(1)(b) of this regulation;

(2) A report of the MCO's consumer advisory board outlining the board's activities and recommendations;

(3) A copy of the MCO's drug formulary;

(4) Any revisions to the MCO’s quality assurance, utilization management, and case management plans;
(5) HealthChoice Financial Monitoring Reports (HFMRs), including any supplemental schedules required by the Department:

(a) In the format required by the Department;

(b) Prepared according to:

(i) The criteria, set forth in Regulation .19-5 of this chapter, for allocating MCO costs to HFMR expense categories; and

(ii) Reporting instructions provided by the Department for the HFMR form and any required supplemental schedules; and

(c) Submitted according to the following schedule:

(i) Services incurred January 1—December 31 of the prior year, reported through March 31 of the current year — due on May 15 of the current year; and

(ii) Services incurred January 1—December 31 of the prior year, reported through September 30 of the current year — due on November 15 of the current year; and

(6) A detailed description of its drug utilization program activities.

F. Unless the MCO is exempt for good cause, an MCO shall submit to the Department when requested the following reports for its enrollee/member services and provider/authorization/preauthorization lines:

(1) Caller abandonment rates;

(2) Caller service level rates; and

(3) Caller average hold time.

G. If the MCO exits the HealthChoice Program for any reason, including those listed in COMAR 10.67.02.06A(1)(e) and (f):

(1) The MCO shall provide the Department with a list of enrollees and the name of each enrollee's PCP, at least 30 days before exiting the program; and

(2) On receiving the list provided by the MCO, the Department shall provide the list to:

(a) The health benefits exchange to assist and provide outreach to participants in selecting an MCO; and

(b) If permitted by State and federal law, the remaining MCOs for linking participants with a PCP.
H. Jurisdictional Reporting to Local Health Departments. The Department shall:

(1) Aggregate by jurisdiction the encounter data it receives from MCOs; and

(2) Provide to local health departments jurisdiction-specific information based on aggregated encounter data for public health monitoring and assessment.

I. For the purposes of Maryland Medicaid Managed Care Program administration or monitoring MCO performance pursuant to this chapter, the MCO shall supply other information as the Department may from time to time request, given a reasonable period of notice.

J. Nonfederally qualified MCOs shall report a description of certain transactions with parties of interest, as described in §1903(m)(4)(A) of the Social Security Act.

K. Upon request, an MCO whose member has disenrolled shall transfer historical utilization data to the member’s new MCO in the time frame and format specified by the Department.

17 Subcontractual Relationships.

A. Subcontracting Permitted.

(1) Consistent with this regulation, an MCO may subcontract services that it is required to provide to its enrollees under COMAR 10.67.06 to a health care provider that is licensed, certified, or otherwise legally authorized to provide those services.

(2) An MCO may not discriminate for the participation, reimbursement, or indemnification of any provider who is acting within the scope of the provider's license or certification under applicable State law, solely on the basis of that license or certification.

(3) An MCO shall have written agreements with subcontractors that comply with 42 CFR §§438.214 and 455.105, as amended, and include at least the following:

(a) A provision that the subcontractor be subject to all of the requirements to which the MCO is subject under its contract with the Department and pursuant to the Department's regulations;

(b) A clear description of the services to be performed under the subcontract sufficient to definitively inform the Department which of the MCO's obligations have been subcontracted;

(c) A provision for the subcontractor's release to the MCO and to the Department, upon request, of any information necessary for the MCO to perform any of its contractual and regulatory obligations under its contract with the Department, including, but not limited to, its records, reporting, and quality assurance duties;

(d) A provision requiring that the subcontractor complies with all State and federal requirements regarding audit, inspection, and evaluation;
(e) A provision that copies of the subcontractor's medical records pertaining to the MCO's enrollees shall be furnished to the MCO upon request for transfer to a subsequent provider in the event of a termination of the subcontract;

(f) A provision to the effect that no termination of the subcontract shall be effective without prior written notice to the Department;

(g) An agreement that the subcontractor will look solely to the MCO for compensation for covered services provided to the MCO's enrollees under the subcontract;

(h) An assurance that evidence of the subcontractor's professional liability coverage will be submitted annually to the MCO;

(i) A provision that no assignment of the subcontract by the subcontractor is effective without prior written notice to the Department;

(j) If the subcontractor is authorized by the MCO to make referrals, a provision requiring the subcontractor to use the uniform consultation referral form adopted by the Maryland Insurance Administration at COMAR 31.10.12.06;

(k) A provision to the effect that each provision of the subcontract that is required under this section supersedes and be controlling over any conflicting terms that appear in the subcontract;

(l) A provision for revocation of the delegation of activities or obligations, or specifying other remedies in instances where the Department or the MCO determines that the subcontractor has not performed satisfactorily;

(m) A provision stating that the MCO has the right to audit the subcontractor pursuant to 42 CFR §438.230(c)(3)(i) for 10 years from the final date of the contract period or from the date of completion of any audit, whichever is later; and

(n) A provision to the effect that all providers and subcontractors are subject to a grievance and appeal system consistent with the requirements of COMAR 10.67.09.

(4) An MCO may not subcontract for hospital services with a hospital or an entity related to a hospital unless that hospital is in compliance with COMAR 10.37.12 (fixed price contracting regulations).

(5) An MCO may not prohibit or otherwise restrict a health care professional, acting within the lawful scope of practice, from advising or advocating on behalf of an enrollee who is the provider's patient for:

(a) The enrollee's health status, medical care, or treatment options, including any alternative treatment that may be self-administered;
(b) Any information the enrollee needs in order to decide among all relevant treatment options;

(c) The risks, benefits, and consequences of treatment or nontreatment; or

(d) The enrollee's right to participate in decisions regarding the enrollee's own health care, including the right to refuse treatment, and to express preferences about future treatment decisions.

B. Subcontractual Relations Reporting Requirements.

(1) An MCO shall submit its standard subcontract to the Department for its approval at least 30 days in advance of the MCO entering into any subcontracts covered by this regulation.

(2) An MCO shall submit to the Department for its prior approval material modifications to, or deviations from, its approved standard subcontract.

(3) An MCO shall submit to the Department a specification of procedures to be followed when reallocating responsibility in the event of a change in obligations in its approved standard subcontract.

(4) Network Provider Termination.

(a) When an MCO and provider terminate their contract the MCO shall provide the Department with a written notice regarding the termination.

(b) If the MCO is terminating the contract, the notice required in §B(4)(a) of this regulation shall be provided 90 days before the effective date of the termination.

(c) If the provider is terminating the contract, the notice required in §B(4)(a) of this regulation shall be provided within 15 days after the MCO receives the notice from the terminating provider.

(d) If 50 to 99 enrollees are affected, the notice shall contain the:

(i) Date of termination;

(ii) Name or names of providers or subcontractors terminating;

(iii) Number of enrollees affected; and

(iv) MCO's plan for transitioning enrollees to other providers.

(e) If more than 99 enrollees are affected, the MCO shall provide the Department with a Department-approved termination survey.
(f) In determining the number of enrollees affected under §B(4)(d) and (e) of this regulation, the MCO shall consider:

(i) For PCPs, the number of enrollees assigned to the PCP; and

(ii) For all other providers, the number of enrollees who are in active treatment or who have had an encounter with the provider in the previous 12 months.

(5) Subcontractor Termination.

(a) When an MCO terminates a subcontract impacting its operations, covered services, or enrollees, the MCO shall provide the Department with written notice regarding the termination that describes:

(i) The dollar amount of the subcontract;

(ii) The effect of the termination on MCO operations;

(iii) The effect of the termination on MCO covered services or enrollees; and

(iv) The MCO’s plan to replace the subcontractor, if applicable.

(b) If the termination of the subcontract impacts MCO operations, the notice required in §B(5)(a) of this regulation shall be provided at least 90 days before the effective date of the termination.

C. By entering into a subcontract to provide health care services on behalf of an MCO, the subcontractor becomes subject to all the requirements concerning audits and inspections by the Department and other government agencies that are imposed upon the MCO by statute or regulation, or by its contract with the Department.

D. An MCO shall monitor the performance of its subcontractors, including, but not limited to, the areas of enrollee and provider complaints, access issues, quality assurance activities, record keeping, and reporting requirements.

E. An MCO shall report to the Department any material deviations from required procedures by its subcontractor which, in the MCO's judgment, can be expected to have a significant effect on quality of care, or on enrollees' ability to access care.

.18 Third-Party Liability.

A. An MCO is responsible for the identification of, and collection of, moneys owing from responsible third parties liable for the cost of medical care furnished by the MCO to enrollees.
B. Upon request from the Department or the U.S. Department of Health and Human Services, an MCO shall convey any information regarding third-party liability to the Department, to the U.S. Department of Health and Human Services, or to another MCO.

C. The Department shall notify an MCO of any third-party liability identified during the course of eligibility determination.

D. The MCO shall submit to the Department any new or changed third-party information in an automated format on a monthly basis.

E. The Department shall provide the MCOs with any new or changed information on a monthly basis in an automated format.

F. In order to facilitate the Department's and the U.S. Department of Health and Human Services' monitoring of its third-party liability collection activities, an MCO shall:

   (1) Submit to the Department, on a monthly basis, reports on third-party collections and activities during the month, including but not limited to amounts the MCO has cost-avoided and recovered and current accounts receivable for all third-party liability cases;

   (2) Submit to the Department, on a quarterly basis and in a format specified by the Department, amounts the MCO has cost-avoided and recovered and the number of cases the MCO has handled in each case area during the quarter;

   (3) Cooperate in site inspections by either the Department or the U.S. Department of Health and Human Services for monitoring purposes; and

   (4) Submit a detailed report of third-party liability collection activities including, but not limited to, cost avoidance, recovered amounts, and current amounts receivable for cases selected by the Department.

G. When both the Department and an MCO have a right of subrogation, they shall coordinate settlement negotiation, ensuring that the funds available are prorated to allow sufficient compensation to settle each party's claim amount.

H. For insurance coverage identified by an MCO with a retroactive effective date, an MCO shall comply with Insurance Article, §15-1008, Annotated Code of Maryland.

I. An MCO may not deny a provider’s request for a preauthorization solely because a recipient has, or is thought to have, third-party insurance.

J. The requirement in §I of this regulation may not apply if an MCO has a process in place to ensure that a claim will not be denied for lack of preauthorization if the claim ultimately becomes the MCO’s responsibility for one of the following reasons:

   (1) The recipient does not have third-party insurance; or
(2) The service received is a noncovered service under the third-party insurance.

.18-1 MCO Reimbursement — GME Exclusion.

A. Capitation Rate Setting Methodology — Extraction of Graduate Medical Education Costs.

(1) Percentage of Teaching Hospitals' Rates Representing GME Costs. The Department, in consultation with the HSCRC, shall:

(a) Determine the amount, expressed as a percentage, of payments by the Program that are attributable to GME, based on historic cost and discharge abstract data that:

(i) Are specific to each individual teaching hospital;

(ii) Are specific to Program recipients who would have been MCO-eligible if COMAR 10.67.01—.12 had been in effect at the time the activity reflected in the data occurred;

(iii) Reflect services that would be, if performed during the contract year to which calculations utilizing a teaching hospital's GME percentage amount relate, included in the mandatory MCO benefits package described in COMAR 10.67.06; and

(iv) Represent activity in FY 1995; and

(b) For any teaching hospital that is not in compliance with the primary care and innovation requirements of COMAR 10.10.67.11, reduce the Program's payments to the hospital deemed to be attributable to GME pursuant to §A(1)(a) of this regulation by the hospital's noncompliance penalty percentage derived in accordance with COMAR 10.67.11.03C.

(2) GME Percentage Start-Up Adjustment. To ameliorate the impact on MCOs that historically have experienced low utilization of teaching hospitals, the Department shall, during the first 3 years of separate GME funding, reduce the GME percentage determined in accordance with §A(1) of this regulation in the following amounts:

(a) FY 1999 ... 10 percent;

(b) FY 2000 ... 6.7 percent;

(c) FY 2001 ... 3.3 percent; and

(d) FY 2002 and thereafter ... 0 percent.

(3) Modifying GME Percentage to Maintain Budget Neutrality.

(a) To maintain budget neutrality in the GME funding procedure established pursuant to this regulation and COMAR 10.67.11, the Department may modify the GME percentages established pursuant to §A(1) and (2) of this regulation.
(b) The Department may use the modified GME percentage authorized by §A(3)(a) of this regulation to calculate non-GME teaching hospital costs pursuant to §A(4) of this regulation, for the purpose of equalizing:

(i) The amount of GME costs to be excluded from capitation rates for the contract year pursuant to §A(4) of this regulation; and

(ii) The amount of GME allocation payments, determined pursuant to COMAR 10.67.11.03C.

(c) Application of the GME percentage modification authorized in §A(3)(a) and (b) of this regulation does not affect the amount of the GME allocation payments made pursuant to COMAR 10.67.11.03C.

(4) GME Adjustment in Capitation Rate-Setting Methodology.

(a) Before determining the average historic costs assigned to the rate cells set forth in Regulation .19B of this chapter, the Department shall, consistent with §A(1)—(3) of this regulation, deduct, for each rate cell, the dollar amount allocatable to GME contained in the Department's base year payments to teaching hospitals.

(b) The deduction referenced in §A(4)(a) of this regulation is calculated as follows:

(i) For each payment included in the base year data made by the Program to a teaching hospital in the contract year, the amount of the payment is multiplied by the hospital-specific GME percentage, established pursuant to §A(1)—(3) of this regulation; and

(ii) The dollar amount attributable to GME that is included in the base year payments, as identified by the procedure described in §A(4)(b)(i) of this regulation, is subtracted from the total amount of the payment to yield the non-GME portion of the payment.

(5) Consistent with §A(4) of this regulation, the Department shall use the GME percentage rates calculated pursuant to §A(1)—(3) of this regulation for purposes of:

(a) Calculating each teaching hospital's GME allocation payment amounts pursuant to COMAR 10.67.11.03C;

(b) Determining the amount of each ACG's average non-GME historic costs for grouping ACGs to make risk adjustment category assignments of the ACGs pursuant to Regulation .19B of this chapter;

(c) Determining the amount of each demographic grouping's average non-GME historic costs; and

(d) Determining, for each risk adjustment category and demographic grouping, the capitation rates set forth in Regulation .19B of this chapter.
B. The Department shall use, in calculating the capitation rates set forth in Regulation .19B of this chapter, a capitation rate-setting methodology that:

(1) Excludes the dollar amount allocatable to GME, consistent with the percentage of GME included in historic payments made by the Program to teaching hospitals that receive GME allocation payments in the contract year, based on calculations that:

   (a) Are consistent with §A of this regulation;

   (b) Reflect any modifications made pursuant to §A(2) and (3) of this regulation to the percentage of the Program's historic payments made to teaching hospitals allocable to GME; and

   (c) Reflect the reduction of hospital-specific GME percentages, by operation of COMAR 10.67.11.03C and §A(1)(b) of this regulation, to decrease the amount of GME allocation payments made, pursuant to COMAR 10.67.11.03B, to teaching hospitals that are not in compliance with the primary care and innovation requirements of COMAR 10.67.11;

(2) Reduces historic costs to reflect savings expected to result from a managed care delivery system;

(3) Includes a trend factor to account for cost differences between the base year and the contract year;

(4) Excludes the dollar amount of historic payments determined, based on an aggregation of individual inpatients' payment data for the base year, to be avoidable by an MCO pursuant to Regulation .22 of this chapter, had the services been furnished during the contract year; and

(5) Beginning in FY 2000, takes into account Maryland Medicaid Managed Care Program enrollment of the newly eligible population entering the Program pursuant to the Maryland Children's Health Program.

.19 MCO Reimbursement.

A. Generally.

(1) Payment to an MCO for each enrollee shall be at a fixed capitation rate, as specified in §B(4) of this regulation.

(2) An MCO shall be reimbursed at rates set forth in this regulation only for individuals enrolled under the Maryland Medicaid Managed Care Program.

(3) The capitation rate paid to an MCO by the Department shall be accepted as payment in full for all benefits provided by the MCO.

(4) An MCO shall conform to the Department's computer coding requirements.
(5) A capitation payment may not be made to an MCO on behalf of an enrollee for whom capitation payment for the same period has been made to any other MCO having an agreement with the Department.

(6) The Department may consider a retroactive capitation payment to an MCO, if the MCO notifies the Department within 9 months of the first missed capitation payment for an enrollee for whom the MCO has not received all appropriate capitation payments.

(7) Monies collected by an MCO for third party liability, as described in Regulation .18 of this chapter, are considered when calculating the capitation payments in §B(4) of this regulation.

B. Capitation Rate-Setting Methodology.

(1) Families and Children. Capitation rates for enrollees who are waiver-eligible based upon receipt of benefits through TCA or programs for medically needy families and children, including SOBRA children and Maryland Children's Health Program (MCHP), shall be established as follows:

(a) For enrollees eligible under COMAR 10.67.02.01A(1) or (3), and for children eligible under COMAR 10.67.02.01A(2) for whom the Department has sufficient clinical data, the Department shall:

   (i) Determine an adjusted clinical group (ACG) assignment utilizing an enrollee's past diagnostic record;

   (ii) Utilizing aggregated enrollee ACG data, on an annual basis define a limited number of risk adjustment categories that reflect levels of relatively homogenous resource utilization by ACG assignment; and

   (iii) Assign an enrollee to a risk adjustment category based upon the enrollee's ACG assignment;

(b) Except as provided in §B(1)(c) of this regulation, for enrollees for whom the Department has insufficient data to generate an ACG assignment, the Department shall assign the enrollee to a risk adjustment category that reflects the enrollee's:

   (i) Age, residence, and gender; and

   (ii) Birth weight with respect to an enrollee born after December 31, 2004; and

(c) On the basis of the enrollee's residence, the Department shall assign:

   (i) All SOBRA mothers enrolled pursuant to COMAR 10.67.02.01A(2) to one of the two "SOBRA mother" payment categories set forth in §B(4)(a) of this regulation; and
(ii) Enrollees with HIV to one of the two HIV payment categories set forth in §B(4)(a) of this regulation.

(2) Disabled. Capitation rates for enrollees who are waiver-eligible based upon receipt of benefits through SSI or as medically needy, aged, blind, or disabled shall be established as follows:

(a) Except as provided in §B(2)(c) of this regulation, for enrollees for whom the Department has sufficient clinical data, the Department shall:

(i) Determine an adjusted clinical group (ACG) assignment utilizing an enrollee's diagnostic record;

(ii) Utilizing aggregated enrollee ACG data, on an annual basis define a limited number of risk adjustment categories that reflect levels of nearly homogenous resource utilization by ACG assignment; and

(iii) Assign an enrollee to a risk adjustment category (RAC) based upon the enrollee's ACG assignment; and

(b) Except as provided in §B(2)(c) of this regulation, for enrollees for whom the Department has insufficient data to generate an ACG assignment, the Department shall assign the enrollee to a risk adjustment category that reflects the enrollee's age, residence, and gender; and

(c) On the basis of the enrollee's residence, the Department shall assign:

(i) Enrollees with HIV to one of the two HIV payment categories set forth in §B(4)(b) of this regulation; and

(ii) Enrollees with AIDS to one of the two AIDS payment categories set forth in §B(4)(b) of this regulation.

(3) Supplemental Delivery/Newborn Payments.

(a) In addition to the monthly payment specified in §B(4)(a) or (b) of this regulation for an enrollee's payment category, the Department shall pay an MCO one supplemental payment per pregnancy in the amount specified in §B(4)(c) of this regulation, upon delivery of one or more infants without regard to method, timing, or place of delivery.

(b) An MCO shall have 12 months from the date of delivery to bill for the supplemental payment.

(4) Except to the extent of adjustments required by Â§D of this regulation or by Regulations .19-1—.19-3 of this chapter, the Department shall make payments monthly at the rates specified in the following tables:
(a) Rate Table for Families and Children Effective January 1, 2019 — December 31, 2019

<table>
<thead>
<tr>
<th>Age/RAC</th>
<th>Gender</th>
<th>PMPM Baltimore City</th>
<th>PMPM Montgomery County</th>
<th>PMPM Rest of State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under age 1 Birth Weight 1500 grams or less</td>
<td>Both</td>
<td>$10,633.45</td>
<td>$9,884.60</td>
<td>$10,042.70</td>
</tr>
<tr>
<td>Under age 1 Birth Weight over 1500 grams</td>
<td>Both</td>
<td>$503.91</td>
<td>$468.42</td>
<td>$475.91</td>
</tr>
<tr>
<td>1—5</td>
<td>Male</td>
<td>$201.37</td>
<td>$187.18</td>
<td>$190.18</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$171.52</td>
<td>$159.44</td>
<td>$161.99</td>
</tr>
<tr>
<td>6—14</td>
<td>Male</td>
<td>$115.66</td>
<td>$107.51</td>
<td>$109.23</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$110.78</td>
<td>$102.98</td>
<td>$104.63</td>
</tr>
<tr>
<td>15—20</td>
<td>Male</td>
<td>$137.88</td>
<td>$128.17</td>
<td>$130.22</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$189.12</td>
<td>$175.80</td>
<td>$178.62</td>
</tr>
<tr>
<td>21—44</td>
<td>Male</td>
<td>$271.41</td>
<td>$225.13</td>
<td>$235.22</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$384.69</td>
<td>$319.09</td>
<td>$333.38</td>
</tr>
<tr>
<td>45—64</td>
<td>Male</td>
<td>$519.10</td>
<td>$430.59</td>
<td>$449.87</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$638.23</td>
<td>$529.41</td>
<td>$553.12</td>
</tr>
</tbody>
</table>

ACG-adjusted cells
<table>
<thead>
<tr>
<th>ACG</th>
<th>RAC 1F</th>
<th>Both</th>
<th>$243.24</th>
<th>$201.77</th>
<th>$210.80</th>
</tr>
</thead>
<tbody>
<tr>
<td>100, 200, 300, 400, 500, 600, 700, 900, 1000, 1100, 1200, 1300, 1600, 1710, 1711, 1712, 1720, 1721, 1722, 1730, 1731, 1732, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3800, 4210, 5100, 5110, 5200, 5230, 5310, 5339</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>800, 1740, 1741, 1742, 1750, 2700, 3600, 1750, 1751, 1752, 2700, 3600, 3700, 3900, 4000, 4100, 220, 4310, 4410, 4510, 4610, 4710, 4720, 4810, 5340</td>
<td>RAC 2F</td>
<td>Both</td>
<td>$391.81</td>
<td>$325.00</td>
<td>$339.55</td>
</tr>
<tr>
<td>1400, 1500, 1750, 1761, 1762, 1770, 1771, 1772, 2600, 4320, 4520, 4620, 4820</td>
<td>RAC 3F</td>
<td>Both</td>
<td>$506.38</td>
<td>$420.03</td>
<td>$438.55</td>
</tr>
<tr>
<td>4330, 4420, 4830, 4910, 4920, 5010, 5020, 5040</td>
<td>RAC 4F</td>
<td>Both</td>
<td>$704.46</td>
<td>$584.34</td>
<td>$610.52</td>
</tr>
<tr>
<td>4430, 4730, 4930, 5030, 5050</td>
<td>RAC 5F</td>
<td>Both</td>
<td>$997.30</td>
<td>$827.24</td>
<td>$864.30</td>
</tr>
<tr>
<td>4940, 5060</td>
<td>RAC 6F</td>
<td>Both</td>
<td>$1,281.41</td>
<td>$1,062.91</td>
<td>$1,110.52</td>
</tr>
<tr>
<td>5070</td>
<td>RAC 7F</td>
<td>Both</td>
<td>$2,083.82</td>
<td>$1,728.50</td>
<td>$1,805.92</td>
</tr>
<tr>
<td>100, 200, 300, 500, 600, 1100, 1600, 2000, 2400, 3400, 5100, 5110, 5200</td>
<td>RAC 1G</td>
<td>Both</td>
<td>$89.37</td>
<td>$83.08</td>
<td>$84.41</td>
</tr>
<tr>
<td>400, 700, 900, 1000, 1200, 1300, 1710, 1711, 1712, 1800, 1900, 2100, 2200, 2300, 2800, 2900, 3000, 3100, 5310</td>
<td>RAC 2G</td>
<td>Both</td>
<td>$114.64</td>
<td>$106.57</td>
<td>$108.27</td>
</tr>
<tr>
<td>ACG 1720, 1721, 1722, 1731, 1732, 1730, 2500, 3200, 3300, 3500, 3800, 4210, 5230, 5339</td>
<td>RAC 3G</td>
<td>Both</td>
<td>$144.33</td>
<td>$134.16</td>
<td>$136.31</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>ACG 800, 1740, 1741, 1750, 2700, 3600, 1751, 1752, 2700, 3600, 3700, 3900, 4000, 4100, 4220, 4310, 4410, 4510, 4610, 4710, 4720, 4810, 5340</td>
<td>RAC 4G</td>
<td>Both</td>
<td>$205.57</td>
<td>$191.09</td>
<td>$194.15</td>
</tr>
<tr>
<td>ACG 1400, 1500, 1750, 1761, 1762, 1770, 1771, 1772, 2600, 4320, 4520, 4620, 4820</td>
<td>RAC 5G</td>
<td>Both</td>
<td>$326.72</td>
<td>$303.71</td>
<td>$308.56</td>
</tr>
<tr>
<td>ACG 4330, 4420, 4830, 4910, 4920, 5010, 5020, 5040</td>
<td>RAC 6G</td>
<td>Both</td>
<td>$395.20</td>
<td>$367.37</td>
<td>$373.24</td>
</tr>
<tr>
<td>ACG 4430, 4730, 4930, 4940, 5030, 5050, 5060, 5070</td>
<td>RAC 7G</td>
<td>Both</td>
<td>$1,030.02</td>
<td>$957.48</td>
<td>$972.79</td>
</tr>
<tr>
<td>SOBRA Mothers</td>
<td></td>
<td></td>
<td>$691.48</td>
<td>$573.58</td>
<td>$599.27</td>
</tr>
<tr>
<td>Persons with HIV</td>
<td>ALL</td>
<td>Both</td>
<td>$678.39</td>
<td>$678.39</td>
<td>$678.39</td>
</tr>
</tbody>
</table>

(b) Rate Table for Disabled Individuals Effective January 1, 2019 — December 31, 2019

<table>
<thead>
<tr>
<th>Age/RAC</th>
<th>Gender</th>
<th>PMPM Baltimore City</th>
<th>PMPM Montgomery County</th>
<th>PMPM Rest of State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under Age 1</td>
<td>Both</td>
<td>$6,429.19</td>
<td>$6,429.19</td>
<td>$6,429.19</td>
</tr>
<tr>
<td>1—5</td>
<td>Male</td>
<td>$1,326.70</td>
<td>$1,326.70</td>
<td>$1,326.70</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$900.96</td>
<td>$900.96</td>
<td>$900.96</td>
</tr>
<tr>
<td>6—14</td>
<td>Male</td>
<td>$298.83</td>
<td>$298.83</td>
<td>$298.83</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>$470.97</td>
<td>$470.97</td>
<td>$470.97</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ACG-adjusted cells**

<p>| ACG 100, 200, 300, 1100, 1300, 1400, 1500, 1600, 1710, 1711, 1712, 1720, 1721, 1722, 1730, 1731, 1732, 1900, 2400, 2600, 2900, 3400, 5100, 5110, 5200, 5310 | RAC 10 | Both | $296.35 | $215.07 | $252.69 |
| ACG 400, 500, 700, 900, 1000, 1200, 1740, 1741, 1742, 1750, 1751, 1752, 1800, 2000, 2100, 2200, 2300, 2500, 2700, 2800, 3000, 3100, 3200, 3300, 3500, 3900, 4000, 4310, 5330 | RAC 11 | Both | $364.82 | $264.76 | $311.07 |
| ACG 600, 1760, 1761, 1762, 3600, 3700, 4100, 4320, 4410, 4710, 4810, 4820 | RAC 12 | Both | $699.42 | $507.60 | $596.38 |
| ACG 3800, 4210, 4220, 4330, 4420, 4720, 4910, 5320 | RAC 13 | Both | $783.85 | $568.51 | $667.95 |
| ACG 800, 4430, 4510, 4610, 5040, 5340 | RAC 14 | Both | $1,096.47 | $795.76 | $934.94 |
| ACG 1770, 1771, 1772, 4520, 4620, 4830, 4920, 5050 | RAC 15 | Both | $1,381.88 | $1,002.89 | $1,178.30 |
| ACG 4730, 4930, 5010 | RAC 16 | Both | $1,423.21 | $1,032.88 | $1,213.54 |</p>
<table>
<thead>
<tr>
<th>ACG 4940, 5020, 5060</th>
<th>RAC 17</th>
<th>Both</th>
<th>$2,170.47</th>
<th>$1,575.21</th>
<th>$1,850.72</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACG 5030, 5070</td>
<td>RAC 18</td>
<td>Both</td>
<td>$3,872.14</td>
<td>$2,810.08</td>
<td>$3,301.70</td>
</tr>
<tr>
<td>Persons with AIDS</td>
<td>All</td>
<td>Both</td>
<td>$1,982.61</td>
<td>$1,269.36</td>
<td>$1,269.36</td>
</tr>
<tr>
<td>Persons with HIV</td>
<td>All</td>
<td>Both</td>
<td>$1,997.41</td>
<td>$1,997.41</td>
<td>$1,997.41</td>
</tr>
</tbody>
</table>

(c) Rate Table for Supplemental Payments for Delivery/Newborn and Hepatitis C Therapy Effective January 1, 2019 — December 31, 2019

<table>
<thead>
<tr>
<th>Supplemental Payment Cells</th>
<th>Age</th>
<th>Gender</th>
<th>Baltimore City</th>
<th>Montgomery County</th>
<th>Rest of State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delivery/Newborn—all births except live birth weight 1,500 grams or less and gestational age of 21 weeks or more</td>
<td>All</td>
<td>Both</td>
<td>$16,395.64</td>
<td>$12,953.96</td>
<td>$14,130.96</td>
</tr>
<tr>
<td>Delivery/Newborn — live birth weight 1,500 grams or less and a gestational age of 21 weeks or more</td>
<td>All</td>
<td>Both</td>
<td>$86,211.08</td>
<td>$86,211.08</td>
<td>$86,211.08</td>
</tr>
<tr>
<td>Delivery/Newborn by same enrollee — subsequent live birth weight 1,500 grams or less with a gestational age less than 21 weeks or does not meet the requirements in §B(4)(i) of this regulation</td>
<td>All</td>
<td>Both</td>
<td>$16,395.64</td>
<td>$12,953.96</td>
<td>$14,130.96</td>
</tr>
<tr>
<td>Hepatitis C Therapy</td>
<td>All</td>
<td>Both</td>
<td>$20,598.22</td>
<td>$20,598.22</td>
<td>$20,598.22</td>
</tr>
</tbody>
</table>

(d) Rate Table for Childless Adult Population Effective January 1, 2019 — December 31, 2019
<table>
<thead>
<tr>
<th>Age/RAC</th>
<th>Gender</th>
<th>PMPM Baltimore City</th>
<th>Montgomery County</th>
<th>PMPM Rest of State</th>
</tr>
</thead>
<tbody>
<tr>
<td>19—44</td>
<td>Male</td>
<td>$347.86</td>
<td>$277.04</td>
<td>$316.60</td>
</tr>
<tr>
<td>19—44</td>
<td>Female</td>
<td>$412.94</td>
<td>$328.87</td>
<td>$375.82</td>
</tr>
<tr>
<td>45—64</td>
<td>Male</td>
<td>$940.05</td>
<td>$748.66</td>
<td>$855.56</td>
</tr>
<tr>
<td>45—64</td>
<td>Female</td>
<td>$865.06</td>
<td>$688.94</td>
<td>$787.30</td>
</tr>
</tbody>
</table>

ACG-adjusted cells

| ACG 100, 200, 300, 400, 500, 600, 700, 900, 1000, 1100, 1200, 1300, 1600, 1710, 1711, 1712, 1720, 1721, 1722, 1730, 1731, 1732, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3800, 4210, 5100, 5110, 5200 5230, 5310, 5339 | RAC 1H  | Both | $308.54 | $245.72 | $280.81 |
| ACG 800, 1740, 1741, 1742, 1750, 2700, 3600, 1750, 1751, 1752, 2700, 3600, 3700, 3900, 4000, 4100, 4220, 4310, 4410, 4510, 4610, 4710, 4720, 4810, 5340 | RAC 2H  | Both | $464.28 | $369.75 | $422.55 |
| ACG 1400, 1500, 1750, 1761, 1762, 1770, 1771, 1772, 2600, 4320, 4520, 4620, 4820 | RAC 3H  | Both | $483.85 | $385.02 | $439.99 |
| ACG 4330, 4420, 4830, 4910, 4920, 5010, 5020, 5040 | RAC 4H  | Both | $838.59 | $667.86 | $763.22 |
| ACG 4430, 4730, 4930, 5030, 5050 | RAC 5H  | Both | $1,049.48 | $835.81 | $955.15 |
| ACG 4940, 5060 | RAC 6H | Both | $1,356.64 | $1,080.43 | $1,234.70 |
(e) Interpretation of Rate Table for Families and Children. The table found at §B(4)(a) of this regulation shows capitation rates for individuals who are:

(i) Waiver eligible based on receipt of benefits through TCA or programs for medically needy families and children;

(ii) SOBRA children;

(iii) SOBRA mothers; and

(iv) The Maryland Children's Health Program.

(f) Interpretation of Rate Table for Disabled Individuals. The table found at §B(4)(b) of this regulation shows the capitation rates for individuals who are waiver-eligible based upon receipt of benefits through SSI or as medically needy, aged, blind, or disabled.

(g) Interpretation of Rate Table for Supplemental Payment for Delivery/Newborn. The table found at §B(4)(c) of this regulation shows a supplemental payment made in connection with deliveries of MCO enrollees, regardless of the enrollee's payment category under COMAR 10.67.04.19B(4)(a) or (b).

(h) Interpretation of Rate Tables in §B(4) of this regulation. "PMPM" means the per member per month payment rate.

(i) An MCO is eligible to receive the subsequent very low birth weight payment in §B(4)(c) of this regulation if the mother:

(i) Had a prior spontaneous preterm delivery;

(ii) Has a current singleton pregnancy;

(iii) Is eligible to receive hydroxyprogesterone caproate;

(iv) Has received the first hydroxyprogesterone caproate injection between 16 weeks gestation and 24 weeks gestation and continued receiving injections until delivery or week 37 gestation; and

(v) Has received at least 2 hydroxyprogesterone caproate injections.

(5) Consistent with the terms set forth in Regulation .19-4 of this chapter, the Department may, in consultation with the Commissioner, adjust the capitation payment of an MCO if it
determines that the MCO’s loss ratio, not including any rebate received by the MCO is less than 85 percent.

C. The Department shall reimburse fee-for-service:

(1) The Departmental share for any enrollee participating in the Stop Loss Program pursuant to Regulation .22 of this chapter; and

(2) The cost of those services specified in COMAR 10.09.69.06—.13 provided to the participant that have been authorized by the participant's case manager in accordance with the participant's plan of care.

D. Interim Rates Adjustments.

(1) Under the circumstances described in §D(2) and (3) of this regulation, the Department shall adjust the capitation rates set forth in §B(4)(a) and (b) of this regulation to reflect changes in service costs during the contract year due to an occurrence listed in §D(2) of this regulation.

(2) The Department shall adjust the payment rates specified in §B(4)(a)—(d) of this regulation to reflect service cost changes that qualify under §D(3) of this regulation and result from:

(a) An addition or deletion of services covered under the HealthChoice benefits package;

(b) An increase or decrease in Medicaid fee-for-service payment rates or copayments, if the MCOs are obligated to adjust their payment rates to providers as a result of those fee-for-service rate changes;

(c) An increase or decrease in the inpatient charge per case as calculated by the change in the restated unit cost provided annually by the HSCRC as compared to the data originally provided; or

(d) An increase or decrease in the outpatient charge per visit as calculated by the change in the restated unit cost provided annually by the HSCRC as compared to the data originally provided.

(3) The Department shall make an interim rates adjustment if the effect of an occurrence listed in §D(2) of this regulation is sufficient to result in program-wide overpayment or underpayment of at least 0.2 percent because of the difference between:

(a) Service cost projections used to develop the rates set forth in §B(4)(a) and (b) of this regulation; and

(b) Service costs for the same period, taking into account an occurrence that is listed in §D(2) of this regulation.
(4) The Department shall make any interim rates adjustments required by this section in amounts that are proportionate to the overpayment or underpayments described in §D(3) of this regulation.

(5) Provider rate adjustments as specified in §D(2)(b) of this regulation may not require the MCOs to pay providers more than the Medicaid fee-for-service rate.

(6) The Department shall make supplemental payments to an MCO that reflect increases in MCO provider payments for trauma services described in COMAR 10.25.10.

.19-1 MCO-Specific Case Mix Adjustment for HIV and AIDS with Hepatitis C.

A. To reflect the higher level of risk associated with providing covered health care services pursuant to COMAR 10.67.06 to HIV/AIDS enrollees who also have Hepatitis C, the Department shall, to the extent provided by this regulation, make MCO-specific adjustments to payments for enrollees in HIV and AIDS payment categories to reflect the proportion of an MCO's HIV/AIDS enrollees who also have Hepatitis C.

B. Identification of HIV/AIDS Enrollees with Hepatitis C.

(1) For each MCO, the Department shall consider historical encounter and fee-for-service data for enrollees assigned to HIV and AIDS payment categories:

   (a) For the initial assessment period, as of June of the calendar year before the rate year; and

   (b) For the mid-year assessment period, as of December of the calendar year before the rate year.

(2) For each MCO, the Department shall determine which of the HIV/AIDS enrollees meeting the criteria set forth in §B(1) of this regulation also have Hepatitis C.

(3) The Department shall use encounter and fee-for-service data documenting services provided to the HIV/AIDS enrollees identified in accordance with §B(1) of this regulation for the appropriate historical diagnostic period:

   (a) For the initial assessment period, through June of the calendar year before the rate year; and

   (b) For the mid-year assessment period, through December of the calendar year before the rate year.

C. Methodology for Determining MCO-specific HIV and AIDS Case Mix Measures. For each MCO, the Department shall:
(1) Based on encounter and fee-for-service data from the appropriate historical diagnostic period, classify the MCO's HIV/AIDS enrollees identified pursuant to §B of this regulation as either:

   (a) Hepatitis C-infected; or

   (b) Hepatitis C-uninfected.

(2) Average relative value for HIV and AIDS payment categories are as follows:

   (a) Apply weights reflecting costs associated with Hepatitis C-infected and Hepatitis C-uninfected enrollees in each HIV and AIDS payment category to the MCO-specific distribution of HIV/AIDS enrollees who are Hepatitis C-infected or Hepatitis C-uninfected, as determined pursuant to §C(1) of this regulation; and

   (b) For each MCO, use the results of the calculations specified in §C(2)(a) of this regulation to separately calculate an average relative value for each of the HIV and AIDS payment categories.

(3) To determine an MCO's relative case mix factors, each MCO's relative values determined pursuant to §C(2)(b) of this regulation are divided by the overall average relative value determined pursuant to §C(2)(a) of this regulation.

D. Methodology for MCO-Specific Case Mix-Adjusted HIV and AIDS Rates. For each MCO, the Department shall:

(1) Calculate MCO-specific HIV and AIDS relative case mix factors for each HIV and AIDS payment group pursuant to §C(3) of this regulation;

(2) Calculate MCO-specific HIV and AIDS rates for the rate adjustment period by multiplying the risk adjustment factor derived pursuant to §D(1) of this regulation by the value specified for each HIV and AIDS payment group for the rate year; and

(3) Apply a budget neutrality adjustment to the values derived pursuant to §D(2) of this regulation so that the aggregate of payments to all MCOs pursuant to this regulation are equivalent to the aggregate of all payments that would be due to all MCOs in the absence of this regulation.

E. Case Mix Updates. The Department shall:

(1) Update current enrollees' region of residence and enrollment categories by repeating the calculations in §§B—D of this regulation every 6 months using residence and enrollment data as of the enrollment month specified below:

   (a) For the initial assessment period of each rate year, June of the calendar year before the rate year; and
(b) For the mid-year assessment period of each rate year, December of the calendar year before the rate year; and

(2) For rate adjustment periods beginning January 1 and July 1 of each rate year, use each MCO's updated Hepatitis C-infected and Hepatitis C-uninfected distribution to compute its risk adjusted HIV and AIDS payment rates for each rate adjustment period, as described in §D of this regulation.

.19-2 MCO Supplemental Payment for Transitional Encounter Data Adjustment.

A. The Department may grant an adjustment to those MCOs for whom the uniform encounter data adjustment results in completeness factors that are below the Statewide average.

B. The encounter adjustment for each MCO shall be determined for the Family and Children RACs and for the Disabled RACs respectively.

.19-3 MCO-Specific Case Mix Adjustment.

A. Definitions.

(1) In this regulation, in addition to the definitions set forth in COMAR 10.67.01, the following terms have the meanings indicated.

(2) Terms Defined.

(a) "Demographic rate cell" means a cell in one of the rates tables in Regulation .19B(4) of this chapter to which an MCO's enrollees are assigned pursuant to Regulation .19B(1)(b) and B(2)(b) of this chapter.

(b) "Initial rate adjustment period" means the 6-month period beginning January 1 of the rate year.

(c) "Mid-year rate adjustment period" means the 6-month period beginning July 1 of the rate year.

(d) "RAC rate cell" means a cell in one of the rates tables in Regulation .19B(4) of this chapter to which an MCO's enrollees are assigned pursuant to Regulation .19B(1)(a) and (2)(a) of this chapter.

(e) "Rate adjustment period" means a 6-month period within the rate year that includes:

   (i) The initial rate adjustment period beginning January 1 of the rate year; and

   (ii) The mid-year rate adjustment period beginning July 1 of the rate year.
(f) "Rate year" means the calendar year to which the rates calculated pursuant to this regulation apply.

(g) "Risk Adjustment Category (RAC)" means a grouping of adjusted clinical groups (ACGs), each of which is associated with a similar level of risk.

(h) "Risk assessment cohort" means each of the eight groupings of enrollees, assigned on the basis of their:

(i) Program eligibility category, either "families and children", as specified in Regulation .19B(1) of this chapter, or "disabled", as specified in Regulation .19B(2) of this chapter;

(ii) Region of residence category, either in "Baltimore City" or in the "rest of State"; and

(iii) Age category, either at least 1 year old but younger than 21 years old, or 21 years old or older.

(i) "Risk assessment year" means the calendar year 2 years before the rate year.

B. For calculating an adjustment to MCO payment rates reflecting the relative level of risk of providing enrollees assigned to demographic rate cells covered health care services pursuant to COMAR 10.67.06, the Department shall, for each MCO, identify the enrollees to be considered as follows:

1) For each rate adjustment period in the rate year, identify the current demographic enrollees for each MCO who:

(a) In the risk assessment year:

(i) Were certified eligible for the Program for at least 6 months;

(ii) Were assigned to a demographic rate cell; and

(iii) As of June 30, were 1 year old or older; and

(b) In the calendar year before the rate year:

(i) For the initial rate adjustment period calculation for the rate year 2004, were enrolled in the MCO in March;

(ii) For the initial rate adjustment period calculation for rate years after 2004, were enrolled in the MCO in June; and

(iii) For the mid-year rate adjustment period calculation, were enrolled in the MCO in December;
(2) Assign each enrollee identified pursuant to §B(1) of this regulation into one of the eight risk assessment cohorts;

(3) Make the determinations necessary for the assignments required by §B(2) of this regulation consistent with the following time frames:

(a) For an initial rate adjustment period calculation for the rate year 2004:

(i) An enrollee's eligibility category and region of residence as of March of the calendar year before the rate year; and

(ii) An enrollee's age category as of March 31 of the calendar year before the rate year;

(b) For an initial rate adjustment period calculation for rate years after 2004:

(i) An enrollee's eligibility category and region of residence as of June of the calendar year before the rate year; and

(ii) An enrollee's age category as of June 30 of the calendar year before the rate year; and

(c) For a mid-year rate adjustment period calculation:

(i) An enrollee's eligibility category and region of residence as of December of the calendar year before the rate year; and

(ii) An enrollee's age category as of December 31 of the calendar year before the rate year; and

(4) For calculating an MCO's case mix adjustment pursuant to this regulation, disregard any risk assessment cohorts to which fewer than 50 of an MCO's enrollees are assigned pursuant to §B(2) of this regulation.

C. Methodology for Determining MCO-specific RAC Case Mix Measures. For each MCO, the Department shall:

(1) Based on encounter and fee-for-service data documenting services delivered during the risk assessment year, determine the diagnoses attributable to an MCO's enrollees identified pursuant to §B of this regulation;

(2) Based on diagnoses in the risk assessment year, assign each enrollee identified pursuant to §B of this regulation to the appropriate risk adjustment category (RAC), consistent with the protocol set forth in Regulation .19B(1)(a) and (2)(a) of this chapter;

(3) Apply the RAC rates for the appropriate rate adjustment period to the RAC distribution determined pursuant to §C(2) of this regulation;
(4) Using the results of the calculations specified in §C(3) of this regulation, calculate an MCO's average RAC rates separately for each of the MCO's risk assessment cohorts derived in accordance with §B of this regulation; and

(5) To determine an MCO's relative RAC case mix factors, divide each of the MCO's average RAC rates determined in accordance with §C(4) of this regulation by each overall average RAC rate for all MCOs for the same risk assessment cohort.

D. Methodology for Determining MCO-specific Demographic Case Mix Measures. For each MCO, the Department shall:

(1) Determine the demographic distribution of its current enrollees as specified in §B of this regulation;

(2) Apply the appropriate demographic rates for the rate adjustment period to the demographic distribution as determined pursuant to §D(1) of this regulation;

(3) Using the results of the calculations specified in §D(2) of this regulation, calculate the MCO's average demographic rates separately for each of the MCO's risk assessment cohorts derived in accordance with §B of this regulation; and

(4) To determine an MCO's relative demographic case mix factors, divide each of the MCO's average demographic rates determined pursuant to §D(3) of this regulation by each of the overall average of demographic rates for all MCOs for the same risk assessment cohort.

E. MCO-Specific Case Mix Adjusted Demographic Rates. The Department shall, for each MCO:

(1) Calculate MCO-specific risk adjustment factors by dividing, for each risk assessment cohort, the relative RAC case mix factor determined pursuant to §C of this regulation, by the relative demographic case mix factor determined pursuant to §D of this regulation;

(2) Modify the MCO-specific risk adjustment factor derived for each risk assessment cohort pursuant to §E(1) of this regulation as follows:

   (a) Reduce each risk adjustment factor that is higher than 1.1 to 1.1; and

   (b) Increase each risk adjustment factor that is lower than 0.9 to 0.9;

(3) Subject to §E(4) of this regulation, calculate the MCO-specific demographic rates for the rate adjustment period by multiplying the risk adjustment factor for each risk assessment cohort, derived pursuant to §E(1) of this regulation, by the value specified in each demographic rate cell for the rate year; and
(4) Apply a budget neutrality adjustment to the values derived in §E(3) of this regulation so that aggregate payments to all MCOs pursuant to this regulation are equivalent to the aggregate payments that would be due to all MCOs in the absence of this regulation.

F. Case Mix Updates. The Department shall:

(1) Repeat the calculations described in §§C—E of this regulation every 6 months to update current MCO enrollees' region of residence, age, and enrollment categories as of the calendar year before the rate year, as provided in §B(3) of this regulation; and

(2) For the rate adjustment periods beginning January 1 and July 1 of each rate year, use each MCO's updated RAC case mix measures and updated demographic case mix measures to compute its demographic rates for the rate adjustment period, as described in §E of this regulation.

.19-4 MCO Medical Loss Ratio.

A. By September 15 of the second calendar year following the MLR reporting year, each MCO shall provide to the Department a completed MLR Reporting Template, including the MCO attestation and any additional documentation supporting the MLR reporting template.

B. The MLR experienced for each MCO in an MLR reporting year is the ratio of the numerator, as defined in §D of this regulation, to the denominator, as defined in §E of this regulation.

C. An MLR may be increased by a credibility adjustment, in accordance with §G of this regulation.

D. Components of MLR — Numerator.

(1) The numerator of an MCO's MLR for an MLR reporting year is the sum of the MCO's incurred claims, the MCO's expenditures for activities that improve health care quality, and fraud prevention activities.

(2) Incurred Claims. Incurred claims include the following:

(a) Direct claims that the MCO paid to providers, including under capitated contracts with network providers, for services or supplies covered under the contract and services meeting the requirements of 42 CFR §438.3(e) provided to enrollees;

(b) Unpaid claims liabilities for the MLR reporting year, including claims reported that are in the process of being adjusted or claims incurred but not reported;

(c) Withholds from payments made to network providers;

(d) Claims that are recoverable for anticipated coordination of benefits;
(e) Claims payments recoveries received because of subrogation;

(f) Incurred but not reported claims based on past experience, and modified to reflect current conditions, such as changes in exposure or claim frequency or severity;

(g) Changes in other claims-related reserves; and

(h) Reserves for contingent benefits and the medical claim portion of lawsuits.

(3) An MCO shall deduct the following amounts from incurred claims:

(a) Overpayment recoveries received from network providers; and

(b) Prescription drug rebates received and accrued.

(4) An MCO shall include the following expenditures in incurred claims:

(a) The amount of incentive and bonus payments made, or expected to be made, to network providers; and

(b) The amount of claims payments recovered through fraud reduction efforts, not to exceed the amount of fraud reduction expenses, and excluding activities specified in §D(3) of this regulation;

(5) An MCO may include or deduct the following amounts from incurred claims:

(a) Net payments; or

(b) Receipts related to State-mandated solvency funds;

(6) An MCO shall exclude the following amounts from incurred claims:

(a) Non-claims costs;

(b) Amounts paid to the State as remittance under §I of this regulation; and

(c) Amounts paid to network providers under to 42 CFR §438.6(d).

(7) Non-claims costs as described in §D(6)(a) of this regulation include the following:

(a) Amounts paid to third-party vendors for secondary network savings;

(b) Amounts paid to third-party vendors for network development, administrative fees, claims processing, and utilization management;
(c) Amounts paid, including amounts paid to a provider, for professional or administrative services that do not represent compensation or reimbursement for State plan services or services meeting the definition in 42 CFR §438.3(e) and provided to an enrollee; and

(d) Fines and penalties assessed by regulatory authorities.

(8) Incurred claims paid by one MCO that are later assumed by another MCO shall be reported by the assuming MCO for the entire MLR reporting year, and no incurred claims for that MLR reporting year may be reported by the ceding MCO.

(9) An MCO shall include activities that improve health care quality in one of the following categories:

   (a) An MCO activity that meets the requirements of 45 CFR §158.150(b) and is not excluded under 45 CFR §158.150(c);

   (b) An MCO activity related to any EQR-related activity as described in 42 CFR §438.358(b) and (c); and

   (c) Any MCO expenditure that is related to Health Information Technology and meaningful use, meets the requirements placed on issuers found in 45 CFR §158.151, and is not considered incurred claims.

(10) Excluding expenses for fraud reduction efforts in §D(4)(b) of this regulation, an MCO shall include expenditures on activities related to fraud prevention as adopted for the private market at 45 CFR part 158.

E. Components of MLR — Denominator.

(1) The denominator of an MCO's MLR for an MLR reporting year shall equal the adjusted premium revenue. The adjusted premium revenue is the MCO's premium revenue minus the MCO's federal, State, and local taxes and licensing and regulatory fees and is aggregated in accordance with §F of this regulation.

(2) Premium revenue includes the following for the MLR reporting year:

   (a) State capitation payments, developed in accordance with 42 CFR §438.4, to the MCO for all enrollees under a risk contract approved under 42 CFR §438.3(a), excluding payments made under 42 CFR §438.6(d);

   (b) State-developed, one-time payments, for specific life events of enrollees;

   (c) Other payments to the MCO approved under 42 CFR §438.6(b)(3);
(d) Unpaid cost-sharing amounts that the MCO could have collected from enrollees under the contract, except those amounts the MCO can show it made a reasonable, but unsuccessful, effort to collect;

(e) All changes to unearned premium reserves; and

(f) Net payments or receipts related to risk sharing mechanisms developed in accordance with 42 CFR §438.5 or 42 CFR §438.6.

(3) Federal, State, and Local Taxes and Licensing and Regulatory Fees. Taxes and licensing and regulatory fees for the MLR reporting year include:

(a) Statutory assessments to defray the operating expenses of any State or federal department;

(b) Examination fees in lieu of premium taxes as specified by State law;

(c) Federal taxes and assessments allocated to MCOs excluding federal income taxes on investment income and capital gains and federal employment taxes;

(d) State and local taxes and assessments including:

(i) Any industrywide (or subset) assessments, other than surcharges on specific claims, paid to the State or locality directly;

(ii) Guaranty fund assessments;

(iii) Assessments of State or locality industrial boards or other boards for operating expenses or for benefits to sick employed persons in connection with disability benefit laws or similar taxes levied by states;

(iv) State or locality income, excise, and business taxes other than premium taxes and State employment and similar taxes and assessments; and

(v) State or locality premium taxes plus State or locality taxes based on reserves, if in lieu of premium taxes; and

(e) Payments made by an MCO that are otherwise exempt from federal income taxes, for community benefit expenditures as defined in 45 CFR §158.162(c), limited to the highest of either:

(i) 3 percent of earned premium; or

(ii) The highest premium tax rate in the State for which the report is being submitted, multiplied by an MCO's earned premium in the State.
(4) The total amount of the denominator for an MCO, which is later assumed by another MCO, shall be reported by the assuming MCO for the entire MLR reporting year and no amount under this section for that year may be reported by the ceding MCO.

F. Allocation of Expense.

(1) Each expense shall be included under only one type of expense, unless a portion of the expense fits under the definition of, or criteria for, one type of expense and the remainder fits into a different type of expense, in which case the MCO shall prorate the expense between types of expenses.

(2) An MCO shall report on a pro-rata basis any expenditures that benefit multiple contracts or populations, or contracts other than those being reported.

(3) Methods Used to Allocate Expenses.

(a) An MCO shall base allocation to each category on a generally accepted accounting method that is expected to yield the most accurate results.

(b) An MCO shall apportion shared expenses, including expenses under the terms of a management contract, pro rata to the contract incurring the expense.

(c) The reporting entity shall bear any expenses that relate solely to its operation and may not apportion its operating expenses to other entities.

G. Credibility Adjustment.

(1) An MCO may add a credibility adjustment to a calculated MLR if the MLR reporting year experience has partial credibility.

(2) An MCO shall add the credibility adjustment to the reported MLR calculation before calculating any remittances if required by the State as described in §I of this regulation.

(3) An MCO may not add a credibility adjustment to a calculated MLR if the MLR reporting year experience has full credibility.

(4) If an MCO's experience has no credibility, it is presumed to meet or exceed the MLR calculation standards in this regulation.

(5) MCOs shall use the base credibility factors CMS publishes on an annual basis that are developed according to the methodology in 42 CFR §438.8(h)(4).

H. Eligibility Groups.

(1) MCOs shall aggregate data for all Medicaid eligibility groups covered under the contract with the Department.
(2) MCOs shall report, and the Department shall calculate, an annual MLR as described in this regulation separately for the childless adult population.

(3) The Department may require separate reporting and a separate MLR calculation for additional populations.

I. An MCO shall provide a remittance for an MLR reporting year if the MLR for that MLR reporting year does not meet the minimum MLR standard of 85 percent.

J. Newly Contracted MCOs.

(1) The Department may exclude an MCO that is newly contracted with the State from the requirements in this section for the first year of the MCO's operation.

(2) Newly contracted MCOs shall comply with the requirements in this section during the next MLR reporting year in which the MCO is in business with the State, even if the first year was not a full 12 months.

K. If the Department makes a retroactive change to the capitation payments for an MLR reporting year where the report has already been submitted to the Department, the MCO shall recalculate the MLR for all MLR reporting years affected by the change and submit a new report.

L. MCOs shall attest to the accuracy of the calculation of the MLR in accordance with requirements of this section when submitting its report to the Department.

M. Notice and Appeal.

(1) Within 30 days of its receipt of the notice of a remittance being due to the Department, an MCO may appeal the remittance as a sanction pursuant to COMAR 10.67.10.02.

(2) An MCO's appeal does not stay the obligation of the MCO to remit the amount owed to the Department.

.19-5 MCO Medical Loss Ratio.

A. By September 15 of the second calendar year following the MLR reporting year, each MCO shall provide to the Department a completed MLR Reporting Template, including the MCO attestation and any additional documentation supporting the MLR reporting template.

B. The MLR experienced for each MCO in an MLR reporting year is the ratio of the numerator, as defined in §D of this regulation, to the denominator, as defined in §E of this regulation.

C. An MLR may be increased by a credibility adjustment, in accordance with §G of this regulation.
D. Components of MLR — Numerator.

(1) The numerator of an MCO's MLR for an MLR reporting year is the sum of the MCO's incurred claims, the MCO's expenditures for activities that improve health care quality, and fraud prevention activities.

(2) Incurred Claims. Incurred claims include the following:

(a) Direct claims that the MCO paid to providers, including under capitated contracts with network providers, for services or supplies covered under the contract and services meeting the requirements of 42 CFR §438.3(e) provided to enrollees;

(b) Unpaid claims liabilities for the MLR reporting year, including claims reported that are in the process of being adjusted or claims incurred but not reported;

(c) Withholds from payments made to network providers;

(d) Claims that are recoverable for anticipated coordination of benefits;

(e) Claims payments recoveries received because of subrogation;

(f) Incurred but not reported claims based on past experience, and modified to reflect current conditions, such as changes in exposure or claim frequency or severity;

(g) Changes in other claims-related reserves; and

(h) Reserves for contingent benefits and the medical claim portion of lawsuits.

(3) An MCO shall deduct the following amounts from incurred claims:

(a) Overpayment recoveries received from network providers; and

(b) Prescription drug rebates received and accrued.

(4) An MCO shall include the following expenditures in incurred claims:

(a) The amount of incentive and bonus payments made, or expected to be made, to network providers; and

(b) The amount of claims payments recovered through fraud reduction efforts, not to exceed the amount of fraud reduction expenses, and excluding activities specified in §D(3) of this regulation;

(5) An MCO may include or deduct the following amounts from incurred claims:

(a) Net payments; or
(b) Receipts related to State-mandated solvency funds;

(6) An MCO shall exclude the following amounts from incurred claims:

(a) Non-claims costs;

(b) Amounts paid to the State as remittance under §I of this regulation; and

(c) Amounts paid to network providers under to 42 CFR §438.6(d).

(7) Non-claims costs as described in §D(6)(a) of this regulation include the following:

(a) Amounts paid to third-party vendors for secondary network savings;

(b) Amounts paid to third-party vendors for network development, administrative fees, claims processing, and utilization management;

(c) Amounts paid, including amounts paid to a provider, for professional or administrative services that do not represent compensation or reimbursement for State plan services or services meeting the definition in 42 CFR §438.3(e) and provided to an enrollee; and

(d) Fines and penalties assessed by regulatory authorities.

(8) Incurred claims paid by one MCO that are later assumed by another MCO shall be reported by the assuming MCO for the entire MLR reporting year, and no incurred claims for that MLR reporting year may be reported by the ceding MCO.

(9) An MCO shall include activities that improve health care quality in one of the following categories:

(a) An MCO activity that meets the requirements of 45 CFR §158.150(b) and is not excluded under 45 CFR §158.150(c);

(b) An MCO activity related to any EQR-related activity as described in 42 CFR §438.358(b) and (c); and

(c) Any MCO expenditure that is related to Health Information Technology and meaningful use, meets the requirements placed on issuers found in 45 CFR §158.151, and is not considered incurred claims.

(10) Excluding expenses for fraud reduction efforts in §D(4)(b) of this regulation, an MCO shall include expenditures on activities related to fraud prevention as adopted for the private market at 45 CFR part 158.

E. Components of MLR — Denominator.
(1) The denominator of an MCO's MLR for an MLR reporting year shall equal the adjusted premium revenue. The adjusted premium revenue is the MCO's premium revenue minus the MCO's federal, State, and local taxes and licensing and regulatory fees and is aggregated in accordance with §F of this regulation.

(2) Premium revenue includes the following for the MLR reporting year:

(a) State capitation payments, developed in accordance with 42 CFR §438.4, to the MCO for all enrollees under a risk contract approved under 42 CFR §438.3(a), excluding payments made under 42 CFR §438.6(d);

(b) State-developed, one-time payments, for specific life events of enrollees;

(c) Other payments to the MCO approved under 42 CFR §438.6(b)(3);

(d) Unpaid cost-sharing amounts that the MCO could have collected from enrollees under the contract, except those amounts the MCO can show it made a reasonable, but unsuccessful, effort to collect;

(e) All changes to unearned premium reserves; and

(f) Net payments or receipts related to risk sharing mechanisms developed in accordance with 42 CFR §438.5 or 42 CFR §438.6.

(3) Federal, State, and Local Taxes and Licensing and Regulatory Fees. Taxes and licensing and regulatory fees for the MLR reporting year include:

(a) Statutory assessments to defray the operating expenses of any State or federal department;

(b) Examination fees in lieu of premium taxes as specified by State law;

(c) Federal taxes and assessments allocated to MCOs excluding federal income taxes on investment income and capital gains and federal employment taxes;

(d) State and local taxes and assessments including:

   (i) Any industrywide (or subset) assessments, other than surcharges on specific claims, paid to the State or locality directly;

   (ii) Guaranty fund assessments;

   (iii) Assessments of State or locality industrial boards or other boards for operating expenses or for benefits to sick employed persons in connection with disability benefit laws or similar taxes levied by states;
(iv) State or locality income, excise, and business taxes other than premium taxes and State employment and similar taxes and assessments; and

(v) State or locality premium taxes plus State or locality taxes based on reserves, if in lieu of premium taxes; and

(e) Payments made by an MCO that are otherwise exempt from federal income taxes, for community benefit expenditures as defined in 45 CFR §158.162(c), limited to the highest of either:

(i) 3 percent of earned premium; or

(ii) The highest premium tax rate in the State for which the report is being submitted, multiplied by an MCO's earned premium in the State.

(4) The total amount of the denominator for an MCO, which is later assumed by another MCO, shall be reported by the assuming MCO for the entire MLR reporting year and no amount under this section for that year may be reported by the ceding MCO.

F. Allocation of Expense.

(1) Each expense shall be included under only one type of expense, unless a portion of the expense fits under the definition of, or criteria for, one type of expense and the remainder fits into a different type of expense, in which case the MCO shall prorate the expense between types of expenses.

(2) An MCO shall report on a pro-rata basis any expenditures that benefit multiple contracts or populations, or contracts other than those being reported.

(3) Methods Used to Allocate Expenses.

(a) An MCO shall base allocation to each category on a generally accepted accounting method that is expected to yield the most accurate results.

(b) An MCO shall apportion shared expenses, including expenses under the terms of a management contract, pro rata to the contract incurring the expense.

(c) The reporting entity shall bear any expenses that relate solely to its operation and may not apportion its operating expenses to other entities.

G. Credibility Adjustment.

(1) An MCO may add a credibility adjustment to a calculated MLR if the MLR reporting year experience has partial credibility.
(2) An MCO shall add the credibility adjustment to the reported MLR calculation before calculating any remittances if required by the State as described in §1 of this regulation.

(3) An MCO may not add a credibility adjustment to a calculated MLR if the MLR reporting year experience has full credibility.

(4) If an MCO's experience has no credibility, it is presumed to meet or exceed the MLR calculation standards in this regulation.

(5) MCOs shall use the base credibility factors CMS publishes on an annual basis that are developed according to the methodology in 42 CFR §438.8(h)(4).

H. Eligibility Groups.

(1) MCOs shall aggregate data for all Medicaid eligibility groups covered under the contract with the Department.

(2) MCOs shall report, and the Department shall calculate, an annual MLR as described in this regulation separately for the childless adult population.

(3) The Department may require separate reporting and a separate MLR calculation for additional populations.

I. An MCO shall provide a remittance for an MLR reporting year if the MLR for that MLR reporting year does not meet the minimum MLR standard of 85 percent.

J. Newly Contracted MCOs.

(1) The Department may exclude an MCO that is newly contracted with the State from the requirements in this section for the first year of the MCO's operation.

(2) Newly contracted MCOs shall comply with the requirements in this section during the next MLR reporting year in which the MCO is in business with the State, even if the first year was not a full 12 months.

K. If the Department makes a retroactive change to the capitation payments for an MLR reporting year where the report has already been submitted to the Department, the MCO shall recalculate the MLR for all MLR reporting years affected by the change and submit a new report.

L. MCOs shall attest to the accuracy of the calculation of the MLR in accordance with requirements of this section when submitting its report to the Department.

M. Notice and Appeal.
(1) Within 30 days of its receipt of the notice of a remittance being due to the Department, an MCO may appeal the remittance as a sanction pursuant to COMAR 10.67.10.02.

(2) An MCO's appeal does not stay the obligation of the MCO to remit the amount owed to the Department.

.20 MCO Payment for Self-Referred, Emergency, Physician, and Hospital Services.

A. MCO Payment for Self-Referred Services.

(1) For undisputed claims that are submitted to the MCO within 6 months of the date of service, an MCO shall reimburse out-of-plan providers within 30 days for eligible services performed upon an enrollee who has self-referred:

(a) To a school-based health clinic pursuant to COMAR 10.67.06.28B, for services described in COMAR 10.67.07;

(b) For family planning services, pursuant to COMAR 10.67.06.28A;

(c) For an initial medical examination for an enrollee who is a child in State-supervised care, pursuant to Regulation .13F of this chapter;

(d) For one annual diagnostic and evaluation service visit for an enrollee diagnosed with human immunodeficiency virus or acquired immune deficiency syndrome (HIV/AIDS) pursuant to COMAR 10.67.06.28E;

(e) For obstetric and gynecologic care provided to a pregnant woman, under the circumstances described in COMAR 10.67.06.28C; and

(f) For an initial medical examination of a newborn when the:

   (i) Examination is performed in a hospital by an on-call physician; and

   (ii) MCO failed to provide for the service before the newborn's discharge from the hospital.

(2) An MCO shall reimburse out-of-plan providers to whom enrollees have self-referred for school-based services as described in COMAR 10.67.07.03 and family planning services including office visits (CPT codes 99201—99205 and 99211—99215), preventive medicine office visits (CPT codes 99383—99386 and 99393—99396), and all FDA-approved contraceptive devices, methods and supplies, at the established Medicaid rates.

(3) An MCO shall reimburse out-of-plan providers to whom enrollees have self-referred for an initial examination for a child in State-supervised care utilizing the Medicaid payment schedule for the following procedure codes:
CPT code Service Description

Initial Comprehensive Preventive Medicine (New Patient)

99381 Infant (younger than 1 year old)
99382 Early childhood (1—4 years old)
99383 Late childhood (5—11 years old)
99384 Adolescent (12—17 years old)

Periodic Comprehensive or Preventive Services (Established Patient)

99391 Infant (younger than 1 year old)
99392 Early childhood (1—4 years old)
99393 Late childhood (5—11 years old)
99394 Adolescent (12—17 years old)

(4) An MCO shall reimburse out-of-plan providers rendering pregnancy-related services, as described in COMAR 10.67.06.28C and K, at the Medicaid rate.

(5) An MCO shall reimburse out-of-plan providers performing the DES for HIV/AIDS at the Medicaid rate.

(6) An MCO may require enrollees to utilize in-plan providers for pharmacy and laboratory services ordered by out-of-plan providers of self-referral services, except as provided in §A(7) of this regulation.

(7) An MCO shall reimburse out-of-plan providers at the Medicaid rate for medically necessary pharmacy and laboratory services when the pharmacy or laboratory service is provided:

(a) In connection with a self-referred service specified in §A(1) of this regulation; and

(b) On-site by the out-of-plan provider at the same location that the self-referred service specified in §A(1) of this regulation was delivered to the MCO's enrollee.
(8) An MCO shall reimburse out-of-plan providers for renal dialysis services in a Medicare-certified facility, at least the Medicaid rate, regardless of whether or not the MCO's preauthorization was secured.

(9) An MCO shall reimburse out-of-plan providers under the circumstances described in COMAR 10.67.06.28G at a rate not less than the fee-for-service Medicaid rate for an initial medical examination of a newborn when the mother’s MCO fails to provide for the service before the newborn is discharged from the hospital.

(10) An MCO shall reimburse out-of-plan providers at the Medicaid fee-for-service rate for services performed in a free-standing birth center as described in COMAR 10.67.06.28.

B. MCO Payment for Emergency Services Provided at a Hospital. An MCO shall reimburse a hospital emergency facility and provider, which is not required to obtain prior authorization or approval for payment from an MCO in order to obtain reimbursement under this regulation, for:

(1) Health care services that meet the definition of emergency services in Health-General Article, §19-701, Annotated Code of Maryland;

(2) Medical screening services rendered to meet the requirements of the federal Emergency Medical Treatment and Active Labor Act;

(3) Medically necessary services if the MCO authorized, referred, or otherwise instructed the enrollee to use the emergency facility and the medically necessary services are related to the emergency condition; and

(4) Medically necessary services that relate to the condition presented and that are provided by the provider in the emergency facility to the enrollee if the MCO fails to provide 24-hour access to a physician.

C. MCO Payment to an Out-of-Network Federally Qualified Health Center for Services Immediately Required Due to an Unforseen Illness, Injury, or Condition.

(1) Effective October 1, 2010, an MCO shall reimburse an out-of-network federally qualified health center (FQHC) for services provided to an enrollee that are immediately required due to an unforeseen illness, injury, or condition if:

(a) The FQHC participates in the Medical Assistance Program;

(b) The FQHC does not have a contract with the MCO;

(c) The services are immediately required due to the enrollee’s unforeseen illness, injury, or condition;

(d) The emergent services are provided on site at the FQHC; and
(e) The FQHC has, before rendering services, verified with the enrollee’s primary care provider that the enrollee cannot be seen within a reasonable amount of time based on the severity of the enrollee’s condition.

(2) An MCO may require that the FQHC provide documentation that the FQHC has obtained the verification required under §C(1)(e) of this regulation. An MCO is not required to reimburse an out-of-network FQHC for emergent services provided to an enrollee if the FQHC fails to provide the documentation.

(3) An MCO may require that the FQHC provide documentation that services were required for the reasons identified under §C(1)(c) of this regulation. An MCO is not required to reimburse an out-of-network FQHC for emergent services provided to an enrollee if the FQHC fails to provide the documentation.

(4) The rate at which the MCO shall reimburse an out-of-network FQHC for services provided under §C(1) of this regulation shall be the rate identified in COMAR 10.67.04.21.

(5) For any reimbursement paid by an MCO under §C of this regulation, the Program shall pay the MCO the difference between the rates identified in COMAR 10.67.04.21 and COMAR 10.09.08.05-1.

D. MCO Payment for Provider Services.

(1) An MCO shall pass on to providers any MCO rate adjustment that is specified by the Department for a fee increase.

(2) For inpatient services performed in hospitals, an MCO shall pay all providers, regardless of the provider's contracting status, at least the Medicaid fee-for-service rate.

(3) The MCO may not be required to pay providers more than the Medicaid fee-for-service rate.

E. Payment for Hospital Services.

(1) An MCO shall reimburse Maryland hospital providers on the basis of rates approved by the Maryland Health Services Cost Review Commission (HSCRC).

(2) An MCO shall reimburse hospital administrative days at the Medicaid fee-for-service rate.

(3) Upon the direction of the Department, an MCO shall reduce payments by 20 percent to a hospital located in a contiguous state or in the District of Columbia for services rendered to its enrollees, if the hospital has failed to supply appropriate discharge data to the Health Services Cost Review Commission.
.21 Payments to Federally Qualified Health Centers (FQHC).

A. FQHC’s shall be reimbursed under the Alternative Payment System (APS).

   (1) The Department shall:

      (a) Pay the MCO a prospective payment based on encounter data; and

      (b) Reconcile the prospective amount paid to the MCO with the MCO's actual expenditure amount, after receipt of MCO encounter data; and

   (2) MCOs shall reimburse any contracted FQHC, the FQHC’s rate established in accordance with COMAR 10.09.08.05-1A.

B. For self-referred services described in Regulation .20 of this chapter, the MCO shall pay the FQHC’s usual rate in accordance with §A of this regulation, regardless of the FQHC’s contracted status with the MCO.

.22 Stop Loss Program.

A. An MCO shall qualify for protection under the Stop Loss Program if:

   (1) It was participating in HealthChoice as of April 1, 1999;

   (2) It was unable to self-insure or obtain a contract with another entity for Stop Loss reinsurance after July 1, 1999; and

   (3) By July 1, 1999, the MCO requested the Department to continue to provide Stop Loss Protection at a rate determined by the Department.

B. An MCO shall notify the Department that the acute inpatient hospital costs of an enrollee are expected to exceed the Stop Loss limit as soon as it knows that this is likely to occur.

C. Upon confirming eligibility for stop loss protection, the Department shall assume liability for reimbursement of 90 percent of accrued acute inpatient hospital charges according to established Medicaid fee-for-service rates for medically necessary acute inpatient treatment rendered to the enrollee above the stop loss limit throughout the remainder of the calendar year.

D. An MCO shall remain financially liable for reimbursing 10 percent of accrued acute inpatient hospital charges for medically necessary treatment rendered to the enrollee above the stop loss limit throughout the remainder of the calendar year, and shall maintain full responsibility for the provision of health care services to the enrollee.

E. At the beginning of the next calendar year, an MCO shall reassume full financial responsibility and full discretion for developing medical treatment plans for any enrollee who qualified for the Stop Loss Program.
F. The Department's Extended Stop Loss Period.

(1) If an inpatient enrollee remains hospitalized at the end of a calendar year and incurs acute hospital costs that exceed the Stop Loss limit into the following calendar year without interruption, the Department's stop loss period shall be extended until the end of that hospitalization.

(2) The MCO shall remain financially liable for costs up to the Stop Loss limit for enrollees who remain hospitalized in an acute setting at the end of the calendar year as specified in §§A and D of this regulation until the enrollee is discharged.

G. For calendar year 2001 and beyond, the MCO shall submit the MCO's Stop Loss Reinsurance Plan or Self-Insurance Plan to the Maryland Insurance Administration.

H. If an MCO chooses to have the Department provide its Stop Loss coverage, an adjustment will be made to the capitation amount the MCO is paid.

I. Upon the termination of the provider agreement between the enrollee's MCO and the Department, if an MCO has failed to fulfill its financial liability under this regulation, the Department shall assume responsibility only for costs that exceed the Stop Loss limit as specified in §C of this regulation.

.23 Marketing.

A. An MCO may not have face-to-face or telephone contact with a recipient, or otherwise solicit a recipient who is not an enrollee of the MCO, unless authorized by the Department or the recipient initiates the contact.

B. Subject to prior approval by the Department, an MCO may engage in marketing activities designed to make recipients aware of their availability, as well as any special services they offer. Unless they involve face-to-face solicitation, these marketing activities may involve campaigns using but not limited to:

(1) Television;

(2) Radio;

(3) Newspaper;

(4) Informational booths at public events;

(5) Billboards and other public displays;

(6) Addressee-blind informational mailings, but only when mailed to the MCO's entire service area;
(7) Magazines;

(8) Airborne marketing displays; or

(9) Public conveyances.

C. An MCO may not engage in any cold call marketing, including activities using or involving any of the following mechanisms:

(1) Direct marketing;

(2) Telephone solicitation;

(3) Door to door flyers;

(4) Email;

(5) Texting;

(6) Material or financial incentives of any kind, with the exception of advertising trinkets such as balloons or pens that have an acquisition cost of $5 or less; or

(7) Influencing enrollment in conjunction with the sale or offer of private insurance.

D. Standards for Departmental Approval of MCO Advertising.

(1) MCO advertising shall:

(a) Be based on documented fact;

(b) Identify all telephone numbers used that do not belong to the MCOs;

(c) Include the statement, "HealthChoice' is a program of the Maryland Department of Health"; and

(d) Be at a fifth grade reading level.

(2) MCO advertising may not:

(a) Be false or misleading;

(b) Ascribe to the MCO unique coverage or services that are otherwise required by State or federal law or regulation;

(c) Assert that a recipient shall enroll in the MCO in order to obtain benefits or in order not to lose benefits; or
(d) Assert that the MCO is endorsed by CMS, the federal or State government or similar entity.

.25 Enrollee Outreach Plan.

A. An MCO shall submit to the Department, on an annual basis, a written enrollee outreach plan that:

(1) Describes how the MCO intends to comply, in the upcoming year, with the outreach requirements of Health-General Article, §15-103(b)(9), Annotated Code of Maryland; and

(2) Provides evidence of the MCO's compliance during the previous year, with the outreach requirements of Health-General Article, §15-103(b)(9), Annotated Code of Maryland.

B. Submission Date.

(1) An MCO applicant shall submit its initial enrollee outreach plan, as part of its MCO application, as required by COMAR 10.09.64.06O.

(2) An MCO shall submit by December 1 an enrollee outreach plan, including the information specified in §A of this regulation, to be reviewed as part of the triennial audit performed by an external quality review organization (EQRO).

(3) For years in which the triennial EQRO audit is not performed, an MCO shall submit by April 30 any changes to the enrollee outreach plan, including the information specified in §A of this regulation.

.26 Time Period for Termination of Provider Agreement.

A. An MCO may terminate its provider agreement with the State as provided in §§B—D of this regulation.

B. The MCO shall provide written notification to the Department of the MCO's intent to terminate the MCO's provider agreement with the State for any given calendar year by the previous October 1.

C. An MCO that has previously terminated the provider agreement with the State and would like to sign a new agreement with the State, shall follow the application process as specified under COMAR 10.67.03.

D. The Department may waive the requirement under §B of this regulation if the Department determines that the circumstances warrant, including but not limited to a reduction in rates outside the normal rate setting process or an MCO exit from the program.
.27 Newborn Coordinator.

A. An MCO shall identify a newborn coordinator who shall be available to providers during the MCO's business hours as a contact for concerns related to eligibility and provision of services to newborns.

B. The newborn coordinator shall provide services for a newborn:

(1) Whose mother is enrolled in the MCO on the date of the newborn's birth; and

(2) Who is enrolled or who is autoassigned to the MCO after birth.

C. The newborn coordinator shall:

(1) Research and confirm the assignment of an eligible newborn to a managed care organization;

(2) Interface with the enrollment agent, the Department, the newborn coordinators of other MCOs, and the provider to resolve any eligibility issues involving multiple MCOs;

(3) Facilitate and confirm the selection of a primary care provider for an eligible newborn;

(4) Request an MCO ID card for a newborn when necessary;

(5) Make retroactive PCP enrollments when necessary;

(6) Facilitate the resolution of claims for services provided to an eligible newborn;

(7) Provide general guidance to providers and their office staff on newborn-related issues;

(8) Coordinate with ancillary care providers to facilitate appropriate delivery of care and payment of claims; and

(9) Coordinate and authorize in-network care when the newborn does not yet appear in EVS or the MCO's system, or out-of-network care when the MCO cannot offer an appropriate in-network provider.
Chapter 05 Maryland Medicaid Managed Care Program: Access

.01 Access Standards: Addressing Enrollees' Individualized Needs.

A. An MCO shall provide access to health care services and information in a manner that addresses the individualized needs of its enrollees, regardless of gender, sexual orientation, or gender identity, including, but not limited to, the delivery of services and information to enrollees:

   (1) In a culturally sensitive manner;

   (2) At an appropriate reading comprehension level;

   (3) In the prevalent non-English languages identified by the State; and

   (4) In a manner that accommodates individuals with disabilities consistent with the requirements of the Americans with Disabilities Act of 1990, P.L. 101-330, 42 U.S.C. §12101 et seq., and regulations promulgated under it.

B. Special Access.

   (1) An MCO shall notify enrollees of the following services and make them available free of charge to the enrollee:

      (a) Written materials in the prevalent non-English languages identified by the State;

      (b) Written materials in alternative formats;

      (c) Oral interpretation services in all non-English languages; and

      (d) Auxiliary aids and services, such as:

          (i) Teletypewriter/Telecommunication Device for the Deaf (TTY/TDD); and

          (ii) American Sign Language.

   (2) An MCO shall include taglines with its written materials that:

      (a) Explain the availability of written translation or oral interpretation to understand the information provided; and

      (b) Provide the toll-free and TTY/TDD telephone number of the MCO’s customer service unit.

   (3) An MCO shall format taglines included with written materials in the following manner:
(a) In a font size no smaller than 18 point; and
(b) In the prevalent non-English languages identified by the State.

C. Written Materials. An MCO shall provide all its written materials in the following manner:

(1) Using language and a format that is easily understood;
(2) In a font size no smaller than 12 point;
(3) Available in alternative formats and through the provision of auxiliary aids and services; and
(4) Available in an appropriate manner that takes into consideration the special needs of enrollees or potential enrollees with disabilities or limited English proficiency.

D. An MCO may provide enrollee information electronically so long as all of the following requirements are met:

(1) The format is readily accessible;
(2) The information is placed in a location on the MCO’s website that is prominent and readily accessible;
(3) The information is provided in an electronic form which can be electronically retained and printed;
(4) The information is consistent with the content and language requirements of this section;
(5) The enrollee is informed that the information is available in paper form without charge upon request; and
(6) Should the enrollee request it, the MCO provides the information in paper form within 5 business days.


A. An MCO shall inform and educate its enrollees about:

(1) Basic information about the MCO;
(2) The availability of health care services and how to access them;
(3) The definitions of managed care terminology in accordance with 42 CFR 438.10(c)(4)(i); and
(4) Enrollee's rights and responsibilities in the MCO, and that the exercise of those rights does not adversely affect the way the MCO, its providers, or the Department treats the enrollee.

B. An MCO shall, at the time of enrollment, and anytime upon request, furnish each enrollee with a copy of the MCO’s enrollee handbook that includes all language in the template provided by the Department and the following current information:

(1) The enrollee's rights and responsibilities in the MCO as described in 42 CFR §438.100(b)(1), as amended;

(2) Information on how to access urgent care and emergency care services, including:

(a) What constitutes an emergency medical condition and emergency services;

(b) The following facts:

   (i) Prior authorization is not required for these services; and

   (ii) The enrollee has a right to use any hospital or other setting for emergency care;

(3) The services included in the MCO's benefits package, including optional benefits provided by the MCO;

(4) How and where to access any benefits provided by the State, including any cost sharing, and how transportation is provided;

(5) The amount, duration, and scope of benefits available in sufficient detail to ensure that enrollees understand the benefits to which they are entitled;

(6) The availability of behavioral health services that are not included in the MCO’s benefits package, and how to access these services;

(7) Information on the availability of self-referral services as well as any restrictions on the enrollee’s freedom of choice among network providers;

(8) Information about how enrollees may obtain benefits from out-of-network providers;

(9) Any policies and procedures necessary to facilitate accessing needed services in compliance with the Maryland Medicaid Managed Care Program, including any requirements for service authorizations or referrals for specialty care and for other benefits not furnished by the enrollee’s primary care provider;

(10) Information about the availability of EPSDT, prenatal care, family planning, and other wellness services, including education programs;
(11) A statement that the MCO cannot require an enrollee to obtain a referral before choosing a family planning provider;

(12) The process of selecting and changing the enrollee’s primary care provider;

(13) A description of any benefits the MCO offers in addition to those required by the Maryland Medicaid Managed Care Program, including applicable terms and conditions for accessing those benefits;

(14) Information on how to access auxiliary aids and services, including additional information in alternative formats or languages;

(15) The toll-free telephone number for member services, medical management, and any other unit providing services directly to enrollees, including:

(a) A description of each unit and number;

(b) An explanation of how the phone numbers can be used to obtain information and assistance; and

(c) An explanation of the MCO’s internal grievance procedure.

(16) Information regarding the importance of scheduling and maintaining appointments for preventive services;

(17) If applicable, a list of services that are not covered by the MCO because of moral or religious objections, and a statement that informs the enrollee that the State will provide information on how and where to obtain these services;

(18) The rule pertaining to poststabilization care services, as set forth in Regulation .08G of this chapter;

(19) Appeal, grievance, and fair hearing procedures and time frames that include the following:

(a) The right to a State fair hearing, including the method for obtaining a hearing and the rules that govern representation at the hearing;

(b) The right to file appeals and grievances;

(c) The requirements and time frames for filing an appeal or grievance;

(d) The availability of assistance in the filing process;

(e) The toll-free numbers that the enrollee may use to file an appeal or grievance by phone;
(f) The fact that, if requested by the enrollee, the benefits will continue if the enrollee files an appeal or a request for a State fair hearing within the time frames specified for filing; and

(g) That the enrollee may be required to pay the cost of the services furnished while the appeal is pending, if the final decision is adverse to the enrollee;

(20) Any appeal rights the State chooses to make available to providers;

(21) Advanced directives as set forth in 42 CFR §438.3(j)(1), as amended;

(22) Information on how to report suspected fraud or abuse;

(23) Additional information that is available upon request, including the following:

   (a) Information on the structure and operation of the MCO; and

   (b) Physician incentive plans.

(24) Information on how to access or obtain the MCO’s provider directory.

C. Provider Directory.

   (1) An MCO shall provide enrollees with information regarding their provider networks including:

      (a) Its primary care service locations;

      (b) A listing of the MCO’s hospital providers, of both inpatient and outpatient services, in the enrollee’s county, their addresses, and services provided;

      (c) A listing of the MCO’s pharmacy providers in the enrollee’s county and their addresses; and

      (d) A listing of the individual practitioners who are the MCO’s primary and specialty care providers in the enrollee’s county, grouped by medical specialty, giving:

         (i) Name;

         (ii) Address;

         (iii) Practice location or locations;

         (iv) Telephone number or numbers;

         (v) Website URL, as appropriate;
(vi) Any group affiliation, as appropriate;

(vii) Cultural and linguistic capabilities, including languages offered by the provider or a skilled medical interpreter at the provider’s offices, American Sign Language interpretation, and whether the provider has completed cultural competence training;

(viii) An indication of whether the provider’s office or facility has accommodations for physical disabilities, including offices, exam room or rooms and equipment;

(ix) An indication of whether or not the provider is accepting new patients;

(x) An indication of the age range of patients accepted or whether there is no age limit; and

(xi) If applicable, how access to the provider is otherwise limited.

(2) Upon request by an enrollee, an MCO shall furnish a paper copy of the provider directory.

D. An MCO shall notify all enrollees of their right to request and obtain the information listed in §§B and C of this regulation at least once a year.

E. The Department may consider the information listed in §§B and C of this regulation to be provided if the MCO:

(1) Mails a printed copy of the information to the enrollee’s mailing address;

(2) Provides the information by email after obtaining the enrollee’s agreement to receive the information by email;

(3) Posts the information on the MCO’s website and advises the enrollee in paper or electronic form that the information is available on the internet and includes the applicable internet address, provided that enrollees with disabilities who cannot access this information online are provided auxiliary aids and services upon request at no cost; or

(4) Provides the information by any other method that can reasonably be expected to result in the enrollee receiving that information.

F. An MCO shall update its online provider directory no later than 30 days after the MCO receives updated provider information.

G. An MCO shall update its paper directory on a monthly basis.

H. An MCO shall make provider directories available on its website in a machine-readable file and format as specified by the Secretary for the U.S. Department of Health and Human Services.
.03 Access Standards: Outreach.

A. An MCO is responsible for delivering needed health care services even when the enrollee is difficult to reach or misses appointments.

B. The assistance of local health departments in contacting and bringing into care enrollees who are difficult to reach or miss appointments is available for the specific categories of enrollees identified in this regulation, but only after the MCO has made documented attempts to contact and bring into care an enrollee who is difficult to reach or misses appointments before seeking the assistance of the local health department.

C. Adults.

   (1) An MCO shall, before referring the enrollee to the local health department, make documented attempts to ensure that follow-up appointments are scheduled in accordance with the enrollee's treatment plan by attempting a variety of contact methods, which may include:

      (a) Written correspondence;

      (b) Telephone contact; and

      (c) Face-to-face contact.

   (2) If the enrollee, due to impaired cognitive ability or psychosocial problems such as homelessness or other conditions, can be expected to have difficulty understanding the importance of treatment instructions or difficulty navigating the health care system, the MCO shall, after exhausting its best efforts to contact and bring into care the enrollee in accordance with §C(1) of this regulation, make, or ensure that the enrollee's provider makes, a written referral to the local health department for its assistance within 10 business days of whichever first occurs:

      (a) The third consecutive missed appointment; or

      (b) The MCO or the enrollee's provider identifies the enrollee's repeated noncompliance with a regimen of care.

D. Child Younger than 2 Years Old Needing EPSDT Screening Services.

   (1) An MCO shall ensure that appointments are scheduled in accordance with the EPSDT periodicity schedule or within 30 days of the MCO's receipt of the health risk assessment, whichever is less.

   (2) If the enrollee fails to keep the appointment, the MCO shall ensure that a second appointment is scheduled within 30 days.
(3) If the enrollee misses the second appointment, a third appointment shall be scheduled within 30 days.

(4) For each scheduled appointment, the MCO shall:

(a) Provide written notice to the enrollee's parent, guardian, or caretaker of the appointment dates; and

(b) Attempt to notify the enrollee's parent, guardian, or caretaker of the appointment dates by telephone.

(5) If the enrollee misses the second appointment in a row, after the MCO has made the notification attempts required by §C(1) of this regulation, the MCO shall, within 10 business days, make, or ensure that the enrollee's provider makes, a written referral to the local health department for its assistance in bringing the enrollee into care.

(6) After referral to the local health department, the MCO shall continue to work collaboratively with the local health department to bring the enrollee into care until the enrollee comes back into compliance with the EPSDT periodicity schedule.

E. Child Younger than 21 Years Old Needing Follow-up Treatment.

(1) An MCO shall ensure that an appointment for follow-up care is scheduled at a time interval appropriate to the enrollee's diagnosed condition.

(2) If the enrollee fails to keep the appointment, the MCO shall reschedule the appointment for the enrollee to be seen within 30 days.

(3) For each scheduled appointment, the MCO shall:

(a) Provide written notice to the enrollee, or to the enrollee's parent, guardian, or caretaker, as appropriate, of the appointment dates by mail; and

(b) Attempt to notify the enrollee, or the enrollee's parent, guardian, or caretaker, as appropriate, of the appointment dates by telephone.

(4) If the enrollee misses the second consecutive follow-up appointment after the MCO has made the notification attempts required by §C(1) of this regulation, the MCO shall, within 10 business days, make, or ensure that the enrollee's provider makes, a written referral to the local health department for its assistance in bringing the enrollee into care.

(5) After referral to the local health department, the MCO shall work collaboratively with the local health department to bring the enrollee into care.

F. Pregnant or Postpartum Woman Needing Prenatal or Postpartum Care.
(1) Initial Visit. An MCO shall schedule an initial visit for the pregnant or postpartum enrollee to be seen within 10 days of her request for an appointment. If she fails to appear for the appointment, the MCO shall reschedule in a timely manner appropriate to her medical condition.

(2) Follow-Up Appointments. After the enrollee has completed an initial visit that includes a comprehensive history, physical exam, and completion of the Maryland Prenatal Risk Assessment, the MCO shall ensure that appointments are scheduled for the enrollee in compliance with the periodicity schedule of the ACOG guidelines. If the enrollee fails to appear for a scheduled appointment, the MCO shall ensure that the appointment is rescheduled for the enrollee to be seen within 10 days.

(3) For each scheduled appointment, the MCO shall:

(a) Provide written notice to the enrollee of the appointment dates; and

(b) Attempt to notify the enrollee of the appointment dates by telephone.

(4) After making the attempts specified in §F(3) of this regulation, if the MCO is unable to bring the enrollee into care within 30 days of the first missed appointment, the MCO shall, within 10 days of the last missed appointment, make, or ensure that the enrollee's provider makes, a written referral to the local health department for its assistance in bringing the enrollee into care.

(5) After referral to the local health department, the MCO shall work collaboratively with the local health department to bring the patient into care, until the enrollee comes back in compliance with the ACOG periodicity schedule.

.04 Access Standards: Information for Providers.

A. An MCO shall develop and make available either electronically or by hard copy to all of its PCP and specialty care providers a Medicaid requirements manual, including periodic updates as appropriate, and shall:

(1) Before distribution, file a copy of its manual with the Department for review;

(2) Include in its manual the information necessary to facilitate the providers' full compliance with federal and State Medicaid requirements, including information on:

(a) Medicaid statutes and regulations;

(b) The benefits package, including optional benefits;

(c) Access requirements, which, at a minimum, comply with the requirements of this chapter;
(d) Quality requirements, which shall, at a minimum, comply with the requirements of COMAR 10.67.04.03;

(e) Continuity of care requirements; and

(f) Requirements for referral to specialist, ancillary, and other providers as necessary to provide the full range of medically necessary services that are covered by the Maryland Medicaid Managed Care Program;

(3) Inform the MCO’s primary and specialty care providers of their responsibility to provide or arrange for medically necessary accessible health care services that are continuous, comprehensive, and coordinated for each enrollee, including:

(a) Preventive health services;

(b) Primary acute medical care;

(c) Chronic medical care;

(d) Consultation, referral, and follow-up in areas including medical specialties and child dental care;

(e) Referral for ancillary and support-related services including but not limited to:

(i) Drug therapies;

(ii) Diagnostic tests;

(iii) Medical supplies;

(iv) Durable medical equipment; and

(v) Case management when appropriate for complex conditions;

(f) 24-hour per day, 7-day per week provider coverage for medically necessary services;

(g) Maintenance of a medical record, including records of referral arrangements and outcomes of those referrals; and

(h) Detection of mental health problems or substance use disorder during routine or follow-up screening, to be treated either through the MCO or referred to the behavioral health ASO for services; and

(4) Inform the providers of the following enrollee appeal, grievance, and fair hearing procedures and time frames:
(a) The enrollee's right to a State fair hearing, how to obtain a hearing, and representation rules at a hearing;

(b) The enrollee's right to file appeals and grievances, and the enrollee's requirements and time frames for filing;

(c) The availability of assistance in filing;

(d) The toll-free numbers to file verbal appeals and grievances;

(e) The enrollee's right to request continuation of benefits during an appeal or State fair hearing filing, and that if the MCO action is upheld in a hearing, the enrollee may be liable for the cost of any continued benefits; and

(f) The provider's right to appeal, on the enrollee's behalf, the failure of the MCO to cover a service.

B. An MCO shall ensure that its PCP and specialty care providers receive adequate information regarding the Medicaid Program to facilitate full compliance with all federal and State Medicaid requirements. The MCO shall:

(1) Ensure that each PCP and specialty care provider receives, at the time they enter into a contract, a copy of the MCO's Medicaid requirements manual, and any other pertinent information; and

(2) Provide each PCP and specialty care provider, on an ongoing basis as appropriate, with periodic updates of the materials required to be provided under §B(1) of this regulation.

C. An MCO shall provide to each PCP an updated list of the PCP's assigned enrollees monthly.

.05 Access Standards: PCPs and MCO's Provider Network.

A. Primary Care Provider (PCP).

(1) An MCO shall assign each enrollee to a primary care provider who is:

(a) Chosen by the enrollee from the MCO's panel of qualified providers; or

(b) Chosen by the MCO from its panel of qualified providers if the enrollee has failed to choose a PCP.

(2) An enrollee may request a change of PCP at any time if the PCP is within the recipient's current MCO's panel of providers.
(3) With respect to enrollees younger than 21 years old, an MCO shall assign the enrollee to a PCP who is certified by the EPSDT program, unless the enrollee or the enrollee's parent, guardian, or caretaker, as appropriate, specifically requests assignment to a PCP who is not EPSDT-certified.

(4) If the enrollee’s parent, guardian, or caretaker, as appropriate, chooses a non-EPSDT certified PCP in accordance to §A(3) of this regulation, within 30 days of enrollment, the MCO shall:

(a) Notify the parent, guardian, or caretaker, by letter, that a non-EPSDT certified PCP has been chosen; and

(b) Include in the notification an explanation of the:

(i) EPSDT preventive screening services to which an enrollee is entitled according to the EPSDT periodicity schedule;

(ii) Importance of accessing the EPSDT preventive screening services; and

(iii) Process for requesting a change to an EPSDT-certified PCP to obtain preventive screening services.

(5) An MCO may include, as appropriate, any of the following practitioners to serve as the primary care provider for an enrollee:

(a) General practitioner;

(b) Family practitioner;

(c) Internist;

(d) Pediatrician;

(e) OB/GYN;

(f) Physician assistant;

(g) Certified nurse midwife;

(h) Nurse practitioner certified in any of the following areas of specialization:

(i) Adult;

(ii) Pediatric;

(iii) Geriatric;
(iv) OB/GYN;
(v) School nurse; or
(vi) Family; and

(i) A physician practicing in a specialty area other than those enumerated in §A(5)(b)—(e) of this regulation.

(6) The enrollee's designated primary care provider (PCP) is the enrollee's primary coordinator of care.

(7) For female enrollees, if the enrollee's PCP is not a women's health specialist, the MCO shall provide direct access, without the need for a referral, to a women's health specialist within the MCO's network for covered services necessary to provide women's routine and preventive health care services.

B. Adequacy of Provider Network.

(1) An MCO shall develop and maintain a complete network of adult and pediatric primary care, specialty care, ancillary service, vision, pharmacy, home health, and any other providers adequate to deliver the full scope of benefits as required by this chapter and COMAR 10.67.06.

(2) An MCO shall clearly define and specify referral requirements to specialty and other providers.

(3) An MCO shall require the PCP to maintain records of referral arrangements, and the feedback and outcomes of those referrals, within each enrollee's medical records.

(4) An MCO shall maintain a list of its proposed and existing subcontracts with health care providers who are necessary to fulfill the MCO's service delivery obligations.

(5) An MCO shall provide a list of its subcontractor providers to the Department.

(6) An MCO shall ensure services are delivered in a culturally competent manner to all enrollees, including enrollees:

(a) With limited English proficiency;

(b) With diverse cultural and ethnic backgrounds; and

(c) Of all genders, sexual orientations, and gender identities.

(7) For enrollees with physical or mental disabilities, an MCO shall ensure its network providers provide:
(a) Physical access;
(b) Reasonable accommodation; and
(c) Accessible equipment.

(8) Capacity.

(a) MCOs shall ensure adequate capacity and services, in compliance with 42 CFR §438.206(b)(1)(i), as amended.

(b) The Department shall assess the MCO's provider network and determine its capacity to serve waiver-eligible recipients in each local access area in its service area.

(c) Unless the MCO can establish to the Department's satisfaction the adequacy of a higher ratio, the Department shall determine the MCO's capacity with respect to any local access area by assuming that in-plan individual practitioners, based on full-time equivalency, will be assigned no more than the number of enrollees that is consistent with a 200:1 ratio of enrollee to practitioner in the local access area.

(d) The Department may not approve an enrollee-to-PCP ratio that is higher than 2,000:1.

(9) To ensure compliance with the timely access requirements in Regulation .07 of this chapter, an MCO shall:

(a) Establish mechanisms to ensure that network providers comply with access requirements;

(b) Monitor regularly to determine compliance; and

(c) Take corrective action if there is a failure to comply.

.05-1 Access Standards: Specialty Provider Network.

A. Standards and Regions.

(1) The Department shall review an MCO’s specialty provider network for MCO’s overall network as defined in this regulation.

(2) Overall Network Standards.

(a) An MCO shall meet either the time or distance standard set forth in Regulation .06A of this chapter for core, major, and pediatric specialties.

(b) The 8 core specialties are:
(i) Cardiology;
(ii) Otolaryngology (ENT);
(iii) Gastroenterology;
(iv) Neurology;
(v) Ophthalmology;
(vi) Orthopedics;
(vii) Surgery; and
(viii) Urology.

(c) The 6 major specialties are:
(i) Allergy and immunology;
(ii) Dermatology;
(iii) Endocrinology;
(iv) Infectious disease;
(v) Nephrology; and
(vi) Pulmonology.

(d) The 4 pediatric subspecialties are:
(i) Cardiology;
(ii) Gastroenterology;
(iii) Neurology; and
(iv) Surgery.

B. If the Department determines that an MCO does not meet the requirements specified in §A(2)(b)–(d) of this regulation, the MCO may provide additional information to support the adequacy of the MCO's specialty network before any action is taken by the Department.

C. If an MCO fails to meet the requirements established by this regulation, the Department may suspend the automatic assignment to the MCO of recipients who live in the affected local
access area. A suspension of automatic assignments may affect the MCO’s ability to qualify for the Statewide supplemental payments specified under COMAR 10.67.04.03-1.

.06 Geographical Access.

A. Except as provided in §C of this regulation, an MCO shall develop and maintain a provider network that meets the following time and distance standards:

(1) For adult and pediatric primary care, pharmacy, diagnostic laboratory and x-ray, and gynecology:
   (a) In urban areas, within 15 minutes or 10 miles;
   (b) In suburban areas, within 30 minutes or 20 miles; and
   (c) In rural areas, within 40 minutes or 30 miles;

(2) For prenatal care, as defined in §B of this regulation:
   (a) In urban areas, within 15 minutes or 10 miles;
   (b) In suburban areas, within 30 minutes or 20 miles; and
   (c) In rural areas, within 90 minutes or 75 miles;

(3) For acute inpatient hospitals:
   (a) In urban areas, within 20 minutes or 10 miles;
   (b) In suburban areas, within 45 minutes or 30 miles; and
   (c) In rural areas, within 75 minutes or 60 miles;

(4) For core specialty types, as defined in Regulation .05-1A(2)(b) of this chapter:
   (a) In urban areas, within 30 minutes or 15 miles;
   (b) In suburban areas, within 60 minutes or 45 miles; and
   (c) In rural areas, within 90 minutes or 75 miles;

(5) For major specialty types, as defined in Regulation .05-1A(2)(c) of this chapter:
   (a) In urban areas, within 30 minutes or 15 miles;
   (b) In suburban areas, within 80 minutes or 60 miles; and
(c) In rural areas, within 110 minutes or 90 miles; and

(6) For pediatric subspecialty types, as defined in Regulation .05-1A(2)(d) of this chapter:

(a) In urban areas, within 30 minutes or 15 miles;

(b) In suburban areas, within 80 minutes or 60 miles; and

(c) In rural areas, within 250 minutes or 200 miles.

B. Prenatal Care Providers. For the purposes of provider network adequacy, prenatal care providers may include, but are not limited to:

(1) Obstetricians;

(2) Certified nurse midwives; and

(3) Family practitioners who provide prenatal care and perform deliveries.

C. If an MCO can otherwise demonstrate to the Department's satisfaction the adequacy of its provider network notwithstanding its inability to meet the requirements of §A of this regulation, the Department may, in its discretion, approve the network if special circumstances exist which, considered along with the overall strength of the MCO's network, establish that the Department's approval of the network will enhance recipients' overall access to quality health care services in the area to be served.


<table>
<thead>
<tr>
<th>Local Access Area</th>
<th>Zip Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allegany</td>
<td>21501, 21502, 21503, 21504, 21505, 21521, 21523, 21524, 21528, 21529, 21530, 21532, 21539, 21540, 21542, 21543, 21545, 21546, 21555, 21556, 21557, 21560, 21562, 21766</td>
</tr>
<tr>
<td>Anne Arundel North</td>
<td>20701, 20724, 20755, 21056, 21060, 21061, 21076, 21077, 21090, 21108, 21113, 21122, 21123, 21144, 21240</td>
</tr>
<tr>
<td>Anne Arundel South</td>
<td>20711, 20733, 20751, 20764, 20765, 20776, 20778, 20779, 21012, 21032, 21035, 21037, 21054, 21106, 21114, 21140, 21146, 21401, 21402, 21403, 21404, 21405, 21409</td>
</tr>
<tr>
<td>Baltimore City SE/Dundalk</td>
<td>21052, 21219, 21222, 21224, 21281</td>
</tr>
<tr>
<td>Location</td>
<td>Zip Codes</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Baltimore City East</td>
<td>21202, 21203, 21205, 21213, 21231, 21287</td>
</tr>
<tr>
<td>Baltimore City North Central</td>
<td>21210, 21211, 21218</td>
</tr>
<tr>
<td>Baltimore City Northeast</td>
<td>21206, 21212, 21214, 21239</td>
</tr>
<tr>
<td>Baltimore City Northwest</td>
<td>21208, 21209, 21215, 21270</td>
</tr>
<tr>
<td>Baltimore City South</td>
<td>21225, 21226, 21230</td>
</tr>
<tr>
<td>Baltimore City West</td>
<td>21201, 21216, 21217, 21223</td>
</tr>
<tr>
<td>Baltimore County East</td>
<td>21021, 21022, 21027, 21051, 21087, 21128, 21156, 21162, 21220, 21221, 21236, 21237</td>
</tr>
<tr>
<td>Baltimore County North</td>
<td>21013, 21023, 21030, 21031, 21053, 21057, 21082, 21092, 21093, 21094, 21105, 21111, 21120, 21131, 21139, 21152, 21153, 21155, 21161, 21204, 21234, 21284, 21285, 21286</td>
</tr>
<tr>
<td>Baltimore County Northwest</td>
<td>21055, 21071, 21117, 21133, 21136, 21163, 21207, 21244, 21282</td>
</tr>
<tr>
<td>Baltimore County Southwest</td>
<td>21227, 21228, 21229</td>
</tr>
<tr>
<td>Calvert</td>
<td>20610, 20615, 20629, 20639, 20657, 20676, 20678, 20685, 20688, 20689, 20714, 20732, 20736, 20754, 20758</td>
</tr>
<tr>
<td>Caroline</td>
<td>21609, 21629, 21632, 21636, 21639, 21640, 21641, 21649, 21655, 21660, 21670</td>
</tr>
<tr>
<td>Carroll</td>
<td>21020, 21048, 21074, 21088, 21102, 21104, 21157, 21158, 21757, 21771, 21776, 21784, 21787, 21791</td>
</tr>
<tr>
<td>Cecil</td>
<td>21901, 21902, 21903, 21904, 21911, 21912, 21913, 21914, 21915, 21916, 21917, 21918, 21919, 21920, 21921, 21922, 21930</td>
</tr>
<tr>
<td>County</td>
<td>Zip Codes</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------------------------</td>
</tr>
<tr>
<td>Charles</td>
<td>20601, 20602, 20603, 20604, 20611, 20612, 20614, 20615, 20616, 20617, 20622, 20625, 20632, 20637, 20640, 20643, 20645, 20646, 20658, 20661, 20662, 20664, 20675, 20677, 20682, 20693, 20695</td>
</tr>
<tr>
<td>Dorchester</td>
<td>21613, 21622, 21626, 21627, 21631, 21634, 21643, 21648, 21659, 21664, 21669, 21672, 21675, 21677, 21835, 21869</td>
</tr>
<tr>
<td>Frederick</td>
<td>21701, 21702, 21703, 21704, 21705, 21710, 21714, 21716, 21717, 21718, 21727, 21754, 21755, 21758, 21759, 21762, 21769, 21770, 21773, 21774, 21775, 21777, 21778, 21780, 21788, 21790, 21792, 21793, 21798</td>
</tr>
<tr>
<td>Garrett</td>
<td>21520, 21522, 21531, 21536, 21538, 21541, 21550, 21561</td>
</tr>
<tr>
<td>Harford East</td>
<td>21001, 21005, 21017, 21018, 21024, 21028, 21034, 21078, 21130</td>
</tr>
<tr>
<td>Harford West</td>
<td>21009, 21010, 21014, 21015, 21040, 21047, 21050, 21084, 21085, 21101, 21132, 21154, 21160</td>
</tr>
<tr>
<td>Howard County</td>
<td>20723, 20759, 20763, 20777, 20794, 21029, 21036, 21041, 21042, 21043, 21044, 21045, 21046, 21150, 21723, 21737, 21738, 21765, 21794, 21797</td>
</tr>
<tr>
<td>Kent</td>
<td>21610, 21620, 21635, 21637, 21645, 21650, 21661, 21667, 21678</td>
</tr>
<tr>
<td>Montgomery Mid-County</td>
<td>20812, 20813, 20814, 20815, 20816, 20817, 20818, 20824, 20825, 20827, 20830, 20832, 20833, 20848, 20849, 20850, 20851, 20852, 20853, 20854, 20855, 20857, 20859, 20889, 20891, 20892, 20895, 20896</td>
</tr>
<tr>
<td>Montgomery North</td>
<td>20837, 20838, 20839, 20841, 20842, 20847, 20871, 20872, 20874, 20875, 20876, 20877, 20878, 20879, 20880, 20882, 20883, 20884, 20885, 20886, 20898, 20997</td>
</tr>
<tr>
<td>Montgomery - Silver Spring</td>
<td>20860, 20861, 20862, 20866, 20868, 20901, 20902, 20903, 20904, 20905, 20906, 20907, 20908, 20910, 20911, 20912, 20913, 20914, 20915, 20916, 20918, 20990</td>
</tr>
<tr>
<td>Prince George's Northeast</td>
<td>20704, 20705, 20707, 20708, 20709, 20715, 20716, 20717, 20718, 20719, 20720, 20721, 20725, 20726, 20769</td>
</tr>
<tr>
<td>Prince George's Northwest</td>
<td>20703, 20706, 20710, 20712, 20722, 20731, 20737, 20738, 20740, 20741, 20742, 20743, 20768, 20770, 20771, 20780, 20781, 20782, 20783, 20784, 20785, 20787, 20788, 20789, 20791, 20792, 20797, 20799</td>
</tr>
<tr>
<td>Prince George's Southeast</td>
<td>20608, 20613, 20623, 20735, 20762, 20772, 20773, 20774, 20775</td>
</tr>
</tbody>
</table>
E. For purposes of this regulation:

(1) Urban enrollment area includes Baltimore City;

(2) Rural enrollment counties include:

(a) Allegany;

(b) Calvert;

(c) Caroline;

(d) Cecil;

(e) Charles;

(f) Dorchester;
(g) Frederick;
(h) Garrett;
(i) Kent;
(j) Queen Anne's;
(k) Saint Mary's;
(l) Somerset;
(m) Talbot;
(n) Washington;
(o) Wicomico; and
(p) Worcester; and
(3) Suburban enrollment counties include:

(a) Baltimore County;
(b) Anne Arundel;
(c) Carroll;
(d) Harford;
(e) Howard;
(f) Montgomery; and
(g) Prince George’s.


A. Appointments.

(1) New Enrollees: Initial Appointment.

(a) On its receipt and review of the health service needs information of a new enrollee, an MCO shall take appropriate action to ensure that the new enrollee who needs special or immediate health care services, as identified by the health service needs information, receives them in a timely manner.
(b) Unless the new enrollee is assigned to a PCP who was the enrollee’s established provider of care immediately before the enrollee’s enrollment, and, consistent with any applicable periodicity schedule, the PCP concludes that no immediate initial appointment is necessary:

(i) Unless a shorter time frame otherwise applies, the MCO shall ensure that a new enrollee's initial appointment is scheduled to occur within 90 days of the date of enrollment;

(ii) Unless the PCP confirms that the enrollee has elected to continue prenatal care with her established provider pursuant to COMAR 10.67.06.28C, the MCO shall ensure that an initial prenatal appointment is scheduled to occur within 10 days of the date that the MCO receives the enrollee's completed health risk assessment, or within 10 days of the enrollee's request for an appointment, whichever is sooner;

(iii) If the new enrollee is a person requesting family planning services, the MCO shall ensure that an initial appointment is scheduled to occur within 10 days of the date of the enrollee's request for an appointment; or

(iv) If the new enrollee is identified to be at high risk by the health service needs information form, the MCO shall ensure that an initial appointment is scheduled to occur within 15 business days of the MCO’s receipt of the enrollee’s completed health risk assessment.

(2) Required Notice to Enrollees of Wellness Services.

(a) An MCO shall notify its enrollees in writing of their due dates for obtaining wellness services, including but not limited to immunizations and examinations, in a timely manner.

(b) An MCO shall perform the notice required in §A(2)(a) of this regulation within 90 days of a new enrollee's enrollment.

(3) Appointment Guidelines.

(a) An MCO shall develop specific guidelines that define how requests for appointments are arranged, which shall include a policy that:

(i) On request, all family members needing appointments will be given appointment times that are approximately concurrent or consecutive, whenever practicable, to facilitate the enrollees' transportation to and from their appointments; and

(ii) When needed, enrollees will be afforded assistance in securing transportation to and from appointments, which shall include, when appropriate, contacting the local transportation grantee agency on behalf of the enrollee for the purpose of securing the enrollee's access to these services.
(b) An MCO shall have procedures that result in an interval between the enrollee's request for an appointment and the actual appointment time being consistent with the following standards:

   (i) When §A(3)(b)(i) of this regulation does not apply, well-child assessments shall be scheduled to be completed within 30 days of the request for an appointment;

   (ii) Initial assessments of pregnant and postpartum women and individuals requesting family planning services shall be scheduled to be completed within 10 business days of the request for an appointment;

   (iii) Individuals requesting urgent care shall be scheduled to be seen within 48 hours of the request;

   (iv) Requests for routine and preventative primary care appointments shall be scheduled to be performed within 30 days of the request;

   (v) Requests for routine specialist follow-up appointments shall be scheduled to be performed within 30 days of the initial authorization from the enrollee's primary care provider, or sooner as deemed necessary by the primary care provider, whose office staff shall make the appointment directly with the specialist's office;

   (vi) At the discretion of the newborn's PCP, the initial visit for newborns shall be scheduled to be performed within 14 days of discharge from the hospital if no home visit has occurred;

   (vii) If a home visit has been provided, the initial visit for newborns shall be scheduled to be performed, at the discretion of the newborn's PCP, within 30 days of discharge from the hospital; and

   (viii) Requests for regular optometry, lab, and X-ray appointments shall be scheduled to be performed within 30 days of the request, and within 48 hours of the request for urgent care.

B. An MCO shall respond in a timely manner to its enrollees' needs and requests, as follows:

   (1) If the enrollee arrives early or on time for a scheduled appointment, waiting time to be seen for a regular office visit may not exceed 1 hour after the scheduled appointment time;

   (2) An MCO representative may not leave an enrollee's telephone call on hold for more than 10 minutes; and

   (3) An MCO representative shall respond to patient inquiries as to whether or not to use emergency facilities within 30 minutes.

C. Hours of Access for Clinical Services.
(1) An MCO shall establish, or require its subcontractors to establish, a reasonable schedule of operating hours during which its service delivery sites are open to the MCO's enrollees as follows:

(a) For the MCO's employee and subcontractor providers who are individual practitioners, operating hours shall be at least 20 hours per week and at least 3 days per week;

(b) For subcontractors who have contracted with the MCO as a group practice or facility, the operating hours shall be at least 35 hours per week;

(c) The distribution of the hours of service shall be consistent with enrollee utilization patterns, but is otherwise at the discretion of the MCO or its subcontractor; and

(d) The operating hours may not be less than:

(i) The hours of operation offered to commercial enrollees; or

(ii) The hours of operation offered to Medicaid fee-for-service, if the provider serves only Medicaid enrollees.

(2) Hours of Access for Pharmacy Services.

(a) An MCO shall establish reasonable hours of access to pharmacy services, including weekend and evening hours, which are equivalent to the hours pharmacy services are generally available in the local access area to the public at large.

(b) If the MCO determines that weekend and evening pharmacy hours are not generally available in the local access area, it may request approval from the Department to offer only limited pharmacy hours as specified in §C(2)(c) of this regulation.

(c) To seek approval to offer limited pharmacy hours, an MCO shall make its request for approval to the Department, and shall include the following:

(i) A specification of the geographical areas where the MCO intends to have limited pharmacy hours;

(ii) An explanation of why only limited pharmacy hours are available in these areas; and

(iii) An identification of where its enrollees would have to go to secure prescriptions in the evenings and on weekends.

(d) Except as permitted in §C(2)(e) of this regulation, an MCO shall ensure that an enrollee receives at the time the prescription is dispensed to the enrollee any medically necessary disposable medical supplies or durable medical equipment needed by the enrollee to administer or monitor the enrollee's prescriptions.
(e) An MCO shall ensure that any disposable supplies or durable medical equipment necessary to administer or monitor an enrollee's prescriptions, if not available at the pharmacy at the time of the dispensing of the prescription, is received in a manner so as not to adversely affect the health of the enrollee, but not later than 24 hours.

D. Clinical Access Outside the MCO's Service Area.

(1) Subject to §D(2) of this regulation, an MCO shall be financially responsible for medically necessary emergency services delivered to its enrollees outside of the MCO's service area.

(2) With the exception of emergency services, an MCO may require authorization before treatment for services delivered to its enrollees outside of the MCO's service area.

(3) If the MCO’s provider network is unable to provide necessary services, covered under the contract, to an enrollee, the MCO shall adequately and timely cover these services out of network for as long as the MCO’s provider network is unable to provide them.

E. The Department may not impose any fines or other sanctions against an MCO for failure to comply with the waiting time standards in §B of this regulation unless there is evidence of a pattern of repeated violations by the MCO.

.08 Emergency Services Access.

A. An MCO shall develop and maintain policies and procedures for the adequate provision of emergency services for all its enrollees, including:

(1) Instituting and monitoring a system for responding to enrollee's emergency medical conditions, with provisions for immediate attention to and appropriate disposition of emergency calls; and

(2) Informing and educating its enrollees in the procedures to be followed in the event of an emergency, whether within or outside of the MCO's service area.

B. An MCO shall provide medically necessary emergency services 24 hours per day, 7 days per week.

C. An MCO shall maintain an emergency telephone service, with a physician on call, for the purpose of rendering medical advice and authorizing care at other facilities when use of the MCO's own facilities is impractical.

D. An MCO may provide emergency services access through adequate and appropriate triage assessments performed by qualified medical professionals.
E. An MCO shall utilize the trauma triage and transfer protocols established through the Maryland Institute for Emergency Medical Services Systems (MIEMSS) as the basis for directing the severely injured enrollee to the most appropriate level designated trauma center.

F. An MCO shall reimburse, within 30 days of invoice, the undisputed claims of hospital emergency facilities and providers for the following services provided to the MCO's enrollees:

1. Emergency services, as defined in COMAR 10.67.01.01B;

2. Medical screening services based on the federal Emergency Medical Treatment and Active Labor Act (EMTALA);

3. If the MCO authorized, referred, or otherwise instructed the enrollee to use the emergency facility, medically necessary services that are related to the emergency condition, including poststabilization services; and

4. If the MCO fails to provide 24 hour access to a physician, medically necessary services that relate to the condition presented and that are provided by the provider in an emergency facility to the enrollee.

G. Poststabilization Services. The MCO may not require preapproval of, and is financially responsible for, poststabilization services obtained in or outside of the MCO's network and administered to maintain, improve, or resolve the enrollee's stabilized condition if:

1. The MCO does not respond to a request for a preapproval within 1 hour;

2. The MCO cannot be contacted; or

3. The MCO representative and the treating physician cannot reach an agreement concerning the enrollee's care, and an MCO physician is not available for consultation, in which case:

   a. The MCO shall give the treating physician the opportunity to consult with an MCO physician; and

   b. The treating physician may continue care of the patient until a plan is reached or one of the following criteria is met:

      i. An MCO physician with privileges at the treating hospital assumes responsibility for the enrollee's care;

      ii. An MCO physician assumes responsibility for the enrollee's care through transfer;

      iii. An MCO representative and the treating physician reach an agreement concerning the enrollee's care; or
(iv) The enrollee is discharged.

H. An MCO may require that any continuing care be obtained from the MCO's providers or from providers approved by the MCO when the following conditions are satisfied:

(1) The enrollee's medical condition is appropriately stabilized and permits transferring responsibility for the enrollee's care, without medically harmful consequences, to these providers; and

(2) The transfer is consistent with the requirements of the federal Emergency Medical Treatment and Active Labor Act (EMTALA).

.09 Access: Hospitals.

A. An MCO shall comply with the access standards specified in Regulation .06A of this chapter.

B. If an MCO’s service area includes a county that is designated as a medically underserved area and there is only one hospital in the county, the MCO shall include the hospital in its network.

Chapter 06 Maryland Medicaid Managed Care Program: Benefits

.01 Required Benefits Package — In General.

A. Except for non-covered services set forth in Regulation .27 of this chapter and the non-capitated services described in COMAR 10.67.08, an MCO shall provide its enrollees with a benefits package that includes the covered services specified in this chapter when these services are deemed to be medically necessary including services covered under the Maryland Medicaid State Plan in the amount, duration, and scope set forth in the State Plan and in accordance with 42 CFR §440.230.

B. An MCO shall ensure that the services provided are sufficient in amount, duration, or scope to reasonably achieve the purpose for which the services are furnished.

C. An MCO is not required to provide non-covered services even when the service is medically necessary.

D. Any limitations set forth in this chapter on covered services are not applicable to services required by enrollees who are younger than 21 years old when it is shown that the services are medically necessary to correct or lessen health problems detected or suspected by EPSDT screening services, as described in Regulation .20 of this chapter.
E. An MCO may place appropriate limits on a service on the basis of criteria applied under the State plan, such as medical necessity.

F. Cost Sharing and Prohibitions.

(1) Except for the following, an MCO may not charge its enrollees any copayments, premiums, or cost sharing:

(a) Up to a $3 copayment for brand-name drugs;

(b) Up to a $1 copayment for generic drugs;

(c) Any other charge up to fee-for-service limits as approved by the Department.

(2) An MCO may not:

(a) Deny services to an individual who is eligible for services because of the individual's inability to pay the cost sharing;

(b) Impose copayments for the following:

   (i) Family planning services and supplies;

   (ii) Individuals younger than 21 years old;

   (iii) Pregnant women;

   (iv) Institutionalized individuals who are inpatients in long-term care facilities or other institutions; and

   (v) Emergency services.

(c) Arbitrarily deny or reduce the amount, duration, or scope of a required service solely because of diagnosis, type of illness, or condition of the enrollee.

G. An MCO shall ensure that all health care services provided under this chapter are performed, to the extent required by law, by an appropriate health care provider who is licensed, certified, or otherwise legally authorized to practice or deliver the services in the state in which the service is provided.

H. An MCO shall provide for a second opinion from a qualified health care professional within the network, or, if necessary, arrange for the enrollee to obtain one outside the MCO network.
.02 Benefits — Primary Care Services.

An MCO shall provide to its enrollees medically necessary primary care services that are provided:

A. By the enrollee's PCP;

B. At the direction of the enrollee's PCP; or

C. With respect to a primary care service that is self-referred pursuant to Regulation .28 of this chapter:
   
   (1) By an appropriate practitioner, acting within the scope of the practitioner's license, certification, or other legal authorization, and in accordance with the practitioner's training and experience; or

   (2) By a clinic that furnishes health care services by or under the direction of a physician.

.03 Benefits — Physician and Advanced Practice Nurse Specialty Care Services.

A. An MCO shall provide to its enrollees medically necessary specialty care services that are outside of the enrollee's PCP's scope of practice, or, in the judgment of the enrollee's PCP, are not services that the PCP customarily provides, is specifically trained for, or is experienced in and are provided by:

   (1) A physician or an advanced practice nurse, acting within the scope of the individual's license or certification, training, and experience;

   (2) A practitioner other than a physician or an advanced practice nurse when the practitioner is in a physician's employ, is under the physician's direct supervision, and performs the service within the scope of the practitioner's license, certification, or other legal authorization, for the purpose of assisting in the provision of the specialty care service;

   (3) A clinic that furnishes health care services by or under the direction of a physician; or

   (4) For enrollees who are younger than 21 years old, a doctor of dental medicine or dental surgery, if the services are surgical services that are also typically performed by physicians.

B. Notwithstanding §A(2) of this regulation, specialty care services provided under Regulations .04—.25 of this chapter may include medically necessary diagnostic and treatment services provided by a physician or other appropriate practitioner, acting within the scope of the practitioner's license, certification, or other legal authorization, and in accordance with the practitioner's training and experience.
.04 Benefits — Pharmacy Services.

A. An MCO shall provide outpatient drugs as defined in §1927(k)(2) of the Social Security Act.

B. An MCO shall provide to its enrollees all medically necessary pharmaceutical services and pharmaceutical counseling, including but not limited to:

   (1) Legend drugs;
   (2) Insulin;
   (3) All FDA approved contraceptives;
   (4) Hypodermic needles and syringes;
   (5) Enteral nutritional and supplemental vitamins and mineral products given by nasogastric, jejunostomy, or gastrostomy tube in the home;
   (6) Enteric coated aspirin prescribed for the treatment of arthritic conditions;
   (7) Nonlegend ferrous sulfate oral preparations;
   (8) Nonlegend chewable tablets of any ferrous salt when combined with vitamin C, multivitamins, multivitamins and minerals, or other minerals in the formulation when the enrollee is younger than 12 years old;
   (9) Medical supplies used in the preparation of compounded prescriptions for home intravenous therapy;
   (10) Medical supplies or equipment used in the administration or monitoring of medication prescribed or ordered for an enrollee by a qualifying provider as specified in §B of this regulation;
   (11) Latex condoms;
   (12) Nonlegend ergocalciferol liquid (Vitamin D); and
   (13) Emergency contraceptives for female recipients.

C. Except as provided in §B of this regulation, an MCO is required to provide only those drugs and related pharmaceutical products that are prescribed or ordered by:

   (1) An MCO provider;
(2) An out-of-plan provider, when the pharmacy services are ordered or prescribed in connection with medical care furnished by the provider to the MCO's enrollee:

(a) In response to the enrollee's emergency medical condition; or

(b) Pursuant to the enrollee's self-referral to the provider, when the care delivered qualifies as a permissible self-referred service under Regulation .28 of this chapter; or

(3) A behavioral health provider for drugs not in the behavioral health formulary.

D. An MCO shall provide over-the-counter emergency contraceptives and latex condoms to enrollees without requiring an order from an authorized prescriber.

E. Drug Formulary.

(1) An MCO shall establish and maintain a drug formulary that is at least equivalent to the standard therapies of the Maryland Medical Assistance Program, and include at a minimum:

(a) Covered generic and name brand medications; and

(b) The tier each medication is on.

(2) An MCO shall include in its formulary drugs that are appropriate for medical management, safe, and effective.

(3) An MCO shall expand its formulary, as needed, to include drugs that are equivalent to new drugs approved by the federal Food and Drug Administration, and which are deemed to be appropriate, safe, and efficacious in the medical management of the MCO's enrollees.

(4) An MCO shall include in its formulary the following drugs:

(a) Leuprolide acetate;

(b) Clonidine;

(c) Guanfacine;

(d) Medroxyprogesterone; and

(e) Liothyronine.

(5) To ensure that its formulary drugs are medically necessary, safe, and efficacious, an MCO shall:

(a) Subject its formulary to a review process that is:
(i) Established and conducted by the MCO’s Pharmacy and Therapeutics Committee;

(ii) Approved by the Department; and

(iii) Coordinated with the formulary review process of the Specialty Mental Health Services delivery system; and

(b) Submit its formulary for the review and approval of the Department, based upon the standards set forth in this regulation.

(6) Unless approved by the Department, an MCO may not require or utilize prior authorization or step therapy criteria for coverage of formulary drugs if such prior authorization or step therapy requires a recipient to use a drug that is included in the behavioral health formulary.

F. Any option for accessing pharmacy services by mail order may be implemented only at the request of the enrollee except for when the drug is a specialty drug as defined in §G of this regulation.

G. In this regulation, the term “specialty drug” means:

(1) A prescription drug that:

(a) Is prescribed for an individual with a complex, chronic or rare medical condition;

(b) Costs $600 or more for up to a 30-day supply;

(c) Is not typically stocked at retail pharmacies; and

(d) Requires a difficult or unusual process of delivery to the patient in the preparation, handling storage, inventory or distribution of the drug; or

(2) Requires enhanced patient education, management, or support, beyond those required for traditional dispensing, before or after administration of the drug.

H. If an enrollee subsequently requests to use a retail pharmacy for specialty drugs the MCO may not limit the enrollee to the use of a mail order pharmacy.

I. An MCO shall:

(1) Establish and maintain a drug utilization review program;

(2) Adhere to the minimum performance standards established by the Department for these programs, whenever used, including but not limited to standards for the following drug use management components:
(a) Formulary management;
(b) Generic substitution;
(c) Therapeutic substitution;
(d) Prior authorization that complies with the requirements of §1927(d)(5) of the Social Security Act;
(e) Drug use evaluation (DUE);
(f) Disease management; and
(g) Pharmacy and Therapeutic Committee;

(3) Establish procedures to distinguish drug utilization data for covered outpatient drugs that are subject to discounts under the 340B drug pricing program; and

(4) Provide to the Department a detailed description of its drug utilization review program activities on an annual basis.

J. The Department shall:

(1) Review each MCO’s drug utilization review program annually; and

(2) Notify an MCO annually if any of the standards established in §I(2) of this regulation have not been met.

K. For any performance standard identified in §J(2) of this regulation, MCOs shall acknowledge any deficiencies within 30 days and correct any deficiencies within 90 days or be subject to sanctions listed in COMAR 10.67.10.01A and B.

.05 Benefits — Home Health Services.

A. Subject to the conditions specified in §B of this regulation, an MCO shall provide to its enrollees medically necessary home health services, including:

(1) Skilled nursing services, including the supervisory visits required by §A(2) of this regulation;

(2) Home health aide services, including biweekly supervisory visits by a registered nurse in the recipient's home, every second visit of which includes observations of the delivery of services by the aide to the enrollee;

(3) Physical therapy services;
(4) Occupational therapy services;

(5) Speech pathology services; and

(6) Medical supplies that are used during a home health visit.

B. An MCO shall provide the home health services specified in §A of this regulation that are:

(1) Certified by the enrollee's PCP or by the enrollee's attending physician to be required on a part-time, intermittent basis; and

(2) Rendered in the enrollee's home.

.06 Benefits — Habilitation Services for Medicaid Expansion Populations

A. An MCO shall provide the following medically necessary habilitation services to enrollees eligible for Medical Assistance under §1902 (a)(10)(A)(i)(VIII) of the Social Security Act:

(1) Physical therapy;

(2) Occupation therapy; and

(3) Speech therapy.

B. At a minimum, an MCO shall provide the services in hospital inpatient and outpatient departments and physical therapy in an outpatient community setting.

.07 Benefits — Inpatient Hospital Services.

A. An MCO shall provide to its enrollees medically necessary inpatient hospital services as specified in this regulation.

B. Admission to Long-Term Care Facility.

(1) An MCO shall provide to its enrollees medically necessary long-term care facility services for:

(a) The first 90 continuous days following the enrollee's admission; and

(b) Any days following the first 90 continuous days of an admission until the date the MCO has obtained the Department's determination that the admission is medically necessary as specified in §B(2) of this regulation.
(2) For any long-term care facility admission that is expected to result in a length of stay exceeding 90 days, an MCO or long-term care facility shall request a determination by the Department that the admission is medically necessary.

(3) The Department’s determination as described in §B(2) of this regulation is only applicable if the enrollee is still in the long-term care facility on the 91st day.

(4) Acute care services provided within the first 90 days following an enrollee's admission to a long-term care facility do not constitute a break in calculating the 90 continuous day requirement if the enrollee is discharged from the hospital back to the long-term care facility.

C. The Department shall render a determination with respect to the medical necessity of a stay in a long-term care facility as specified in §B of this regulation within 3 business days of receipt of a complete application from the MCO.

D. Childbirth — Length of Stay and Home Visits.

(1) Except as provided in §D(2) and (3) of this regulation, the criteria and standards used by an MCO in performing utilization review of hospital services related to maternity and newborn care, including length of stay, shall be in accordance with the medical criteria outlined in the Guidelines for Perinatal Care, which is incorporated by reference in COMAR 10.67.04.01.

(2) Unless the enrollee decides, in consultation with her attending provider, that less time is needed for recovery, an MCO shall provide or reimburse the cost of hospitalization including at least the following length of stay for an enrollee recovering from childbirth:

(a) 48 hours of inpatient hospitalization care following an uncomplicated vaginal delivery; or

(b) 96 hours of inpatient hospitalization care following an uncomplicated cesarean section.

(3) If the enrollee elects to be discharged earlier than the length of stay specified in §D(2) of this regulation, the MCO is required to provide a home visit or visits pursuant to Regulation .21B—D of this chapter.

E. In addition to the mother's length of stay required to be afforded by §D(2) of this regulation, whenever a mother is required to remain hospitalized after childbirth for medical reasons and she requests that her newborn remain in the hospital while she is hospitalized, the MCO shall afford the newborn additional hospitalization while the mother remains hospitalized, for up to 4 days.

F. If an enrollee is in the hospital at the time of disenrollment from the MCO, and remains eligible for Medical Assistance, the MCO is responsible for covering the remainder of that hospital admission following disenrollment.

G. An MCO shall provide for a private hospital room when:
(1) The enrollee's condition requires a need for isolation; or

(2) The enrollee requires admission and only private rooms are available.

H. Payment For Ancillary Services.

(1) Effective January 1, 2009, an MCO shall pay for all medically necessary ancillary services provided on inpatient hospital days including those days for which the inpatient hospitalization is otherwise appropriately denied.

(2) A denial of an inpatient ancillary service shall be based on the medical necessity of the specific ancillary service.

(3) An MCO is not required to pay for ancillary services if the entire hospitalization in §H(1) of this regulation is appropriately denied.

I. Transports between hospitals are covered by the MCO when:

(1) A medically necessary covered service is not available at the hospital where an enrollee is being treated; and

(2) The enrollee is not being discharged from the sending hospital.

.08 Benefits — Outpatient Hospital Services.

An MCO's benefits package shall include medically necessary outpatient hospital services.

.09 Benefits — Transplants.

An MCO shall provide to its enrollees medically necessary transplants.

.11 Benefits — Diagnostic and Laboratory Services.

An MCO shall provide to its enrollees medically necessary:

A. Diagnostic services; and

B. Laboratory services, performed by a provider who:

(1) Is Clinical Laboratory Improvement Amendments (CLIA) certified; or

(2) Has a waiver of a certificate registration along with a CLIA identification number.
.12 Benefits — Long-Term Care Facility Services.

A. An MCO shall provide to its enrollees medically necessary services in a chronic hospital, a chronic rehabilitation hospital, or a nursing facility for:

   (1) The first 90 continuous days following the enrollee's admission; and

   (2) Any days following the first 90 continuous days of an admission until the date the MCO has obtained the Department’s determination that the admission is medically necessary as specified in §C of this regulation.

B. Acute care services provided within the first 90 days following an enrollee's admission to a long-term care facility do not constitute a break in calculating the 90 continuous day requirement if the enrollee is discharged from the hospital back to the long-term care facility.

C. For any long-term care facility admission that is expected to result in a length of stay exceeding 90 days, an MCO or long-term care facility shall request a determination by the Department that the admission is medically necessary.

D. The Department’s determination as described in §C of this regulation is only applicable if the enrollee is still in the long-term care facility on the 91st day.

E. The Department shall render a determination with respect to the medical necessity of a stay in a nursing facility as specified in §C of this regulation within 3 business days of receipt of a complete application from the MCO.

F. A determination by the Department that the admission is medically necessary does not relieve the MCO of the obligation to pay for the admission through the day on which the determination is made.

G. An MCO shall use the Department’s criteria for determining medical necessity for the days described in §A(1) of this regulation.

.13 Benefits — Disposable Medical Supplies and Durable Medical Equipment.

A. An MCO shall provide to its enrollees medically necessary disposable medical supplies and durable medical equipment, including but not limited to:

   (1) All supplies and equipment used in the administration or monitoring of prescriptions by the enrollees; and

   (2) Incontinency pants and disposable underpads for medical conditions associated with prolonged urinary or bowel incontinence if necessary to prevent institutionalization or infection.

B. Except as required in §C(1), an MCO shall provide preauthorization within 72 hours for DMS/DME services and supplies that require preauthorization by the MCO.
C. An MCO shall provide its enrollees the disposable medical supplies and durable medical equipment in a timely manner so as to not adversely affect the health of the enrollees, in accordance with the following:

(1) For medical equipment or supplies, or both, when there is an urgent medical need such as to facilitate hospital discharge or when a potential exists for worsening of enrollee's condition, the MCO shall provide needed items within 24 hours of request; and

(2) For all other requests for DMS/DME, the MCO shall provide these items within 7 days from the date of request unless the MCO can document to the Department that justification for additional time is necessary.

D. An MCO is responsible for paying for any durable medical equipment authorized and ordered while the member is active with the MCO if:

(1) The delivery of the item occurs within 90 days after the member's termination date from the MCO; and

(2) The member remains a Medicaid recipient.

.14 Benefits — Vision Care Services.

A. An MCO shall provide to its enrollees medically necessary vision care services as specified in this regulation.

B. For enrollees who are 21 years old or older, the MCO is responsible for providing at least one eye examination every 2 years.

C. For its enrollees who are younger than 21 years old, the MCO is responsible for providing medically necessary vision services, including but not limited to:

(1) At least one eye examination every year in addition to any vision screen performed as part of an EPSDT screen;

(2) Eyeglasses, limited to one pair per year unless lost, stolen, broken, or no longer vision appropriate; and

(3) Contact lenses, if medically necessary and if eyeglasses are not efficacious for the condition.

.15 Benefits — Podiatry Services.

A. An MCO shall provide for its enrollees medically necessary podiatry services.

B. In addition to the services described in §A of this regulation, an MCO shall provide:
Appendix O

(1) Diabetes care services specified in COMAR 10.67.06.24; and

(2) Routine foot care for enrollees, 21 years old or older with vascular disease affecting the lower extremities.

.16 Benefits — Outpatient Rehabilitative Services.

An MCO shall provide to its enrollees medically necessary outpatient rehabilitative services, including but not limited to physical therapy for adult enrollees.

.17 Benefits — Oxygen and Related Respiratory Equipment.

An MCO shall provide to its enrollees medically necessary oxygen and related respiratory equipment services.

.18 Benefits — Dialysis Services.

An MCO shall provide to its enrollees medically necessary dialysis services.

.19 Benefits — Family Planning Services.

A. An MCO shall provide to its enrollees comprehensive family planning services, including but not limited to medically necessary office visits and laboratory tests, all FDA-approved contraceptive devices, methods, and supplies, and voluntary sterilizations.

B. An MCO may place appropriate limits on family planning services for the purpose of utilization control, provided that the services are provided in a manner that protects and enables the enrollee’s freedom to choose the method of family planning to be used consistent with 42 CFR §441.20.

C. An MCO may not apply a copayment or coinsurance requirement for contraceptive drugs or devices.

D. An MCO shall provide coverage for a single dispensing of a supply of prescription contraceptives for a 12-month period.

.20 Benefits — EPSDT Services.

A. An MCO shall provide, to enrollees younger than 21 years old, medically necessary Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) services, including:

(1) EPSDT comprehensive well-child services provided in accordance with the EPSDT periodicity schedule and performed by an EPSDT-certified provider, including:
(a) A comprehensive health and developmental history, including an evaluation of both physical and mental health development;

(b) A comprehensive unclothed physical exam;

(c) Immunizations appropriate to age and health history;

(d) Laboratory tests, including blood lead level assessment, as appropriate to age and risk;

(e) Health education, including anticipatory guidance; and

(f) Vision, hearing, and dental screening;

(2) EPSDT partial or interperiodic well-child services; and

(3) Health care services that are:

(a) Necessary to prevent, treat, or ameliorate physical, mental, or developmental problems or conditions identified by an EPSDT-certified provider or other health professional;

(b) Sufficient in amount, duration, and scope to treat the identified condition; and

(c) Subject to limitation only on the basis of medical necessity.

B. The health care services described in §A(3) of this regulation shall include, at a minimum, all services described in this chapter, and the following:

(1) Chiropractic services;

(2) Nutrition counseling services;

(3) Private duty nursing services including:

(a) An initial assessment and development of a plan of care by a registered nurse; and

(b) On-going private duty nursing services delivered by a licensed practical nurse or a registered nurse; and

(4) Durable medical equipment.

C. An MCO shall provide referrals for services not covered by Medicaid, but which are furnished at little or no cost to recipients, including appropriate referrals to:

(1) The Head Start Program;

(2) The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC);
(3) School Health-Related Special Education Services;

(4) Vocational Rehabilitation; and

(5) Maternal and Child Health Services located at local health departments.

.21 Benefits — Pregnancy-Related Services.

A. An MCO shall provide to its pregnant and postpartum enrollees medically necessary pregnancy-related services, including:

(1) Comprehensive prenatal, perinatal, and postpartum care, including high-risk specialty care when appropriate;

(2) Prenatal risk assessment and development of an individualized plan of care that specifies the actions required to address each identified need and is appropriately modified during the course of care;

(3) Enriched maternity services, including:

(a) Prenatal and postpartum counseling and education;

(b) Basic nutritional education;

(c) Substance abuse treatment, as provided in Regulation .10 of this chapter;

(d) Appropriate referrals to services that may improve the pregnancy outcome, including:

(i) Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), and

(ii) Healthy Start services;

(e) High-risk nutrition counseling services for nutritionally high-risk pregnant women;

(f) Appropriate levels of inpatient care, including emergency transfer of pregnant women and newborns to tertiary care centers; and

(g) Smoking cessation education and treatment.

B. When an enrollee recovering from childbirth elects to be discharged before 48 hours following a normal vaginal delivery or 96 hours following an uncomplicated cesarean section, the MCO is responsible for providing:

(1) One home visit scheduled to occur within 24 hours after discharge; and
(2) An additional home visit as may be prescribed by the attending provider.

C. When an enrollee recovering from childbirth and her newborn enrollee remain in the hospital for at least as long as the period of time provided under §B of this regulation, the MCO shall provide a home visit as prescribed by the attending provider.

D. An MCO shall provide for home visits required by §§B and C of this regulation to be performed by a registered nurse and in accordance with generally accepted standards of nursing practice for home care of a mother and newborn child, including:

(1) An evaluation of the presence of immediate problems of dehydration, sepsis, infection, jaundice, respiratory distress, cardiac distress, or other adverse physical symptoms of the infant;

(2) An evaluation of the presence of immediate problems of dehydration, sepsis, infection, bleeding, pain, or other adverse symptoms of the mother;

(3) Collection of a blood specimen for newborn screening if not previously completed;

(4) Referrals for any medically necessary continuing health care services; and

(5) Any other nursing services ordered by the referring provider.

.22 Benefits — Case Management Services for HIV-Infected Individuals.

An MCO shall provide medically necessary case management services to its qualifying enrollees, as specified in COMAR 10.67.04.10C.

.23 Benefits — Hospice Care Services.

A. An MCO shall include in its benefits package medically necessary hospice care services to enrollees who are terminally ill.

B. The Department shall allow an enrollee to disenroll from an MCO and choose a new MCO if:

(1) The enrollee was auto-assigned to the MCO; and

(2) The enrollee's hospice provider does not contract with the enrollee's assigned MCO.

C. If an enrollee who is in a hospice that does not contract with the enrollee's MCO and the enrollee will not voluntarily choose a new MCO, the enrollee's current MCO:

(1) Shall authorize and pay the out-of-network hospice provider at the established Medicaid rate, to ensure continuity of care; and
(2) May not require the hospice care enrollee to change their out-of-network hospice provider to an in-network hospice provider.

.24 Benefits — Diabetes Prevention and Care Services.

A. An MCO shall provide to its qualifying enrollees medically necessary diabetes prevention and care services as specified in this regulation.

B. National Diabetes Prevention Program.

(1) In addition to the services included in its usual benefits package, an MCO shall make available to its enrollees who meet the Centers for Disease Control and Prevention (CDC) eligibility criteria defined in §B(2) of this regulation the National Diabetes Prevention Program through a CDC-recognized lifestyle change organization.

(2) To be eligible for participation in the National Diabetes Prevention Program, a HealthChoice enrollee:

(a) Shall be 18 through 64 years old;

(b) Shall be overweight or obese;

(c) Shall have an elevated blood glucose level or a history of gestational diabetes mellitus;

(d) May not have a previous diagnosis of type 1 or type 2 diabetes prior to enrollment; and

(e) May not be currently pregnant.

C. In addition to the services included in its usual benefits package, an MCO shall provide enrollees with a diabetes diagnosis the following medically necessary special diabetes-related services:

(1) Diabetes nutrition counseling, consisting of one initial one-on-one session and up to 4 subsequent sessions annually;

(2) Diabetes outpatient education;

(3) Diabetes-related durable medical equipment, disposable medical supplies, and therapeutic footwear and related services, when ordered as medically necessary, including:

(a) Therapeutic footwear, orthopedic shoes, arch supports, orthotic devices, in-shoe supports, elastic support, or examinations for prescription or fitting and related services to prevent or delay a foot amputation that would be highly probable in the absence of the specialized footwear;

(b) Blood glucose monitoring supplies;
(c) Diagnostic reagent strips and tablets used in testing for ketones and glucose in urine and glucose in blood;

(d) Finger-sticking devices used in obtaining blood samples for blood glucose testing; and

(e) Blood glucose reflectance meters for home use;

(4) Routine foot care; and

(5) Vision care consisting of:

(a) One ophthalmologic examination per year; and

(b) One pair of eyeglasses per year.

.25 Benefits — Blood and Blood Products.

An MCO shall provide to its enrollees medically necessary blood, blood products, derivatives, components, biologics, and serums to include autologous services, whole blood, red blood cells, platelets, plasma, immunoglobulin, and albumin.

.26 Benefits — Primary Mental Health Services.

An MCO shall provide to its enrollees medically necessary primary mental health services, including appropriate referrals for service to the Department’s behavioral health ASO as described in COMAR 10.09.59.

.26-1 Clinical Trial Items and Services — Coverage for Routine Costs.

A. Subject to the conditions specified in §§B—F of this regulation, an MCO shall provide coverage for cost to an enrollee in an approved clinical trial for:

(1) Treatment provided for life-threatening conditions; or

(2) Prevention, early detection, and treatment studies on cancer.

B. Clinical trials are deemed to be automatically approved if:

(1) The treatment is:

(a) Being provided or the studies are being conducted in a Phase I, Phase II, Phase III, or Phase IV clinical trials for cancer; or

(b) Being provided in Phase I, Phase II, Phase III, or Phase IV clinical trial for any other life-threatening condition;
(2) The treatment is being provided in a clinical trial:

(a) Approved by:

(i) The National Institutes of Health (NIH);

(ii) An NIH cooperative group or an NIH center;

(iii) The Centers for Disease Control and Prevention;

(iv) The Agency for Healthcare Research and Quality;

(v) The Centers for Medicare and Medicaid Services (CMS);

(vi) The Department of Defense;

(vii) The Department of Veterans Affairs; or

(viii) An institutional review board of an institution in the State that has a multiple project assurance contract approved by the Office of Protection from Research Risks of the NIH; or

(b) Conducted:

(i) At National Cancer Institute Centers;

(ii) Under Investigational New Drug application (IND) reviewed by the Food and Drug Administration (FDA); or

(iii) As a clinical trial with deemed status through an exemption from having an IND under 21 CFR §312.2(b)(1);

(3) The facility and the personnel providing the treatment are capable of doing so by virtue of the facility and the personnel's experience, training, and volume of patients treated to maintain expertise;

(4) There is no clearly superior, non-investigational treatment alternative; and

(5) The available clinical or preclinical data provide a reasonable expectation that the treatment will be at least as effective as the non-investigational alternative.

C. Enrollee cost includes the following:

(1) The cost of all medically necessary items and services that are otherwise available to Medicaid beneficiaries such as hospital services, physician services, or diagnostic tests; and
(2) The cost of medically necessary items or services required solely for the provision of the following:

(a) Investigational item or service such as administration of a noncovered chemotherapeutic agent;

(b) The clinically appropriate monitoring of the effects of the item or service; or

(c) The prevention, diagnosis, and treatment of complications.

D. Enrollee cost does not include the following:

(1) The cost of the investigational item or service itself;

(2) The cost of items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the enrollee;

(3) The cost of items and services customarily provided by the research sponsors free of charge for any enrollee in the trial; and

(4) The cost of non-health care services that an enrollee may be required to receive as a result of the treatment being provided for purposes of the clinical trial.

E. If the enrollee has insurance or other coverage, or if any other person is obligated, either legally or contractually, to pay for, or to reimburse the enrollee for, services covered by this regulation, the provider shall seek payment from that source first.

F. The MCO shall authorize the request for participation in an approved clinical trial within 5 working days of the request.


An MCO shall provide to an enrollee medically necessary surgery to correct a deformity from disease, trauma, congenital or developmental anomalies, or to restore body functions.

.26-3 Gender Transition Services.

An MCO shall provide medically necessary gender reassignment surgery and other somatic specialty care for members with gender identity disorder.

.26-4 Audiology.

An MCO shall provide enrollees medically necessary audiology services as described in COMAR 10.09.51, including:

A. Hearing aids;
B. Cochlear implants;

C. Auditory osseointegrated devices; and

D. Related services.

.26-5 Remote Patient Monitoring.

An MCO shall provide its enrollees medically necessary remote patient monitoring services as described in COMAR 10.09.96.

.27 Benefits — Limitations.

A. The benefits or services not required to be provided by an MCO are as follows:

(1) Experimental or investigational services, including organ transplants determined by Medicare to be experimental, except when an enrollee is participating in an authorized clinical trial as specified in Regulation .26-1 of this chapter;

(2) Any service or treatment that is not medically necessary;

(3) Services performed or prescribed under the direction of a person who is not a health care practitioner;

(4) Services that are beyond the scope of practice of the health care practitioner performing the service;

(5) Transportation services provided through grants to local governments pursuant to COMAR 10.09.19, other than assisting enrollees to access nonemergency transportation services through their local transportation grantee agency;

(6) Health-related services and targeted case management services provided to children when the services are:

   (a) Specified in the enrollee's individualized family service plan (IFSP), or an individualized education program (IEP); and

   (b) Delivered in the schools or through Children's Medical Services community-based providers;

(7) Autopsies;

(8) Immunizations required for travel outside the continental United States;

(9) Services received while the enrollee is outside the United States;
(10) Abortions;

(11) Diet and exercise programs for the loss of weight;

(12) Prescriptions or injections for central nervous system stimulants and anorectic agents when used for controlling weight;

(13) In vitro fertilization, ovum transplants and gamete intrafallopian tube transfer, zygote intrafallopian transfer, or cryogenic or other preservation techniques used in these or similar procedures;

(14) Services to reverse a voluntary sterilization procedure;

(15) Lifestyle improvements, including smoking cessation, nutrition counseling, or physical fitness programs, unless specifically included as a covered service;

(16) Nonmedical ancillary services such as vocational rehabilitation, employment counseling, or educational therapy;

(17) Private duty nursing for adults 21 years old and older;

(18) Services incurred before the effective date of coverage for an enrollee;

(19) Dental or orthodontic care for adults 21 years old or older;

(20) Piped-in oxygen or oxygen prescribed for standby purposes or on an as-needed basis;

(21) Ovulation stimulants administered orally or parenterally;

(22) Cosmetic surgery when performed solely to maintain normal physical appearance or enhance beyond average level toward an aesthetic ideal; and

(23) Services to reverse gender reassignment procedures.

B. An MCO is not required to provide any of the benefits or services which are reimbursed directly by the Department as described in COMAR 10.67.08.

.28 Benefits — Self-Referral Services.

A. An MCO shall be financially responsible for reimbursing, in accordance with COMAR 10.67.04.20, an out-of-plan provider chosen by the participant for the following services:

(1) Family planning services specified in COMAR 10.67.04.20A(2), (6), and (7);

(2) Services performed by school-based health centers (SBHCs), as provided in COMAR 10.09.76;
(3) Pregnancy-related services for women who are pregnant and, at the time of initial enrollment, have received prenatal care during their current pregnancy from an out-of-plan provider, and this pre-enrollment care consists of at least the following:

(a) A full prenatal examination;

(b) A risk assessment; and

(c) Appropriate laboratory services;

(4) Initial medical examination for children in State custody when performed by an EPSDT certified provider;

(5) One annual diagnostic and evaluation service (DES) visit for any enrollee diagnosed with HIV/AIDS, which the MCO is responsible for facilitating on the enrollee's behalf;

(6) Renal dialysis services performed in a Medicare-certified facility;

(7) Initial medical examination of a newborn when the:

(a) Examination is performed in a hospital by an on-call physician; and

(b) MCO failed to provide for the service before the newborn's discharge from the hospital;

(8) Emergency services as described in COMAR 10.67.05.08B; and

(9) Prenatal, intrapartum, and postpartum services performed at a free-standing birth center located in Maryland or a contiguous state.

B. An MCO shall pay undisputed claims of the SBHC for services provided to its participants within 30 days of the MCO’s receipt of the invoice.

C. An MCO shall provide SBHCs in its service area with the current information needed to facilitate communication between the SBHC, PCP, and the MCO regarding care provided to the MCO’s participant, and to effect reimbursement by the MCO, including:

(1) Information concerning the MCO’s policies and procedures regarding the provision of pharmacy and laboratory services;

(2) Instructions for submitting claims; and

(3) Contact information, including names and phone numbers of the following individuals:

(a) The MCO representative who serves as an SBHC’s contact person for coordination of care; and
(b) The student-participant’s PCP.

.29 Optional Services.

A. An MCO may provide its enrollees with additional health care services that are not required by this chapter.

B. Optional health care services that an applicant intends to include in its benefits package shall be specified, including the terms and conditions for, and limitations to the provision of these services, in the applicant's initial application to the Department, as well as for periodic Departmental review.

C. An MCO's provision of optional services that it has represented to be available to its enrollees is subject to monitoring of complaints and consumer satisfaction surveys, and to random audits.

D. An MCO's provision of additional services that are not required by this regulation may not be taken into account when setting the MCO's capitation rate.

E. Effective January 1, 2015, any changes to the health care services being offered by the MCO under §A of this regulation, including reducing or waiving pharmacy co-pays, shall be effective for an entire calendar year.

F. An MCO shall notify the Department of any changes to their optional services by September 15 for the following calendar year.

G. The Department may waive the requirement under §E of this regulation if the Department determines that the circumstance warrant, including but not limited to a reduction in rates outside the normal rate setting process.

.31 Benefits — Telemedicine Services.

An MCO shall provide to its enrollees medically necessary telemedicine services as described in COMAR 10.09.49.
Chapter 07 Maryland Medicaid Managed Care Program: Program Integrity

.01 Requirements to Detect and Prevent Fraud, Waste, and Abuse.

A. An MCO or its responsible subcontractor shall implement and maintain arrangements or procedures that are designed to detect and prevent fraud, waste, and abuse, which includes a compliance program that has, at a minimum, the following elements:

1. Written policies, procedures, and standards of conduct that include the MCO’s commitment to comply with all applicable:
   (a) Requirements and standards under the contract; and
   (b) Federal and State requirements including:
      (i) Written policies for all employees and those of any contractor or agent that provide detailed information about the False Claims Act and other Federal and State laws described in §1902(a)(68) of the Social Security Act; and
      (ii) Information about rights of employees to be protected as whistleblowers.

2. The designation of a compliance officer, who reports directly to the chief executive officer and the board of directors and is responsible for developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements of the contract, and at minimum the following staff members:
   (a) An investigator who is responsible for fraud, waste, and abuse investigations;
   (b) An auditor who is responsible for identifying potential fraud, waste, and abuse through analysis of claims and related information; and
   (c) An analyst capable of reviewing data and codes who is responsible for reviewing and researching evidence of potential fraud, waste, and abuse.

3. Staffing and resources located in Maryland to identify and investigate potential fraud, waste, and abuse, which shall be based on criteria determined by the Department that may include but are not limited to:
   (a) Number of enrollees;
   (b) Number of claims received on an annual basis;
   (c) Volume of suspected fraudulent and abusive claims currently being detected;
   (d) Other factors relating to the vulnerability of the MCO to fraud and abuse; and
(e) An assessment of optimal caseload which can be handled by an investigator on an annual basis.

(4) The establishment of a regulatory compliance committee, which reports to the board of directors and to the MCO’s senior management level and is charged with overseeing the organization’s compliance program and its compliance with the requirements under the contract;

(5) A system for training and educating the compliance officer, the organization’s senior management, and the organization’s employees regarding the federal and State standards and requirements under the contract;

(6) Effective lines of communication between the compliance officer and the organization’s employees;

(7) Enforcement of standards through well-publicized disciplinary guidelines;

(8) Establishment and implementation of procedures and a system with dedicated staff for:

(a) Routine internal monitoring and auditing of compliance risks;

(b) Prompt response to compliance issues as they are raised;

(c) Investigation of potential compliance problems as identified in the course of self-evaluation and audits;

(d) Correction of problems, identified under §A(7)(c) of this regulation, promptly and thoroughly, or coordination of suspected criminal acts with law enforcement agencies, to reduce the potential for recurrence; and

(e) Ongoing compliance with the requirements under the contract.

B. An MCO shall ensure that a subcontractor is legally qualified to furnish the services provided for in the subcontract.

C. An MCO may not contract with the State unless conflict of interest safeguards at least equal to federal safeguards under section 27 of 41 U.S.C. §423, as amended, are in place.

D. An MCO may not knowingly have a relationship of the type described in §E of this regulation with the following:

(1) An individual or entity that is debarred, suspended, or otherwise excluded from:

(a) Participating in procurement activities under the Federal Acquisition Regulation; or

(b) Participating in non-procurement activities under Executive Order Number 12549, 3 CFR 189 (1986); or
(2) An individual or entity who is an affiliate, as defined in 48 CFR §2.101, of a person described in §D(1) of this regulation.

E. The relationships described in §D of this Regulation, are as follows:

(1) A director, officer, or partner of the MCO;

(2) A subcontractor of the MCO;

(3) A person with beneficial ownership of 5 percent or more of the MCO’s equity; or

(4) A network provider or person with an employment, consulting or other arrangement with the MCO for the provision of items and services that is significant and material to the MCO’s obligations under its contract with the Department.

F. An MCO may not have a relationship with an individual or entity that is excluded from participation in any Federal health care program under §1128 or 1128A of the Social Security Act.

G. An MCO shall monitor the Department’s correspondence and any database publicizing Department-initiated terminations of providers from the Program.

H. An MCO shall terminate the contract of, or refrain from contracting with, providers terminated or excluded from participation in the Program.

I. An MCO shall suspend payments to a network provider for which the Department has determined that there is a credible allegation of fraud in accordance with 42 CFR §455.23.

J. An MCO shall establish a system to verify, by sampling or other methods, whether services that have been represented to have been delivered by network providers were received by enrollees and shall apply such verification processes at least annually.

K. An MCO shall require and have a mechanism for a network provider to report to the MCO when it has received an overpayment and to:

   (1) Return the overpayment to the MCO within 60 calendar days after the date on which the overpayment was identified; and

   (2) Notify the MCO in writing of the reason for the overpayment.

L. Overpayments to Providers and Subcontractors.

   (1) Overpayments recovered by an MCO, including those recovered due to waste, fraud and abuse, may be retained by the MCO, so long as it is reported to the Department.
(2) If the Department, Federal government, or its agents identified the potential fraud, waste, or abuse that leads to recovery of funds paid to an MCO provider, and the MCO did not previously identify and report the provider for potential overpayments, the State shall have the right to recover from the MCO the entire amount of the overpayment.

(3) The State shall have the sole right of recovery of an overpayment when the MCO has identified the overpayment and the MCO has not initiated recovery within 90 days after the completion of the MCO’s investigation.

(4) The MCO shall have the right to appeal, pursuant to COMAR 10.67.10.02, the Department’s recovery of an overpayment.

M. The Department has the authority to recover any overpayments made to MCOs.

N. An MCO shall ensure that all of its network providers are screened, enrolled, and revalidated by the State as Medicaid providers, in accordance with 42 CFR part 455, subparts B and E.

.02 Access to Information.

A. An MCO, its subcontractors, and its subcontractor’s subcontractors shall permit the following organizations or their designees to inspect, evaluate, or audit books, records, contracts, computer or other electronic systems, premises, and facilities that pertain to the MCO’s Medicaid enrollees, and any aspect of services and activities performed, or determination of amounts payable under, the MCO’s contract with the Department:

(1) The Department and its agents;

(2) The Medicaid Fraud Control Unit of the Office of the Attorney General;

(3) The Insurance Fraud Division of the Maryland Insurance Administration;

(4) The Centers for Medicare and Medicaid Services;

(5) The Inspector General of the Department of Health and Human Services;

(6) The Comptroller General; and

(7) Other authorized State or federal agencies.

B. The right to inspect, audit, and evaluate shall exist for 10 years from the final date of the contract period or from the completion of any audit, whichever is later, except, if the Department, Centers for Medicare and Medicaid Services, or the Department of Health and Human Services Inspector General determines that there is a reasonable possibility of fraud, or similar risk, those agencies may inspect, audit, and evaluate at any time.
C. Notwithstanding §B of this regulation, the Department has the right to inspect the accuracy, truthfulness, and completeness of the encounter data submitted by, or on behalf of, the MCO.

.03 Reporting.

A. An MCO shall submit to the Department the following:

(1) Encounter data in the form and manner described in COMAR 10.67.04.15B, 42 CFR §438.242(c), and 42 CFR §438.818.

(2) Data required by the Department in order to certify the actuarial soundness of capitation rates to an MCO, under 42 CFR §438.3, including base data described in 42 CFR §438.5(c) that is generated by the MCO.

(3) Data required by the Department to determine compliance of the MCO with the medical loss ratio requirement described in 42 CFR §438.8.

(4) Data required by the Department and the Maryland Insurance Administration to determine that the MCO has made adequate provision against the risk of insolvency as required under 42 CFR §438.116.

(5) Documentation described in 42 CFR §438.207(b) on which the Department bases its certification that the MCO has complied with the State’s requirements for availability and accessibility of services, including the adequacy of the provider network, as set forth in 42 CFR §438.206.

(6) In accordance with §F of this regulation, information on ownership and control described in 42 CFR §455.104 from an MCO and its subcontractors, as governed by 42 CFR §438.230.

(7) An annual report of overpayment recoveries as required in 42 CFR §438.608(d)(3).

(8) Any other data, documentation, or information relating to the performance of the entity’s obligations under its contract with the Department, or required by the Department or the Secretary of the Department of Health and Human Services.

B. An MCO shall report to the Department any identified inaccuracies in the encounter data reported by the MCO or its subcontractors within 30 days of the date discovered regardless of the effect which the inaccuracy has upon MCO reimbursement.

C. An MCO shall promptly report to the Department’s Office of Inspector General (OIG) any potential fraud, waste, abuse, or information it has received from whistleblowers relating to the integrity of the MCO, its network providers, or its subcontractors.

D. An MCO shall report any potential fraud directly to the Medicaid Fraud Control Unit and the Department’s OIG, including fraud by providers, employees and subcontractors of the MCO, enrollment agents, and enrollees.
E. After reporting any potential fraud, waste, or abuse to the Department’s OIG and to the Medicaid Fraud Control Unit, the MCO may not take the following actions without prior written approval from the State:

1. Contact the subject of the investigation about any matter related to the investigation;
2. Enter into or attempt to negotiate any settlement or agreement regarding the incident; or
3. Accept any monetary or other type of consideration offered by the subject of the investigation in connection with the incident.

F. For complaints of provider fraud and abuse that warrant a preliminary investigation, the MCO’s reports required in §§C and D of this regulation shall include:

1. The number of complaints;
2. The name and identification number of the provider being investigated;
3. The source of the complaint;
4. The type of provider;
5. The nature of the complaint;
6. The approximate dollar amount involved;
7. The legal and administrative disposition of the case; and
8. The method by which the MCO verified that the services being investigated were actually provided to the enrollee.

G. An MCO shall provide to the Department written disclosure of any affiliation prohibited under 42 CFR §438.610 and take action as directed by the Department.

H. An MCO shall provide to the Department written disclosures of information on ownership and control required under 42 CFR §455.104, including:

1. The following information for any individual or corporation with an ownership or control interest in the MCO:
   a. For individuals:
      i. Name;
      ii. Address;
(iii) Date of birth; and

(iv) Social Security number; and

(b) For corporate entities:

(i) Name;

(ii) Applicable primary business address;

(iii) Every business location and applicable P.O. Box address; and

(iv) Other tax identification number or any subcontractor in which the MCO has a 5 percent or more interest;

(2) Whether the individual or corporation with an ownership or control interest in the MCO:

(a) Is related to another person with ownership or control interest in the disclosing entity as a spouse, parent, child, or sibling; or

(b) Whether the individual or corporation with an ownership or control interest in any subcontractor in which the MCO has a 5 percent or more interest is related to another person with ownership or control interest in the MCO as a spouse, parent, child, or sibling;

(3) The name of any other MCO in which an owner of the MCO has an ownership or control interest;

(4) The name, address, date of birth, and Social Security number of any managing employee or agent of the MCO;

(5) Disclosures of ownership and control information from MCOs are due at the following times:

(a) Upon application;

(b) Upon the managed care entity executing the contract with the State;

(c) Upon renewal or extension of the contract; and

(d) Within 35 days after any change in ownership of the managed care entity.

I. An MCO shall report to the Department all overpayments identified and recovered, specifying the overpayments due to fraud.

J. An MCO shall report third-party liability collection activities as described in COMAR 10.67.04.18.
K. An MCO shall report to the Department the amounts the MCO has cost-avoided and the number of third-party liability cases the MCO has handled.

L. An MCO shall notify the Department promptly when it has knowledge of an enrollee’s change of residence or death.

M. An MCO shall notify the Department promptly when the MCO receives information about a change in a network provider’s circumstances that may affect the network provider’s eligibility to participate in the Program, including the termination of the provider agreement with the MCO.

N. An MCO shall submit all required data, documentation and information in the format specified by the Department.

O. An MCO’s chief executive officer, chief financial officer, or directly-reporting authorized employee shall certify to the best of that individual’s information, knowledge, and belief, that any records, data, or other documents requested under regulations are accurate, complete and truthful.

P. As directed by the Department’s OIG, the MCO shall submit written reports documenting its Program Integrity efforts, including but not limited to:

(1) The dollar amount of losses and recoveries attributable to overpayment, abuse, and fraud; and

(2) The number of referrals to the Department’s OIG during the prior State fiscal year.

Chapter 08 Maryland Medicaid Managed Care Program: Non-Capitated Covered Services

.01 Scope.

This chapter describes the services that are not the responsibility of the MCOs but are covered by the Department on a fee-for-service basis.

.02 Behavioral Health Non-Capitated Covered Services.

A. An MCO is not responsible for reimbursing for the following substance use disorder services, regardless of diagnosis:

(1) Services delivered by a community-based provider as described in COMAR 10.09.80 with the following procedure codes:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H0001</td>
<td>Alcohol/drug assessment</td>
</tr>
<tr>
<td>H0004</td>
<td>Alcohol/drug individual counseling and therapy</td>
</tr>
</tbody>
</table>
(2) Substance use disorder services provided to children in an ICF-A with the revenue code 0100, Residential Services, child and adolescent.

B. An MCO is not responsible for reimbursing for the following services performed by free-standing laboratories, regardless of diagnosis:

(1) Presumptive drug tests; and

(2) Definitive drug tests.

C. An MCO is not responsible for reimbursing for the laboratory services described in §B of this regulation unless billed by a:

(1) Primary care provider; or

(2) Other somatic care provider.
D. An MCO is not responsible for reimbursing for the following substance use disorder services if the MCO is billed with a primary diagnosis listed in §K of this regulation:

(1) Services delivered by an inpatient hospital with the following revenue codes:

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0114</td>
<td>Room and Board, Private Bed, Psychiatric</td>
</tr>
<tr>
<td>0116</td>
<td>Room and Board, Private Bed, Detoxification</td>
</tr>
<tr>
<td>0124</td>
<td>Room and Board, Semi-Private Bed, Psychiatric</td>
</tr>
<tr>
<td>0126</td>
<td>Room and Board, Semi-Private Bed, Detoxification</td>
</tr>
<tr>
<td>0134</td>
<td>Room and Board, 3-4 Beds, Psychiatric</td>
</tr>
<tr>
<td>0136</td>
<td>Room and Board, 3-4 Beds, Detoxification</td>
</tr>
<tr>
<td>0154</td>
<td>Room and Board, Ward, Psychiatric</td>
</tr>
<tr>
<td>0156</td>
<td>Room and Board, Ward, Detoxification</td>
</tr>
<tr>
<td>0762</td>
<td>Room and Board, Observation Room</td>
</tr>
</tbody>
</table>

(2) Services delivered by an outpatient hospital with the following revenue codes:

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0900</td>
<td>Behavioral Health Treatments/Services-General Classification</td>
</tr>
<tr>
<td>0905</td>
<td>Intensive Outpatient Services-Psychiatric</td>
</tr>
<tr>
<td>0906</td>
<td>Intensive Outpatient Services-Chemical Dependency</td>
</tr>
<tr>
<td>0911</td>
<td>Behavioral Health-Rehabilitation</td>
</tr>
<tr>
<td>0912</td>
<td>Partial Hospitalization-Less Intensive</td>
</tr>
<tr>
<td>0913</td>
<td>Partial Hospitalization-Intensive</td>
</tr>
<tr>
<td>0914</td>
<td>Behavioral Health-Individual Therapy</td>
</tr>
<tr>
<td>0915</td>
<td>Behavioral Health-Group Therapy</td>
</tr>
</tbody>
</table>
(3) Services delivered by an emergency department with the following revenue codes:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0450</td>
<td>General classification</td>
</tr>
<tr>
<td>0451</td>
<td>EMTALA</td>
</tr>
<tr>
<td>0452</td>
<td>ER Beyond EMTALA</td>
</tr>
<tr>
<td>0456</td>
<td>Urgent Care</td>
</tr>
<tr>
<td>0459</td>
<td>Other Emergency Room</td>
</tr>
</tbody>
</table>

E. An MCO is not responsible for reimbursing for mental health services with a primary diagnosis listed in §M of this regulation when the services are provided by a hospital and the services are the result of the treatment of mental health diagnosis.

F. An MCO shall be responsible for reimbursing for behavioral health services delivered by the participant’s primary care provider.

G. An MCO shall be responsible for reimbursing for somatic services related to gender identity disorder, including gender reassignment surgery.

H. An MCO is not responsible for reimbursing the behavioral poisoning diagnoses listed in §O of this regulation in an emergency department setting.

I. An MCO is not responsible for services billed by specialty mental health providers listed in COMAR 10.09.59 when the bill includes the specialty behavioral health diagnoses listed in §L or M in the primary diagnosis field.

J. An MCO is not responsible for behavioral health medications.
K. An MCO is not responsible for reimbursing for services billed by a physician related to prescribing buprenorphine or Vivitrol when the following conditions are met:

(1) The physician delivering buprenorphine has a DATA 2000 waiver;

(2) The physician is not the participant’s primary care provider;

(3) The primary diagnosis is substance use disorder;

(4) The primary reason for the visit is substance use disorder treatment; and

(5) The procedure code listed on the claims is one of the following:

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99201</td>
<td>Evaluation and Management, Minimal, new patient</td>
</tr>
<tr>
<td>99202</td>
<td>Evaluation and Management, Straight forward, new patient</td>
</tr>
<tr>
<td>99203</td>
<td>Evaluation and Management, Low complexity, new patient</td>
</tr>
<tr>
<td>99204</td>
<td>Evaluation and Management, Moderately complex, new patient</td>
</tr>
<tr>
<td>99205</td>
<td>Evaluation and Management, Highly complex, new patient</td>
</tr>
<tr>
<td>99211</td>
<td>Evaluation and Management, Minimal</td>
</tr>
<tr>
<td>99212</td>
<td>Evaluation and Management, Straight forward</td>
</tr>
<tr>
<td>99213</td>
<td>Evaluation and Management, Low complexity</td>
</tr>
<tr>
<td>99214</td>
<td>Evaluation and Management, Moderately complex</td>
</tr>
<tr>
<td>99215</td>
<td>Evaluation and Management, Highly complex</td>
</tr>
<tr>
<td>J8499</td>
<td>Prescription drug, oral, non-chemotherapeutic; buprenorphine</td>
</tr>
<tr>
<td>J2315</td>
<td>Vivitrol</td>
</tr>
<tr>
<td>J0571</td>
<td>Buprenorphine, oral, 1 mg</td>
</tr>
<tr>
<td>J0572</td>
<td>Buprenorphine/naloxone, oral, less than or equal to 3 mg of buprenorphine</td>
</tr>
</tbody>
</table>
### J0573
Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg
buprenorphine

### J0574
Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg
buprenorphine

### 80305
Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service

### 80307
Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers (e.g., immunoassay, enzyme assay, TOF, MALDI, LDLD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service (when provider has appropriately licensed and has adequate instrumentation)

**L. Table of substance use disorder diagnoses:**

(1) For dates of service before October 1, 2015:

<table>
<thead>
<tr>
<th>Code</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>291.0</td>
<td>Alcohol withdrawal delirium</td>
</tr>
<tr>
<td>291.3</td>
<td>Alcohol-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>291.4</td>
<td>Idiosyncratic alcohol intoxication</td>
</tr>
<tr>
<td>291.5</td>
<td>Alcohol-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>291.81</td>
<td>Alcohol withdrawal</td>
</tr>
<tr>
<td>291.82</td>
<td>Alcohol induced sleep disorders</td>
</tr>
<tr>
<td>291.89</td>
<td>Other alcohol-induced mental disorders</td>
</tr>
<tr>
<td>291.9</td>
<td>Unspecified alcohol-induced mental disorders</td>
</tr>
<tr>
<td>292.0</td>
<td>Drug withdrawal</td>
</tr>
<tr>
<td>292.11</td>
<td>Drug-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>Code</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------</td>
</tr>
<tr>
<td>292.12</td>
<td>Drug-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>292.2</td>
<td>Pathological drug intoxication</td>
</tr>
<tr>
<td>292.81</td>
<td>Drug-induced delirium</td>
</tr>
<tr>
<td>292.84</td>
<td>Drug-induced mood disorder</td>
</tr>
<tr>
<td>292.85</td>
<td>Drug induced sleep disorders</td>
</tr>
<tr>
<td>292.89</td>
<td>Other specified drug-induced mental disorders</td>
</tr>
<tr>
<td>292.9</td>
<td>Unspecified drug-induced mental disorder</td>
</tr>
<tr>
<td>303.00</td>
<td>Acute alcoholic intoxication in alcoholism, unspecified</td>
</tr>
<tr>
<td>303.01</td>
<td>Acute alcoholic intoxication in alcoholism, continuous</td>
</tr>
<tr>
<td>303.02</td>
<td>Acute alcoholic intoxication in alcoholism, episodic</td>
</tr>
<tr>
<td>303.03</td>
<td>Acute alcoholic intoxication in alcoholism, in remission</td>
</tr>
<tr>
<td>303.90</td>
<td>Other and unspecified alcohol dependence, unspecified</td>
</tr>
<tr>
<td>303.91</td>
<td>Other and unspecified alcohol dependence, continuous</td>
</tr>
<tr>
<td>303.92</td>
<td>Other and unspecified alcohol dependence, episodic</td>
</tr>
<tr>
<td>303.93</td>
<td>Other and unspecified alcohol dependence, in remission</td>
</tr>
<tr>
<td>304.00</td>
<td>Opioid type dependence, unspecified</td>
</tr>
<tr>
<td>304.01</td>
<td>Opioid type dependence, continuous</td>
</tr>
<tr>
<td>304.02</td>
<td>Opioid type dependence, episodic</td>
</tr>
<tr>
<td>304.03</td>
<td>Opioid type dependence, in remission</td>
</tr>
<tr>
<td>304.10</td>
<td>Sedative, hypnotic or anxiolytic dependence, unspecified</td>
</tr>
<tr>
<td>304.11</td>
<td>Sedative, hypnotic or anxiolytic dependence, continuous</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>304.12</td>
<td>Sedative, hypnotic or anxiolytic dependence, episodic</td>
</tr>
<tr>
<td>304.13</td>
<td>Sedative, hypnotic or anxiolytic dependence, in remission</td>
</tr>
<tr>
<td>304.20</td>
<td>Cocaine dependence, unspecified</td>
</tr>
<tr>
<td>304.21</td>
<td>Cocaine dependence, continuous</td>
</tr>
<tr>
<td>304.22</td>
<td>Cocaine dependence, episodic</td>
</tr>
<tr>
<td>304.23</td>
<td>Cocaine dependence, in remission</td>
</tr>
<tr>
<td>304.30</td>
<td>Cannabis dependence, unspecified</td>
</tr>
<tr>
<td>304.31</td>
<td>Cannabis dependence, continuous</td>
</tr>
<tr>
<td>304.32</td>
<td>Cannabis dependence, episodic</td>
</tr>
<tr>
<td>304.33</td>
<td>Cannabis dependence, in remission</td>
</tr>
<tr>
<td>304.40</td>
<td>Amphetamine and other psychostimulant dependence, unspecified</td>
</tr>
<tr>
<td>304.41</td>
<td>Amphetamine and other psychostimulant dependence, continuous</td>
</tr>
<tr>
<td>304.42</td>
<td>Amphetamine and other psychostimulant dependence, episodic</td>
</tr>
<tr>
<td>304.43</td>
<td>Amphetamine and other psychostimulant dependence, in remission</td>
</tr>
<tr>
<td>304.50</td>
<td>Hallucinogen dependence, unspecified</td>
</tr>
<tr>
<td>304.51</td>
<td>Hallucinogen dependence, continuous</td>
</tr>
<tr>
<td>304.52</td>
<td>Hallucinogen dependence, episodic</td>
</tr>
<tr>
<td>304.53</td>
<td>Hallucinogen dependence, in remission</td>
</tr>
<tr>
<td>304.60</td>
<td>Other specified drug dependence, unspecified</td>
</tr>
<tr>
<td>304.61</td>
<td>Other specified drug dependence, continuous</td>
</tr>
<tr>
<td>304.62</td>
<td>Other specified drug dependence, episodic</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>304.63</td>
<td>Other specified drug dependence, in remission</td>
</tr>
<tr>
<td>304.70</td>
<td>Combinations of opioid type drug with any other drug dependence, unspecified</td>
</tr>
<tr>
<td>304.71</td>
<td>Combinations of opioid type drug with any other drug dependence, continuous</td>
</tr>
<tr>
<td>304.72</td>
<td>Combinations of opioid type drug with any other drug dependence, episodic</td>
</tr>
<tr>
<td>304.73</td>
<td>Combinations of opioid type drug with any other drug dependence, in remission</td>
</tr>
<tr>
<td>304.80</td>
<td>Combinations of drug dependence excluding opioid type drug, unspecified</td>
</tr>
<tr>
<td>304.81</td>
<td>Combinations of drug dependence excluding opioid type drug, continuous</td>
</tr>
<tr>
<td>304.82</td>
<td>Combinations of drug dependence excluding opioid type drug, episodic</td>
</tr>
<tr>
<td>304.83</td>
<td>Combinations of drug dependence excluding opioid type drug, in remission</td>
</tr>
<tr>
<td>304.90</td>
<td>Unspecified drug dependence, unspecified</td>
</tr>
<tr>
<td>304.91</td>
<td>Unspecified drug dependence, continuous</td>
</tr>
<tr>
<td>304.92</td>
<td>Unspecified drug dependence, episodic</td>
</tr>
<tr>
<td>304.93</td>
<td>Unspecified drug dependence, in remission</td>
</tr>
<tr>
<td>305.00</td>
<td>Alcohol abuse, unspecified</td>
</tr>
<tr>
<td>305.01</td>
<td>Alcohol abuse, continuous</td>
</tr>
<tr>
<td>305.02</td>
<td>Alcohol abuse, episodic</td>
</tr>
<tr>
<td>305.03</td>
<td>Alcohol abuse, in remission</td>
</tr>
<tr>
<td>305.1</td>
<td>Tobacco use disorder</td>
</tr>
<tr>
<td>305.20</td>
<td>Cannabis abuse, unspecified</td>
</tr>
<tr>
<td>305.21</td>
<td>Cannabis abuse, continuous</td>
</tr>
<tr>
<td>305.22</td>
<td>Cannabis abuse, episodic</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>305.23</td>
<td>Cannabis abuse, in remission</td>
</tr>
<tr>
<td>305.30</td>
<td>Hallucinogen abuse, unspecified</td>
</tr>
<tr>
<td>305.31</td>
<td>Hallucinogen abuse, continuous</td>
</tr>
<tr>
<td>305.32</td>
<td>Hallucinogen abuse, episodic</td>
</tr>
<tr>
<td>305.33</td>
<td>Hallucinogen abuse, in remission</td>
</tr>
<tr>
<td>305.40</td>
<td>Sedative, hypnotic or anxiolytic abuse, unspecified</td>
</tr>
<tr>
<td>305.41</td>
<td>Sedative, hypnotic or anxiolytic abuse, continuous</td>
</tr>
<tr>
<td>305.42</td>
<td>Sedative, hypnotic or anxiolytic abuse, episodic</td>
</tr>
<tr>
<td>305.43</td>
<td>Sedative, hypnotic or anxiolytic abuse, in remission</td>
</tr>
<tr>
<td>305.50</td>
<td>Opioid abuse, unspecified</td>
</tr>
<tr>
<td>305.51</td>
<td>Opioid abuse, continuous</td>
</tr>
<tr>
<td>305.52</td>
<td>Opioid abuse, episodic</td>
</tr>
<tr>
<td>305.53</td>
<td>Opioid abuse, in remission</td>
</tr>
<tr>
<td>305.60</td>
<td>Cocaine abuse, unspecified</td>
</tr>
<tr>
<td>305.61</td>
<td>Cocaine abuse, continuous</td>
</tr>
<tr>
<td>305.62</td>
<td>Cocaine abuse, episodic</td>
</tr>
<tr>
<td>305.63</td>
<td>Cocaine abuse, in remission</td>
</tr>
<tr>
<td>305.70</td>
<td>Amphetamine or related acting sympathomimetic abuse, unspecified</td>
</tr>
<tr>
<td>305.71</td>
<td>Amphetamine or related acting sympathomimetic abuse, continuous</td>
</tr>
<tr>
<td>305.72</td>
<td>Amphetamine or related acting sympathomimetic abuse, episodic</td>
</tr>
<tr>
<td>305.73</td>
<td>Amphetamine or related acting sympathomimetic abuse, in remission</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>305.80</td>
<td>Antidepressant type abuse, unspecified</td>
</tr>
<tr>
<td>305.81</td>
<td>Antidepressant type abuse, continuous</td>
</tr>
<tr>
<td>305.82</td>
<td>Antidepressant type abuse, episodic</td>
</tr>
<tr>
<td>305.83</td>
<td>Antidepressant type abuse, in remission</td>
</tr>
<tr>
<td>305.90</td>
<td>Other, mixed, or unspecified drug abuse, unspecified</td>
</tr>
<tr>
<td>305.91</td>
<td>Other, mixed, or unspecified drug abuse, continuous</td>
</tr>
<tr>
<td>305.92</td>
<td>Other, mixed, or unspecified drug abuse, episodic</td>
</tr>
<tr>
<td>305.93</td>
<td>Other, mixed, or unspecified drug abuse, in remission</td>
</tr>
<tr>
<td>648.30</td>
<td>Drug dependence of mother, unspecified as to episode of care or not applicable</td>
</tr>
<tr>
<td>648.31</td>
<td>Drug dependence of mother, delivered, with or without mention of antepartum condition</td>
</tr>
<tr>
<td>648.32</td>
<td>Drug dependence of mother, delivered, with mention of postpartum complication</td>
</tr>
<tr>
<td>648.33</td>
<td>Drug dependence of mother, antepartum condition or complication</td>
</tr>
<tr>
<td>648.34</td>
<td>Drug dependence of mother, postpartum condition or complication</td>
</tr>
</tbody>
</table>

(2) For dates of service on or after October 1, 2015:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1010</td>
<td>Alcohol abuse, uncomplicated</td>
</tr>
<tr>
<td>F10120</td>
<td>Alcohol abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F10121</td>
<td>Alcohol abuse with intoxication delirium</td>
</tr>
<tr>
<td>F10129</td>
<td>Alcohol abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1014</td>
<td>Alcohol abuse with alcohol-induced mood disorder</td>
</tr>
<tr>
<td>F10150</td>
<td>Alcohol abuse with alcohol-induce psychotic disorder with delusions</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td>F10151</td>
<td>Alcohol abuse with alcohol-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F10159</td>
<td>Alcohol abuse with alcohol-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F10180</td>
<td>Alcohol abuse with alcohol-induced anxiety disorder</td>
</tr>
<tr>
<td>F10181</td>
<td>Alcohol abuse with alcohol-induced sexual dysfunction</td>
</tr>
<tr>
<td>F10182</td>
<td>Alcohol abuse with alcohol-induced sleep disorder</td>
</tr>
<tr>
<td>F10188</td>
<td>Alcohol abuse with other alcohol-induced disorder</td>
</tr>
<tr>
<td>F1019</td>
<td>Alcohol abuse with unspecified alcohol-induced disorder</td>
</tr>
<tr>
<td>F1020</td>
<td>Alcohol dependence, uncomplicated</td>
</tr>
<tr>
<td>F1021</td>
<td>Alcohol dependence, in remission</td>
</tr>
<tr>
<td>F10220</td>
<td>Alcohol dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F10221</td>
<td>Alcohol dependence with intoxication delirium</td>
</tr>
<tr>
<td>F10229</td>
<td>Alcohol dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F10230</td>
<td>Alcohol dependence with withdrawal, uncomplicated</td>
</tr>
<tr>
<td>F10231</td>
<td>Alcohol dependence with withdrawal delirium</td>
</tr>
<tr>
<td>F10232</td>
<td>Alcohol dependence with withdrawal with perceptual disturbance</td>
</tr>
<tr>
<td>F10239</td>
<td>Alcohol dependence with withdrawal, unspecified</td>
</tr>
<tr>
<td>F1024</td>
<td>Alcohol dependence with alcohol-induced mood disorder</td>
</tr>
<tr>
<td>F10250</td>
<td>Alcohol dependence with alcohol-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F10251</td>
<td>Alcohol dependence with alcohol-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F10259</td>
<td>Alcohol dependence with alcohol-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F10280</td>
<td>Alcohol dependence with alcohol-induced anxiety disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>F10281</td>
<td>Alcohol dependence with alcohol-induced sexual dysfunction</td>
</tr>
<tr>
<td>F10282</td>
<td>Alcohol dependence with alcohol-induced sleep disorder</td>
</tr>
<tr>
<td>F10288</td>
<td>Alcohol dependence with other alcohol-induced disorder</td>
</tr>
<tr>
<td>F1029</td>
<td>Alcohol dependence with unspecified alcohol-induced disorder</td>
</tr>
<tr>
<td>F10920</td>
<td>Alcohol use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F10921</td>
<td>Alcohol use, unspecified with intoxication delirium</td>
</tr>
<tr>
<td>F10929</td>
<td>Alcohol use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1094</td>
<td>Alcohol use, unspecified with alcohol-induced mood disorder</td>
</tr>
<tr>
<td>F10950</td>
<td>Alcohol use, unspecified with alcohol-induce psychotic disorder with delusions</td>
</tr>
<tr>
<td>F10951</td>
<td>Alcohol use, unspecified with alcohol-induce psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F10959</td>
<td>Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F10980</td>
<td>Alcohol use, unspecified with alcohol-induced anxiety disorder</td>
</tr>
<tr>
<td>F10981</td>
<td>Alcohol use, unspecified with alcohol-induced sexual dysfunction</td>
</tr>
<tr>
<td>F10982</td>
<td>Alcohol use, unspecified with alcohol-induced sleep disorder</td>
</tr>
<tr>
<td>F10988</td>
<td>Alcohol use, unspecified with other alcohol-induced disorder</td>
</tr>
<tr>
<td>F1099</td>
<td>Alcohol use, unspecified with unspecified alcohol-induced disorder</td>
</tr>
<tr>
<td>F1110</td>
<td>Opioid abuse, uncomplicated</td>
</tr>
<tr>
<td>F11120</td>
<td>Opioid abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F11121</td>
<td>Opioid abuse with intoxication delirium</td>
</tr>
<tr>
<td>F11122</td>
<td>Opioid abuse with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F11129</td>
<td>Opioid abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>F1114</td>
<td>Opioid abuse with opioid-induced mood disorder</td>
</tr>
<tr>
<td>F11150</td>
<td>Opioid abuse with opioid-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F11151</td>
<td>Opioid abuse with opioid-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F11159</td>
<td>Opioid abuse with opioid-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F11181</td>
<td>Opioid abuse with opioid-induced sexual dysfunction</td>
</tr>
<tr>
<td>F11182</td>
<td>Opioid abuse with opioid-induced sleep disorder</td>
</tr>
<tr>
<td>F11188</td>
<td>Opioid abuse with other opioid-induced disorder</td>
</tr>
<tr>
<td>F1119</td>
<td>Opioid abuse with unspecified opioid-induced disorder</td>
</tr>
<tr>
<td>F1120</td>
<td>Opioid dependence, uncomplicated</td>
</tr>
<tr>
<td>F1121</td>
<td>Opioid dependence, in remission</td>
</tr>
<tr>
<td>F11220</td>
<td>Opioid dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F11221</td>
<td>Opioid dependence with intoxication delirium</td>
</tr>
<tr>
<td>F11222</td>
<td>Opioid dependence with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F11229</td>
<td>Opioid dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F1123</td>
<td>Opioid dependence with withdrawal</td>
</tr>
<tr>
<td>F1124</td>
<td>Opioid dependence with opioid-induced mood disorder</td>
</tr>
<tr>
<td>F11250</td>
<td>Opioid dependence with opioid-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F11251</td>
<td>Opioid dependence with opioid-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F11259</td>
<td>Opioid dependence with opioid-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F11281</td>
<td>Opioid dependence with opioid-induced sexual dysfunction</td>
</tr>
<tr>
<td>F11282</td>
<td>Opioid dependence with opioid-induced sleep disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>F11288</td>
<td>Opioid dependence with other opioid-induced disorder</td>
</tr>
<tr>
<td>F1129</td>
<td>Opioid dependence with unspecified opioid-induced disorder</td>
</tr>
<tr>
<td>F1190</td>
<td>Opioid use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F11920</td>
<td>Opioid use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F11921</td>
<td>Opioid use, unspecified with intoxication delirium</td>
</tr>
<tr>
<td>F11922</td>
<td>Opioid use, unspecified with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F11929</td>
<td>Opioid use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1193</td>
<td>Opioid use, unspecified with withdrawal</td>
</tr>
<tr>
<td>F1194</td>
<td>Opioid use, unspecified with opioid-induced mood disorder</td>
</tr>
<tr>
<td>F11950</td>
<td>Opioid use, unspecified with opioid-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F11951</td>
<td>Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F11959</td>
<td>Opioid use, unspecified with opioid-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F11981</td>
<td>Opioid use, unspecified with opioid-induced sexual dysfunction</td>
</tr>
<tr>
<td>F11982</td>
<td>Opioid use, unspecified with opioid-induced sleep disorder</td>
</tr>
<tr>
<td>F11988</td>
<td>Opioid use, unspecified with other opioid-induced disorder</td>
</tr>
<tr>
<td>F1199</td>
<td>Opioid use, unspecified with unspecified opioid-induced disorder</td>
</tr>
<tr>
<td>F1210</td>
<td>Cannabis abuse, uncomplicated</td>
</tr>
<tr>
<td>F12120</td>
<td>Cannabis abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F12121</td>
<td>Cannabis abuse with intoxication delirium</td>
</tr>
<tr>
<td>F12122</td>
<td>Cannabis abuse with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F12129</td>
<td>Cannabis abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>F12150</td>
<td>Cannabis abuse with psychotic disorder with delusions</td>
</tr>
<tr>
<td>F12151</td>
<td>Cannabis abuse with psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F12159</td>
<td>Cannabis abuse with psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F12180</td>
<td>Cannabis abuse with cannabis-induced anxiety disorder</td>
</tr>
<tr>
<td>F12188</td>
<td>Cannabis abuse with other cannabis-induced disorder</td>
</tr>
<tr>
<td>F1219</td>
<td>Cannabis abuse with unspecified cannabis-induced disorder</td>
</tr>
<tr>
<td>F1220</td>
<td>Cannabis dependence, uncomplicated</td>
</tr>
<tr>
<td>F1221</td>
<td>Cannabis dependence, in remission</td>
</tr>
<tr>
<td>F12220</td>
<td>Cannabis dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F12221</td>
<td>Cannabis dependence with intoxication delirium</td>
</tr>
<tr>
<td>F12222</td>
<td>Cannabis dependence with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F12229</td>
<td>Cannabis dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F1223</td>
<td>Cannabis dependence with withdrawal</td>
</tr>
<tr>
<td>F12250</td>
<td>Cannabis dependence with psychotic disorder with delusions</td>
</tr>
<tr>
<td>F12251</td>
<td>Cannabis dependence with psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F12259</td>
<td>Cannabis dependence with psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F12280</td>
<td>Cannabis dependence with cannabis-induced anxiety disorder</td>
</tr>
<tr>
<td>F12288</td>
<td>Cannabis dependence with other cannabis-induced disorder</td>
</tr>
<tr>
<td>F1229</td>
<td>Cannabis dependence with unspecified cannabis-induced disorder</td>
</tr>
<tr>
<td>F1290</td>
<td>Cannabis use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F12920</td>
<td>Cannabis use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>F12921</td>
<td>Cannabis use, unspecified with intoxication delirium</td>
</tr>
<tr>
<td>F12922</td>
<td>Cannabis use, unspecified with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F12929</td>
<td>Cannabis use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1293</td>
<td>Cannabis use, unspecified with withdrawal</td>
</tr>
<tr>
<td>F12950</td>
<td>Cannabis use, unspecified with psychotic disorder with delusions</td>
</tr>
<tr>
<td>F12951</td>
<td>Cannabis use, unspecified with psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F12959</td>
<td>Cannabis use, unspecified with psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F12980</td>
<td>Cannabis use, unspecified with anxiety disorder</td>
</tr>
<tr>
<td>F12988</td>
<td>Cannabis use, unspecified with other cannabis-induced disorder</td>
</tr>
<tr>
<td>F1299</td>
<td>Cannabis use, unspecified with unspecified cannabis-induced disorder</td>
</tr>
<tr>
<td>F1310</td>
<td>Sedative, hypnotic or anxiolytic abuse, uncomplicated</td>
</tr>
<tr>
<td>F13120</td>
<td>Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F13121</td>
<td>Sedative, hypnotic or anxiolytic abuse with intoxication delirium</td>
</tr>
<tr>
<td>F13129</td>
<td>Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1314</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder</td>
</tr>
<tr>
<td>F13150</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F13151</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F13159</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F13180</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder</td>
</tr>
<tr>
<td>F13181</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction</td>
</tr>
<tr>
<td>F13182</td>
<td>Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder</td>
</tr>
<tr>
<td>F13188</td>
<td>Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder</td>
</tr>
<tr>
<td>F1319</td>
<td>Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder</td>
</tr>
<tr>
<td>F1320</td>
<td>Sedative, hypnotic or anxiolytic dependence, uncomplicated</td>
</tr>
<tr>
<td>F1321</td>
<td>Sedative, hypnotic or anxiolytic dependence, in remission</td>
</tr>
<tr>
<td>F13220</td>
<td>Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F13221</td>
<td>Sedative, hypnotic or anxiolytic dependence with intoxication delirium</td>
</tr>
<tr>
<td>F13229</td>
<td>Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F13230</td>
<td>Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated</td>
</tr>
<tr>
<td>F13231</td>
<td>Sedative, hypnotic or anxiolytic dependence with withdrawal delirium</td>
</tr>
<tr>
<td>F13232</td>
<td>Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance</td>
</tr>
<tr>
<td>F13239</td>
<td>Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified</td>
</tr>
<tr>
<td>F1324</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder</td>
</tr>
<tr>
<td>F13250</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F13251</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F13259</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F13280</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder</td>
</tr>
<tr>
<td>F13281</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction</td>
</tr>
<tr>
<td>F13282</td>
<td>Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder</td>
</tr>
<tr>
<td>F13288</td>
<td>Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder</td>
</tr>
<tr>
<td>F1329</td>
<td>Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder</td>
</tr>
<tr>
<td>F1390</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F13920</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F13921</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with intoxication delirium</td>
</tr>
<tr>
<td>F13929</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F13930</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with withdrawal, uncomplicated</td>
</tr>
<tr>
<td>F13931</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with withdrawal delirium</td>
</tr>
<tr>
<td>F13932</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with withdrawal with perceptual disturbances</td>
</tr>
<tr>
<td>F13939</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with withdrawal, unspecified</td>
</tr>
<tr>
<td>F1394</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced mood disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F13950</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F13951</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F13959</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced psychotic disorder with, unspecified</td>
</tr>
<tr>
<td>F13980</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced anxiety disorder</td>
</tr>
<tr>
<td>F13981</td>
<td>Sedative, hypnotic, or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced sexual dysfunction</td>
</tr>
<tr>
<td>F13982</td>
<td>Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic, or anxiolytic-induced sleep disorder</td>
</tr>
<tr>
<td>F13988</td>
<td>Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic, or anxiolytic-induced disorder</td>
</tr>
<tr>
<td>F1399</td>
<td>Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic, or anxiolytic-induced disorder</td>
</tr>
<tr>
<td>F1410</td>
<td>Cocaine abuse, uncomplicated</td>
</tr>
<tr>
<td>F14120</td>
<td>Cocaine abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F14121</td>
<td>Cocaine abuse with intoxication with delirium</td>
</tr>
<tr>
<td>F14122</td>
<td>Cocaine abuse with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F14129</td>
<td>Cocaine abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1414</td>
<td>Cocaine abuse with cocaine-induced mood disorder</td>
</tr>
<tr>
<td>F14150</td>
<td>Cocaine abuse with cocaine-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F14151</td>
<td>Cocaine abuse with cocaine-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F14159</td>
<td>Cocaine abuse with cocaine-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Disorder Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>F14180</td>
<td>Cocaine abuse with cocaine-induced anxiety disorder</td>
</tr>
<tr>
<td>F14181</td>
<td>Cocaine abuse with cocaine-induced sexual dysfunction</td>
</tr>
<tr>
<td>F14182</td>
<td>Cocaine abuse with cocaine-induced sleep disorder</td>
</tr>
<tr>
<td>F14188</td>
<td>Cocaine abuse with other cocaine-induced disorder</td>
</tr>
<tr>
<td>F1419</td>
<td>Cocaine abuse with unspecified cocaine-induced disorder</td>
</tr>
<tr>
<td>F1420</td>
<td>Cocaine dependence, uncomplicated</td>
</tr>
<tr>
<td>F1421</td>
<td>Cocaine dependence, in remission</td>
</tr>
<tr>
<td>F14220</td>
<td>Cocaine dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F14221</td>
<td>Cocaine dependence with intoxication delirium</td>
</tr>
<tr>
<td>F14222</td>
<td>Cocaine dependence with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F14229</td>
<td>Cocaine dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F1423</td>
<td>Cocaine dependence with withdrawal</td>
</tr>
<tr>
<td>F1424</td>
<td>Cocaine dependence with cocaine-induced mood disorder</td>
</tr>
<tr>
<td>F14250</td>
<td>Cocaine dependence with cocaine-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F14251</td>
<td>Cocaine dependence with cocaine-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F14259</td>
<td>Cocaine dependence with cocaine-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F14280</td>
<td>Cocaine dependence with cocaine-induced anxiety disorder</td>
</tr>
<tr>
<td>F14281</td>
<td>Cocaine dependence with cocaine-induced sexual dysfunction</td>
</tr>
<tr>
<td>F14282</td>
<td>Cocaine dependence with cocaine-induced sleep disorder</td>
</tr>
<tr>
<td>F14288</td>
<td>Cocaine dependence with other cocaine-induced disorder</td>
</tr>
<tr>
<td>F1429</td>
<td>Cocaine dependence with unspecified cocaine-induced disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>F1490</td>
<td>Cocaine use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F14920</td>
<td>Cocaine use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F14921</td>
<td>Cocaine use, unspecified with intoxication delirium</td>
</tr>
<tr>
<td>F14922</td>
<td>Cocaine use, unspecified with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F14929</td>
<td>Cocaine use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1494</td>
<td>Cocaine use, unspecified with cocaine-induced mood disorder</td>
</tr>
<tr>
<td>F14950</td>
<td>Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F14951</td>
<td>Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F14959</td>
<td>Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F14980</td>
<td>Cocaine use, unspecified with cocaine-induced anxiety disorder</td>
</tr>
<tr>
<td>F14981</td>
<td>Cocaine use, unspecified with cocaine-induced sexual dysfunction</td>
</tr>
<tr>
<td>F14982</td>
<td>Cocaine use, unspecified with cocaine-induced sleep disorder</td>
</tr>
<tr>
<td>F14988</td>
<td>Cocaine use, unspecified with other cocaine-induced disorder</td>
</tr>
<tr>
<td>F1499</td>
<td>Cocaine use, unspecified with unspecified cocaine-induced disorder</td>
</tr>
<tr>
<td>F1510</td>
<td>Other stimulant abuse, uncomplicated</td>
</tr>
<tr>
<td>F15120</td>
<td>Other stimulant abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F15121</td>
<td>Other stimulant abuse with intoxication delirium</td>
</tr>
<tr>
<td>F15122</td>
<td>Other stimulant abuse with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F15129</td>
<td>Other stimulant abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1514</td>
<td>Other stimulant abuse with stimulant-induced mood disorder</td>
</tr>
<tr>
<td>F15150</td>
<td>Other stimulant abuse with stimulant-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>F15151</td>
<td>Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F15159</td>
<td>Other stimulant abuse with stimulant-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F15180</td>
<td>Other stimulant abuse with stimulant-induced anxiety disorder</td>
</tr>
<tr>
<td>F15181</td>
<td>Other stimulant abuse with stimulant-induced sexual dysfunction</td>
</tr>
<tr>
<td>F15182</td>
<td>Other stimulant abuse with stimulant-induced sleep disorder</td>
</tr>
<tr>
<td>F15188</td>
<td>Other stimulant abuse with other stimulant-induced disorder</td>
</tr>
<tr>
<td>F1519</td>
<td>Other stimulant abuse with unspecified stimulant-induced disorder</td>
</tr>
<tr>
<td>F1520</td>
<td>Other stimulant dependence, uncomplicated</td>
</tr>
<tr>
<td>F1521</td>
<td>Other stimulant dependence, in remission</td>
</tr>
<tr>
<td>F15220</td>
<td>Other stimulant dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F15221</td>
<td>Other stimulant dependence with intoxication delirium</td>
</tr>
<tr>
<td>F15222</td>
<td>Other stimulant dependence with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F15229</td>
<td>Other stimulant dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F1523</td>
<td>Other stimulant dependence with withdrawal</td>
</tr>
<tr>
<td>F1524</td>
<td>Other stimulant dependence with stimulant-induced mood disorder</td>
</tr>
<tr>
<td>F15250</td>
<td>Other stimulant dependence with stimulant-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F15251</td>
<td>Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F15259</td>
<td>Other stimulant dependence with stimulant-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F15280</td>
<td>Other stimulant dependence with stimulant-induced anxiety disorder</td>
</tr>
<tr>
<td>F15281</td>
<td>Other stimulant dependence with stimulant-induced sexual dysfunction</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>F15282</td>
<td>Other stimulant dependence with stimulant-induced sleep disorder</td>
</tr>
<tr>
<td>F15288</td>
<td>Other stimulant dependence with other stimulant-induced disorder</td>
</tr>
<tr>
<td>F1529</td>
<td>Other stimulant dependence with unspecified stimulant-induced disorder</td>
</tr>
<tr>
<td>F1590</td>
<td>Other stimulant use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F15920</td>
<td>Other stimulant use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F15921</td>
<td>Other stimulant use, unspecified with intoxication delirium</td>
</tr>
<tr>
<td>F15922</td>
<td>Other stimulant use, unspecified with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F15929</td>
<td>Other stimulant use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1593</td>
<td>Other stimulant use, unspecified with withdrawal</td>
</tr>
<tr>
<td>F1594</td>
<td>Other stimulant use, unspecified with stimulant-induced mood disorder</td>
</tr>
<tr>
<td>F15950</td>
<td>Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F15951</td>
<td>Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F15959</td>
<td>Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F15980</td>
<td>Other stimulant use, unspecified with stimulant-induced anxiety disorder</td>
</tr>
<tr>
<td>F15981</td>
<td>Other stimulant use, unspecified with stimulant-induced sexual dysfunction</td>
</tr>
<tr>
<td>F15982</td>
<td>Other stimulant use, unspecified with stimulant-induced sleep disorder</td>
</tr>
<tr>
<td>F15988</td>
<td>Other stimulant use, unspecified with other stimulant-induced disorder</td>
</tr>
<tr>
<td>F1599</td>
<td>Other stimulant use, unspecified with unspecified stimulant-induced disorder</td>
</tr>
<tr>
<td>F1610</td>
<td>Hallucinogen abuse, uncomplicated</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>F16120</td>
<td>Hallucinogen abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F16121</td>
<td>Hallucinogen abuse with intoxication with delirium</td>
</tr>
<tr>
<td>F16122</td>
<td>Hallucinogen abuse with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F16129</td>
<td>Hallucinogen abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1614</td>
<td>Hallucinogen abuse with hallucinogen-induced mood disorder</td>
</tr>
<tr>
<td>F16150</td>
<td>Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F16151</td>
<td>Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F16159</td>
<td>Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F16180</td>
<td>Hallucinogen abuse with hallucinogen-induced anxiety disorder</td>
</tr>
<tr>
<td>F16183</td>
<td>Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)</td>
</tr>
<tr>
<td>F16188</td>
<td>Hallucinogen abuse with other hallucinogen-induced disorder</td>
</tr>
<tr>
<td>F1619</td>
<td>Hallucinogen abuse with unspecified hallucinogen-induced disorder</td>
</tr>
<tr>
<td>F1620</td>
<td>Hallucinogen dependence, uncomplicated</td>
</tr>
<tr>
<td>F1621</td>
<td>Hallucinogen dependence, in remission</td>
</tr>
<tr>
<td>F16220</td>
<td>Hallucinogen dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F16221</td>
<td>Hallucinogen dependence with intoxication with delirium</td>
</tr>
<tr>
<td>F16229</td>
<td>Hallucinogen dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F1624</td>
<td>Hallucinogen dependence with hallucinogen-induced mood disorder</td>
</tr>
<tr>
<td>F16250</td>
<td>Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F16251</td>
<td>Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F16259</td>
<td>Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F16280</td>
<td>Hallucinogen dependence with hallucinogen-induced anxiety disorder</td>
</tr>
<tr>
<td>F16283</td>
<td>Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)</td>
</tr>
<tr>
<td>F16288</td>
<td>Hallucinogen dependence with other hallucinogen-induced disorder</td>
</tr>
<tr>
<td>F1629</td>
<td>Hallucinogen dependence with unspecified hallucinogen-induced disorder</td>
</tr>
<tr>
<td>F1690</td>
<td>Hallucinogen use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F16920</td>
<td>Hallucinogen use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F16921</td>
<td>Hallucinogen use, unspecified with intoxication with delirium</td>
</tr>
<tr>
<td>F16929</td>
<td>Hallucinogen use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1694</td>
<td>Hallucinogen use, unspecified with hallucinogen-induced mood disorder</td>
</tr>
<tr>
<td>F16950</td>
<td>Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F16951</td>
<td>Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F16959</td>
<td>Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F16980</td>
<td>Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder</td>
</tr>
<tr>
<td>F16983</td>
<td>Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)</td>
</tr>
<tr>
<td>F16988</td>
<td>Hallucinogen use, unspecified with other hallucinogen-induced disorder</td>
</tr>
<tr>
<td>F1699</td>
<td>Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder</td>
</tr>
<tr>
<td>F17200</td>
<td>Nicotine dependence, unspecified, uncomplicated</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F17201</td>
<td>Nicotine dependence, unspecified, in remission</td>
</tr>
<tr>
<td>F17203</td>
<td>Nicotine dependence unspecified, with withdrawal</td>
</tr>
<tr>
<td>F17208</td>
<td>Nicotine dependence, unspecified, with other nicotine-induced disorders</td>
</tr>
<tr>
<td>F17209</td>
<td>Nicotine dependence, unspecified, with unspecified nicotine-induced disorders</td>
</tr>
<tr>
<td>F17210</td>
<td>Nicotine dependence, cigarettes, uncomplicated</td>
</tr>
<tr>
<td>F17211</td>
<td>Nicotine dependence, cigarettes, in remission</td>
</tr>
<tr>
<td>F17213</td>
<td>Nicotine dependence, cigarettes, with withdrawal</td>
</tr>
<tr>
<td>F17218</td>
<td>Nicotine dependence, cigarettes, with other nicotine-induced disorders</td>
</tr>
<tr>
<td>F17219</td>
<td>Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders</td>
</tr>
<tr>
<td>F17220</td>
<td>Nicotine dependence, chewing tobacco, uncomplicated</td>
</tr>
<tr>
<td>F17221</td>
<td>Nicotine dependence, chewing tobacco, in remission</td>
</tr>
<tr>
<td>F17223</td>
<td>Nicotine dependence, chewing tobacco, with withdrawal</td>
</tr>
<tr>
<td>F17228</td>
<td>Nicotine dependence, chewing tobacco, with other nicotine-induced disorders</td>
</tr>
<tr>
<td>F17229</td>
<td>Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders</td>
</tr>
<tr>
<td>F17230</td>
<td>Nicotine dependence, other tobacco product, uncomplicated</td>
</tr>
<tr>
<td>F17231</td>
<td>Nicotine dependence, other tobacco product, in remission</td>
</tr>
<tr>
<td>F17232</td>
<td>Nicotine dependence, other tobacco product, with withdrawal</td>
</tr>
<tr>
<td>F17233</td>
<td>Nicotine dependence, other tobacco product, with other nicotine-induced disorders</td>
</tr>
<tr>
<td>F17234</td>
<td>Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders</td>
</tr>
<tr>
<td>F1810</td>
<td>Inhalant abuse, uncomplicated</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F18120</td>
<td>Inhalant abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F18121</td>
<td>Inhalant abuse with intoxication delirium</td>
</tr>
<tr>
<td>F18129</td>
<td>Inhalant abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1814</td>
<td>Inhalant abuse with inhalant-induced mood disorder</td>
</tr>
<tr>
<td>F18150</td>
<td>Inhalant abuse with inhalant-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F18151</td>
<td>Inhalant abuse with inhalant-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F18159</td>
<td>Inhalant abuse with inhalant-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F1817</td>
<td>Inhalant abuse with inhalant-induced dementia</td>
</tr>
<tr>
<td>F18180</td>
<td>Inhalant abuse with inhalant-induced anxiety disorder</td>
</tr>
<tr>
<td>F18188</td>
<td>Inhalant abuse with other inhalant-induced disorder</td>
</tr>
<tr>
<td>F1819</td>
<td>Inhalant abuse with unspecified inhalant-induced disorder</td>
</tr>
<tr>
<td>F1820</td>
<td>Inhalant dependence, uncomplicated</td>
</tr>
<tr>
<td>F1821</td>
<td>Inhalant dependence, in remission</td>
</tr>
<tr>
<td>F18220</td>
<td>Inhalant dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F18221</td>
<td>Inhalant dependence with intoxication delirium</td>
</tr>
<tr>
<td>F18229</td>
<td>Inhalant dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F1824</td>
<td>Inhalant dependence with inhalant-induced mood disorder</td>
</tr>
<tr>
<td>F18250</td>
<td>Inhalant dependence with inhalant-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F18251</td>
<td>Inhalant dependence with inhalant-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F18259</td>
<td>Inhalant dependence with inhalant-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F1827</td>
<td>Inhalant dependence with inhalant-induced dementia</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>F18280</td>
<td>Inhalant dependence with inhalant-induced anxiety disorder</td>
</tr>
<tr>
<td>F18288</td>
<td>Inhalant dependence with other inhalant-induced disorder</td>
</tr>
<tr>
<td>F1829</td>
<td>Inhalant dependence with unspecified inhalant-induced disorder</td>
</tr>
<tr>
<td>F1890</td>
<td>Inhalant use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F18920</td>
<td>Inhalant use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F18921</td>
<td>Inhalant use, unspecified with intoxication with delirium</td>
</tr>
<tr>
<td>F18929</td>
<td>Inhalant use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F1894</td>
<td>Inhalant use, unspecified with inhalant-induced mood disorder</td>
</tr>
<tr>
<td>F18950</td>
<td>Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F18951</td>
<td>Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F18959</td>
<td>Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F18980</td>
<td>Inhalant use, unspecified with inhalant-induced anxiety disorder</td>
</tr>
<tr>
<td>F18988</td>
<td>Inhalant use, unspecified with other inhalant-induced disorder</td>
</tr>
<tr>
<td>F1899</td>
<td>Inhalant use, unspecified with unspecified inhalant-induced disorder</td>
</tr>
<tr>
<td>F1910</td>
<td>Other psychoactive substance abuse, uncomplicated</td>
</tr>
<tr>
<td>F19120</td>
<td>Other psychoactive substance abuse with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F19121</td>
<td>Other psychoactive substance abuse with intoxication delirium</td>
</tr>
<tr>
<td>F19122</td>
<td>Other psychoactive substance abuse with intoxication with perceptual disturbances</td>
</tr>
<tr>
<td>F19129</td>
<td>Other psychoactive substance abuse with intoxication, unspecified</td>
</tr>
<tr>
<td>F1914</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced mood disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F19150</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F19151</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F19159</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F19180</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder</td>
</tr>
<tr>
<td>F19181</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction</td>
</tr>
<tr>
<td>F19182</td>
<td>Other psychoactive substance abuse with psychoactive substance-induced sleep disorder</td>
</tr>
<tr>
<td>F19188</td>
<td>Other psychoactive substance abuse with other psychoactive substance-induced disorder</td>
</tr>
<tr>
<td>F1919</td>
<td>Other psychoactive substance abuse with unspecified substance-induced disorder</td>
</tr>
<tr>
<td>F1920</td>
<td>Other psychoactive substance dependence, uncomplicated</td>
</tr>
<tr>
<td>F1921</td>
<td>Other psychoactive substance dependence, in remission</td>
</tr>
<tr>
<td>F19220</td>
<td>Other psychoactive substance dependence with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F19221</td>
<td>Other psychoactive substance dependence with intoxication delirium</td>
</tr>
<tr>
<td>F19222</td>
<td>Other psychoactive substance dependence with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>F19229</td>
<td>Other psychoactive substance dependence with intoxication, unspecified</td>
</tr>
<tr>
<td>F19230</td>
<td>Other psychoactive substance dependence with withdrawal, uncomplicated</td>
</tr>
<tr>
<td>F19231</td>
<td>Other psychoactive substance dependence with withdrawal delirium</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F19232</td>
<td>Other psychoactive substance dependence with withdrawal with perceptual disturbance</td>
</tr>
<tr>
<td>F19239</td>
<td>Other psychoactive substance dependence with withdrawal, unspecified</td>
</tr>
<tr>
<td>F1924</td>
<td>Other psychoactive substance dependence with psychoactive substance-induced mood disorder</td>
</tr>
<tr>
<td>F19250</td>
<td>Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F19251</td>
<td>Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F19259</td>
<td>Other psychoactive substance dependence with substance-induced psychotic disorder, unspecified</td>
</tr>
<tr>
<td>F19280</td>
<td>Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder</td>
</tr>
<tr>
<td>F19281</td>
<td>Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction</td>
</tr>
<tr>
<td>F19282</td>
<td>Other psychoactive substance dependence with psychoactive substance-induced sleep disorder</td>
</tr>
<tr>
<td>F19288</td>
<td>Other psychoactive substance dependence with other psychoactive substance-induced disorder</td>
</tr>
<tr>
<td>F1929</td>
<td>Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder</td>
</tr>
<tr>
<td>F1990</td>
<td>Other psychoactive substance use, unspecified, uncomplicated</td>
</tr>
<tr>
<td>F19920</td>
<td>Other psychoactive substance use, unspecified with intoxication, uncomplicated</td>
</tr>
<tr>
<td>F19921</td>
<td>Other psychoactive substance use, unspecified with intoxication with delirium</td>
</tr>
<tr>
<td>F19922</td>
<td>Other psychoactive substance use, unspecified with intoxication with perceptual disturbance</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F19929</td>
<td>Other psychoactive substance use, unspecified with intoxication, unspecified</td>
</tr>
<tr>
<td>F19930</td>
<td>Other psychoactive substance use, unspecified with withdrawal, uncomplicated</td>
</tr>
<tr>
<td>F19931</td>
<td>Other psychoactive substance use, unspecified with withdrawal delirium</td>
</tr>
<tr>
<td>F19932</td>
<td>Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance</td>
</tr>
<tr>
<td>F19939</td>
<td>Other psychoactive substance use, unspecified with withdrawal, unspecified</td>
</tr>
<tr>
<td>F1994</td>
<td>Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder</td>
</tr>
<tr>
<td>F19950</td>
<td>Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions</td>
</tr>
<tr>
<td>F19951</td>
<td>Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations</td>
</tr>
<tr>
<td>F19959</td>
<td>Other psychoactive substance use, unspecified with psychoactive disorder, unspecified</td>
</tr>
<tr>
<td>F19980</td>
<td>Other psychoactive substance use, unspecified with anxiety disorder</td>
</tr>
<tr>
<td>F19981</td>
<td>Other psychoactive substance use, unspecified with sexual dysfunction</td>
</tr>
<tr>
<td>F19982</td>
<td>Other psychoactive substance use, unspecified with sleep disorder</td>
</tr>
<tr>
<td>F19988</td>
<td>Other psychoactive substance use, unspecified with other disorder</td>
</tr>
<tr>
<td>F1999</td>
<td>Other psychoactive substance use, unspecified with unspecified disorder</td>
</tr>
<tr>
<td>O99310</td>
<td>Alcohol use complicating pregnancy, unspecified trimester</td>
</tr>
<tr>
<td>O99311</td>
<td>Alcohol use complicating pregnancy, first trimester</td>
</tr>
<tr>
<td>O99312</td>
<td>Alcohol use complicating pregnancy, second trimester</td>
</tr>
<tr>
<td>O99313</td>
<td>Alcohol use complicating pregnancy, third trimester</td>
</tr>
<tr>
<td>O99314</td>
<td>Alcohol use complicating childbirth</td>
</tr>
</tbody>
</table>
### Appendix O

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>O99315</td>
<td>Alcohol use complicating the puerperium</td>
</tr>
<tr>
<td>O99320</td>
<td>Drug use complicating pregnancy, unspecified trimester</td>
</tr>
<tr>
<td>O99321</td>
<td>Drug use complicating pregnancy, first trimester</td>
</tr>
<tr>
<td>O99322</td>
<td>Drug use complicating pregnancy, second trimester</td>
</tr>
<tr>
<td>O99323</td>
<td>Drug use complicating pregnancy, third trimester</td>
</tr>
<tr>
<td>O99324</td>
<td>Drug use complicating childbirth</td>
</tr>
<tr>
<td>O99325</td>
<td>Drug use complicating the puerperium</td>
</tr>
<tr>
<td>R780</td>
<td>Finding of alcohol in blood</td>
</tr>
<tr>
<td>R781</td>
<td>Finding of opiate drug in blood</td>
</tr>
<tr>
<td>R782</td>
<td>Finding of cocaine in blood</td>
</tr>
<tr>
<td>R783</td>
<td>Finding of hallucinogen in blood</td>
</tr>
<tr>
<td>R784</td>
<td>Finding of other drugs of addictive potential in blood</td>
</tr>
<tr>
<td>R785</td>
<td>Finding of other psychotropic drug in blood</td>
</tr>
</tbody>
</table>

M. Table of mental health diagnoses:

(1) For dates of service before October 1, 2015:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>295.00</td>
<td>Simple type schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.01</td>
<td>Simple type schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.02</td>
<td>Simple type schizophrenia, chronic</td>
</tr>
<tr>
<td>295.03</td>
<td>Simple type schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.04</td>
<td>Simple type schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>295.05</td>
<td>Simple type schizophrenia, in remission</td>
</tr>
<tr>
<td>295.10</td>
<td>Disorganized type schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.11</td>
<td>Disorganized type schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.12</td>
<td>Disorganized type schizophrenia, chronic</td>
</tr>
<tr>
<td>295.13</td>
<td>Disorganized type schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.14</td>
<td>Disorganized type schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.15</td>
<td>Disorganized type schizophrenia, in remission</td>
</tr>
<tr>
<td>295.20</td>
<td>Catatonic type schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.21</td>
<td>Catatonic type schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.22</td>
<td>Catatonic type schizophrenia, chronic</td>
</tr>
<tr>
<td>295.23</td>
<td>Catatonic type schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.24</td>
<td>Catatonic type schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.25</td>
<td>Catatonic type schizophrenia, in remission</td>
</tr>
<tr>
<td>295.30</td>
<td>Paranoid type schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.31</td>
<td>Paranoid type schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.32</td>
<td>Paranoid type schizophrenia, chronic</td>
</tr>
<tr>
<td>295.33</td>
<td>Paranoid type schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.34</td>
<td>Paranoid type schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.35</td>
<td>Paranoid type schizophrenia, in remission</td>
</tr>
<tr>
<td>295.40</td>
<td>Schizophreniform disorder, unspecified</td>
</tr>
<tr>
<td>295.41</td>
<td>Schizophreniform disorder, subchronic</td>
</tr>
<tr>
<td>Code</td>
<td>Disorder Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>295.42</td>
<td>Schizophreniform disorder, chronic</td>
</tr>
<tr>
<td>295.43</td>
<td>Schizophreniform disorder, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.44</td>
<td>Schizophreniform disorder, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.45</td>
<td>Schizophreniform disorder, in remission</td>
</tr>
<tr>
<td>295.50</td>
<td>Latent schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.51</td>
<td>Latent schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.52</td>
<td>Latent schizophrenia, chronic</td>
</tr>
<tr>
<td>295.53</td>
<td>Latent schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.54</td>
<td>Latent schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.55</td>
<td>Latent schizophrenia, in remission</td>
</tr>
<tr>
<td>295.60</td>
<td>Schizophrenic disorders, residual type, unspecified</td>
</tr>
<tr>
<td>295.61</td>
<td>Schizophrenic disorders, residual type, subchronic</td>
</tr>
<tr>
<td>295.62</td>
<td>Schizophrenic disorders, residual type, chronic</td>
</tr>
<tr>
<td>295.63</td>
<td>Schizophrenic disorders, residual type, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.64</td>
<td>Schizophrenic disorders, residual type, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.65</td>
<td>Schizophrenic disorders, residual type, in remission</td>
</tr>
<tr>
<td>295.70</td>
<td>Schizoaffective disorder, unspecified</td>
</tr>
<tr>
<td>295.71</td>
<td>Schizoaffective disorder, subchronic</td>
</tr>
<tr>
<td>295.72</td>
<td>Schizoaffective disorder, chronic</td>
</tr>
<tr>
<td>295.73</td>
<td>Schizoaffective disorder, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.74</td>
<td>Schizoaffective disorder, chronic with acute exacerbation</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>295.75</td>
<td>Schizoaffective disorder, in remission</td>
</tr>
<tr>
<td>295.80</td>
<td>Other specified types of schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.81</td>
<td>Other specified types of schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.82</td>
<td>Other specified types of schizophrenia, chronic</td>
</tr>
<tr>
<td>295.83</td>
<td>Other specified types of schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.84</td>
<td>Other specified types of schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.85</td>
<td>Other specified types of schizophrenia, in remission</td>
</tr>
<tr>
<td>295.90</td>
<td>Unspecified schizophrenia, unspecified</td>
</tr>
<tr>
<td>295.91</td>
<td>Unspecified schizophrenia, subchronic</td>
</tr>
<tr>
<td>295.92</td>
<td>Unspecified schizophrenia, chronic</td>
</tr>
<tr>
<td>295.93</td>
<td>Unspecified schizophrenia, subchronic with acute exacerbation</td>
</tr>
<tr>
<td>295.94</td>
<td>Unspecified schizophrenia, chronic with acute exacerbation</td>
</tr>
<tr>
<td>295.95</td>
<td>Unspecified schizophrenia, in remission</td>
</tr>
<tr>
<td>296.00</td>
<td>Bipolar I disorder, single manic episode, unspecified</td>
</tr>
<tr>
<td>296.01</td>
<td>Bipolar I disorder, single manic episode, mild</td>
</tr>
<tr>
<td>296.02</td>
<td>Bipolar I disorder, single manic episode, moderate</td>
</tr>
<tr>
<td>296.03</td>
<td>Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.04</td>
<td>Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>296.05</td>
<td>Bipolar I disorder, single manic episode, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.06</td>
<td>Bipolar I disorder, single manic episode, in full remission</td>
</tr>
<tr>
<td>296.10</td>
<td>Manic affective disorder, recurrent episode, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>296.11</td>
<td>Manic affective disorder, recurrent episode, mild</td>
</tr>
<tr>
<td>296.12</td>
<td>Manic affective disorder, recurrent episode, moderate</td>
</tr>
<tr>
<td>296.13</td>
<td>Manic affective disorder, recurrent episode, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.14</td>
<td>Manic affective disorder, recurrent episode, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>296.15</td>
<td>Manic affective disorder, recurrent episode, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.16</td>
<td>Manic affective disorder, recurrent episode, in full remission</td>
</tr>
<tr>
<td>296.20</td>
<td>Major depressive affective disorder, single episode, unspecified</td>
</tr>
<tr>
<td>296.21</td>
<td>Major depressive affective disorder, single episode, mild</td>
</tr>
<tr>
<td>296.22</td>
<td>Major depressive affective disorder, single episode, moderate</td>
</tr>
<tr>
<td>296.23</td>
<td>Major depressive affective disorder, single episode, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.24</td>
<td>Major depressive affective disorder, single episode, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>296.25</td>
<td>Major depressive affective disorder, single episode, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.26</td>
<td>Major depressive affective disorder, single episode, in full remission</td>
</tr>
<tr>
<td>296.30</td>
<td>Major depressive affective disorder, recurrent episode, unspecified</td>
</tr>
<tr>
<td>296.31</td>
<td>Major depressive affective disorder, recurrent episode, mild</td>
</tr>
<tr>
<td>296.32</td>
<td>Major depressive affective disorder, recurrent episode, moderate</td>
</tr>
<tr>
<td>296.33</td>
<td>Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.34</td>
<td>Major depressive affective disorder, recurrent episode, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>296.35</td>
<td>Major depressive affective disorder, recurrent episode, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.36</td>
<td>Major depressive affective disorder, recurrent episode, in full remission</td>
</tr>
<tr>
<td>296.40</td>
<td>Bipolar I disorder, most recent episode (or current) manic, unspecified</td>
</tr>
<tr>
<td>296.41</td>
<td>Bipolar I disorder, most recent episode (or current) manic, mild</td>
</tr>
<tr>
<td>296.42</td>
<td>Bipolar I disorder, most recent episode (or current) manic, moderate</td>
</tr>
<tr>
<td>296.43</td>
<td>Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.44</td>
<td>Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>296.45</td>
<td>Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.46</td>
<td>Bipolar I disorder, most recent episode (or current) manic, in full remission</td>
</tr>
<tr>
<td>296.50</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, unspecified</td>
</tr>
<tr>
<td>296.51</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, mild</td>
</tr>
<tr>
<td>296.52</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, moderate</td>
</tr>
<tr>
<td>296.53</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.54</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>296.55</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.56</td>
<td>Bipolar I disorder, most recent episode (or current) depressed, in full remission</td>
</tr>
<tr>
<td>296.60</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>296.61</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, mild</td>
</tr>
<tr>
<td>296.62</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, moderate</td>
</tr>
<tr>
<td>296.63</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior</td>
</tr>
<tr>
<td>296.64</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior</td>
</tr>
<tr>
<td>296.65</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission</td>
</tr>
<tr>
<td>296.66</td>
<td>Bipolar I disorder, most recent episode (or current) mixed, in full remission</td>
</tr>
<tr>
<td>296.7</td>
<td>Bipolar I disorder, most recent episode (or current) unspecified</td>
</tr>
<tr>
<td>296.80</td>
<td>Bipolar disorder, unspecified</td>
</tr>
<tr>
<td>296.81</td>
<td>Atypical manic disorder</td>
</tr>
<tr>
<td>296.82</td>
<td>Atypical depressive disorder</td>
</tr>
<tr>
<td>296.89</td>
<td>Other bipolar disorders</td>
</tr>
<tr>
<td>296.90</td>
<td>Unspecified episodic mood disorder</td>
</tr>
<tr>
<td>296.99</td>
<td>Other specified episodic mood disorder</td>
</tr>
<tr>
<td>297.0</td>
<td>Paranoid state, simple</td>
</tr>
<tr>
<td>297.1</td>
<td>Delusional disorder</td>
</tr>
<tr>
<td>297.2</td>
<td>Paraphrenia</td>
</tr>
<tr>
<td>297.3</td>
<td>Shared psychotic disorder</td>
</tr>
<tr>
<td>297.8</td>
<td>Other specified paranoid states</td>
</tr>
<tr>
<td>297.9</td>
<td>Unspecified paranoid state</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>298.0</td>
<td>Depressive type psychosis</td>
</tr>
<tr>
<td>298.1</td>
<td>Excitative type psychosis</td>
</tr>
<tr>
<td>298.2</td>
<td>Reactive confusion</td>
</tr>
<tr>
<td>298.3</td>
<td>Acute paranoid reaction</td>
</tr>
<tr>
<td>298.4</td>
<td>Psychogenic paranoid psychosis</td>
</tr>
<tr>
<td>298.8</td>
<td>Other and unspecified reactive psychosis</td>
</tr>
<tr>
<td>298.9</td>
<td>Unspecified psychosis</td>
</tr>
<tr>
<td>299.90</td>
<td>Unspecified pervasive development disorder, current or active state</td>
</tr>
<tr>
<td>299.91</td>
<td>Unspecified pervasive development disorder, residual state</td>
</tr>
<tr>
<td>300.00</td>
<td>Anxiety state, unspecified</td>
</tr>
<tr>
<td>300.01</td>
<td>Panic disorder without agoraphobia</td>
</tr>
<tr>
<td>300.02</td>
<td>Generalized anxiety disorder</td>
</tr>
<tr>
<td>300.09</td>
<td>Other anxiety states</td>
</tr>
<tr>
<td>300.10</td>
<td>Hysteria, unspecified</td>
</tr>
<tr>
<td>300.11</td>
<td>Conversion disorder</td>
</tr>
<tr>
<td>300.12</td>
<td>Dissociative amnesia</td>
</tr>
<tr>
<td>300.13</td>
<td>Dissociative fugue</td>
</tr>
<tr>
<td>300.14</td>
<td>Dissociative identity disorder</td>
</tr>
<tr>
<td>300.15</td>
<td>Dissociative disorder or reaction, unspecified</td>
</tr>
<tr>
<td>300.16</td>
<td>Factitious disorder with predominantly psychological signs and symptoms</td>
</tr>
<tr>
<td>300.19</td>
<td>Other and unspecified factitious illness</td>
</tr>
<tr>
<td>Code</td>
<td>Disorder</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>300.20</td>
<td>Phobia, unspecified</td>
</tr>
<tr>
<td>300.21</td>
<td>Agoraphobia with panic disorder</td>
</tr>
<tr>
<td>300.22</td>
<td>Agoraphobia without mention of panic attacks</td>
</tr>
<tr>
<td>300.23</td>
<td>Social phobia</td>
</tr>
<tr>
<td>300.29</td>
<td>Other isolated or specific phobias</td>
</tr>
<tr>
<td>300.3</td>
<td>Obsessive-compulsive disorders</td>
</tr>
<tr>
<td>300.4</td>
<td>Dysthymic disorder</td>
</tr>
<tr>
<td>300.5</td>
<td>Neurasthenia</td>
</tr>
<tr>
<td>300.6</td>
<td>Depersonalization disorder</td>
</tr>
<tr>
<td>300.7</td>
<td>Hypochondriasis</td>
</tr>
<tr>
<td>300.81</td>
<td>Somatization disorder</td>
</tr>
<tr>
<td>300.82</td>
<td>Undifferentiated somatoform disorder</td>
</tr>
<tr>
<td>300.89</td>
<td>Other somatoform disorders</td>
</tr>
<tr>
<td>300.9</td>
<td>Unspecified nonpsychotic mental disorder</td>
</tr>
<tr>
<td>301.0</td>
<td>Paranoid personality disorder</td>
</tr>
<tr>
<td>301.10</td>
<td>Affective personality disorder, unspecified</td>
</tr>
<tr>
<td>301.11</td>
<td>Chronic hypomanic personality disorder</td>
</tr>
<tr>
<td>301.12</td>
<td>Chronic depressive personality disorder</td>
</tr>
<tr>
<td>301.13</td>
<td>Cyclothymic disorder</td>
</tr>
<tr>
<td>301.20</td>
<td>Schizoid personality disorder, unspecified</td>
</tr>
<tr>
<td>301.21</td>
<td>Introverted personality</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>301.22</td>
<td>Schizotypal personality disorder</td>
</tr>
<tr>
<td>301.3</td>
<td>Explosive personality disorder</td>
</tr>
<tr>
<td>301.4</td>
<td>Obsessive-compulsive personality disorder</td>
</tr>
<tr>
<td>301.50</td>
<td>Histrionic personality disorder, unspecified</td>
</tr>
<tr>
<td>301.59</td>
<td>Other histrionic personality disorder</td>
</tr>
<tr>
<td>301.6</td>
<td>Dependent personality disorder</td>
</tr>
<tr>
<td>301.81</td>
<td>Narcissistic personality disorder</td>
</tr>
<tr>
<td>301.82</td>
<td>Avoidant personality disorder</td>
</tr>
<tr>
<td>301.83</td>
<td>Borderline personality disorder</td>
</tr>
<tr>
<td>301.84</td>
<td>Passive-aggressive personality</td>
</tr>
<tr>
<td>301.89</td>
<td>Other personality disorders</td>
</tr>
<tr>
<td>301.9</td>
<td>Unspecified personality disorder</td>
</tr>
<tr>
<td>302.0</td>
<td>Ego-dystonic sexual orientation</td>
</tr>
<tr>
<td>302.1</td>
<td>Zoophilia</td>
</tr>
<tr>
<td>302.2</td>
<td>Pedophilia</td>
</tr>
<tr>
<td>302.3</td>
<td>Transvestic fetishism</td>
</tr>
<tr>
<td>302.4</td>
<td>Exhibitionism</td>
</tr>
<tr>
<td>302.50</td>
<td>Trans-sexualism with unspecified sexual history</td>
</tr>
<tr>
<td>302.51</td>
<td>Trans-sexualism with asexual history</td>
</tr>
<tr>
<td>302.52</td>
<td>Trans-sexualism with homosexual history</td>
</tr>
<tr>
<td>302.53</td>
<td>Trans-sexualism with heterosexual history</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>302.6</td>
<td>Gender identity disorder in children</td>
</tr>
<tr>
<td>302.81</td>
<td>Fetishism</td>
</tr>
<tr>
<td>302.82</td>
<td>Voyeurism</td>
</tr>
<tr>
<td>302.83</td>
<td>Sexual masochism</td>
</tr>
<tr>
<td>302.84</td>
<td>Sexual sadism</td>
</tr>
<tr>
<td>302.85</td>
<td>Gender identity disorder in adolescents or adults</td>
</tr>
<tr>
<td>302.89</td>
<td>Other specified psychosexual disorders</td>
</tr>
<tr>
<td>302.9</td>
<td>Unspecified psychosexual disorder</td>
</tr>
<tr>
<td>307.1</td>
<td>Anorexia nervosa</td>
</tr>
<tr>
<td>307.3</td>
<td>Stereotypic movement disorder</td>
</tr>
<tr>
<td>307.50</td>
<td>Eating disorder, unspecified</td>
</tr>
<tr>
<td>307.51</td>
<td>Bulimia nervosa</td>
</tr>
<tr>
<td>307.52</td>
<td>Pica</td>
</tr>
<tr>
<td>307.53</td>
<td>Rumination disorder</td>
</tr>
<tr>
<td>307.54</td>
<td>Psychogenic vomiting</td>
</tr>
<tr>
<td>307.59</td>
<td>Other disorders of eating</td>
</tr>
<tr>
<td>307.6</td>
<td>Enuresis</td>
</tr>
<tr>
<td>307.7</td>
<td>Encopresis</td>
</tr>
<tr>
<td>307.80</td>
<td>Psychogenic pain, site unspecified</td>
</tr>
<tr>
<td>307.89</td>
<td>Other pain disorders related to psychological factors</td>
</tr>
<tr>
<td>308.0</td>
<td>Predominant disturbance of emotions</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>308.3</td>
<td>Other acute reactions to stress</td>
</tr>
<tr>
<td>308.4</td>
<td>Mixed disorders as reaction to stress</td>
</tr>
<tr>
<td>308.9</td>
<td>Unspecified acute reaction to stress</td>
</tr>
<tr>
<td>309.0</td>
<td>Adjustment disorder with depressed mood</td>
</tr>
<tr>
<td>309.1</td>
<td>Prolonged depressive reaction</td>
</tr>
<tr>
<td>309.21</td>
<td>Separation anxiety disorder</td>
</tr>
<tr>
<td>309.22</td>
<td>Emancipation disorder of adolescence and early adult life</td>
</tr>
<tr>
<td>309.24</td>
<td>Adjustment disorder with anxiety</td>
</tr>
<tr>
<td>309.28</td>
<td>Adjustment disorder with mixed anxiety and depressed mood</td>
</tr>
<tr>
<td>309.29</td>
<td>Other adjustment reactions with predominant disturbance of other emotions</td>
</tr>
<tr>
<td>309.3</td>
<td>Adjustment disorder with disturbance of conduct</td>
</tr>
<tr>
<td>309.4</td>
<td>Adjustment disorder with mixed disturbance of emotions and conduct</td>
</tr>
<tr>
<td>309.81</td>
<td>Posttraumatic stress disorder</td>
</tr>
<tr>
<td>309.82</td>
<td>Adjustment reaction with physical symptoms</td>
</tr>
<tr>
<td>309.83</td>
<td>Adjustment reaction with withdrawal</td>
</tr>
<tr>
<td>309.89</td>
<td>Other specified adjustment reactions</td>
</tr>
<tr>
<td>309.9</td>
<td>Unspecified adjustment reaction</td>
</tr>
<tr>
<td>311</td>
<td>Depressive disorder, not elsewhere classified</td>
</tr>
<tr>
<td>312.00</td>
<td>Undersocialized conduct disorder, aggressive type, unspecified</td>
</tr>
<tr>
<td>312.01</td>
<td>Undersocialized conduct disorder, aggressive type, mild</td>
</tr>
<tr>
<td>312.02</td>
<td>Undersocialized conduct disorder, aggressive type, moderate</td>
</tr>
<tr>
<td>Code</td>
<td>Disorder</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>312.03</td>
<td>Undersocialized conduct disorder, aggressive type, severe</td>
</tr>
<tr>
<td>312.10</td>
<td>Undersocialized conduct disorder, unaggressive type, unspecified</td>
</tr>
<tr>
<td>312.11</td>
<td>Undersocialized conduct disorder, unaggressive type, mild</td>
</tr>
<tr>
<td>312.12</td>
<td>Undersocialized conduct disorder, unaggressive type, moderate</td>
</tr>
<tr>
<td>312.13</td>
<td>Undersocialized conduct disorder, unaggressive type, severe</td>
</tr>
<tr>
<td>312.20</td>
<td>Socialized conduct disorder, unspecified</td>
</tr>
<tr>
<td>312.21</td>
<td>Socialized conduct disorder, mild</td>
</tr>
<tr>
<td>312.22</td>
<td>Socialized conduct disorder, moderate</td>
</tr>
<tr>
<td>312.23</td>
<td>Socialized conduct disorder, severe</td>
</tr>
<tr>
<td>312.30</td>
<td>Impulse control disorder, unspecified</td>
</tr>
<tr>
<td>312.31</td>
<td>Pathological gambling</td>
</tr>
<tr>
<td>312.32</td>
<td>Kleptomania</td>
</tr>
<tr>
<td>312.33</td>
<td>Pyromania</td>
</tr>
<tr>
<td>312.34</td>
<td>Intermittent explosive disorder</td>
</tr>
<tr>
<td>312.35</td>
<td>Isolated explosive disorder</td>
</tr>
<tr>
<td>312.39</td>
<td>Other disorders of impulse control</td>
</tr>
<tr>
<td>312.4</td>
<td>Mixed disturbance of conduct and emotions</td>
</tr>
<tr>
<td>312.81</td>
<td>Conduct disorder, childhood onset type</td>
</tr>
<tr>
<td>312.82</td>
<td>Conduct disorder, adolescent onset type</td>
</tr>
<tr>
<td>312.89</td>
<td>Other conduct disorder</td>
</tr>
<tr>
<td>312.9</td>
<td>Unspecified disturbance of conduct</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>313.0</td>
<td>Overanxious disorder specific to childhood and adolescence</td>
</tr>
<tr>
<td>313.1</td>
<td>Misery and unhappiness disorder specific to childhood and adolescence</td>
</tr>
<tr>
<td>313.21</td>
<td>Shyness disorder of childhood</td>
</tr>
<tr>
<td>313.22</td>
<td>Introverted disorder of childhood</td>
</tr>
<tr>
<td>313.23</td>
<td>Selective mutism</td>
</tr>
<tr>
<td>313.3</td>
<td>Relationship problems specific to childhood and adolescence</td>
</tr>
<tr>
<td>313.81</td>
<td>Oppositional defiant disorder</td>
</tr>
<tr>
<td>313.82</td>
<td>Identity disorder of childhood or adolescence</td>
</tr>
<tr>
<td>313.89</td>
<td>Other emotional disturbances of childhood or adolescence</td>
</tr>
<tr>
<td>313.9</td>
<td>Unspecified emotional disturbance of childhood or adolescence</td>
</tr>
<tr>
<td>314.00</td>
<td>Attention deficit disorder without mention of hyperactivity</td>
</tr>
<tr>
<td>314.01</td>
<td>Attention deficit disorder with hyperactivity</td>
</tr>
<tr>
<td>314.2</td>
<td>Hyperkinetic conduct disorder</td>
</tr>
<tr>
<td>314.8</td>
<td>Other specified manifestations of hyperkinetic syndrome</td>
</tr>
<tr>
<td>314.9</td>
<td>Unspecified hyperkinetic syndrome</td>
</tr>
<tr>
<td>332.1</td>
<td>Secondary parkinsonism</td>
</tr>
<tr>
<td>333.90</td>
<td>Unspecified extrapyramidal disease and abnormal movement disorder</td>
</tr>
<tr>
<td>333.99</td>
<td>Other extrapyramidal diseases and abnormal movement disorders</td>
</tr>
<tr>
<td>648.40</td>
<td>Mental disorders of mother complicating pregnancy childbirth of the puerperium unspecified as to the episode of care</td>
</tr>
<tr>
<td>648.41</td>
<td>Mental disorders of mother with delivery</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>648.42</td>
<td>Mental disorders of mother with delivery with postpartum complication</td>
</tr>
<tr>
<td>648.43</td>
<td>Antepartum mental disorders of mother</td>
</tr>
<tr>
<td>648.44</td>
<td>Postpartum mental disorder of mother</td>
</tr>
</tbody>
</table>

(2) For dates of service on or after October 1, 2015:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F200</td>
<td>Paranoid schizophrenia</td>
</tr>
<tr>
<td>F201</td>
<td>Disorganized schizophrenia</td>
</tr>
<tr>
<td>F202</td>
<td>Catatonic schizophrenia</td>
</tr>
<tr>
<td>F203</td>
<td>Undifferentiated schizophrenia</td>
</tr>
<tr>
<td>F205</td>
<td>Residual schizophrenia</td>
</tr>
<tr>
<td>F2081</td>
<td>Schizophreniform disorder</td>
</tr>
<tr>
<td>F2089</td>
<td>Other schizophrenia</td>
</tr>
<tr>
<td>F209</td>
<td>Schizophrenia, unspecified</td>
</tr>
<tr>
<td>F21</td>
<td>Schizotypal disorder</td>
</tr>
<tr>
<td>F22</td>
<td>Delusional disorders</td>
</tr>
<tr>
<td>F23</td>
<td>Brief psychotic disorder</td>
</tr>
<tr>
<td>F24</td>
<td>Shared psychotic disorder</td>
</tr>
<tr>
<td>F250</td>
<td>Schizoaffective disorder, bipolar type</td>
</tr>
<tr>
<td>F251</td>
<td>Schizoaffective disorder, depressive type</td>
</tr>
<tr>
<td>F258</td>
<td>Other schizoaffective disorders</td>
</tr>
<tr>
<td>F259</td>
<td>Schizoaffective disorder, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F28</td>
<td>Other psychotic disorder not due to a substance or known physiological condition</td>
</tr>
<tr>
<td>F29</td>
<td>Unspecified psychosis not due to a substance or known physiological condition</td>
</tr>
<tr>
<td>F3010</td>
<td>Manic episode without psychotic symptoms, unspecified</td>
</tr>
<tr>
<td>F3011</td>
<td>Manic episode without psychotic symptoms, mild</td>
</tr>
<tr>
<td>F3012</td>
<td>Manic episode without psychotic symptoms, moderate</td>
</tr>
<tr>
<td>F3013</td>
<td>Manic episode, severe, without psychotic symptoms</td>
</tr>
<tr>
<td>F302</td>
<td>Manic episode, severe with psychotic symptoms</td>
</tr>
<tr>
<td>F303</td>
<td>Manic episode in partial remission</td>
</tr>
<tr>
<td>F304</td>
<td>Manic episode in full remission</td>
</tr>
<tr>
<td>F308</td>
<td>Other manic episodes</td>
</tr>
<tr>
<td>F309</td>
<td>Manic episode, unspecified</td>
</tr>
<tr>
<td>F310</td>
<td>Bipolar disorder, current episode hypomanic</td>
</tr>
<tr>
<td>F3110</td>
<td>Bipolar disorder, current episode manic without psychotic features, unspecified</td>
</tr>
<tr>
<td>F3111</td>
<td>Bipolar disorder, current episode manic without psychotic features, mild</td>
</tr>
<tr>
<td>F3112</td>
<td>Bipolar disorder, current episode manic without psychotic features, mod</td>
</tr>
<tr>
<td>F3113</td>
<td>Bipolar disorder, current episode manic without psychotic features, severe</td>
</tr>
<tr>
<td>F312</td>
<td>Bipolar disorder, current episode manic severe with psychotic features</td>
</tr>
<tr>
<td>F3130</td>
<td>Bipolar disorder, current episode depressed, mild or moderate severity, unspecified</td>
</tr>
<tr>
<td>F3131</td>
<td>Bipolar disorder, current episode depressed, mild</td>
</tr>
<tr>
<td>F3132</td>
<td>Bipolar disorder, current episode depressed, moderate</td>
</tr>
<tr>
<td>F314</td>
<td>Bipolar disorder, current episode depressed, severe, without psychotic features</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>F315</td>
<td>Bipolar disorder, current episode depressed, severe, with psychotic features</td>
</tr>
<tr>
<td>F3160</td>
<td>Bipolar disorder, current episode mixed, unspecified</td>
</tr>
<tr>
<td>F3161</td>
<td>Bipolar disorder, current episode mixed, mild</td>
</tr>
<tr>
<td>F3162</td>
<td>Bipolar disorder, current episode mixed, moderate</td>
</tr>
<tr>
<td>F3163</td>
<td>Bipolar disorder, current episode mixed, severe, without psychotic features</td>
</tr>
<tr>
<td>F3164</td>
<td>Bipolar disorder, current episode mixed, severe, with psychotic features</td>
</tr>
<tr>
<td>F3170</td>
<td>Bipolar disorder, currently in remission, most recent episode unspecified</td>
</tr>
<tr>
<td>F3171</td>
<td>Bipolar disorder, in partial remission, most recent episode hypomanic</td>
</tr>
<tr>
<td>F3172</td>
<td>Bipolar disorder, in full remission, most recent episode hypomanic</td>
</tr>
<tr>
<td>F3173</td>
<td>Bipolar disorder, in partial remission, most recent episode manic</td>
</tr>
<tr>
<td>F3174</td>
<td>Bipolar disorder, in full remission, most recent episode manic</td>
</tr>
<tr>
<td>F3175</td>
<td>Bipolar disorder, in partial remission, most recent episode depressed</td>
</tr>
<tr>
<td>F3176</td>
<td>Bipolar disorder, in full remission, most recent episode depressed</td>
</tr>
<tr>
<td>F3177</td>
<td>Bipolar disorder, in partial remission, most recent episode mixed</td>
</tr>
<tr>
<td>F3178</td>
<td>Bipolar disorder, in full remission, most recent episode mixed</td>
</tr>
<tr>
<td>F3181</td>
<td>Bipolar II disorder</td>
</tr>
<tr>
<td>F3189</td>
<td>Other bipolar disorder</td>
</tr>
<tr>
<td>F319</td>
<td>Bipolar disorder, unspecified</td>
</tr>
<tr>
<td>F320</td>
<td>Major depressive disorder, single episode, mild</td>
</tr>
<tr>
<td>F321</td>
<td>Major depressive disorder, single episode, moderate</td>
</tr>
<tr>
<td>F322</td>
<td>Major depressive disorder, single episode, severe without psychotic features</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>F323</td>
<td>Major depressive disorder, single episode, severe with psychotic features</td>
</tr>
<tr>
<td>F324</td>
<td>Major depressive disorder, single episode, in partial remission</td>
</tr>
<tr>
<td>F325</td>
<td>Major depressive disorder, single episode, in full remission</td>
</tr>
<tr>
<td>F3281</td>
<td>Premenstrual dysphoric disorder</td>
</tr>
<tr>
<td>F3289</td>
<td>Other specified depressive episodes</td>
</tr>
<tr>
<td>F329</td>
<td>Major depressive disorder, single episode, unspecified</td>
</tr>
<tr>
<td>F330</td>
<td>Major depressive disorder, recurrent, mild</td>
</tr>
<tr>
<td>F331</td>
<td>Major depressive disorder, recurrent, moderate</td>
</tr>
<tr>
<td>F332</td>
<td>Major depressive disorder, recurrent severe without psychotic features</td>
</tr>
<tr>
<td>F333</td>
<td>Major depressive disorder, recurrent, severe with psychotic symptoms</td>
</tr>
<tr>
<td>F3340</td>
<td>Major depressive disorder, recurrent, in remission, unspecified</td>
</tr>
<tr>
<td>F3341</td>
<td>Major depressive disorder, recurrent, in partial remission</td>
</tr>
<tr>
<td>F3342</td>
<td>Major depressive disorder, recurrent, in full remission</td>
</tr>
<tr>
<td>F338</td>
<td>Other recurrent depressive disorders</td>
</tr>
<tr>
<td>F339</td>
<td>Major depressive disorder, recurrent, unspecified</td>
</tr>
<tr>
<td>F340</td>
<td>Cyclothymic disorder</td>
</tr>
<tr>
<td>F341</td>
<td>Dysthymic disorder</td>
</tr>
<tr>
<td>F3481</td>
<td>Disruptive mood dysregulation disorder</td>
</tr>
<tr>
<td>F3489</td>
<td>Other specified persistent mood disorders</td>
</tr>
<tr>
<td>F349</td>
<td>Persistent mood (affective) disorder, unspecified</td>
</tr>
<tr>
<td>F39</td>
<td>Unspecified mood (affective) disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>F4000</td>
<td>Agoraphobia, unspecified</td>
</tr>
<tr>
<td>F4001</td>
<td>Agoraphobia with panic disorder</td>
</tr>
<tr>
<td>F4002</td>
<td>Agoraphobia without panic disorder</td>
</tr>
<tr>
<td>F4010</td>
<td>Social phobia, unspecified</td>
</tr>
<tr>
<td>F4011</td>
<td>Social phobia, generalized</td>
</tr>
<tr>
<td>F4020</td>
<td>Arachnophobia</td>
</tr>
<tr>
<td>F40210</td>
<td>Other animal type phobia</td>
</tr>
<tr>
<td>F40220</td>
<td>Fear of thunderstorms</td>
</tr>
<tr>
<td>F40228</td>
<td>Other natural environment type phobia</td>
</tr>
<tr>
<td>F40230</td>
<td>Fear of blood</td>
</tr>
<tr>
<td>F40231</td>
<td>Fear of injections and transfusions</td>
</tr>
<tr>
<td>F40232</td>
<td>Fear of other medical care</td>
</tr>
<tr>
<td>F40233</td>
<td>Fear of injury</td>
</tr>
<tr>
<td>F40240</td>
<td>Claustrophobia</td>
</tr>
<tr>
<td>F40241</td>
<td>Acrophobia</td>
</tr>
<tr>
<td>F40242</td>
<td>Fear of bridges</td>
</tr>
<tr>
<td>F40243</td>
<td>Fear of flying</td>
</tr>
<tr>
<td>F40248</td>
<td>Other situational type phobia</td>
</tr>
<tr>
<td>F40290</td>
<td>Androphobia</td>
</tr>
<tr>
<td>F40291</td>
<td>Gynephobia</td>
</tr>
<tr>
<td>F40298</td>
<td>Other specified phobia</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>F408</td>
<td>Other phobic anxiety disorders</td>
</tr>
<tr>
<td>F409</td>
<td>Phobic anxiety disorder, unspecified</td>
</tr>
<tr>
<td>F410</td>
<td>Panic disorder without agoraphobia</td>
</tr>
<tr>
<td>F411</td>
<td>Generalized anxiety disorder</td>
</tr>
<tr>
<td>F413</td>
<td>Other mixed anxiety disorders</td>
</tr>
<tr>
<td>F418</td>
<td>Other specified anxiety disorders</td>
</tr>
<tr>
<td>F419</td>
<td>Anxiety disorder, unspecified</td>
</tr>
<tr>
<td>F422</td>
<td>Mixed obsessional thoughts and acts</td>
</tr>
<tr>
<td>F423</td>
<td>Hoarding disorder</td>
</tr>
<tr>
<td>F424</td>
<td>Excoriation (skin-picking) disorder</td>
</tr>
<tr>
<td>F428</td>
<td>Other obsessive compulsive disorder</td>
</tr>
<tr>
<td>F429</td>
<td>Obsessive-compulsive disorder, unspecified</td>
</tr>
<tr>
<td>F430</td>
<td>Acute stress reaction</td>
</tr>
<tr>
<td>F4310</td>
<td>Post-traumatic stress disorder, unspecified</td>
</tr>
<tr>
<td>F4311</td>
<td>Post-traumatic stress disorder, acute</td>
</tr>
<tr>
<td>F4312</td>
<td>Post-traumatic stress disorder, chronic</td>
</tr>
<tr>
<td>F4320</td>
<td>Adjustment disorder, unspecified</td>
</tr>
<tr>
<td>F4321</td>
<td>Adjustment disorder with depressed mood</td>
</tr>
<tr>
<td>F4322</td>
<td>Adjustment disorder with anxiety</td>
</tr>
<tr>
<td>F4323</td>
<td>Adjustment disorder with mixed anxiety and depressed mood</td>
</tr>
<tr>
<td>F4324</td>
<td>Adjustment disorder with disturbance of conduct</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>F4325</td>
<td>Adjustment disorder with mixed disturbance of emotions and conduct</td>
</tr>
<tr>
<td>F4329</td>
<td>Adjustment disorder with other symptoms</td>
</tr>
<tr>
<td>F438</td>
<td>Other reactions to severe stress</td>
</tr>
<tr>
<td>F439</td>
<td>Reaction to severe stress, unspecified</td>
</tr>
<tr>
<td>F440</td>
<td>Dissociative amnesia</td>
</tr>
<tr>
<td>F441</td>
<td>Dissociative fugue</td>
</tr>
<tr>
<td>F442</td>
<td>Dissociative stupor</td>
</tr>
<tr>
<td>F444</td>
<td>Conversion disorder with motor symptom or deficit</td>
</tr>
<tr>
<td>F446</td>
<td>Conversion disorder with sensory symptom or deficit</td>
</tr>
<tr>
<td>F4481</td>
<td>Dissociative identity disorder</td>
</tr>
<tr>
<td>F4489</td>
<td>Other dissociative and conversion disorders</td>
</tr>
<tr>
<td>F449</td>
<td>Dissociative and conversion disorder, unspecified</td>
</tr>
<tr>
<td>F450</td>
<td>Somatization disorder</td>
</tr>
<tr>
<td>F451</td>
<td>Undifferentiated somatoform disorder</td>
</tr>
<tr>
<td>F4520</td>
<td>Hypochondriacal disorder, unspecified</td>
</tr>
<tr>
<td>F4521</td>
<td>Hypochondriasis</td>
</tr>
<tr>
<td>F4522</td>
<td>Body dysmorphic disorder</td>
</tr>
<tr>
<td>F4529</td>
<td>Other hypochondriacal disorders</td>
</tr>
<tr>
<td>F4541</td>
<td>Pain disorder exclusively related to psychological factors</td>
</tr>
<tr>
<td>F458</td>
<td>Other somatoform disorders</td>
</tr>
<tr>
<td>F459</td>
<td>Somatoform disorder, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------</td>
</tr>
<tr>
<td>F481</td>
<td>Depersonalization-derealization syndrome</td>
</tr>
<tr>
<td>F488</td>
<td>Other specified nonpsychotic mental disorders</td>
</tr>
<tr>
<td>F489</td>
<td>Nonpsychotic mental disorder, unspecified</td>
</tr>
<tr>
<td>F5000</td>
<td>Anorexia nervosa, unspecified</td>
</tr>
<tr>
<td>F5001</td>
<td>Anorexia nervosa, restricting type</td>
</tr>
<tr>
<td>F5002</td>
<td>Anorexia nervosa, binge eating/purging type</td>
</tr>
<tr>
<td>F502</td>
<td>Bulimia nervosa</td>
</tr>
<tr>
<td>F5081</td>
<td>Binge eating disorder</td>
</tr>
<tr>
<td>F5082</td>
<td>Avoidant/restrictive food intake disorder</td>
</tr>
<tr>
<td>F5089</td>
<td>Other specified eating disorder</td>
</tr>
<tr>
<td>F509</td>
<td>Eating disorder, unspecified</td>
</tr>
<tr>
<td>F531</td>
<td>Puerperal psychosis</td>
</tr>
<tr>
<td>F54</td>
<td>Psychological and behavioral factors associated with disorders or diseases classified elsewhere</td>
</tr>
<tr>
<td>F600</td>
<td>Paranoid personality disorder</td>
</tr>
<tr>
<td>F601</td>
<td>Schizoid personality disorder</td>
</tr>
<tr>
<td>F603</td>
<td>Borderline personality disorder</td>
</tr>
<tr>
<td>F604</td>
<td>Histrionic personality disorder</td>
</tr>
<tr>
<td>F605</td>
<td>Obsessive-compulsive personality disorder</td>
</tr>
<tr>
<td>F606</td>
<td>Avoidant personality disorder</td>
</tr>
<tr>
<td>F607</td>
<td>Dependent personality disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Disorder</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>F6081</td>
<td>Narcissistic personality disorder</td>
</tr>
<tr>
<td>F6089</td>
<td>Other specific personality disorders</td>
</tr>
<tr>
<td>F609</td>
<td>Personality disorder, unspecified</td>
</tr>
<tr>
<td>F630</td>
<td>Pathological gambling</td>
</tr>
<tr>
<td>F631</td>
<td>Pyromania</td>
</tr>
<tr>
<td>F632</td>
<td>Kleptomania</td>
</tr>
<tr>
<td>F633</td>
<td>Trichotillomania</td>
</tr>
<tr>
<td>F6381</td>
<td>Intermittent explosive disorder</td>
</tr>
<tr>
<td>F6389</td>
<td>Other impulse disorders</td>
</tr>
<tr>
<td>F639</td>
<td>Impulse disorder, unspecified</td>
</tr>
<tr>
<td>F640</td>
<td>Transsexualism</td>
</tr>
<tr>
<td>F641</td>
<td>Gender identity disorder in adolescence and adulthood</td>
</tr>
<tr>
<td>F642</td>
<td>Gender identity disorder of childhood</td>
</tr>
<tr>
<td>F648</td>
<td>Other gender identity disorders</td>
</tr>
<tr>
<td>F649</td>
<td>Gender identity disorder, unspecified</td>
</tr>
<tr>
<td>F650</td>
<td>Fetishism</td>
</tr>
<tr>
<td>F651</td>
<td>Transvestic fetishism</td>
</tr>
<tr>
<td>F652</td>
<td>Exhibitionism</td>
</tr>
<tr>
<td>F653</td>
<td>Voyeurism</td>
</tr>
<tr>
<td>F654</td>
<td>Pedophilia</td>
</tr>
<tr>
<td>F6550</td>
<td>Sadomasochism, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>F6551</td>
<td>Sexual masochism</td>
</tr>
<tr>
<td>F6552</td>
<td>Sexual sadism</td>
</tr>
<tr>
<td>F6581</td>
<td>Frotteurism</td>
</tr>
<tr>
<td>F6589</td>
<td>Other paraphilias</td>
</tr>
<tr>
<td>F659</td>
<td>Paraphilia, unspecified</td>
</tr>
<tr>
<td>F66</td>
<td>Other sexual disorders</td>
</tr>
<tr>
<td>F6811</td>
<td>Factitious disorder with predominantly psychological signs and symptoms</td>
</tr>
<tr>
<td>F6813</td>
<td>Factitious disorder with combined psychological and physical signs and symptoms</td>
</tr>
<tr>
<td>F688</td>
<td>Other specified disorders of adult personality and behavior</td>
</tr>
<tr>
<td>F68A</td>
<td>Factitious disorder imposed on another</td>
</tr>
<tr>
<td>F69</td>
<td>Unspecified disorder of adult personality and behavior</td>
</tr>
<tr>
<td>F843</td>
<td>Other childhood disintegrative disorder</td>
</tr>
<tr>
<td>F900</td>
<td>Attention-deficit hyperactivity disorder, predominantly inattentive type</td>
</tr>
<tr>
<td>F901</td>
<td>Attention-deficit hyperactivity disorder, predominantly hyperactive type</td>
</tr>
<tr>
<td>F902</td>
<td>Attention-deficit hyperactivity disorder, combined type</td>
</tr>
<tr>
<td>F908</td>
<td>Attention-deficit hyperactivity disorder, other type</td>
</tr>
<tr>
<td>F909</td>
<td>Attention-deficit hyperactivity disorder, unspecified type</td>
</tr>
<tr>
<td>F910</td>
<td>Conduct disorder confined to family context</td>
</tr>
<tr>
<td>F911</td>
<td>Conduct disorder, childhood-onset type</td>
</tr>
<tr>
<td>F912</td>
<td>Conduct disorder, adolescent-onset type</td>
</tr>
<tr>
<td>F913</td>
<td>Oppositional defiant disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>F918</td>
<td>Other conduct disorders</td>
</tr>
<tr>
<td>F919</td>
<td>Conduct disorder, unspecified</td>
</tr>
<tr>
<td>F930</td>
<td>Separation anxiety disorder of childhood</td>
</tr>
<tr>
<td>F938</td>
<td>Other childhood emotional disorders</td>
</tr>
<tr>
<td>F939</td>
<td>Childhood emotional disorder, unspecified</td>
</tr>
<tr>
<td>F940</td>
<td>Selective mutism</td>
</tr>
<tr>
<td>F941</td>
<td>Reactive attachment disorder of childhood</td>
</tr>
<tr>
<td>F942</td>
<td>Disinhibited attachment disorder of childhood</td>
</tr>
<tr>
<td>F948</td>
<td>Other childhood disorders of social functioning</td>
</tr>
<tr>
<td>F949</td>
<td>Childhood disorder of social functioning, unspecified</td>
</tr>
<tr>
<td>F980</td>
<td>Enuresis not due to a substance or known physiological condition</td>
</tr>
<tr>
<td>F981</td>
<td>Encopresis not due to a substance or known physiological condition</td>
</tr>
<tr>
<td>F984</td>
<td>Stereotyped movement disorders</td>
</tr>
<tr>
<td>F988</td>
<td>Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence</td>
</tr>
<tr>
<td>F989</td>
<td>Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence</td>
</tr>
<tr>
<td>F99</td>
<td>Mental disorder, not otherwise specified</td>
</tr>
<tr>
<td>G2111</td>
<td>Neuroleptic induced parkinsonism</td>
</tr>
<tr>
<td>G2402</td>
<td>Drug induced acute dystonia</td>
</tr>
<tr>
<td>G2589</td>
<td>Other specified extrapyramidal and movement disorders</td>
</tr>
<tr>
<td>G259</td>
<td>Extrapyramidal and movement disorder, unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>R457</td>
<td>State of emotional shock and stress, unspecified</td>
</tr>
<tr>
<td>R45850</td>
<td>Homicidal ideations</td>
</tr>
<tr>
<td>R45851</td>
<td>Suicidal ideations</td>
</tr>
<tr>
<td>O99340</td>
<td>Other mental disorders complicating pregnancy, unspecified trimester</td>
</tr>
<tr>
<td>O99341</td>
<td>Other mental disorders complicating pregnancy, first trimester</td>
</tr>
<tr>
<td>O99342</td>
<td>Other mental disorders complicating pregnancy, second trimester</td>
</tr>
<tr>
<td>O99343</td>
<td>Other mental disorders complicating pregnancy, third trimester</td>
</tr>
<tr>
<td>O99344</td>
<td>Other mental disorders complicating childbirth</td>
</tr>
<tr>
<td>O99345</td>
<td>Other mental disorders complicating the puerperium</td>
</tr>
<tr>
<td>Z046</td>
<td>Encounter for general psychiatric examination requested by the authority</td>
</tr>
</tbody>
</table>

N. An MCO is not responsible for services billed by a psychiatrist when the claim includes one of the following primary diagnoses:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G24.4</td>
<td>Orofacial dyskinesia</td>
</tr>
<tr>
<td>G25.1</td>
<td>Drug-induced tremor</td>
</tr>
<tr>
<td>G21.0</td>
<td>Neuroleptic malignant syndrome</td>
</tr>
</tbody>
</table>

O. Table of poisoning diagnoses, for dates of service on or after July 1, 2016:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T360X2A</td>
<td>Poisoning by penicillins, intentional self-harm</td>
</tr>
<tr>
<td>T361X2A</td>
<td>Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm</td>
</tr>
<tr>
<td>T362X2A</td>
<td>Poisoning by chloramphenicol group, intentional self-harm</td>
</tr>
<tr>
<td>T363X2A</td>
<td>Poisoning by macrolides, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T364X2A</td>
<td>Poisoning by tetracyclines, intentional self-harm</td>
</tr>
<tr>
<td>T365X2A</td>
<td>Poisoning by aminoglycosides, intentional self-harm</td>
</tr>
<tr>
<td>T366X2A</td>
<td>Poisoning by rifampicins, intentional self-harm</td>
</tr>
<tr>
<td>T367X2A</td>
<td>Poisoning by antifungal antibiotics, systemically used, intentional self-harm</td>
</tr>
<tr>
<td>T368X2A</td>
<td>Poisoning by other systemic antibiotics, intentional self-harm</td>
</tr>
<tr>
<td>T369X2A</td>
<td>Poisoning by unspecified systemic antibiotic, intentional self-harm</td>
</tr>
<tr>
<td>T370X2A</td>
<td>Poisoning by sulfonamides, intentional self-harm</td>
</tr>
<tr>
<td>T371X2A</td>
<td>Poisoning by antitubercular drugs, intentional self-harm</td>
</tr>
<tr>
<td>T372X2A</td>
<td>Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm</td>
</tr>
<tr>
<td>T373X2A</td>
<td>Poisoning by other antiprotozoal drugs, intentional self-harm</td>
</tr>
<tr>
<td>T374X2A</td>
<td>Poisoning by anthelmintics, intentional self-harm</td>
</tr>
<tr>
<td>T375X2A</td>
<td>Poisoning by antiviral drugs, intentional self-harm</td>
</tr>
<tr>
<td>T378X2A</td>
<td>Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm</td>
</tr>
<tr>
<td>T3792XA</td>
<td>Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm</td>
</tr>
<tr>
<td>T380X2A</td>
<td>Poisoning by glucocorticoids and synthetic analogues, intentional self-harm</td>
</tr>
<tr>
<td>T381X2A</td>
<td>Poisoning by thyroid hormones and substitutes, intentional self-harm</td>
</tr>
<tr>
<td>T382X2A</td>
<td>Poisoning by antithyroid drugs, intentional self-harm</td>
</tr>
<tr>
<td>T383X2A</td>
<td>Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm</td>
</tr>
<tr>
<td>T384X2A</td>
<td>Poisoning by oral contraceptives, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T385X2A</td>
<td>Poisoning by other estrogens and progestogens, intentional self-harm</td>
</tr>
<tr>
<td>T386X2A</td>
<td>Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm</td>
</tr>
<tr>
<td>T387X2A</td>
<td>Poisoning by androgens and anabolic congeners, intentional self-harm</td>
</tr>
<tr>
<td>T38802A</td>
<td>Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm</td>
</tr>
<tr>
<td>T38812A</td>
<td>Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm</td>
</tr>
<tr>
<td>T38892A</td>
<td>Poisoning by other hormones and synthetic substitutes, intentional self-harm</td>
</tr>
<tr>
<td>T38902A</td>
<td>Poisoning by unspecified hormone antagonists, intentional self-harm</td>
</tr>
<tr>
<td>T38992A</td>
<td>Poisoning by other hormone antagonists, intentional self-harm</td>
</tr>
<tr>
<td>T39012A</td>
<td>Poisoning by aspirin, intentional self-harm</td>
</tr>
<tr>
<td>T39092A</td>
<td>Poisoning by salicylates, intentional self-harm</td>
</tr>
<tr>
<td>T391X2A</td>
<td>Poisoning by 4-Aminophenol derivatives, intentional self-harm</td>
</tr>
<tr>
<td>T392X2A</td>
<td>Poisoning by pyrazolone derivatives, intentional self-harm</td>
</tr>
<tr>
<td>T39312A</td>
<td>Poisoning by propionic acid derivatives, intentional self-harm</td>
</tr>
<tr>
<td>T39392A</td>
<td>Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm</td>
</tr>
<tr>
<td>T394X2A</td>
<td>Poisoning by antirheumatics, not elsewhere classified, intentional self-harm</td>
</tr>
<tr>
<td>T398X2A</td>
<td>Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm</td>
</tr>
<tr>
<td>T3992XA</td>
<td>Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm</td>
</tr>
<tr>
<td>T400X2A</td>
<td>Poisoning by opium, intentional self-harm</td>
</tr>
<tr>
<td>T401X2A</td>
<td>Poisoning by heroin, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T402X2A</td>
<td>Poisoning by other opioids, intentional self-harm</td>
</tr>
<tr>
<td>T403X2A</td>
<td>Poisoning by methadone, intentional self-harm</td>
</tr>
<tr>
<td>T404X2A</td>
<td>Poisoning by other synthetic narcotics, intentional self-harm</td>
</tr>
<tr>
<td>T405X2A</td>
<td>Poisoning by cocaine, intentional self-harm</td>
</tr>
<tr>
<td>T40602A</td>
<td>Poisoning by unspecified narcotics, intentional self-harm</td>
</tr>
<tr>
<td>T40692A</td>
<td>Poisoning by other narcotics, intentional self-harm</td>
</tr>
<tr>
<td>T407X2A</td>
<td>Poisoning by cannabis (derivatives), intentional self-harm</td>
</tr>
<tr>
<td>T408X2A</td>
<td>Poisoning by lysergide [LSD], intentional self-harm</td>
</tr>
<tr>
<td>T40902A</td>
<td>Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm</td>
</tr>
<tr>
<td>T40992A</td>
<td>Poisoning by other psychodysleptics [hallucinogens], intentional self-harm</td>
</tr>
<tr>
<td>T410X2A</td>
<td>Poisoning by inhaled anesthetics, intentional self-harm</td>
</tr>
<tr>
<td>T411X2A</td>
<td>Poisoning by intravenous anesthetics, intentional self-harm</td>
</tr>
<tr>
<td>T41202A</td>
<td>Poisoning by unspecified general anesthetics, intentional self-harm</td>
</tr>
<tr>
<td>T41292A</td>
<td>Poisoning by other general anesthetics, intentional self-harm</td>
</tr>
<tr>
<td>T413X2A</td>
<td>Poisoning by local anesthetics, intentional self-harm</td>
</tr>
<tr>
<td>T4142XA</td>
<td>Poisoning by unspecified anesthetic, intentional self-harm</td>
</tr>
<tr>
<td>T415X2A</td>
<td>Poisoning by therapeutic gases, intentional self-harm</td>
</tr>
<tr>
<td>T420X2A</td>
<td>Poisoning by hydantoin derivatives, intentional self-harm</td>
</tr>
<tr>
<td>T421X2A</td>
<td>Poisoning by iminostilbenes, intentional self-harm</td>
</tr>
<tr>
<td>T422X2A</td>
<td>Poisoning by succinimides and oxazolidinediones, intentional self-harm</td>
</tr>
<tr>
<td>T423X2A</td>
<td>Poisoning by barbiturates, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T424X2A</td>
<td>Poisoning by benzodiazepines, intentional self-harm</td>
</tr>
<tr>
<td>T425X2A</td>
<td>Poisoning by mixed antiepileptics, intentional self-harm</td>
</tr>
<tr>
<td>T426X2A</td>
<td>Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T4272XA</td>
<td>Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T428X2A</td>
<td>Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm</td>
</tr>
<tr>
<td>T43012A</td>
<td>Poisoning by tricyclic antidepressants, intentional self-harm</td>
</tr>
<tr>
<td>T43022A</td>
<td>Poisoning by tetracyclic antidepressants, intentional self-harm</td>
</tr>
<tr>
<td>T431X2A</td>
<td>Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm</td>
</tr>
<tr>
<td>T43202A</td>
<td>Poisoning by unspecified antidepressants, intentional self-harm</td>
</tr>
<tr>
<td>T43212A</td>
<td>Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm</td>
</tr>
<tr>
<td>T43222A</td>
<td>Poisoning by selective serotonin reuptake inhibitors, intentional self-harm</td>
</tr>
<tr>
<td>T43292A</td>
<td>Poisoning by other antidepressants, intentional self-harm</td>
</tr>
<tr>
<td>T433X2A</td>
<td>Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm</td>
</tr>
<tr>
<td>T434X2A</td>
<td>Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm</td>
</tr>
<tr>
<td>T43502A</td>
<td>Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm</td>
</tr>
<tr>
<td>T43592A</td>
<td>Poisoning by other antipsychotics and neuroleptics, intentional self-harm</td>
</tr>
<tr>
<td>T43602A</td>
<td>Poisoning by unspecified psychostimulants, intentional self-harm</td>
</tr>
<tr>
<td>T43612A</td>
<td>Poisoning by caffeine, intentional self-harm</td>
</tr>
<tr>
<td>T43622A</td>
<td>Poisoning by amphetamines, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T43632A</td>
<td>Poisoning by methylphenidate, intentional self-harm</td>
</tr>
<tr>
<td>T43692A</td>
<td>Poisoning by other psychostimulants, intentional self-harm</td>
</tr>
<tr>
<td>T438X2A</td>
<td>Poisoning by other psychotropic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T4392XA</td>
<td>Poisoning by unspecified psychotropic drug, intentional self-harm</td>
</tr>
<tr>
<td>T440X2A</td>
<td>Poisoning by anticholinesterase agents, intentional self-harm</td>
</tr>
<tr>
<td>T441X2A</td>
<td>Poisoning by other parasympathomimetics [cholinergics], intentional self-harm</td>
</tr>
<tr>
<td>T442X2A</td>
<td>Poisoning by ganglionic blocking drugs, intentional self-harm</td>
</tr>
<tr>
<td>T443X2A</td>
<td>Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm</td>
</tr>
<tr>
<td>T444X2A</td>
<td>Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm</td>
</tr>
<tr>
<td>T445X2A</td>
<td>Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm</td>
</tr>
<tr>
<td>T446X2A</td>
<td>Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm</td>
</tr>
<tr>
<td>T447X2A</td>
<td>Poisoning by beta-adrenoreceptor antagonists, intentional self-harm</td>
</tr>
<tr>
<td>T448X2A</td>
<td>Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm</td>
</tr>
<tr>
<td>T44902A</td>
<td>Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm</td>
</tr>
<tr>
<td>T44992A</td>
<td>Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm</td>
</tr>
<tr>
<td>T450X2A</td>
<td>Poisoning by antiallergic and antiemetic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T451X2A</td>
<td>Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm</td>
</tr>
<tr>
<td>T452X2A</td>
<td>Poisoning by vitamins, intentional self-harm</td>
</tr>
<tr>
<td>T453X2A</td>
<td>Poisoning by enzymes, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T454X2A</td>
<td>Poisoning by iron and its compounds, intentional self-harm</td>
</tr>
<tr>
<td>T45512A</td>
<td>Poisoning by anticoagulants, intentional self-harm</td>
</tr>
<tr>
<td>T45522A</td>
<td>Poisoning by antithrombotic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T45602A</td>
<td>Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm</td>
</tr>
<tr>
<td>T45612A</td>
<td>Poisoning by thrombolytic drug, intentional self-harm</td>
</tr>
<tr>
<td>T45622A</td>
<td>Poisoning by hemostatic drug, intentional self-harm</td>
</tr>
<tr>
<td>T45692A</td>
<td>Poisoning by other fibrinolysis-affecting drugs, intentional self-harm</td>
</tr>
<tr>
<td>T457X2A</td>
<td>Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm</td>
</tr>
<tr>
<td>T458X2A</td>
<td>Poisoning by other primarily systemic and hematological agents, intentional self-harm</td>
</tr>
<tr>
<td>T4592XA</td>
<td>Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm</td>
</tr>
<tr>
<td>T460X2A</td>
<td>Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm</td>
</tr>
<tr>
<td>T461X2A</td>
<td>Poisoning by calcium-channel blockers, intentional self-harm</td>
</tr>
<tr>
<td>T462X2A</td>
<td>Poisoning by other antidysrhythmic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T463X2A</td>
<td>Poisoning by coronary vasodilators, intentional self-harm</td>
</tr>
<tr>
<td>T464X2A</td>
<td>Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm</td>
</tr>
<tr>
<td>T465X2A</td>
<td>Poisoning by other antihypertensive drugs, intentional self-harm</td>
</tr>
<tr>
<td>T466X2A</td>
<td>Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T467X2A</td>
<td>Poisoning by peripheral vasodilators, intentional self-harm</td>
</tr>
<tr>
<td>T468X2A</td>
<td>Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T46902A</td>
<td>Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm</td>
</tr>
<tr>
<td>T46992A</td>
<td>Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm</td>
</tr>
<tr>
<td>T470X2A</td>
<td>Poisoning by histamine H2-receptor blockers, intentional self-harm</td>
</tr>
<tr>
<td>T471X2A</td>
<td>Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm</td>
</tr>
<tr>
<td>T472X2A</td>
<td>Poisoning by stimulant laxatives, intentional self-harm</td>
</tr>
<tr>
<td>T473X2A</td>
<td>Poisoning by saline and osmotic laxatives, intentional self-harm</td>
</tr>
<tr>
<td>T474X2A</td>
<td>Poisoning by other laxatives, intentional self-harm</td>
</tr>
<tr>
<td>T475X2A</td>
<td>Poisoning by digestants, intentional self-harm</td>
</tr>
<tr>
<td>T476X2A</td>
<td>Poisoning by antidiarrheal drugs, intentional self-harm</td>
</tr>
<tr>
<td>T477X2A</td>
<td>Poisoning by emetics, intentional self-harm</td>
</tr>
<tr>
<td>T478X2A</td>
<td>Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm</td>
</tr>
<tr>
<td>T4792XA</td>
<td>Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm</td>
</tr>
<tr>
<td>T480X2A</td>
<td>Poisoning by oxytocic drugs, intentional self-harm</td>
</tr>
<tr>
<td>T481X2A</td>
<td>Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm</td>
</tr>
<tr>
<td>T48202A</td>
<td>Poisoning by unspecified drugs acting on muscles, intentional self-harm</td>
</tr>
<tr>
<td>T48292A</td>
<td>Poisoning by other drugs acting on muscles, intentional self-harm</td>
</tr>
<tr>
<td>T483X2A</td>
<td>Poisoning by antitussives, intentional self-harm</td>
</tr>
<tr>
<td>T484X2A</td>
<td>Poisoning by expectorants, intentional self-harm</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>T485X2A</td>
<td>Poisoning by other anti-common-cold drugs, intentional self-harm</td>
</tr>
<tr>
<td>T486X2A</td>
<td>Poisoning by antiasthmatics, intentional self-harm</td>
</tr>
<tr>
<td>T48902A</td>
<td>Poisoning by unspecified agents primarily acting on the respiratory system,</td>
</tr>
<tr>
<td></td>
<td>intentional self-harm</td>
</tr>
<tr>
<td>T48992A</td>
<td>Poisoning by other agents primarily acting on the respiratory system,</td>
</tr>
<tr>
<td></td>
<td>intentional self-harm</td>
</tr>
<tr>
<td>T490X2A</td>
<td>Poisoning by local antifungal, anti-infective and anti-inflammatory drugs,</td>
</tr>
<tr>
<td></td>
<td>intentional self-harm</td>
</tr>
<tr>
<td>T491X2A</td>
<td>Poisoning by antipruritics, intentional self-harm</td>
</tr>
<tr>
<td>T492X2A</td>
<td>Poisoning by local astringents and local detergents, intentional self-harm</td>
</tr>
<tr>
<td>T493X2A</td>
<td>Poisoning by emollients, demulcents and protectants, intentional self-harm</td>
</tr>
<tr>
<td>T494X2A</td>
<td>Poisoning by keratolytics, keratoplastics, and other hair treatment drugs</td>
</tr>
<tr>
<td></td>
<td>and preparations, intentional self-harm</td>
</tr>
<tr>
<td>T495X2A</td>
<td>Poisoning by ophthalmological drugs and preparations, intentional self-harm</td>
</tr>
<tr>
<td>T496X2A</td>
<td>Poisoning by otorhinolaryngological drugs and preparations, intentional</td>
</tr>
<tr>
<td></td>
<td>self-harm</td>
</tr>
<tr>
<td>T497X2A</td>
<td>Poisoning by dental drugs, topically applied, intentional self-harm</td>
</tr>
<tr>
<td>T498X2A</td>
<td>Poisoning by other topical agents, intentional self-harm</td>
</tr>
<tr>
<td>T4992XA</td>
<td>Poisoning by unspecified topical agent, intentional self-harm</td>
</tr>
<tr>
<td>T500X2A</td>
<td>Poisoning by mineralocorticoids and their antagonists, intentional self-harm</td>
</tr>
<tr>
<td>T501X2A</td>
<td>Poisoning by loop [high-ceiling] diuretics, intentional self-harm</td>
</tr>
<tr>
<td>T502X2A</td>
<td>Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other</td>
</tr>
<tr>
<td></td>
<td>diuretics, intentional self-harm</td>
</tr>
<tr>
<td>T503X2A</td>
<td>Poisoning by electrolytic, caloric and water-balance agents, intentional</td>
</tr>
<tr>
<td></td>
<td>self-harm</td>
</tr>
</tbody>
</table>
Appendix O

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T504X2A</td>
<td>Poisoning by drugs affecting uric acid metabolism, intentional self-harm</td>
</tr>
<tr>
<td>T505X2A</td>
<td>Poisoning by appetite depressants, intentional self-harm</td>
</tr>
<tr>
<td>T506X2A</td>
<td>Poisoning by antidotes and chelating agents, intentional self-harm</td>
</tr>
<tr>
<td>T507X2A</td>
<td>Poisoning by analeptics and opioid receptor antagonists, intentional self-harm</td>
</tr>
<tr>
<td>T508X2A</td>
<td>Poisoning by diagnostic agents, intentional self-harm</td>
</tr>
<tr>
<td>T50902A</td>
<td>Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm</td>
</tr>
<tr>
<td>T50992A</td>
<td>Poisoning by other drugs, medicaments and biological substances, intentional self-harm</td>
</tr>
</tbody>
</table>

.03 Nonbehavioral Health Fee-For-Service Benefits.

An MCO may not be required to provide any of the following benefits or services that are reimbursed directly by the Department:

A. The remaining days of a hospital admission following enrollment in the MCO if the recipient was admitted to the hospital before the date of the recipient’s enrollment;

B. Long-term care services except for those outlined in COMAR 10.67.06.07B and COMAR 10.67.06.12A;

C. Intermediate Care Facilities for Individuals with Intellectual Disabilities or Persons with Related Conditions (ICF/IID) services;

D. Personal care services pursuant to COMAR 10.09.20;

E. Medical day care services, for adults and children;

F. The following HIV/AIDS services:

   (1) Genotypic, phenotypic, or other HIV/AIDS drug resistance testing used in the treatment of HIV/AIDS, if the service is:

   (a) Rendered by a Department-approved provider; and

   (b) Medically necessary; and
(2) Viral load testing used in treatment of HIV/AIDS.

G. Physical therapy, speech therapy, and occupational therapy services when:

(1) The enrollee is younger than 21 years old; and

(2) The services are not part of home health services or an inpatient hospital stay;

H. Augmentative communication devices;

I. Dental:

(1) Services for enrollees younger than 21 years old and pregnant women; and

(2) Outpatient surgery fees for the facility and general anesthesia for pregnant women and enrollees younger than 21 years old;

J. Except when a woman has been determined eligible for Medical Assistance benefits under COMAR 10.09.11, an abortion pursuant to COMAR 10.09.02.04G;

K. Emergency transportation;

L. Transportation services provided through grants to local governments pursuant to COMAR 10.09.19;

M. Services provided to members participating in the State’s Health Home Program as described in COMAR 10.09.33; and

N. Applied behavioral analysis (ABA) services as described in COMAR 10.09.28.

Chapter 09 Maryland Medicaid Managed Care Program: MCO Dispute Resolution Procedures

.01 MCO Enrollee Services.

An MCO shall:

A. Maintain a member services unit that operates an enrollee services line at least during normal business hours;

B. Operate its enrollee services line as a triage device to handle or properly refer enrollees' questions or complaints; and

C. Provide information in the member handbook about how to use the MCO enrollee services line to obtain information and assistance.
.02 MCO Enrollee Complaint Process.

A. An MCO shall have written complaint procedures by which an enrollee who is dissatisfied with the MCO or its network providers, or decisions made by the MCO or a provider, may seek recourse verbally or in writing within the MCO at any time.

B. An MCO shall:

(1) Submit its written internal complaint procedures to the Department for its approval;

(2) Give enrollees any reasonable assistance in completing forms and taking other procedural steps related to a grievance or appeal in a manner consistent with COMAR 10.67.05.01A;

(3) Prepare the document describing the MCO’s internal complaint process:

   (a) In a culturally sensitive manner;

   (b) At an appropriate reading comprehension level; and

   (c) In the prevalent non-English languages, identified by the State;

(4) Deliver a copy of the MCO’s complaint procedures to each enrollee:

   (a) With the MCO’s initial contact with a new enrollee; and

   (b) At any time upon an enrollee’s request;

(5) Maintain an accurate and accessible record of grievances and appeals for monitoring by the State and CMS, which includes, at a minimum:

   (a) A general description of the reason for the appeal or grievance;

   (b) The date received;

   (c) The date of each review or, if applicable, review meeting;

   (d) Resolution at each level of the appeal or grievance, if applicable;

   (e) Date of resolution at each level, if applicable; and

   (f) Name of the enrollee for whom the appeal or grievance was filed; and

(6) Provide in its written procedures that an enrollee may file appeals and grievances orally or in writing.
C. An MCO shall submit for Department approval an internal complaint process detailing the procedures for registering and responding to appeals and grievances in a timely fashion, which:

(1) Includes a specific standard for grievance decisions, monitored by the MCO for compliance, directing that:

   (a) The decision time for emergency medically related grievances may not exceed 24 hours;

   (b) The decision time for nonemergency medically related grievances may not exceed 5 days; and

   (c) For administrative grievances, the decision time may not exceed 30 days;

(2) Includes participation by the provider, if appropriate;

(3) Allows participation by the ombudsman, if appropriate;

(4) Ensures the participation of individuals within the MCO who have the authority to require corrective action;

(5) Requires documentation of the substance of the grievances and steps taken;

(6) Includes a procedure for the aggregation and analysis of appeals and grievance data and use of the data for quality improvement;

(7) Includes a documented procedure for reporting:

   (a) Appeals and grievances received by the MCO to:

      (i) The provider involved;

      (ii) Appropriate quality assurance committees and departments within the MCO;

      (iii) The MCO's consumer advisory board; and

      (iv) The Department as requested; and

   (b) The quarterly appeal and grievance analysis performed by the MCO as specified in COMAR 10.67.04.15D(1)(b);

(8) Includes a documented procedure for written notification of the MCO's determination:

   (a) To the enrollee who filed the grievance; and
(b) To those individuals and entities required to be notified of the grievance pursuant to §C(7) of this regulation;

(9) Ensures that decision makers on appeals and grievances:

(a) Were not involved in previous levels of decision-making;

(b) Are not subordinates of people involved in previous levels of decision-making;

(c) Are healthcare professionals with clinical expertise in treating the enrollee’s condition or disease, if any of the following apply:

(i) The appeal is a denial based on lack of medical necessity;

(ii) The grievance is regarding denial of expedited resolution of an appeal; or

(iii) The appeal or grievance involves clinical issues; and

(d) Take into account all comments, documents, records, and other information submitted by the enrollee or their representative, without regard to whether such information was submitted or considered in the initial action.

.02-1 Member Complaints — Time Frames for MCOs to Respond to the Department.

An MCO shall:

A. Acknowledge an enrollee appeal or grievance reported to it by the Department’s complaint resolution unit within 1 business day;

B. Respond to the Department’s request for information regarding disputed nonemergency medical care actions within 3 business days;

C. Provide updates in a time frame specified by the Department;

D. Provide medical records within 5 days of the request; and

E. Provide a corrective action plan upon request and within the time frame specified, but not later than 10 days from the date of the request.

.03 MCO Provider Complaint Process.

A. An MCO shall have a complaint procedure for providers that is:

(1) Documented in writing;
(2) Disseminated in writing to all of the MCO's providers at the time they join the MCO's provider panel, and furnished to a provider at any time, upon request; and

(3) Linked to the MCO's internal quality assurance program.

B. An MCO shall include in its provider complaint process at least the following elements:

(1) Procedures for registering and responding to provider grievances in a timely fashion, including standards for timeliness that recognize the need for expedited determinations in situations that are time-sensitive, that is, when an enrollee's treatment outcome may be significantly affected by the promptness of treatment, as set forth in Regulation .02C(1)(a) and (b) of this chapter apply;

(2) Notification to the provider of an MCO's determination that affects the provider or that provider's patient, which includes a description of how to file an internal appeal with the MCO;

(3) Documentation of the substance of complaints and steps taken;

(4) Procedures to ensure the timely resolution of the complaint and response by the MCO to the provider;

(5) Procedures for the termination or withdrawal of a provider from the MCO's provider panel, including:

(a) At least 90 days prior notice to the primary care providers in the MCO's provider panel of the MCO's termination of a specialty services provider when the reason for the termination is unrelated to fraud, patient abuse, incompetency, or loss of licensure status;

(b) If possible, at least 90 days prior notice to the primary care providers in the MCO's provider panel of a specialty services provider's withdrawal from the MCO's provider panel; and

(c) Notices to primary care providers informing them of the enrollee’s right to change MCOs as described in COMAR 10.67.02.06A(1)(e).

(6) Mechanisms to aggregate and analyze appeal and grievance data and to use the data for quality improvement;

(7) An appeal process which:

(a) Is available when the provider's appeal or grievance is not resolved to the provider's satisfaction, or when the MCO acts to reduce, suspend, or terminate provider's privileges with the MCO;

(b) Acknowledges receipt of provider appeals within 5 business days of receipt by the MCO;
(c) Allows providers 90 business days from the date of a denial to file an initial appeal;

(d) Allows providers at least 15 business days from the date of denial to file each subsequent level of appeal;

(e) Resolves appeals, regardless of the number of appeal levels allowed by the MCO, within 90 business days of receipt of the initial appeal by the MCO;

(f) Pays claim within 30 days of the appeal decision when a claim denial is overturned;

(g) Provides at its final level an opportunity for the provider to be heard by the MCO's chief executive officer, or the chief executive officer's designee;

(h) Provides timely written notice to the provider of the results of the internal appeal; and

(i) Provides for written notice of the substance of the dispute and the result of the internal appeal to appropriate quality assurance committees and departments within the MCO; and

(8) A protocol for transmitting provider appeal and grievance reports and aggregate provider grievance and appeal data to the Department when requested.

C. An MCO may not take any punitive action against a provider for utilizing the MCO provider complaint process, for supporting an enrollee's appeal, or for requesting expedited resolution for an enrollee's appeal.

D. An MCO or its pharmacy benefits manager shall resolve pharmacy appeals concerning drug pricing within 21 days of the receipt of a request.

.03-1 Independent Review Organization (IRO).

For provider disputes involving medical necessity, an MCO shall participate in the IRO process as specified in COMAR 10.67.13.

.03-2 Provider Complaints — Time Frames for MCOs to Respond to the Department.

An MCO shall:

A. Acknowledge provider grievances within 3 business days;

B. Provide findings to the Department within 5 days; and

C. Provide a corrective action plan to the Department within 10 days from the date of the request.
.04 MCO Actions and Decisions.

A. For certain services to enrollees that require preauthorization the following conditions apply:

(1) For standard authorization decisions, the MCO shall make a determination within 2 business days of receipt of necessary clinical information, but not later than 14 calendar days from the date of the initial request so as not to adversely affect the health of the enrollee;

(2) For expedited authorization decisions, the MCO shall make a determination and provide notice no later than 72 hours after receipt of the request for service if the provider indicates or the MCO determines that the standard time frame stated in §A(1) of this regulation could jeopardize:

(a) The enrollee’s life;

(b) The enrollee’s health; or

(c) The enrollee’s ability to attain, maintain, or regain maximum function;

(3) For all covered outpatient drug authorization decisions, the MCO shall provide notice by telephone or other telecommunication device within 24 hours of a preauthorization request in accordance with section 1927(d)(5)(A) of the Social Security Act;

(4) Standard and expedited authorization decisions may be extended up to 14 calendar days, if the following conditions are met:

(a) The enrollee or the provider requests an extension; or

(b) The MCO justifies to the Department, upon request, a need for additional information and how the extension is in the enrollee’s interest; and

(5) If the MCO successfully justifies extending the standard service authorization decision time frame, the MCO shall:

(a) Give the enrollee written notice of the reason for the decision to extend the time frame;

(b) Inform the enrollee of the right to file a grievance if he or she disagrees with the extension decision; and

(c) Issue and carry out the MCO’s determination as expeditiously as the enrollee’s health condition requires but not later than the date the extension expires.

B. Any decision to deny a service authorization request or to authorize a service in an amount, duration, or scope that is less than requested:
(1) Shall be made by a health care professional who has appropriate clinical expertise in
treating the enrollee's condition or disease; and

(2) May not be based solely on diagnosis, type of illness, or condition.

C. An MCO shall ensure that compensation to individuals or entities that conduct utilization
management activities is not structured to provide incentives for the individual or entity to deny,
limit, or discontinue medically necessary services to any enrollee.

D. Notices of a decision to deny a standard authorization shall be provided to the enrollee and
the requesting provider within 72 hours from the date of determination.

E. An MCO shall give an enrollee written notice of any action within the following time
frames:

(1) At least 10 days before the action for termination, suspension, or reduction of a
previously authorized covered service;

(2) The notice period is reduced to 5 days if probable enrollee fraud has been verified;

(3) By the date of the action for the following:

(a) The MCO has factual information confirming the death of an enrollee;

(b) A signed written enrollee statement requesting service termination or giving
information requiring termination or reduction of services, where the enrollee understands that
this is the result of supplying that information;

(c) The enrollee's admission to an institution where they are ineligible for further services;

(d) The enrollee's address is unknown and mail directed to the enrollee has no forwarding
address;

(e) The enrollee has been accepted for Medicaid services by another jurisdiction;

(f) The enrollee's physician prescribes a change in the level of medical care; or

(g) An adverse determination made with regard to the preadmission screening
requirements for nursing facility admissions; and

(4) As soon as practicable for nursing facility transfers or discharges when:

(a) The safety or health of individuals in the facility would be endangered;

(b) The enrollee’s health improves sufficiently to allow a more immediate transfer or
discharge; or
(c) An immediate transfer or discharge is required by the enrollee’s urgent medical needs; and

(5) For denial of payment, at the time of any action affecting the claim.

F. A notice of adverse action shall:

(1) Be in writing;

(2) Meet the following requirements:

   (a) Be translated for enrollees who speak prevalent non-English languages;

   (b) Include language clarifying that oral interpretation is available for all languages and how to access it;

   (c) Be written in an easily understood language and format that takes into consideration enrollees with special needs;

   (d) Be available in alternative formats; and

   (e) Inform enrollees that information is available in alternative formats and how to access those formats; and

(3) Contain the following information:

   (a) The action the MCO has made or intends to make;

   (b) The reasons for the action, including the right for the enrollee to be provided upon request and free of charge, reasonable access to and copies of all documents, records, and other information relevant to the MCO’s action, including:

      (i) Medical necessity criteria; and

      (ii) Any processes, strategies, or evidentiary standards used in setting coverage limits;

   (c) The enrollee’s right to request an appeal of the MCO’s action, including information on:

      (i) Exhausting the MCO’s one level of appeal; and

      (ii) The right to request a State fair hearing;

   (d) The procedures for exercising the rights described;
Appendix O

(e) The circumstances under which an appeal process can be expedited and how to request it;

(f) The enrollee’s right to have benefits continue pending resolution of the appeal;

(g) How to request that benefits be continued; and

(h) The circumstances under which the enrollee may be required to pay the costs of the services.

G. If an MCO does not make an authorization decision within the times specified in §A of this regulation, the untimely decision is considered a denial and thus an adverse action subject to the notice requirements in §§C and E of this regulation.

.05 MCO Appeal Process for Enrollees.

A. An MCO's appeal process shall:

(1) Require that an enrollee, or a provider acting on the enrollee’s behalf, file an appeal within 60 days from the date on the MCO’s notice of action;

(2) Include procedures for acknowledging receipt of appeals within 5 business days;

(3) Permit an enrollee to request an appeal either orally or in writing;

(4) Provide that oral requests for appeal are considered the initiation of the appeal to establish the earliest possible filing date, and are confirmed in writing, unless the enrollee, their representative, or the provider requests an expedited appeal;

(5) Provide reasonable opportunity to present evidence and allegations of fact or law, in person as well as in writing, and in the case of expedited appeals, the MCO shall inform the enrollee of the limited time available for the enrollee to present this evidence;

(6) Provide the case file upon request to the enrollee and the enrollee's representative, free of charge and sufficiently in advance of the resolution time frame for appeals, which includes:

(a) Medical records;

(b) Other documents and records; and

(c) Any new or additional evidence considered, relied upon, or generated by the MCO in connection with the action.

(7) Allow a provider or authorized representative acting on behalf of an enrollee to file an appeal with the enrollee’s written consent;
(8) Consider the enrollee, the enrollee's representative, or the estate representative of a deceased enrollee as parties to the appeal;

(9) Establish and maintain an expedited review process, when the MCO determines or the provider indicates that taking the time for a standard resolution could seriously jeopardize the enrollee’s life, physical or mental health, or ability to attain, maintain, or regain maximum function; and

(10) Ensure that punitive action is not taken against a provider who requests an expedited resolution or supports an enrollee’s appeal.

B. Resolution.

(1) Except for expedited appeals as described in §C, an MCO shall resolve each appeal and provide notice of resolution, as expeditiously as the enrollee’s health condition requires, and unless extended pursuant to §B(2) of this regulation, within 30 days from the day the MCO receives the appeal.

(2) The time frames in §B(1) of this regulation may be extended up to 14 calendar days if:

(a) The enrollee requests the extension; or

(b) The MCO shows, upon the Department's request, that there is a need for additional information and how the delay is in the enrollee's interest.

(3) For any extension not requested by the enrollee, the MCO shall:

(a) Give the enrollee written notice; and

(b) Make reasonable efforts to give the enrollee verbal notice of the reason for the delay.

(4) Continuation of Benefits. The MCO shall continue the enrollee’s benefits pending the outcome of the appeal if all of the following occur:

(a) The enrollee timely files for continuation of benefits;

(b) The appeal is filed timely, meaning on or before the later of the following:

   (i) Within 10 days of the MCO mailing the notice of action; or

   (ii) The intended effective date of the MCO's proposed action;

(c) The appeal involves the termination, suspension, or reduction of a previously authorized service;

(d) The services were ordered by an authorized provider; and
(e) The authorization period has not expired.

(5) If the MCO continues or reinstates the enrollee's benefits while the appeal is pending, the benefits shall continue until one of the following occurs:

(a) The enrollee withdraws the appeal;

(b) The enrollee fails to request a State fair hearing and continuation of benefits within 10 days after the MCO sends the notice of an adverse resolution to the enrollee’s appeal; or

(c) A State fair hearing decision adverse to the enrollee is made.

(6) If the MCO or State fair hearing officer reverses a decision to deny, limit, or delay services, the MCO shall authorize or provide the disputed services promptly and as expeditiously as the enrollee’s health condition requires but no later than 72 hours of the date the MCO receives the reversal.

C. Expedited Appeals.

(1) An expedited resolution may be approved when the MCO determines or the provider indicates that taking the time for a standard resolution could seriously jeopardize:

(a) The enrollee’s life;

(b) The enrollee’s physical or mental health; or

(c) The enrollee’s ability to attain, maintain, or regain maximum function.

(2) Expedited appeals shall be resolved as expeditiously as the enrollee’s health condition requires but no later than 72 hours after the MCO receives the appeal.

(3) If the MCO denies a request for expedited resolution of an appeal, the MCO shall:

(a) Transfer the appeal to the standard time frame of not longer than 30 days from the day the MCO receives the appeal with a possible 14-day extension as described in §B(2) of this regulation; and

(b) Make reasonable efforts to give the enrollee prompt verbal notice of the denial of expedited resolution and provide a written notice within 2 calendar days.

D. Notification.

(1) The MCO shall provide written notice of resolution which includes:

(a) The results and date of the appeal resolution;
Appendix O

(b) The reasons for the action;

(c) For decisions not wholly in the enrollee’s favor:

(i) The right to request a State fair hearing;

(ii) How to request a State fair hearing;

(iii) The right to continue to receive benefits pending a hearing;

(iv) How to request the continuation of benefits; and

(v) A statement that the enrollee may be liable for the cost of any continued benefits if the MCO’s action is upheld in a hearing.

(2) For notice of an expedited resolution, in addition to requirements listed in §D(1) of this regulation, the MCO shall also make reasonable efforts to provide oral notice of the decision.

E. If an MCO fails to adhere to the notice and timing requirements, as described in §§A—D of this regulation, the enrollee is deemed to have exhausted the MCO’s appeals process and may initiate a State fair hearing.

F. State Fair Hearing.

(1) An enrollee may exercise State fair hearing rights pursuant to the Department’s regulations and State Government Article, §10-201 et seq., Annotated Code of Maryland, subject to the requirements of this regulation.

(2) An enrollee may request a State fair hearing for an MCO appeal resolution after first exhausting the MCO’s appeal process by appealing to the Office of Administrative Hearings using the process specified in COMAR 10.01.04.

(3) An enrollee shall file for a State fair hearing within 120 days from the date the MCO provides on the written notice of appeal resolution.

(4) The parties to an appeal to the Office of Administrative Hearings under this section are the:

(a) MCO;

(b) Enrollee; and

(c) Enrollee’s representative or the personal representative of a deceased enrollee’s estate.
5) The MCO shall provide documentation regarding medical determinations to enrollees and the Office of Administrative Hearings as required by COMAR 10.01.04 and other applicable law.

6) The MCO shall continue the enrollee’s benefits pending the outcome of the State fair hearing if all of the following occur:

   a) The enrollee files for continuation of benefits within 10 days of the MCO upholding its action;

   b) The State fair hearing request is filed timely, meaning on or before the later of the following:

      i) 10 days from the date on the MCO’s notice of appeal resolution; or

      ii) The intended effective date of the MCO's proposed action;

   c) The State fair hearing involves the termination, suspension, or reduction of a previously authorized service;

   d) The services were ordered by an authorized provider; and

   e) The authorization period has not expired.

7) If the MCO continues or reinstates the enrollee's benefits while the State fair hearing is pending, the benefits shall continue until one of the following occurs:

   a) The enrollee withdraws the State fair hearing; or

   b) A State fair hearing decision adverse to the enrollee is issued by the Office of Administrative Hearings.

8) The final decision of the Office of Administrative Hearings is appealable to the circuit court, and is governed by State Government Article, §10-201 et seq., Annotated Code of Maryland, and the Maryland Rules.

G. The Department may order an MCO to provide a benefit or service based on its evaluation of the MCO’s action.
Chapter 10 Maryland Medicaid Managed Care Program: Sanctions

.01 Sanction by the Department.

A. If the Department determines, after a sufficient investigation, that an MCO or any agent or employee of the MCO, or any person with an ownership interest in an MCO, or related party of the MCO, has failed to comply with any applicable law, regulation, or contract term, or for other good cause shown, the Department may impose sanctions on the MCO, including but not limited to:

   (1) Fines;
   (2) Suspension of further enrollment;
   (3) Withholding all or part of the capitation payment;
   (4) Termination of the current HealthChoice Managed Care Organization Agreement;
   (5) Disqualification from future participation in the Maryland Medicaid Managed Care Program;
   (6) Orders to provide a benefit or service to enrollees; and

B. Corrective Action.

   (1) Subject to §B(2) of this regulation, before imposing a sanction pursuant to §A of this regulation, the Department may permit an MCO an opportunity to take corrective action in accordance with a plan approved by the Department.

   (2) The MCO shall submit a corrective action plan within a time frame specified by the Department.

.01-1 Sanction by Center for Medicare and Medicaid Services (CMS).

The Department shall comply with notification requirements of CMS at 42 CFR §438.730 for sanction determinations as specified in 42 CFR §438.700(b)(1)—(b)(6).

.02 Appeal.

A. From the decisions set forth in §B(1)—(8) of this regulation, an MCO may exercise the appeal rights set forth in §C of this regulation.

B. The following Department decisions are appealable by the MCO or MCO applicant:
(1) Denial of an entity’s completed application to become an MCO;

(2) Decision to terminate the MCO's participation in the Maryland Medicaid Managed Care Program;

(3) Decision to impose a fine or other sanction on the MCO as described in Regulation .01 of this chapter;

(4) Order to provide benefits or services to enrollees as described in COMAR 10.67.09.05;

(5) Order that the MCO is impaired or in “hazardous financial condition”;

(6) An adverse decision by the IRO as described in COMAR 10.67.13.08;

(7) The amount of a penalty or incentive as described in COMAR 10.67.04.03;

(8) The denial of a hepatitis C payment as described in COMAR 10.67.04.19;

(9) Overpayments recovered by the Department as described in COMAR 10.67.07.01; and

(10) Remittances to the Department as described in COMAR 10.67.04.19-5.

C. An MCO may appeal a decision listed in §B of this regulation to the Office of Administrative Hearings as specified in COMAR 10.01.03 and COMAR 10.09.36.09.

D. The parties to an appeal to the Office of Administrative Hearings under §C of this regulation are the Department and the MCO. The enrollee is not a party at this hearing.

E. The following sanctions shall take effect immediately and are not subject to stay during the pendency of an appeal:

(1) Any fines imposed;

(2) Orders to provide a benefit or service to enrollees;

(3) Any full or partial withhold of the capitation payment;

(4) Any remittances to the Department as described in COMAR 10.67.04.19-5; or

(5) Any overpayments recovered by the Department as described in COMAR 10.67.07.01.

.03 Incentives.

A. All monies collected from the MCOs as a result of the imposition of a financial sanction shall be deposited in the HealthChoice Performance Incentive Fund.
B. This nonlapsing fund shall include all sanctions imposed on the MCOs starting in calendar year 1999.

C. The fund shall be used to provide financial incentive awards to the MCOs that meet or exceed specific performance targets as established by the Department, unless otherwise directed by law.

Chapter 11 Maryland Medicaid Managed Care Program: Contribution to Graduate Medical Education Costs

.01 Scope.

This chapter applies to teaching hospitals that provide health care services to recipients enrolled in Maryland Medicaid Managed Care Program MCOs.

.02 GME Allocation Payment.

A. Purpose. GME allocation payments to teaching hospitals are intended to:

(1) Reaffirm the Program's historic commitment to preserving graduate medical education at each of the State's teaching hospitals, by maintaining Program payments supporting graduate medical education at levels equivalent to inflation-adjusted FY 1995 expenditures;

(2) Promote the training of primary care practitioners;

(3) Promote the development of innovative approaches to improve the Program population's access to health care services; and

(4) Ameliorate the new funding procedure's impact on MCOs that historically have experienced low utilization of teaching hospitals, by adopting an initial moderate reduction, pursuant to §B(4) of this regulation and COMAR 10.67.05.15, of the amount of GME-allocatable dollars included in teaching hospitals' GME allocation payments during the first 3 years of separate GME funding.

B. GME Allocation Payments to Teaching Hospitals. Beginning in FY 1999, the Department shall, on a quarterly basis, pay each teaching hospital a GME allocation payment, calculated as follows:

(1) The Department shall calculate the combined dollar amount of payments made by the Program to teaching hospitals during FY 1995, including only those payments attributable to utilization:

(a) Of services that, if delivered during the fiscal year during which the GME allocation payment is made, would be included in the Maryland Medicaid Managed Care Program mandatory benefits package established by COMAR 10.67.06; and
Appendix O

(b) By recipients who, if the utilization had occurred during the fiscal year in which the GME allocation payment is made:

(i) Would have met the eligibility criteria for the Maryland Medicaid Managed Care Program, pursuant to COMAR 10.67.02.01; and

(ii) Would not have met the eligibility criteria for the rare and expensive case management program, pursuant to COMAR 10.09.69.03;

(2) The amount resulting from the calculation described in §B(1) of this regulation is reduced by the dollar amount of included payments for inpatient hospital services that, if they had been incurred during the fiscal year of the GME allocation payment, would have been subject to avoidance by an MCO pursuant to the stop-loss provisions of COMAR 10.67.04.22;

(3) The amount resulting from the calculation described in §B(2) of this regulation is trended forward to adjust for the time differential between the base year (FY 1995) and the contract year;

(4) The amount resulting from the calculation described in §B(3) of this regulation is reduced to reflect the managed care discount incorporated into capitation rates pursuant to COMAR 10.67.04.18-1B(2);

(5) The amount resulting from the calculation described in §B(4) of this regulation is multiplied by the percentage of Program payments considered, pursuant to COMAR 10.67.04.18-1A(1)—(3), to be attributable to GME; and

(6) The amount resulting from the calculation described in §B(5) of this regulation is multiplied by 0.25, to reflect the GME allocation's quarterly payment schedule.

Chapter 12 Maryland Medicaid Managed Care Program: Corrective Managed Care

.01 General.

A. An MCO shall establish a corrective managed care plan that, at minimum, provides for:

(1) The identification of an enrollee that has abused MCO pharmacy benefits; and

(2) The enrollment of an enrollee that has been determined to have abused MCO pharmacy benefits in the MCO’s corrective managed care plan.

B. Enrollee abuse exists when an enrollee:

(1) Has engaged in behaviors identified in COMAR 10.09.24.14-1; or

(2) Engages in Medicaid fraud as defined under COMAR 10.09.24.14.
.02 Corrective Managed Care Plan.

A. An MCO’s corrective managed care plan:

(1) Shall cover enrollee abuse of medical assistance pharmacy benefits; and

(2) May cover enrollee abuse of nonpharmacy medical assistance benefits.

B. For all benefit abuse covered by an MCO’s corrective managed care plan, the plan shall:

(1) Use the criteria as described in Regulation .01B of this regulation to determine if enrollees have abused benefits;

(2) Provide for a medical review of the alleged abuse consistent with §C of this regulation;

(3) Provide that an enrollee found to have abused benefits will be enrolled in the program for 24 months;

(4) Provide that an enrollee who has been enrolled in a 24 month plan and is subsequently found to have abused MCO benefits shall be enrolled in the plan for an additional 36 months;

(5) Provide for the MCO to select any participating provider in the MCO that meets the requirements of COMAR 10.67.05.05A to serve as the enrollee’s primary care, specialty care, and pharmacy providers for enrollees in corrective managed care, as appropriate to the type of benefit the enrollee has been found to have abused;

(6) Require an enrollee to obtain prescribed drugs only from a single designated pharmacy provider, which may be any pharmacy or any single branch of a pharmacy chain that participates in the MCO and meets the requirements of COMAR 10.67.05.06B and .07C(2) unless the prescription is:

    (a) Pursuant to an emergency department visit;

    (b) Pursuant to hospital inpatient treatment; or

    (c) A specialty drug as defined in COMAR 10.67.06.04;

(7) Provide enrollees determined to have abused benefits the ability to suggest primary care, specialty care, or pharmacy providers;

(8) Require the MCO to accept the enrollee’s suggestion referenced in §B(7) of this regulation unless the MCO determines that the recipient’s choice of provider would not serve the enrollee’s best interest in achieving appropriate use of the health care systems and benefits available through the MCO;
(9) Provide an enrollee determined to have abused benefits 20 days from the date of the notice to present additional documentation to explain the facts that serve as the basis for the MCO’s determination of benefit abuse, consistent with §D of this regulation;

(10) Provide for the designation of a new primary care, specialty care, or pharmacy provider if the enrollee moves out of the service area of the current primary care or pharmacy provider;

(11) Provide for prompt reporting to the Department the name of any enrollee enrolled in the MCO’s program, the duration of enrollment, or any change in the duration of enrollment; and

(12) Be submitted to the Department for review and approval:
   (a) Within 60 days of the effective date of this regulation; and
   (b) Before the implementation of any modification.

C. The medical review required in §B(2) of this regulation shall:

   (1) Be performed by a medical reviewer who is a licensed health care professional;

   (2) Consider all information that is relevant and available to the MCO, including but not limited to MCO payment records and information secured from any interviews conducted; and

   (3) Where appropriate, consider records obtained from other sources, including:

      (a) Providers of medical services;

      (b) Statistical reports;

      (c) Outside complaints;

      (d) Referrals from other agencies; or

      (e) Any other appropriate sources.

D. If an enrollee provides additional information pursuant to §B(9) of this regulation within 20 days:

   (1) The effective date of the enrollment provided in the notice shall be tolled pending the MCO’s review of the additional information;

   (2) The MCO shall consider whether the additional information changes the MCO’s determination regarding the appropriateness of the enrollee’s enrollment in corrective managed care;
(3) The MCO shall notify the enrollee of its decision whether the MCO is affirming or reversing its determination to enroll the enrollee in corrective managed care; and

(4) If the MCO confirms its determination to enroll the enrollee in corrective managed care, the notice shall:

(a) Identify the effective date and duration of that enrollment; and

(b) Include an explanation of the enrollee’s right to appeal the determination as described in Regulation .05 of this chapter.

E. An MCO’s corrective managed care plan may include a process for re-considering, at any interval of time, a decision to enroll an enrollee in the MCO’s corrective managed care plan, if the process entitles the enrollee to appeal the decision pursuant to Regulation .05 of this chapter at the same interval of time.

.03 Enrollee Notice.

The MCO shall provide an enrollee determined to have abused MCO benefits a written notice that includes the following:

A. An explanation of the reason or reasons for the determination that the enrollee abused benefits;

B. A statement that the enrollee has 20 days to provide:

(1) Additional information for the MCO to consider before enrollment will become effective; and

(2) The address where the additional information shall be sent;

C. A statement that the enrollee will be enrolled in corrective managed care and the effective date and duration of that enrollment;

D. An explanation that the effective date will be tolled pending the MCO’s review of any additional information the enrollee provides pursuant to §B of this regulation;

E. A statement that the enrollee may identify a preference for an assigned primary medical care provider, specialty care provider, or pharmacy; and

F. An explanation of the enrollee’s right to appeal the MCO’s determination as described in Regulation .05 of this chapter.
.04 Effective Date of Enrollment.

A. Except as provided in §B of this regulation, the effective date of enrollment shall be 20 days from the date of the notice described in Regulation .03A and B of this chapter, whichever is later.

B. If an enrollee determined to have abused benefits appeals the determination, the effective date of the enrollment shall be tolled pending the outcome of the appeal.

C. The duration of an enrollee’s enrollment in a plan may not be altered because of changes in how the individual receives medical assistance, including but not limited to a change in the enrollee’s MCO enrollment.

.05 Enrollee Appeal.

A. An enrollee shall have 20 days to appeal an MCO’s determination of benefit abuse.

B. Except for the time frame specified in §A of this regulation, an appeal shall be handled as specified in COMAR 10.67.09.05.

C. If the appeal results in a hearing, an MCO shall:

   (1) Attend the hearing; and

   (2) Provide justification for enrollment in the program.
Chapter 13 Maryland Medicaid Managed Care Program: Independent Review Organization (IRO)

.01 Scope and Purpose.

This chapter provides for a complaint resolution process for disputes between managed care organizations (MCOs) and providers regarding adverse medical necessity decision made by MCOs. Pursuant to this chapter, providers that receive an adverse medical necessity decision on claims for reimbursement may submit the adverse decision for review by an Independent Review Organization (IRO) designated by the Department.

.02 Definitions.

A. In this chapter, the following terms have the meanings indicated.

B. Terms Defined.

(1) "Adverse decision" means a review determination by a managed care organization that a health care service for which a provider seeks reimbursement is not medically necessary.

(2) "Affiliate" means a person who, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with another person.

(3) "Case record" means documentation submitted to an independent review organization consisting of:

   (a) A claim and only the supporting documentation, including medical records, originally submitted to a managed care organization by a provider prior to the managed care organization’s adverse decision on the claim;

   (b) The managed care organization’s adverse decision; and

   (c) The managed care organization’s written rationale for the adverse decision.

(4) "Claim" means a clean claim as defined in COMAR 31.10.11.02.

(5) "Complaint" means an appeal of an adverse decision filed with the independent review organization.

(6) "Department" means the Maryland Department of Health.

(7) "Expert reviewer" means a physician or other appropriate health care provider who contracts with the independent review organization to conduct a review of a managed care organization’s adverse decision.
Appendix O

(8) "Health care service" means a health or medical care procedure or service rendered by a provider including:

(a) Testing, diagnosis, or treatment of a human disease or dysfunction;

(b) Dispensing of drugs, medical devices, medical appliances, or medical goods for the treatment of a human disease or dysfunction; or

(c) Any other care, service, or treatment of disease or injury, the correction of defects, or the maintenance of the physical and mental well-being of human beings.

(9) "Independent review organization" means an entity that contracts with the Department to conduct independent review of managed care organizations’ adverse decisions.

(10) "Managed care organization (MCO)" has the meaning stated in Health-General Article, §15-101, Annotated Code of Maryland.

(11) "Medicaid" means the program administered by the State under Title XIX of the Social Security Act, which provides comprehensive medical and other health-related care for persons.

(12) "Medical record" has the meaning stated in Health-General Article, §4-301, Annotated Code of Maryland.

(13) "Medically necessary" means a health care service that is:

(a) Directly related to diagnostic, preventive, curative, palliative, rehabilitative, or ameliorative treatment of an illness, injury, disability, or health condition;

(b) Consistent with currently accepted standards of good medical practice;

(c) The most cost-efficient service that can be provided without sacrificing effectiveness or access to care; and

(d) Not primarily for the convenience of the consumer, the consumer's family, or the provider.

(14) "Provider" means any individual or entity that has a valid provider agreement with a Medicaid managed care organization or is a nonparticipating provider rendering covered Medicaid services to the managed care organization’s enrollees.

.03 Use of Independent Review Organizations.

A. The Department shall procure the services of an IRO to make determinations of medical necessity on provider complaints regarding adverse decisions.
B. An IRO that contracts with the Department shall assure, in accordance with its contract with the Department, the:

(1) Timeliness and quality of the reviews;

(2) Qualifications and independence of the IRO and expert reviewers; and

(3) Confidentiality of medical records and review materials, consistent with federal and State laws.

C. An IRO designated by the Department shall have the authority to conduct the following functions:

(1) Obtaining all case information relative to the complaint from the MCO pursuant to time frames established by the Department;

(2) Assigning an expert reviewer for review of an adverse decision;

(3) Performing conflicts checks relative to the independent review organization and the expert reviewer assigned to review the adverse decision;

(4) Communicating procedural rules, as approved by the Department, and other information regarding appeals to the parties;

(5) Rendering a timely final decision in accordance with Regulation .06F of this chapter.


A. An IRO or expert reviewer may not be an affiliate or have a financial, familial or professional relationship with any facility, provider, or organization that has filed a complaint.

B. Upon request by the Department, the IRO shall provide to the Department information demonstrating compliance with the requirement in §A of this regulation.

.05 Assignment of an Expert Reviewer.

A. The IRO shall ensure that an expert reviewer:

(1) Has appropriate clinical expertise in the treatment of the specific medical condition being reviewed and holds a nonrestricted license as a health care provider in the United States; and

(2) Has no history of disciplinary investigations, actions, or sanctions, including loss of staff privileges or participation restrictions that have been taken or are pending by any hospital, governmental agency or unit, or regulatory body.
B. Upon request by the Department, the independent review organization shall provide to the Department information demonstrating compliance with the requirements in §A of this regulation.

.06 Independent Review.

A. A provider shall exhaust an MCO’s provider appeal process before filing a complaint with the IRO.

B. A provider shall file a complaint with the IRO in the form provided by the IRO not later than 30 calendar days following the date of an MCO’s adverse decision.

C. A review of an adverse decision shall be based on the case record.

D. The IRO shall, after reviewing the case record, issue a final decision as to whether the health care services that are the subject of the complaint were medically necessary.

E. The final decision shall state in writing the factual bases for the decision of the expert reviewer and reference the criteria and standards on which the expert reviewer's decision was based.

F. Final decisions shall be rendered within 45 days of submission of the case record, unless the time period is extended by the Department.

.07 Payment of Fees and Sanctions.

A. In the event that a provider’s complaint is unsuccessful, the provider is responsible for paying to the IRO the case review charge established by the Department.

B. The case review charge established by the Department shall be based on the contract between the Department and the IRO arrived at through a competitive procurement process.

C. An MCO that is determined by the IRO to have improperly denied, either in whole or in part, a provider’s claim on medical necessity grounds is subject to the following:

   (1) Within 60 calendar days of the date of an adverse decision by an IRO, the MCO shall fully reimburse the provider for claims determined to be medically necessary by the IRO, including any interest owed under Health Insurance Article, §15-1005(f), Annotated Code of Maryland; and

   (2) Within 60 calendar days of the date of invoice by the IRO, the MCO shall reimburse the IRO the case review charge established by the Department.

D. In the event that the unsuccessful party does not pay the IRO within 60 calendar days of the date of the invoice, the Department shall impose penalties as follows:
(1) First delinquency: 17 percent of the invoice amount;

(2) Second delinquency: 35 percent of the invoice amount; and

(3) Third delinquency: 50 percent of the invoice amount plus:

   (a) For providers, suspension from using the independent case review services for 1 year; or

   (b) For MCOs, any sanction set forth in COMAR 10.67.10.01A(1)—(5), as determined by the Department.

.08 Appeal.

A. As a prerequisite for participating in the IRO complaint adjudication process, a provider waives all other administrative and judicial appeal rights and accepts the IRO’s decision as final and binding.

B. An MCO that receives an adverse decision from an independent review organization may file an appeal in accordance with COMAR 10.67.10.02.